0000721371-24-000038.txt : 20240502 0000721371-24-000038.hdr.sgml : 20240502 20240502084736 ACCESSION NUMBER: 0000721371-24-000038 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 90 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240502 DATE AS OF CHANGE: 20240502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CARDINAL HEALTH INC CENTRAL INDEX KEY: 0000721371 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 310958666 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11373 FILM NUMBER: 24905575 BUSINESS ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147573033 MAIL ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: CARDINAL DISTRIBUTION INC DATE OF NAME CHANGE: 19920703 10-Q 1 cah-20240331.htm 10-Q cah-20240331
0000721371--06-302024Q3falsehttp://fasb.org/us-gaap/2024#GainLossOnSalesOfAssetsAndAssetImpairmentCharges00007213712023-07-012024-03-3100007213712024-04-26xbrli:shares00007213712024-01-012024-03-31iso4217:USD00007213712023-01-012023-03-3100007213712022-07-012023-03-31iso4217:USDxbrli:shares00007213712024-03-3100007213712023-06-300000721371us-gaap:CommonStockMember2023-12-310000721371us-gaap:RetainedEarningsMember2023-12-310000721371us-gaap:TreasuryStockCommonMember2023-12-310000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000721371us-gaap:NoncontrollingInterestMember2023-12-3100007213712023-12-310000721371us-gaap:NoncontrollingInterestMember2024-01-012024-03-310000721371us-gaap:CommonStockMember2024-01-012024-03-310000721371us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000721371us-gaap:RetainedEarningsMember2024-01-012024-03-310000721371us-gaap:CommonStockMember2024-03-310000721371us-gaap:RetainedEarningsMember2024-03-310000721371us-gaap:TreasuryStockCommonMember2024-03-310000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000721371us-gaap:NoncontrollingInterestMember2024-03-310000721371us-gaap:CommonStockMember2022-12-310000721371us-gaap:RetainedEarningsMember2022-12-310000721371us-gaap:TreasuryStockCommonMember2022-12-310000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000721371us-gaap:NoncontrollingInterestMember2022-12-3100007213712022-12-310000721371us-gaap:NoncontrollingInterestMember2023-01-012023-03-310000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000721371us-gaap:CommonStockMember2023-01-012023-03-310000721371us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000721371us-gaap:RetainedEarningsMember2023-01-012023-03-310000721371us-gaap:CommonStockMember2023-03-310000721371us-gaap:RetainedEarningsMember2023-03-310000721371us-gaap:TreasuryStockCommonMember2023-03-310000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000721371us-gaap:NoncontrollingInterestMember2023-03-3100007213712023-03-310000721371us-gaap:CommonStockMember2023-06-300000721371us-gaap:RetainedEarningsMember2023-06-300000721371us-gaap:TreasuryStockCommonMember2023-06-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000721371us-gaap:NoncontrollingInterestMember2023-06-300000721371us-gaap:NoncontrollingInterestMember2023-07-012024-03-310000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012024-03-310000721371us-gaap:CommonStockMember2023-07-012024-03-310000721371us-gaap:TreasuryStockCommonMember2023-07-012024-03-310000721371us-gaap:RetainedEarningsMember2023-07-012024-03-310000721371us-gaap:CommonStockMember2022-06-300000721371us-gaap:RetainedEarningsMember2022-06-300000721371us-gaap:TreasuryStockCommonMember2022-06-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000721371us-gaap:NoncontrollingInterestMember2022-06-3000007213712022-06-300000721371us-gaap:NoncontrollingInterestMember2022-07-012023-03-310000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012023-03-310000721371us-gaap:CommonStockMember2022-07-012023-03-310000721371us-gaap:TreasuryStockCommonMember2022-07-012023-03-310000721371us-gaap:RetainedEarningsMember2022-07-012023-03-310000721371cah:PharmaceuticalAndSpecialtySolutionsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercah:OptumRxMember2022-07-012023-06-30xbrli:pure0000721371cah:SpecialtyNetworksMember2024-01-012024-03-310000721371cah:SpecialtyNetworksMemberus-gaap:CustomerRelationshipsMember2024-03-180000721371cah:SpecialtyNetworksMembercah:TrademarksAndPatentsMember2024-03-180000721371cah:SpecialtyNetworksMemberus-gaap:DevelopedTechnologyRightsMember2024-03-180000721371cah:SpecialtyNetworksMember2024-03-180000721371cah:TransactionDataSystemInvestmentMember2024-03-310000721371cah:OutcomesDivestitureMember2023-07-012024-03-310000721371us-gaap:FairValueInputsLevel3Membercah:TransactionDataSystemInvestmentMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-07-100000721371us-gaap:EmployeeSeveranceMember2023-06-300000721371us-gaap:FacilityClosingMember2023-06-300000721371us-gaap:EmployeeSeveranceMember2023-07-012024-03-310000721371us-gaap:FacilityClosingMember2023-07-012024-03-310000721371us-gaap:EmployeeSeveranceMember2024-03-310000721371us-gaap:FacilityClosingMember2024-03-310000721371cah:PharmaceuticalAndSpecialtySolutionsMember2023-06-300000721371cah:GMPDMember2023-06-300000721371us-gaap:AllOtherSegmentsMember2023-06-300000721371cah:PharmaceuticalAndSpecialtySolutionsMember2023-07-012024-03-310000721371cah:GMPDMember2023-07-012024-03-310000721371us-gaap:AllOtherSegmentsMember2023-07-012024-03-310000721371cah:PharmaceuticalAndSpecialtySolutionsMember2024-03-310000721371cah:GMPDMember2024-03-310000721371us-gaap:AllOtherSegmentsMember2024-03-310000721371cah:OptiFreightLogisticsMember2024-03-310000721371cah:PharmaceuticalAndSpecialtySolutionsMember2022-07-012023-06-300000721371us-gaap:AllOtherSegmentsMember2022-07-012023-06-300000721371cah:GMPDMember2024-01-010000721371cah:OptiFreightLogisticsMemberus-gaap:AllOtherSegmentsMember2024-03-310000721371cah:GMPDMember2024-01-012024-03-310000721371cah:GMPDMember2024-03-31utr:Rate0000721371cah:GMPDMember2023-07-012023-09-300000721371cah:GMPDMember2022-10-012022-12-310000721371cah:GMPDMember2022-07-012022-09-300000721371cah:GMPDMember2023-03-310000721371cah:IPRDTrademarksandOtherMember2024-03-310000721371us-gaap:CustomerRelationshipsMember2024-03-310000721371cah:TrademarksAndPatentsMember2024-03-310000721371us-gaap:DevelopedTechnologyRightsMember2024-03-310000721371cah:IPRDTrademarksandOtherMember2023-06-300000721371us-gaap:CustomerRelationshipsMember2023-06-300000721371cah:TrademarksAndPatentsMember2023-06-300000721371us-gaap:DevelopedTechnologyRightsMember2023-06-300000721371cah:A3.079Notesdue2024Member2024-03-310000721371cah:A3.079Notesdue2024Member2023-06-300000721371cah:A3.5NotesDue2024Member2024-03-310000721371cah:A3.5NotesDue2024Member2023-06-300000721371cah:A3.75NotesDue2025Member2024-03-310000721371cah:A3.75NotesDue2025Member2023-06-300000721371cah:A3.41Notesdue2027Member2024-03-310000721371cah:A3.41Notesdue2027Member2023-06-300000721371cah:A5.125NotesDue2029Member2024-03-310000721371cah:A5.125NotesDue2029Member2023-06-300000721371cah:A5.45NotesDue2034Member2024-03-310000721371cah:A5.45NotesDue2034Member2023-06-300000721371cah:A4.6Notesdue2043Member2024-03-310000721371cah:A4.6Notesdue2043Member2023-06-300000721371cah:A4.5Notesdue2044Member2024-03-310000721371cah:A4.5Notesdue2044Member2023-06-300000721371cah:A4.9Notesdue2045Member2024-03-310000721371cah:A4.9Notesdue2045Member2023-06-300000721371cah:A4.368Notesdue2047Member2024-03-310000721371cah:A4.368Notesdue2047Member2023-06-300000721371cah:A7.0Debenturesduefiscal2027Member2024-03-310000721371cah:A7.0Debenturesduefiscal2027Member2023-06-300000721371cah:A5.125NotesDue2029Member2023-07-012024-03-310000721371cah:A5.45NotesDue2034Member2023-07-012024-03-310000721371cah:RemainingCashFromDebtProceedsMember2024-03-310000721371us-gaap:CommercialPaperMember2024-03-310000721371us-gaap:RevolvingCreditFacilityMember2024-03-310000721371cah:ShortTermCreditFacilitiesMembercah:CommittedReceivablesSalesFacilityProgramMember2024-03-310000721371cah:CommittedReceivablesSalesFacilityProgramMember2023-07-012024-03-310000721371cah:ShortTermCreditFacilitiesMember2024-03-310000721371cah:CVSHealthMember2014-07-312014-07-310000721371cah:NewYorkOpioidStewardshipActMember2018-04-300000721371cah:NewYorkOpioidStewardshipActMember2022-07-012023-06-300000721371cah:NewYorkOpioidStewardshipActMember2023-06-300000721371cah:TotalOpioidLitigationMember2024-03-310000721371cah:TotalOpioidLitigationMember2024-01-012024-03-310000721371cah:OpioidLawsuitsMember2024-03-31cah:statescah:numberOfUSTerritories0000721371stpr:ALcah:OpioidLawsuitsMember2023-11-300000721371stpr:ALcah:OpioidLawsuitsMember2023-07-012024-03-310000721371us-gaap:SubsequentEventMembercah:OpioidLawsuitsMember2021-07-012024-04-300000721371us-gaap:SubsequentEventMembercah:OpioidLawsuitsMember2024-05-012038-12-310000721371stpr:WVcah:OpioidLawsuitsMember2022-07-310000721371cah:NativeAmericanTribesMembercah:OpioidLawsuitsMember2022-10-310000721371cah:OpioidLawsuitsMember2024-01-012024-03-310000721371cah:PrivatePartiesMemberus-gaap:SubsequentEventMembercah:OpioidLawsuitsMember2024-04-26cah:lawsuit0000721371cah:PrivatePartiesMembercah:ClassActionLawsuitsMemberus-gaap:SubsequentEventMembercah:OpioidLawsuitsMember2024-04-260000721371cah:PrivatePartiesMembercah:ClassActionLawsuitsMembercah:OpioidLawsuitsMember2024-03-310000721371cah:PrivatePartiesMemberstpr:GAcah:OpioidLawsuitsMember2023-01-012023-03-31cah:plaintiff0000721371stpr:ALcah:PrivatePartiesMemberus-gaap:SubsequentEventMembercah:OpioidLawsuitsMember2024-07-012024-07-010000721371cah:OpioidLawsuitsMember2022-07-012023-06-300000721371us-gaap:SubsequentEventMembercah:ProductLiabilityLawsuitsMember2024-04-260000721371cah:AlamedaCountyMemberus-gaap:SubsequentEventMembercah:ProductLiabilityLawsuitsMember2024-04-262024-04-260000721371cah:ProductLiabilityLawsuitsMembercah:IVCApril2023AgreementMember2023-04-302023-04-300000721371cah:ProductLiabilityLawsuitsMembercah:IVCApril2023AgreementMember2023-04-300000721371cah:ProductLiabilityLawsuitsMembercah:IVCApril2023AgreementMember2023-05-012023-09-300000721371cah:ProductLiabilityLawsuitsMembercah:OtherAgreementsMemberus-gaap:SubsequentEventMember2021-07-012024-04-260000721371cah:ProductLiabilityLawsuitsMember2022-07-012023-06-300000721371cah:ProductLiabilityLawsuitsMembersrt:MinimumMember2024-03-310000721371srt:ScenarioForecastMembercah:GMPDMember2023-07-012024-06-300000721371cah:GMPDMemberus-gaap:SubsequentEventMember2024-04-012024-06-300000721371srt:MinimumMember2024-03-310000721371srt:MaximumMember2024-03-310000721371cah:CareFusionMember2024-03-310000721371cah:CareFusionMember2023-06-300000721371us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000721371us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000721371us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000721371us-gaap:FairValueMeasurementsRecurringMember2024-03-310000721371us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300000721371us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300000721371us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300000721371us-gaap:FairValueMeasurementsRecurringMember2023-06-300000721371us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMember2024-03-310000721371us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMember2023-03-310000721371us-gaap:CashFlowHedgingMember2024-01-012024-03-310000721371us-gaap:CashFlowHedgingMember2023-01-012023-03-310000721371us-gaap:CashFlowHedgingMember2023-07-012024-03-310000721371us-gaap:CashFlowHedgingMember2022-07-012023-03-310000721371us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2024-01-012024-03-310000721371us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2023-01-012023-03-310000721371us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2023-07-012024-03-310000721371us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-07-012023-03-310000721371srt:ScenarioForecastMemberus-gaap:CashFlowHedgingMemberus-gaap:SubsequentEventMemberus-gaap:ForeignExchangeContractMember2024-04-012025-03-310000721371cah:September2025Memberus-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2024-03-31iso4217:JPY0000721371us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembercah:June2027Member2024-03-310000721371us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembercah:January2023Member2024-03-310000721371cah:January2023Member2023-07-012024-03-310000721371cah:September2025Memberus-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2023-03-310000721371us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembercah:June2027Member2023-03-310000721371us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembercah:March2025Member2023-03-31iso4217:EUR0000721371us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembercah:March2026Member2023-03-310000721371us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembercah:March2022Member2023-03-310000721371us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembercah:September2018Member2023-03-310000721371cah:March2022Member2023-01-012023-03-310000721371cah:September2018Member2023-01-012023-03-310000721371us-gaap:ForeignExchangeContractMember2024-01-012024-03-310000721371us-gaap:ForeignExchangeContractMember2023-07-012024-03-310000721371us-gaap:ForeignExchangeContractMember2022-07-012023-03-310000721371us-gaap:ForeignExchangeContractMember2023-01-012023-03-310000721371us-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2022-07-012023-03-310000721371us-gaap:FairValueInputsLevel2Member2024-03-310000721371us-gaap:FairValueInputsLevel2Member2023-06-300000721371cah:A250MillionShareRepurchaseProgramMember2023-10-012023-12-310000721371cah:A250MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-10-012023-12-310000721371cah:A250MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-11-022023-11-020000721371cah:A250MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-12-132023-12-130000721371cah:A500MillionShareRepurchaseProgramMember2023-07-012023-09-300000721371cah:A500MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-07-012023-09-300000721371cah:A500MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-07-012023-12-310000721371cah:A500MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-10-312023-10-310000721371cah:A500MillionShareRepurchaseProgramMember2023-04-012023-06-300000721371cah:A500MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-04-012023-06-300000721371cah:A500MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-04-012023-09-300000721371cah:A500MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-08-162023-08-160000721371cah:A250MillionShareRepurchaseProgramMember2023-01-012023-03-310000721371cah:A250MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-01-012023-03-310000721371cah:A250MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-01-012023-02-280000721371cah:A250MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2023-02-282023-02-280000721371cah:A300MillionShareRepurchaseProgramMember2022-10-012022-12-310000721371us-gaap:TreasuryStockCommonMembercah:A300MillionShareRepurchaseProgramMember2022-10-012022-12-310000721371us-gaap:TreasuryStockCommonMembercah:A300MillionShareRepurchaseProgramMember2022-10-012023-03-310000721371us-gaap:TreasuryStockCommonMembercah:A300MillionShareRepurchaseProgramMember2023-01-132023-01-130000721371cah:A500MillionShareRepurchaseProgramMember2022-07-012022-09-300000721371cah:A500MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2022-07-012022-09-300000721371cah:A500MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2022-07-012022-12-230000721371cah:A500MillionShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2022-12-232022-12-230000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-07-012024-03-310000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2023-07-012024-03-310000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-07-012024-03-310000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-03-310000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2024-03-310000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-03-310000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-07-012023-03-310000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2022-07-012023-03-310000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-07-012023-03-310000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-03-31cah:segmentcah:Segments0000721371cah:PharmaceuticalAndSpecialtySolutionsMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000721371cah:PharmaceuticalAndSpecialtySolutionsMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000721371cah:GMPDMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000721371cah:GMPDMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000721371us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMembercah:NuclearPrecisionHealthSolutionsMember2024-01-012024-03-310000721371us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMembercah:NuclearPrecisionHealthSolutionsMember2023-01-012023-03-310000721371us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMembercah:AtHomeSolutionsMember2024-01-012024-03-310000721371us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMembercah:AtHomeSolutionsMember2023-01-012023-03-310000721371cah:OptiFreightLogisticsMemberus-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000721371cah:OptiFreightLogisticsMemberus-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000721371us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000721371us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000721371us-gaap:OperatingSegmentsMember2024-01-012024-03-310000721371us-gaap:OperatingSegmentsMember2023-01-012023-03-310000721371us-gaap:CorporateNonSegmentMember2024-01-012024-03-310000721371us-gaap:CorporateNonSegmentMember2023-01-012023-03-310000721371cah:PharmaceuticalAndSpecialtySolutionsMemberus-gaap:OperatingSegmentsMember2023-07-012024-03-310000721371cah:PharmaceuticalAndSpecialtySolutionsMemberus-gaap:OperatingSegmentsMember2022-07-012023-03-310000721371cah:GMPDMemberus-gaap:OperatingSegmentsMember2023-07-012024-03-310000721371cah:GMPDMemberus-gaap:OperatingSegmentsMember2022-07-012023-03-310000721371us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMembercah:NuclearPrecisionHealthSolutionsMember2023-07-012024-03-310000721371us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMembercah:NuclearPrecisionHealthSolutionsMember2022-07-012023-03-310000721371us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMembercah:AtHomeSolutionsMember2023-07-012024-03-310000721371us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMembercah:AtHomeSolutionsMember2022-07-012023-03-310000721371cah:OptiFreightLogisticsMemberus-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2023-07-012024-03-310000721371cah:OptiFreightLogisticsMemberus-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2022-07-012023-03-310000721371us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2023-07-012024-03-310000721371us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2022-07-012023-03-310000721371us-gaap:OperatingSegmentsMember2023-07-012024-03-310000721371us-gaap:OperatingSegmentsMember2022-07-012023-03-310000721371us-gaap:CorporateNonSegmentMember2023-07-012024-03-310000721371us-gaap:CorporateNonSegmentMember2022-07-012023-03-310000721371country:US2024-01-012024-03-310000721371country:US2023-01-012023-03-310000721371us-gaap:NonUsMember2024-01-012024-03-310000721371us-gaap:NonUsMember2023-01-012023-03-310000721371country:US2023-07-012024-03-310000721371country:US2022-07-012023-03-310000721371us-gaap:NonUsMember2023-07-012024-03-310000721371us-gaap:NonUsMember2022-07-012023-03-310000721371cah:GMPDMember2022-07-012023-03-310000721371cah:PharmaceuticalAndSpecialtySolutionsMemberus-gaap:OperatingSegmentsMember2024-03-310000721371cah:PharmaceuticalAndSpecialtySolutionsMemberus-gaap:OperatingSegmentsMember2023-06-300000721371cah:GMPDMemberus-gaap:OperatingSegmentsMember2024-03-310000721371cah:GMPDMemberus-gaap:OperatingSegmentsMember2023-06-300000721371us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2024-03-310000721371us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2023-06-300000721371us-gaap:CorporateNonSegmentMember2024-03-310000721371us-gaap:CorporateNonSegmentMember2023-06-300000721371us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310000721371us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310000721371us-gaap:PerformanceSharesMember2024-01-012024-03-310000721371us-gaap:PerformanceSharesMember2023-01-012023-03-310000721371us-gaap:RestrictedStockUnitsRSUMember2023-07-012024-03-310000721371us-gaap:RestrictedStockUnitsRSUMember2022-07-012023-03-310000721371us-gaap:PerformanceSharesMember2023-07-012024-03-310000721371us-gaap:PerformanceSharesMember2022-07-012023-03-310000721371us-gaap:RestrictedStockUnitsRSUMember2023-06-300000721371us-gaap:RestrictedStockUnitsRSUMember2024-03-310000721371cah:Fiscal2023Membersrt:MinimumMemberus-gaap:PerformanceSharesMember2023-07-012024-03-310000721371cah:Fiscal2022Membersrt:MinimumMemberus-gaap:PerformanceSharesMember2023-07-012024-03-310000721371srt:MaximumMembercah:Fiscal2023Memberus-gaap:PerformanceSharesMember2023-07-012024-03-310000721371cah:Fiscal2022Membersrt:MaximumMemberus-gaap:PerformanceSharesMember2023-07-012024-03-310000721371srt:MinimumMembercah:Fiscal2024Memberus-gaap:PerformanceSharesMember2023-07-012024-03-310000721371srt:MaximumMembercah:Fiscal2024Memberus-gaap:PerformanceSharesMember2023-07-012024-03-310000721371us-gaap:PerformanceSharesMember2023-06-300000721371us-gaap:PerformanceSharesMember2024-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________ to ________
Commission File Number: 1-11373
Cardinal Health, Inc.
(Exact name of registrant as specified in its charter)
Ohio31-0958666
(State or other jurisdiction of
incorporation or organization)		(IRS Employer
Identification No.)
7000 Cardinal Place,Dublin,Ohio43017
(Address of principal executive offices)(Zip Code)
(614) 757-5000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common shares (without par value)CAHNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes    þ    No    o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes    þ    No    o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☑Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes    ☐    No    þ
The number of the registrant’s common shares, without par value, outstanding as of April 26, 2024, was the following: 243,566,952.


Cardinal Health
Q3 Fiscal 2024 Form 10-Q
Table of Contents

About Cardinal Health
Cardinal Health, Inc., an Ohio corporation formed in 1979, is a global healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination. Effective January 1, 2024, we began operating under an updated organizational structure and re-aligned our financial reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions ("PSS") segment and Global Medical Products and Distribution ("GMPD") segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics. As used in this report, “we,” “our,” “us,” and similar pronouns refer to Cardinal Health, Inc. and its majority-owned and consolidated subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2024 and fiscal 2023 and to FY24 and FY23 are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively.
Forward-Looking Statements
This Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), but there are others in this Form 10-Q, which may be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “will,” “should,” “could,” “would,” “project,” “continue,” “likely,” and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (our “2023 Form 10-K”), our Forms 10-Q for the quarters ending September 30, 2023 and December 31, 2023, and other SEC filings made since June 30, 2023. Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.
Non-GAAP Financial Measures
In the "Overview of Consolidated Results" section of MD&A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the United States Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the “Explanation and Reconciliation of Non-GAAP Financial Measures” section following MD&A in this Form 10-Q.

 1
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


MD&A
Overview
Management's Discussion and Analysis of Financial Condition and Results of Operations
The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at March 31, 2024 and June 30, 2023, and in our condensed consolidated statements of earnings for the three and nine months ended March 31, 2024 and 2023. All comparisons presented are with respect to the prior-year period, unless stated otherwise. Our previously reported segment results have been recast to conform to our new reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change. The discussion and analysis in this Form 10-Q should be read in conjunction with the MD&A included in our 2023 Form 10-K.

 2
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


MD&AOverview
Overview of Consolidated Results
Revenue
During the three and nine months ended March 31, 2024, revenue increased 9 percent and 10 percent to $54.9 billion and $167.1 billion, respectively, primarily due to branded and specialty pharmaceutical sales growth from existing customers.
GAAP and Non-GAAP Operating Earnings
Three Months Ended March 31,Nine Months Ended March 31,
(in millions)20242023Change20242023Change
GAAP operating earnings
$367 $572 (36)%$835 $590 42 %
State opioid assessment related to prior fiscal years— — — (6)
Shareholder cooperation agreement costs
1 — 1 8 
Restructuring and employee severance53 16 106 62 
Amortization and other acquisition-related costs80 74 207 216 
Impairments and (gain)/loss on disposal of assets, net84 20 622 883 
Litigation (recoveries)/charges, net81 (76)29 (256)
Non-GAAP operating earnings$666 $606 10 %$1,799 $1,497 20 %
The sum of the components and certain computations may reflect rounding adjustments.
We had GAAP operating earnings of $367 million and $572 million during the three months ended March 31, 2024 and 2023, respectively, and $835 million and $590 million during the nine months ended March 31, 2024 and 2023, respectively. GAAP operating earnings during the three and nine months ended March 31, 2024 were favorably impacted by GMPD and Pharmaceutical and Specialty Solutions segment profit. GAAP operating earnings also reflects the pre-tax non-cash goodwill impairment charges related to the GMPD segment of $90 million during the three months ended March 31, 2024 and the $671 million and $863 million during the nine months ended March 31, 2024 and 2023, respectively. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 5 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
GAAP operating earnings during the three months ended March 31, 2024 reflects $193 million of litigation charges recognized in connection with opioid-related matters, which were partially offset by a benefit of $105 million related to opioid-related prepayments. GAAP operating earnings during the three and nine months ended March 31, 2023 were favorably impacted by litigation recoveries and a reduction in litigation reserves. See "Results of Operations" section of this MD&A and Note 7 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
Non-GAAP operating earnings during the three and nine months ended March 31, 2024 increased 10 percent and 20 percent, respectively, due to increases in GMPD and Pharmaceutical and Specialty Solutions segment profit.


 3
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


MD&AOverview
GAAP and Non-GAAP Diluted EPS
Three Months Ended March 31,Nine Months Ended March 31,
($ per share)2024
2023
Change2024
2023
Change
GAAP diluted EPS (1)
$1.05 $1.34 (22)%$2.49 $1.23 N.M.
State opioid assessment related to prior fiscal years— — — 0.02 
Shareholder cooperation agreement costs
— — — (0.02)
Restructuring and employee severance0.16 0.05 0.32 0.18 
Amortization and other acquisition-related costs0.24 0.21 0.62 0.61 
Impairments and (gain)/loss on disposal of assets, net (2)
0.44 0.35 2.14 2.82 
Litigation (recoveries)/charges, net0.19 (0.21)0.05 (0.60)
Non-GAAP diluted EPS (1)
$2.08 $1.74 20 %$5.62 $4.24 33 %
The sum of the components and certain computations may reflect rounding adjustments.
The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures."
(1)Diluted earnings per share attributable to Cardinal Health, Inc. ("diluted EPS").
(2)For the three and nine months ended March 31, 2024, impairments and (gain)/loss on disposal of assets, net includes pre-tax goodwill impairment charges of $90 million and $671 million, respectively, related to the GMPD segment. For fiscal 2024, the estimated net tax benefit related to the impairments is $56 million and is included in the annual effective tax rate. The incremental interim tax benefit recognized during the nine months ended March 31, 2024 is $36 million and will reverse in the fourth quarter of the fiscal year.
For the nine months ended March 31, 2023, impairments and (gain)/loss on disposal of assets, net included cumulative pre-tax goodwill impairment charges of $863 million related to the former Medical segment. For fiscal 2023, the net tax benefit related to the impairment was $68 million and was included in the annual effective tax rate. The incremental interim tax benefit recognized during the nine months ended March 31, 2023 was $66 million and reversed in the fourth quarter of fiscal 2023.
The changes in GAAP diluted EPS during the three and nine months ended March 31, 2024 were primarily due to the factors impacting GAAP operating earnings. GAAP diluted EPS was adversely impacted by goodwill impairment charges related to the GMPD segment, which had a $(0.29) per share after tax impact during the three months ended March 31, 2024, and a $(2.35) and $(2.76) per share after tax impact during the nine months ended March 31, 2024 and 2023, respectively. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A, and Note 5 and Note 8 of the "Notes to Condensed Consolidated Financial Statements" for additional details.
During the three and nine months ended March 31, 2024, non-GAAP diluted EPS increased 20 percent and 33 percent to $2.08 and $5.62 per share, respectively, due to higher non-GAAP operating earnings and a lower share count.

Cash and Equivalents
Our cash and equivalents balance was $3.7 billion at March 31, 2024 compared to $4.0 billion at June 30, 2023. During the nine months ended March 31, 2024, net cash provided by operating activities was $1.7 billion, which includes the impact of our annual payment of $378 million and prepayments of $239 million primarily related to the agreement to settle the vast majority of the opioid lawsuits filed by states and local governmental entities (the "National Opioid Settlement Agreement"). During the three months ended March 31, 2024, we issued additional long-term debt and received net proceeds of $1.14 billion, of which $589 million were classified as cash and equivalents in our condensed consolidated balance sheets as of March 31, 2024. The remaining proceeds were invested in short-term time deposits with initial effective maturities of more than three months and classified as prepaid expenses and other. In addition, during the nine months ended March 31, 2024, we deployed $1.2 billion for the Specialty Networks acquisition, $750 million for share repurchases, $377 million for cash dividends and $318 million for capital expenditures.

 4
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


MD&AOverview
Significant Developments in Fiscal 2024 and Trends
Operating and Segment Reporting Structure Changes
Effective January 1, 2024, we began operating under an updated organizational structure and re-aligned our financial reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions segment and GMPD segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other. The following indicates the changes from the second quarter of fiscal 2024 to the new reporting structure:
•Pharmaceutical and Specialty Solutions segment: This reportable segment is comprised of all businesses formerly within our Pharmaceutical segment except Nuclear and Precision Health Solutions.
•GMPD segment: This reportable segment is comprised of all businesses formerly within our Medical segment except at-Home Solutions and OptiFreight® Logistics.
•Other: This is comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics.
Our previously reported segment results have been recast to conform to our new reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change.

Pharmaceutical and Specialty Solutions Segment
OptumRx Contracts
On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. Sales to OptumRx generated 16% of our consolidated revenue in fiscal 2023. Total sales to OptumRx generate a meaningfully lower operating margin than the overall Pharmaceutical and Specialty Solutions segment. We expect the nonrenewal of the OptumRx contracts to adversely impact our results of operations, including segment profit, financial condition and cash flows. In particular, we expect to generate lower than average operating cash flow in fiscal 2025 due to the unwinding of the negative net working capital associated with the contract.
Specialty Networks Acquisition
On March 18, 2024, we completed the acquisition of Specialty Networks for a purchase price of $1.2 billion in cash, subject to certain adjustments. Specialty Networks creates clinical and economic value for independent specialty providers and partners across multiple specialty group purchasing organizations ("GPOs"): UroGPO,Gastrologix and GastroGPO, and United Rheumatology. Specialty Networks’ PPS Analytics platform analyzes data from electronic medical records, practice management, imaging, and dispensing systems and transforms it into meaningful and actionable insights for providers and other stakeholders by using artificial intelligence and modern data analytics capabilities. The acquisition further expands our offerings in key therapeutic areas, accelerates our upstream data and research opportunities with biopharma manufacturers, and creates a platform for our expansion across therapeutic areas. We expect the Specialty Networks acquisition to positively impact Pharmaceutical and Specialty Solutions segment revenue and profit while increasing amortization and other acquisition-related costs during the remainder of fiscal 2024 and fiscal 2025.
COVID-19 Vaccine Distribution
Pharmaceutical and Specialty Solutions segment profit was favorably impacted during the nine months ended March 31, 2024 and on a year-over-year basis in part due to the company beginning to distribute the commercially available COVID-19 vaccines following U.S. Food and Drug Administration approval of updated vaccines in September 2023. The timing, magnitude and profit impact of vaccine distribution volume for the remainder of fiscal 2024 and beyond remains uncertain.
Generics Program
The performance of our Pharmaceutical and Specialty Solutions segment generics program positively impacted the year-over-year comparison of Pharmaceutical and Specialty Solutions segment profit during the three and nine months ended March 31, 2024. The Pharmaceutical and Specialty Solutions segment generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes, the Red Oak Sourcing, LLC venture ("Red Oak Sourcing") with CVS Health Corporation ("CVS Health") and generic pharmaceutical contract manufacturing and sourcing costs.

 5
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


MD&AOverview
The frequency, timing, magnitude and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, generic pharmaceutical manufacturer pricing changes and generic pharmaceutical contract manufacturing and sourcing costs all impact Pharmaceutical and Specialty Solutions segment profit and are subject to risks and uncertainties. These risks and uncertainties may impact Pharmaceutical and Specialty Solutions segment profit and consolidated operating earnings during the remainder of fiscal 2024.

Global Medical Products and Distribution Segment
Inflationary Impacts
Beginning in fiscal 2022, GMPD segment profit was negatively affected by incremental inflationary impacts, primarily related to transportation (including ocean and domestic freight), commodities and labor, and global supply chain constraints. Since that time, we have taken actions to partially mitigate these impacts, including implementing certain price increases and evolving our pricing and commercial contracting processes to provide us with greater pricing flexibility. In addition, decreases in some product-related costs have been recognized as the higher-cost inventory moved through our supply chain and was replaced by lower-cost inventory. These net inflationary impacts negatively affected the GMPD segment profit during fiscal 2023. The net inflationary impacts were less significant during the three and nine months ended March 31, 2024 and had a favorable impact on GMPD segment profit on a year-over-year basis.
We expect these net inflationary impacts to continue to affect GMPD segment profit during the remainder of fiscal 2024, but to a significantly lesser extent than in fiscal 2023 and prior periods due to our mitigation actions, together with continued decreases in certain product-related costs. However, these inflationary costs are difficult to predict and may be greater than we expect or continue longer than our current expectations. Our actions to increase prices and evolve our contracting strategies are subject to contingencies and uncertainties and it is possible that our results of operations will be adversely impacted to a greater extent than we currently anticipate or that we may not be able to mitigate the negative impact to the extent or on the timeline we anticipate.
Volumes
The GMPD segment profit was adversely impacted during fiscal 2023 in part due to lower volumes, which includes our Cardinal Health branded medical products. We have experienced Cardinal Health branded medical products sales growth during fiscal 2024 and expect further growth for the remainder of fiscal 2024 and beyond. The timing, magnitude and profit impact of this anticipated sales growth is subject to risks and uncertainties, which may impact GMPD segment profit.
Goodwill
The change in segment structure as discussed above resulted in changes to the composition of our reporting units. Accordingly, we are required to reallocate the goodwill in reporting units affected by the change using a relative fair value approach and assess goodwill for impairment both before and after the reallocation.
During the three months ended March 31, 2024, we allocated $90 million and $48 million of goodwill from the former Medical segment excluding our at-Home Solutions division (the "Medical Unit") to the GMPD reporting unit and the OptiFreight® Logistics reporting unit, respectively. We also assessed GMPD's goodwill for impairment and determined there was an impairment of GMPD’s remaining goodwill balance of $90 million. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 5 of the "Notes to Condensed Consolidated Financial Statements" for additional detail.

Shareholder Cooperation Agreement
In September 2022, we entered into a Cooperation Agreement (the "Cooperation Agreement") with Elliott Associates, L.P. and Elliott International, L.P. (together, "Elliott") under which our Board of Directors (the "Board"), among other things, (1) appointed four new independent directors, including a representative from Elliott, and (2) formed an advisory Business Review Committee of the Board, which is tasked with undertaking a comprehensive review of our strategy, portfolio, capital-allocation framework and operations. In May 2023, we extended the term of the Cooperation Agreement until the later of July 15, 2024 or until Elliott's representative ceases to serve on, or resigns from, the Board. In connection with this extension, the Board has extended the term of the Business Review Committee until July 15, 2024.
The evaluation and implementation of any actions recommended by the Business Review Committee and the Board have impacted and may continue to impact our business, financial position and results of operations during the remainder of fiscal 2024 and beyond. We have incurred, and may incur additional legal, consulting and other expenses related to the Cooperation Agreement and the activities of the Business Review Committee.

 6
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


MD&AResults of Operations
Results of Operations
Revenue
36376047313972475
Three Months Ended March 31,Nine Months Ended March 31,
(in millions)20242023Change20242023Change
Pharmaceutical and Specialty Solutions$50,651 $46,496 9 %$154,524 $139,441 11 %
Global Medical Products and Distribution3,113 2,989 4 %9,264 9,140 1 %
Other1,167 1,025 14 %3,392 3,038 12 %
Total segment revenue54,931 50,510 9 %167,180 151,619 10 %
Corporate(20)(23)N.M.(61)(60)N.M.
Total revenue$54,911 $50,487 9 %$167,119 $151,559 10 %
Pharmaceutical and Specialty Solutions
Pharmaceutical and Specialty Solutions segment revenue increased $4.2 billion and $15.1 billion during the three and nine months ended March 31, 2024, respectively, due to branded and specialty pharmaceutical sales growth from existing customers.
Global Medical Products and Distribution
GMPD segment revenue increased during the three and nine months ended March 31, 2024, driven by higher volumes from existing customers. Additionally, during the nine months ended March 31, 2024 GMPD segment revenue was adversely impacted by personal protective equipment ("PPE") volumes and pricing, partially offset by price increases to mitigate inflationary impacts.
Other
Other revenue increased during the three and nine months ended March 31, 2024 due to growth across the three operating segments: at-Home Solutions, Nuclear and Precision Health Solutions and OptiFreight® Logistics.

Cost of Products Sold
Cost of products sold for the three and nine months ended March 31, 2024 increased 9 percent and 10 percent to $53.0 billion and $161.6 billion, respectively, compared to the prior-year periods due to the factors affecting the changes in revenue and gross margin.



 7
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


MD&AResults of Operations
Gross Margin
10851086
Three Months Ended March 31,Nine Months Ended March 31,
(in millions)20242023Change20242023Change
Gross margin$1,947 $1,785 9 %$5,561 $5,062 10 %

Gross margin increased during the three and nine months ended March 31, 2024 primarily due to the beneficial comparison of the prior-year net inflationary impacts in the GMPD segment and the performance of our generics program in the Pharmaceutical and Specialty Solutions segment. Gross margin also increased during the nine months ended March 31, 2024 due to increased contribution from branded pharmaceutical and specialty pharmaceutical products in the Pharmaceutical and Specialty Solutions segment, which includes the favorable impact of COVID-19 vaccine distribution.
Gross margin rates were relatively flat during the three and nine months ended March 31, 2024 with the impact of the overall product mix mostly offset by the beneficial comparison to the prior-year net inflationary impacts in the GMPD segment. The changes in overall product mix were primarily driven by increased pharmaceutical distribution branded sales, which have a dilutive impact on our overall gross margin rate.
Distribution, Selling, General and Administrative ("SG&A") Expenses
Three Months Ended March 31,Nine Months Ended March 31,
(in millions)20242023Change20242023Change
SG&A expenses$1,282 $1,179 9 %$3,762 $3,567 5 %
During the three and nine months ended March 31, 2024, SG&A expenses increased primarily due to investment projects, higher costs to support sales growth, and compensation-related costs.












 8
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


MD&AResults of Operations
Segment Profit
We evaluate segment performance based on segment profit, among other measures. See Note 13 of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.
Three Months Ended March 31,Nine Months Ended March 31,
(in millions)20242023Change20242023Change
Pharmaceutical and Specialty Solutions$580 $560 4 %$1,541 $1,394 11 %
Global Medical Products and Distribution20 (46)N.M.18 (175)N.M.
Other111 106 5 %319 305 5 %
Total segment profit711 620 15 %1,878 1,524 23 %
Corporate(344)(48)N.M.(1,043)(934)N.M.
Total consolidated operating earnings
$367 $572 (36)%$835 $590 (31)%
Pharmaceutical and Specialty Solutions
Pharmaceutical and Specialty Solutions segment profit increased during the three and nine months ended March 31, 2024 primarily due to the performance of our generics program. During the nine months ended March 31, 2024, Pharmaceutical and Specialty Solutions segment profit also increased due to the increased contribution from branded pharmaceutical and specialty pharmaceutical products, which includes the favorable impact of COVID-19 vaccine distribution, partially offset by higher costs to support sales growth.
Global Medical Products and Distribution
Global Medical Product and Distribution segment profit increased during the three and nine months ended March 31, 2024 primarily due to beneficial comparison to the prior-year inflationary impacts, net of the effects of mitigation actions.
Other
Other segment profit increased during the three and nine months ended March 31, 2024 primarily due to the performance of OptiFreight® Logistics.
Corporate
The changes in Corporate during the three and nine months ended March 31, 2024 were due to the factors discussed in the "Other Components of Consolidated Operating Earnings" section that follows.

 9
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


MD&AResults of Operations
Other Components of Consolidated Operating Earnings
In addition to revenue, gross margin and SG&A expenses discussed previously, consolidated operating earnings were impacted by the following:
Three Months Ended March 31,Nine Months Ended March 31,
(in millions)2024202320242023
Restructuring and employee severance$53 $16 $106 $62 
Amortization and other acquisition-related costs80 74 207 216 
Impairments and (gain)/loss on disposal of assets, net84 20 622 883 
Litigation (recoveries)/charges, net81 (76)29 (256)
Restructuring and Employee Severance
Restructuring and employee severance costs during the three and nine months ended March 31, 2024 and 2023 include costs related to the implementation of certain enterprise-wide cost-savings measures, which include certain initiatives to rationalize our manufacturing operations. The increase in restructuring costs during the three and nine months ended March 31, 2024 was primarily due to these initiatives and certain projects resulting from the review of our strategy portfolio, capital-allocation framework and operations. During the three and nine months ended March 31, 2023, restructuring and employee severance costs also included costs related to the divestiture of the Cordis business.
Amortization and Other Acquisition-Related Costs
Amortization of acquisition-related intangible assets was $64 million and $69 million for the three months ended March 31, 2024 and 2023, respectively, and $191 million and $211 million for the nine months ended March 31, 2024 and 2023, respectively.
Impairments and (Gain)/Loss on Disposal of Assets, Net
We recognized a $90 million pre-tax non-cash goodwill impairment charge related to the GMPD segment during the three months ended March 31, 2024 and charges of $671 million and $863 million during the nine months ended March 31, 2024 and 2023, respectively, as discussed further in the "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 5 of the "Notes to Condensed Consolidated Financial Statements."
Litigation (Recoveries)/Charges, Net
During the three months ended March 31, 2024, we recognized expense of $193 million in connection with opioid-related matters, which was offset by a benefit of $105 million related to prepayments at a prenegotiated discount of certain future payment amounts totaling $344 million. During the nine months ended March 31, 2024, we also recognized a $22 million charge related to an agreement in principle with the Alabama Attorney General. See Note 7 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
We recognized income for net recoveries in class action antitrust lawsuit in which we were a class member or plaintiff of $6 million and $77 million during the three and nine months ended March 31, 2024, respectively, and $66 million during the nine months ended March 31, 2023.
During the three and nine months ended March 31, 2023, we recognized income of $71 million and $95 million, respectively, primarily related to a reduction of the reserve for the estimated settlement and defense costs for the Cordis OptEase and TrapEase inferior vena cava ("IVC") product liability due to the execution of certain settlement agreements.
During the nine months ended March 31, 2023, we recognized income of $93 million due to net proceeds from the settlement of a shareholder derivative litigation matter.
Earnings Before Income Taxes
In addition to the items discussed above, earnings before income taxes were impacted by the following:
Three Months Ended March 31,Nine Months Ended March 31,
(in millions)20242023Change20242023Change
Other (income)/expense, net$(7)$— N.M.$(25)$(5)N.M.
Interest expense, net33 28 18 %55 78 (29)%

 10
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


MD&AResults of Operations
Interest Expense, Net
During the nine months ended March 31, 2024, interest expense decreased by 29 percent primarily due to increased interest income from cash and equivalents.
Provision for Income Taxes
The effective tax rate was 24.2 percent and 36.3 percent during the three months ended March 31, 2024 and 2023, respectively, and 23.2 percent and 36.7 percent during the nine months ended March 31, 2024 and 2023, respectively. These tax rates reflect the impact of the tax effects of goodwill impairment charges as well as certain other discrete items. See Note 8 of the "Notes to Condensed Consolidated Financial Statements" for additional information, during the three and nine months ended March 31, 2024 and 2023.
Tax Effects of Goodwill Impairment Charges
During the nine months ended March 31, 2024, we recognized cumulative pre-tax goodwill impairment charges of $671 million related to the GMPD segment. The net tax benefit related to these charges is $56 million for fiscal 2024.
Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.
The tax effect of the goodwill impairment charges recorded during the nine months ended March 31, 2024 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to the pre-tax income for the nine months ended March 31, 2024 resulted in recognizing an incremental interim tax benefit of approximately $36 million, which impacted the provision for income taxes in the condensed consolidated statements of earnings during the nine months ended March 31, 2024 and prepaid expenses and other assets in the condensed consolidated balance sheet at March 31, 2024. The incremental interim tax benefit will reverse in the fourth quarter of fiscal 2024.

 11
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


MD&ALiquidity and Capital Resources
Liquidity and Capital Resources
We currently believe that, based on available capital resources and projected operating cash flow, we have adequate capital resources to fund our operations and expected future cash needs as described below. If we decide to engage in one or more acquisitions we may need to access capital markets for additional financing, depending on the size and timing of such transactions.
Cash and Equivalents
Our cash and equivalents balance was $3.7 billion at March 31, 2024 compared to $4.0 billion at June 30, 2023.
During the nine months ended March 31, 2024, net cash provided by operating activities was $1.7 billion, which includes the impact of our annual payment of $378 million and prepayments of $239 million primarily related to the National Opioid Settlement Agreement. During the three months ended March 31, 2024, we issued additional long-term debt and received net proceeds of $1.14 billion, of which $589 million were classified as cash and equivalents in our condensed consolidated balance sheets as of March 31, 2024. The remaining proceeds were invested in short-term time deposits with initial effective maturities of more than three months and classified as prepaid expenses and other. In addition, we deployed cash of $750 million for share repurchases, $377 million for cash dividends and $318 million for capital expenditures.
On March 18, 2024, we completed the acquisition of Specialty Networks for a purchase price of $1.2 billion in cash, subject to certain adjustments. See Note 2 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
At March 31, 2024, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments.
Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of customer payments, inventory purchases, payments to vendors and tax payments in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix.
The cash and equivalents balance at March 31, 2024 includes $650 million of cash held by subsidiaries outside of the United States.



Other Financing Arrangements and Financial Instruments
Credit Facilities and Commercial Paper
In addition to cash and equivalents and operating cash flow, other sources of liquidity at March 31, 2024 include a $2.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At March 31, 2024, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.
In February 2023, we extended our $2.0 billion revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC ("CHF") through September 30, 2025. In September 2023, Cardinal Health 23 Funding, LLC was added as a seller under our committed receivables sales facility.
Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of March 31, 2024, we were in compliance with this financial covenant.

Long-Term Debt and Other Short-Term Borrowings
We had total long-term obligations, including the current portion and other short-term borrowings, of $5.9 billion and $4.7 billion at March 31, 2024 and June 30, 2023, respectively.
In February 2024, we issued additional debt with the aggregate principal amount of $1.15 billion to fund the repayment of all of the aggregate principal amount outstanding of our 3.5% Notes due 2024 and 3.079% Notes due 2024, at their respective maturities, and for general corporate purposes. The notes issued are $650 million aggregate principal amount of 5.125% Notes that mature on February 15, 2029 and $500 million aggregate principal amount of 5.45% Notes that mature on February 15, 2034. The proceeds of the notes issued, net of discounts, premiums, and debt issuance costs were $1.14 billion. A portion of the proceeds were invested in short-term time deposits of $550 million with initial effective maturities of more than three months and classified as prepaid expenses and other in our condensed consolidated balance sheets as of March 31, 2024. The remaining proceeds of $589 million were invested in short-term time deposits classified as cash and equivalents in our condensed consolidated balance sheets as of March 31, 2024.

 12
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


MD&ALiquidity and Capital Resources
Capital Deployment
Opioid Litigation Settlement Agreement
We had $5.3 billion accrued at March 31, 2024 related to certain opioid litigation, as further described within Note 7 of the "Notes to Condensed Consolidated Financial Statements." We expect the majority of the remaining payment amounts to occur through 2038. During the nine months ended March 31, 2024, we made our third annual payment of $378 million under the National Opioid Settlement Agreement. The amounts of future annual payments may differ from the payments that we have already made.
In January 2024, we made additional payments of approximately $239 million to prepay at a prenegotiated discount of certain future payment amounts totaling approximately $344 million owed under each of the National Opioid Settlement Agreement, West Virginia Subdivisions Settlement Agreement and settlement agreements with Native American tribes and Cherokee Nation. The majority of the prepayment relates to the seventh annual payment due under the National Opioid Settlement Agreement. As a result of these prepayments, we recognized income of $105 million in litigation charges/(recoveries), net in our condensed consolidated statements of earnings during the nine months ended March 31, 2024.
Capital Expenditures
Capital expenditures during the nine months ended March 31, 2024 and 2023 were $318 million and $264 million, respectively.

Dividends
On each of May 11, 2023, August 9, 2023, November 14, 2023 and February 6, 2024, our Board of Directors approved a quarterly dividend of $0.5006 per share, or $2.00 per share on an annualized basis, which were paid on July 15, 2023, October 15, 2023, January 15, 2024 and April 15, 2024 to shareholders of record on July 3, 2023, October 3, 2023, January 2, 2024 and April 1, 2024, respectively.
Share Repurchases
During the nine months ended March 31, 2024, we deployed $750 million of our common shares, in the aggregate, under accelerated share repurchase ("ASR") programs. We funded the ASR programs with available cash. See Note 11 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
As of March 31, 2024, we have $3.5 billion remaining under our existing share repurchase authorization.
Specialty Networks Acquisition
On March 18, 2024, we completed the acquisition of Specialty Networks for a purchase price of $1.2 billion in cash, subject to certain adjustments. See Note 2 of the "Notes to Condensed Consolidated Financial Statements" for additional information.

 13
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


MD&AOther Items

Other Items
The MD&A in our 2023 Form 10-K addresses our contractual obligations and cash requirements, as of and for the fiscal year ended June 30, 2023. Other than the acquisition of Specialty Networks and our debt issuance, there have been no subsequent material changes outside of the ordinary course of business to those items. See Note 2 and Note 6 of the "Notes to Condensed Consolidated Financial Statements" for additional information.


Critical Accounting Policies and Sensitive Accounting Estimates
The discussion and analysis presented below is a supplemental disclosure to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheet at June 30, 2023. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in our 2023 Form 10-K and our Form 10-Q for the quarters ended September 30, 2023 and December 31, 2023.
Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management’s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ, including due to the risks discussed in "Risk Factors" and other risks discussed in our 2023 Form 10-K and our other filings with the SEC since June 30, 2023.
Goodwill
Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component).
Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Our qualitative evaluation considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.
As discussed in the Overview section of this MD&A, effective January 1, 2024, we implemented a new enterprise operating and segment reporting structure. The updated structure is comprised of two reportable segments: Pharmaceutical and Specialty Solutions segment and Global Medical Products and Distribution segment. All remaining operating segments that are not significant enough to
require separate reportable segment disclosures are included in Other.
This change in segment structure resulted in changes to the composition of our former Medical operating segment excluding at-Home Solutions reporting unit ("Medical Unit"). Effective January 1, 2024, our reporting units are: Pharmaceutical and Specialty Solutions, GMPD, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics. GMPD and OptiFreight® Logistics comprised our former Medical Unit.
Accordingly, we allocated $90 million and $48 million of goodwill from the former Medical Unit to GMPD and OptiFreight® Logistics, respectively, based on the estimated relative fair values of the reporting units. We also assessed goodwill for impairment for these reporting units before and after the reallocation and determined there was no impairment for the Medical Unit and OptiFreight® Logistics during the three months ended March 31, 2024 as their fair values substantially exceeded their carrying values. However, the quantitative test resulted in an impairment of GMPD’s remaining goodwill balance of $90 million.
Our previously reported goodwill balances have been recast to conform to the new structure. Prior-period goodwill impairment charges related to the former Medical Unit were primarily driven by the performance and long-term financial plan assumptions of GMPD and have been fully allocated to GMPD under the new structure.
Global Medical Products and Distribution Goodwill
Our determinations of the estimated fair value of GMPD was based on a combination of the income-based approach (using a discount rate of 11 percent and a terminal growth rate of 2 percent) and market-based approaches at January 1, 2024. Additionally, we

 14
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


MD&A
Other Items
assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method.
During the three months ended September 30, 2023, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the former Medical Unit. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $581 million for the three months ended September 30, 2023. We did not identify any indicators of impairment during the three months ended December 31, 2023.
During the three months ended December 31, 2022 and September 30, 2022, we performed quantitative goodwill impairment testing for the former Medical Unit and recorded impairment charges of $709 million and $154 million, respectively. We also performed interim quantitative goodwill impairment testing at March 31, 2023 and concluded that there was no impairment as of March 31, 2023 as the estimated fair value of the former Medical Unit exceeded its carrying value by approximately 4 percent.

 15
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Explanation and Reconciliation of Non-GAAP Financial Measures
Explanation and Reconciliation of Non-GAAP Financial Measures
The "Overview of Consolidated Results" section within MD&A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP.
In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated.
Exclusions from Non-GAAP Financial Measures
Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors’ assessment of the business for the reasons identified below:
•LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies’ financial results. We did not recognize any LIFO charges or credits during the periods presented.
•State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals due to changes in estimates or when the underlying assessments were invalidated by a Court or reimbursed by manufacturers.
•Shareholder cooperation agreement costs includes costs such as legal, consulting and other expenses incurred in relation to the agreement (the "Cooperation Agreement") entered into among Elliott Associates, L.P., Elliott International, L.P. (together, "Elliott") and Cardinal Health, including costs incurred to negotiate and finalize the Cooperation Agreement and costs incurred by the Business Review Committee of the Board of Directors, which was formed under this Cooperation Agreement. We have excluded these costs from our non-GAAP metrics because they do not occur in or reflect the ordinary course of our ongoing business operations and may obscure analysis of trends and financial performance.
•Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business and include, but are not limited to, costs related to divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance and realigning operations.
•Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity’s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions.

 16
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Explanation and Reconciliation of Non-GAAP Financial Measures
•Impairments and gain or loss on disposal of assets, net are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.
•Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.
•Loss on early extinguishment of debt is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions.
The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.

Definitions
Growth rate calculation: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.
Non-GAAP operating earnings: operating earnings excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, net and (7) litigation (recoveries)/charges, net.
Non-GAAP earnings before income taxes: earnings before income taxes excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, net, (7) litigation (recoveries)/charges, net and (8) loss on early extinguishment of debt.
Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, net, (7) litigation (recoveries)/charges, net and (8) loss on early extinguishment of debt, each net of tax.
Non-GAAP effective tax rate: provision for income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, net, (7) litigation (recoveries)/charges, net and (8) loss on early extinguishment of debt divided by (earnings before income taxes adjusted for the eight items above).
Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.

 17
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Explanation and Reconciliation of Non-GAAP Financial Measures
GAAP to Non-GAAP Reconciliation
(in millions, except per common share amounts)Operating EarningsOperating Earnings Growth RateEarnings Before Income TaxesProvision for Income Taxes
Net Earnings1
Net Earnings1 Growth Rate
Diluted EPS1
Diluted EPS1 Growth Rate
Three Months Ended March 31, 2024
GAAP$367 (36)%$341 $82 $258 (25)%$1.05 (22)%
Shareholder cooperation agreement costs1 1 — 1 — 
Restructuring and employee severance53 53 14 39 0.16 
Amortization and other acquisition-related costs80 80 21 59 0.24 
Impairments and (gain)/loss on disposal of assets, net 2
84 84 (21)105 0.44 
Litigation (recoveries)/charges, net 81 81 34 47 0.19 
Non-GAAP$666 10 %$640 $130 $509 14 %$2.08 20 %
Three Months Ended March 31, 2023
GAAP$572 N.M.$544 $197 $345 N.M.$1.34 N.M.
Restructuring and employee severance16 16 4 12 0.05 
Amortization and other acquisition-related costs74 74 19 55 0.21 
Impairments and (gain)/loss on disposal of assets, net
20 20 (69)89 0.35 
Litigation (recoveries)/charges, net(76)(76)(22)(54)(0.21)
Non-GAAP$606 11 %$578 $129 $447 11 %$1.74 20 %
Nine Months Ended March 31, 2024
GAAP
$835 42 %$805 $186 $616 90 %$2.49 N.M.
Shareholder cooperation agreement costs1 1 — 1 — 
Restructuring and employee severance106 106 28 78 0.32 
Amortization and other acquisition-related costs207 207 54 153 0.62 
Impairments and (gain)/loss on disposal of assets, net 2
622 622 92 530 2.14 
Litigation (recoveries)/charges, net29 29 17 12 0.05 
Non-GAAP
$1,799 20 %$1,769 $377 $1,389 24 %$5.62 33 %
Nine Months Ended March 31, 2023
GAAP$590 N.M.$517 $189 $325 N.M.$1.23 N.M.
State opioid assessment related to prior fiscal years(6)(6)(2)(4)0.02 
Shareholder cooperation agreement costs8 8 2 6 (0.02)
Restructuring and employee severance62 62 14 48 0.18 
Amortization and other acquisition-related costs216 216 56 160 0.61 
Impairments and (gain)/loss on disposal of assets, net 2
883 883 138 745 2.82 
Litigation (recoveries)/charges, net(256)(256)(98)(158)(0.60)
Non-GAAP$1,497 (3)%$1,424 $299 $1,122 (1)%$4.24 6 %
1     Attributable to Cardinal Health, Inc.
2    For the three and nine months ended March 31, 2024, impairments and (gain)/loss on disposal of assets, net includes pre-tax goodwill impairment charges of $90 million and $671 million, respectively, related to the GMPD segment. For fiscal 2024, the estimated net tax benefit related to the impairments is $56 million and is included in the annual effective tax rate. The incremental interim tax benefit recognized during the nine months ended March 31, 2024 is $36 million and will reverse in the fourth quarter of the fiscal year.
For the nine months ended March 31, 2023, impairments and (gain)/loss on disposal of assets, net included cumulative pre-tax goodwill impairment charges of $863 million related to the former Medical segment. For fiscal 2023, the net tax benefit related to the impairment was $68 million and was included in the annual effective tax rate. The incremental interim tax benefit recognized during the nine months ended March 31, 2023 was $66 million and reversed in the fourth quarter of fiscal 2023.
The sum of the components and certain computations may reflect rounding adjustments.
We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.


 18
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Other

Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in the quantitative and qualitative market risk disclosures included in our 2023 Form 10-K since the end of fiscal 2023 through March 31, 2024.
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of March 31, 2024. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of March 31, 2024, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 19
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Other
Legal Proceedings
The legal proceedings described in Note 7 of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.
Risk Factors
You should carefully consider the information in this Form 10-Q including the Risk Factors below and the risk factors discussed in "Risk Factors" and other risks discussed in our 2023 Form 10-K, our Forms 10-Q for the quarters ended December 31, 2023 and September 30, 2023, and our other filings with the SEC since June 30, 2023. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.
Changes to the U.S. healthcare environment may not be favorable to us.
Over a number of years, the U.S. healthcare industry has undergone significant changes designed to increase access to medical care, improve safety and patient outcomes, contain costs and increase efficiencies. These changes include a general decline in Medicare and Medicaid reimbursement levels, efforts by healthcare insurance companies to limit or reduce payments to pharmacies and providers, the basis for payments beginning to transition from a fee-for-service model to value-based payments and risk-sharing models and the industry shifting away from traditional healthcare venues like hospitals and into clinics, physician offices and patients’ homes.
We expect the U.S. healthcare industry to continue to change significantly in the future. Possible changes include changes in
legislation or regulations governing prescription pharmaceutical pricing, healthcare services, U.S.-based medical product manufacturing, mandated benefits, efforts to promote increased transparency in the pharmaceutical supply chain, drug shortages, further reduction of or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to further limit payments for products and services. For example, the Federal Trade Commission has issued public requests for information related to pharmaceutical wholesalers' and group purchasing organizations' impacts on generic drug shortages and the impact of pharmacy benefits managers on drug affordability and access. These possible changes, and the uncertainty surrounding these possible changes, may directly or indirectly adversely affect us.
Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
PeriodTotal Number
of Shares
Purchased (1)
Average Price Paid per Share
Total Number of Shares
Purchased
as Part of Publicly Announced Programs (2)
Approximate
Dollar Value of
Shares That May
Yet be Purchased
Under the Program (2)
(in millions)
January 2024106 $105.98 — $3,493 
February 2024157 107.33 — 3,493 
March 202451 110.14 — 3,493 
Total314 $107.33 — $3,493 
(1)Reflects 106, 157 and 51 common shares purchased in January, February, and March 2024, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.
(2)On June 7, 2023, our Board of Directors approved a new $3.5 billion share repurchase program, which will expire on December 31, 2027. As of March 31, 2024, we had $3.5 billion authorized for share repurchases remaining under this program.
Other Information
Rule 10b5-1 Plan Adoptions and Modifications
During the three months ended March 31, 2024, no director or officer adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule10b5-1 trading arrangement" as each term is defined in Section 408(a) of Regulation S-K under the Exchange Act.

 20
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Financial Statements

Condensed Consolidated Statements of Earnings
(Unaudited)
Three Months Ended March 31,Nine Months Ended March 31,
(in millions, except per common share amounts)2024202320242023
Revenue$54,911 $50,487 $167,119 $151,559 
Cost of products sold52,964 48,702 161,558 146,497 
Gross margin1,947 1,785 5,561 5,062 
Operating expenses:
Distribution, selling, general and administrative expenses1,282 1,179 3,762 3,567 
Restructuring and employee severance53 16 106 62 
Amortization and other acquisition-related costs80 74 207 216 
Impairments and (gain)/loss on disposal of assets, net84 20 622 883 
Litigation (recoveries)/charges, net81 (76)29 (256)
Operating earnings367 572 835 590 
Other (income)/expense, net(7)— (25)(5)
Interest expense, net33 28 55 78 
Earnings before income taxes341 544 805 517 
Provision for income taxes82 197 186 189 
Net earnings259 347 619 328 
Less: Net earnings attributable to noncontrolling interests(1)(2)(3)(3)
Net earnings attributable to Cardinal Health, Inc.$258 $345 $616 $325 
Earnings per common share attributable to Cardinal Health, Inc.:
Basic$1.06 $1.35 $2.51 $1.24 
Diluted1.05 1.34 2.49 1.23 
Weighted-average number of common shares outstanding:
Basic243256245263
Diluted245258247264
Cash dividends declared per common share$0.5006 $0.4957 $1.5018 $1.4871 
See notes to condensed consolidated financial statements.

 21
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Financial Statements
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended March 31,Nine Months Ended March 31,
(in millions)2024202320242023
Net earnings$259 $347 $619 $328 
Other comprehensive income/(loss):
Foreign currency translation adjustments and other1 4 (4)(34)
Net unrealized gain/(loss) on derivative instruments, net of tax(6)— (5)6 
Total other comprehensive income/(loss), net of tax(5)4 (9)(28)
Total comprehensive income254 351 610 300 
Less: comprehensive income attributable to noncontrolling interests(1)(2)(3)(3)
Total comprehensive income attributable to Cardinal Health, Inc.$253 $349 $607 $297 
See notes to condensed consolidated financial statements.


 22
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Financial Statements
Condensed Consolidated Balance Sheets
(in millions)March 31, 2024June 30, 2023
(Unaudited)
Assets
Current assets:
Cash and equivalents$3,718 $4,043 
Trade receivables, net11,566 11,344 
Inventories, net17,277 15,940 
Prepaid expenses and other3,161 2,362 
Assets held for sale12 144 
Total current assets35,734 33,833 
Property and equipment, net2,470 2,462 
Goodwill and other intangibles, net6,507 6,081 
Other assets1,169 1,041 
Total assets$45,880 $43,417 
Liabilities and Shareholders’ Deficit
Current liabilities:
Accounts payable$32,089 $29,813 
Current portion of long-term obligations and other short-term borrowings1,187 792 
Other accrued liabilities3,030 3,059 
Liabilities related to assets held for sale— 42 
Total current liabilities36,306 33,706 
Long-term obligations, less current portion4,667 3,909 
Deferred income taxes and other liabilities8,169 8,653 
Shareholders’ deficit:
Preferred shares, without par value:
Authorized—500 thousand shares, Issued—none
— — 
Common shares, without par value:
Authorized—755 million shares, Issued—327 million shares at March 31, 2024 and June 30, 2023
2,887 2,747 
Accumulated deficit(289)(534)
Common shares in treasury, at cost: 83 million shares and 76 million shares at March 31, 2024 and June 30, 2023, respectively
(5,703)(4,914)
Accumulated other comprehensive loss(160)(151)
Total Cardinal Health, Inc. shareholders' deficit(3,265)(2,852)
Noncontrolling interests3 1 
Total shareholders’ deficit(3,262)(2,851)
Total liabilities and shareholders’ deficit$45,880 $43,417 
See notes to condensed consolidated financial statements.


 23
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Financial Statements
Condensed Consolidated Statements of Shareholders' Deficit
(Unaudited)
Common Shares
Accumulated Deficit
Treasury SharesAccumulated Other
Comprehensive
Loss		Noncontrolling Interests
Total
Shareholders’ Deficit
(in millions)Shares IssuedAmountSharesAmount
Three Months Ended March 31, 2024
Balance at December 31, 2023327 $2,855 $(425)(83)$(5,724)$(155)$2 $(3,447)
Net earnings
258 1 259 
Other comprehensive loss, net of tax
(5)(5)
Employee stock plans activity, net of shares withheld for employee taxes— 32 — 21 53 
Dividends declared(123)(123)
Other1 1 
Balance at March 31, 2024327 $2,887 $(289)(83)$(5,703)$(160)$3 $(3,262)
Three Months Ended March 31, 2023
Balance at December 31, 2022327 $2,747 $(560)(68)$(4,254)$(146)$1 $(2,212)
Net earnings345 2 347 
Other comprehensive income, net of tax4 4 
Employee stock plans activity, net of shares withheld for employee taxes— 21 — 3 24 
Share repurchase program activity50 (4)(303)(253)
Dividends declared(128)(128)
Other1 (1)— 
Balance at March 31, 2023327 $2,818 $(342)(72)$(4,554)$(142)$2 $(2,218)
Nine Months Ended March 31, 2024
Balance at June 30, 2023327 $2,747 $(534)(76)$(4,914)$(151)$1 $(2,851)
Net earnings
616 3 619 
Other comprehensive loss, net of tax(9)(9)
Employee stock plans activity, net of shares withheld for employee taxes— 40 1 70 110 
Share repurchase program activity100 (9)(859)(759)
Dividends declared(372)(372)
Other1 1 (1)— 
Balance at March 31, 2024327 $2,887 $(289)(83)$(5,703)$(160)$3 $(3,262)
Nine Months Ended March 31, 2023
Balance at June 30, 2022327 $2,813 $(280)(54)$(3,128)$(114)$3 $(706)
Net earnings325 3 328 
Other comprehensive loss, net of tax(28)(28)
Purchase of noncontrolling interests
(2)(2)
Employee stock plans activity, net of shares withheld for employee taxes— 5 2 77 82 
Share repurchase program activity(20)(1,503)(1,503)
Dividends declared(388)(388)
Other1 (2)(1)
Balance at March 31, 2023327 $2,818 $(342)(72)$(4,554)$(142)$2 $(2,218)
See notes to condensed consolidated financial statements.

 24
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Financial Statements
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Nine Months Ended March 31,
(in millions)20242023
Cash flows from operating activities:
Net earnings
$619 $328 
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization524 516 
Impairments and (gain)/loss on disposal of assets, net622 883 
Share-based compensation88 69 
Provision for bad debts59 79 
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:
Increase in trade receivables(262)(510)
Increase in inventories(1,371)(1,012)
Increase in accounts payable2,276 2,473 
Other accrued liabilities and operating items, net(870)(845)
Net cash provided by operating activities1,685 1,981 
Cash flows from investing activities:
Acquisition of subsidiaries, net of cash acquired(1,192)(10)
Proceeds from divestitures, net of cash sold9 — 
Additions to property and equipment(318)(264)
Proceeds from disposal of property and equipment10 2 
Purchases of investments(3)(6)
Proceeds from investments1 1 
Proceeds from net investment hedge terminations28 29 
Purchases of short-term time deposits
(550)— 
Net cash used in investing activities(2,015)(248)
Cash flows from financing activities:
Proceeds from long-term obligations, net of issuance costs1,139 — 
Reduction of long-term obligations(23)(571)
Net tax proceeds from share-based compensation
23 11 
Dividends on common shares(377)(399)
Purchase of treasury shares(750)(1,500)
Net cash provided by/(used in) financing activities12 (2,459)
Effect of exchange rate changes on cash and equivalents(7)(1)
Net decrease in cash and equivalents(325)(727)
Cash and equivalents at beginning of period4,043 4,717 
Cash and equivalents at end of period$3,718 $3,990 
See notes to condensed consolidated financial statements.

 25
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements
Notes to Condensed Consolidated Financial Statements
1. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.
References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2024 and 2023 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts.
In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2024 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2024. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (our "2023 Form 10-K").
Major Customers
On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. Sales to OptumRx generated 16% of our consolidated revenue in fiscal 2023.
Recently Issued Financial Accounting Standards
and Disclosure Rules Not Yet Adopted
We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2023 Form 10-K.
Segment Reporting
In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in our fiscal 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Income Tax Disclosure
In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in our fiscal 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Climate-Related Disclosures
In March 2024, the SEC issued final rules on climate-related disclosures that will require annual disclosure of material climate-related risks and material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the rules require disclosure in the notes to the financial statements of the effects of severe weather events and other natural conditions, subject to certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates. These rules also require disclosure of climate risk oversight practices of the Board of Directors and management, and the disclosure of governance, risk management and strategy related to material climate-related risks. In April 2024, the SEC voluntarily stayed the new rules pending the completion of judicial review. The disclosure requirements, if ultimately upheld as adopted, will begin phasing in for reports and registration statements including financial information with respect to annual periods beginning in our fiscal 2026. We are currently evaluating the impact of adoption of these final rules on our disclosures.

 26
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements
Recently Adopted Financial Accounting Standards
There were no new material accounting standards adopted during the nine months ended March 31, 2024.
Updated Segment Reporting Structure
Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions segment and Global Medical Products and Distribution ("GMPD") segment. The remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics, are not significant enough to require separate reportable disclosures and are included in Other. The Pharmaceutical and Specialty Solutions reportable segment consists of all businesses formerly within our Pharmaceutical segment, excluding Nuclear and Precision Health Solutions. The Global Medical Products and Distribution reportable segment consists of all businesses formerly within our Medical segment, excluding at-Home Solutions and OptiFreight® Logistics. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change. See Note 13 for segment results under the new reporting structure.
2. Acquisitions
On March 18, 2024, we completed the acquisition of Specialty Networks for a purchase price of $1.2 billion in cash, subject to certain adjustments. Specialty Networks creates clinical and economic value for providers and partners across multiple specialty group purchasing organizations ("GPOs"): UroGPO, Gastrologix and GastroGPO, and United Rheumatology.
Specialty Networks’ PPS Analytics platform analyzes data from electronic medical records, practice management, imaging, and dispensing systems and transforms it into meaningful and actionable insights for providers and other stakeholders by using artificial intelligence and modern data analytics capabilities. The acquisition further expands our offering in key therapeutic areas, accelerates our upstream data and research opportunities with biopharma manufacturers, and creates a platform for our expansion across therapeutic areas.
The pro forma results of operations and the results of operations for Specialty Networks have not been separately disclosed because the effects were not significant compared to the condensed consolidated financial statements.
Transaction costs associated with the Specialty Networks acquisition were $15 million during the three and nine months ended March 31, 2024, and are included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings.
Fair Value of Assets Acquired and Liabilities Assumed
The allocation of the purchase price for the acquisition of Specialty Networks is not yet finalized and is subject to adjustment as we complete the valuation analysis of the acquisition. The purchase price is also subject to adjustment based on working capital requirements as set forth in the acquisition agreement.
The valuation of identifiable intangible assets utilizes significant unobservable inputs and thus represents a Level 3 nonrecurring fair value measurement. The estimated fair value of the identifiable intangible assets was determined using an income-based approach, which includes market participant expectations of the cash flows that an asset could generate over its remaining useful life, discounted back to present value using an appropriate rate of return. The discount rate used to arrive at the present value of the identifiable intangible assets was 10 percent, and reflects the internal rate of return and uncertainty in the cash flow projections.
The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date for Specialty Networks:
(in millions)
Specialty Networks
Identifiable intangible assets:
Customer relationships (1)
$404 
Trade names (2)
15 
Developed technology (3)
20 
Total identifiable intangible assets acquired
439 
Identifiable net assets/(liabilities):
Cash and equivalents
23 
Trade receivables, net
19 
Prepaid expenses and other
2 
Other accrued liabilities
(15)
Deferred income taxes and other liabilities
(109)
Total identifiable net assets/(liabilities) acquired
359 
Goodwill
856 
Total net assets acquired
$1,215 
(1)    The weighted-average useful life of customer relationships is 14 years.
(2)    The weighted-average useful life of trade names is 8 years.
(3)    The weighted-average useful life of developed technology is 9 years.


 27
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements
3. Divestitures
On June 5, 2023 we signed a definitive agreement to contribute the OutcomesTM business to Transaction Data Systems ("TDS"), a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. The transaction closed on July 10, 2023 and we recognized a pre-tax gain of $53 million during the nine months ended March 31, 2024, which was included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This gain includes our initial recognition of an equity method investment in the combined entity for $147 million.
We determined that the divestiture of the OutcomesTM business does not meet the criteria to be classified as discontinued operations. The OutcomesTM business operated within our former Pharmaceutical segment.

4. Restructuring and Employee Severance
The following tables summarize restructuring and employee severance:
Three Months Ended March 31,
(in millions)20242023
Employee-related$36 $3 
Facility exit and other17 13 
Total restructuring and employee severance$53 $16 
Nine Months Ended March 31,
(in millions)20242023
Employee-related$51 $32 
Facility exit and other55 30 
Total restructuring and employee severance$106 $62 

Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional, project management and other service fees to support divestitures, costs associated with vacant facilities, and certain other divestiture-related costs.
Restructuring and employee severance costs during the three and nine months ended March 31, 2024 and 2023 include costs related to the implementation of certain enterprise-wide cost-savings measures, which include certain initiatives to rationalize our manufacturing operations. The increase in restructuring costs during the three and nine months ended March 31, 2024 was primarily due to these initiatives and certain projects resulting from the review of our strategy portfolio, capital-allocation framework and operations. During the three and nine months ended March 31, 2023, restructuring and employee severance costs also included costs related to the divestiture of the Cordis business.
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)Employee-
Related Costs		Facility Exit
and Other Costs		Total
Balance at June 30, 2023$44 $2 $46 
Additions38 13 51 
Payments and other adjustments(21)(6)(27)
Balance at March 31, 2024$61 $9 $70 

 28
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements

5. Goodwill and Other Intangible Assets
Goodwill
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions)Pharmaceutical and Specialty SolutionsGlobal Medical Products and Distribution (1)
Other (2) (3)
Total
Balance at June 30, 2023 (4)
$2,762 $677 $1,170 $4,609 
Goodwill acquired, net of purchase price adjustments856 (3)— 853 
Foreign currency translation adjustments and other— (3)— (3)
Goodwill impairment— (671)— (671)
Balance at March 31, 2024$3,618 $— $1,170 $4,788 
(1) Prior-period goodwill impairment charges related to the former Medical segment were allocated to the GMPD segment. At March 31, 2024 and June 30, 2023, the GMPD segment accumulated goodwill impairment loss was $5.4 billion and $4.7 billion, respectively.
(2) Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics.
(3) Reflects $48 million allocated to OptiFreight® Logistics.
(4) Reflects a $110 million reclassification between Pharmaceutical and Specialty Solutions and Other, which does not impact our previously reported condensed consolidated financial statements or results of our impairment tests.
The increase in the Pharmaceutical and Specialty Solutions segment goodwill is due to the Specialty Networks acquisition. Goodwill recognized in connection with this acquisition primarily represents the expected benefits from anticipated growth from new technology capabilities, synergies of integrating this business and the existing workforce of the acquired entity.
As a result of the segment change discussed in Note 1, we allocated $90 million and $48 million of goodwill from the former Medical Unit to GMPD and OptiFreight® Logistics, respectively, based on the estimated relative fair values of the reporting units. We also assessed goodwill for impairment for these reporting units before and after the reallocation and determined there was no impairment for the Medical Unit and OptiFreight® Logistics during the three months ended March 31, 2024 as their fair values substantially exceeded their carrying values. However, the quantitative test resulted in an impairment of GMPD’s remaining goodwill balance of $90 million.
Our determination of the estimated fair value of the GMPD reporting unit is based on a combination of the income-based approach (using a discount rate of 11 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public
company method, and 10 percent to the guideline transaction method.
During the three months ended December 31, 2023, we did not identify any indicators of impairment within our reporting units. During the three months ended September 30, 2023, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the former Medical Unit due to an increase in the risk-free interest rate used in the discount rate. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $581 million for the former Medical Unit, which was recognized during the three months ended September 30, 2023 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This impairment charge was driven by an increase of 1 percent in the discount rate primarily due to an increase in the risk-free interest rate.
During the three months ended December 31, 2022 and September 30, 2022, we performed quantitative goodwill impairment testing for the former Medical Unit. This quantitative testing resulted in the carrying amount of the former Medical Unit exceeding the fair value, resulting in pre-tax goodwill impairment charges of $709 million and $154 million recorded during the three months ended December 31, 2022 and September 30, 2022, respectively. We also performed interim quantitative goodwill impairment testing at March 31, 2023 and concluded that there was no impairment as of March 31, 2023 as the estimated fair value of the former Medical Unit exceeded its carrying value by approximately 4 percent. The impairment charge recognized in the second quarter of fiscal 2023 was driven by certain reductions in our long-term financial plan assumptions, and the impairment charge recognized in the first quarter of fiscal 2023 was driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate.

 29
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements

Other Intangible Assets
The following tables summarize other intangible assets by class at:
March 31, 2024
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible		Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents$11 $— $11 N/A
Total indefinite-life intangibles11 — 11 N/A
Definite-life intangibles:
Customer relationships3,564 2,387 1,177 10
Trademarks, trade names and patents561 401 160 7
Developed technology and other1,043 672 371 7
Total definite-life intangibles5,168 3,460 1,708 9
Total other intangible assets$5,179 $3,460 $1,719 N/A
June 30, 2023
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible
Indefinite-life intangibles:
Trademarks and patents$11 $— $11 
Total indefinite-life intangibles11 — 11 
Definite-life intangibles:
Customer relationships3,174 2,274 900 
Trademarks, trade names and patents546 380 166 
Developed technology and other1,021 626 395 
Total definite-life intangibles4,741 3,280 1,461 
Total other intangible assets$4,752 $3,280 $1,472 
The increase in definite-life intangibles is due to the Specialty Networks acquisition. Total amortization of intangible assets was $64 million and $69 million for the three months ended March 31, 2024 and 2023, respectively, and $191 million and $211 million for the nine months ended March 31, 2024 and 2023, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2024 through 2028 is as follows: $69 million, $256 million, $241 million, $213 million and $186 million.
6. Long-Term Obligations and Other Short-Term Borrowings
The following table summarizes long-term obligations and other short-term borrowings at:
(in millions) (1)March 31, 2024June 30, 2023
3.079% Notes due 2024$753 $764 
3.5% Notes due 2024402 404 
3.75% Notes due 2025508 513 
3.41% Notes due 20271,192 1,184 
5.125% Notes due 2029644 — 
5.45% Notes due 2034494 — 
4.6% Notes due 2043311 306 
4.5% Notes due 2044330 331 
4.9% Notes due 2045428 428 
4.368% Notes due 2047564 561 
7.0% Debentures due 2026124 124 
Other Obligations104 86 
Total5,854 4,701 
Less: current portion of long-term obligations and other short-term borrowings1,187 792 
Long-term obligations, less current portion$4,667 $3,909 
(1)    Maturities are presented on a calendar year basis.
Maturities of existing long-term obligations and other short-term borrowings for the remainder of fiscal 2024 through 2028 and thereafter are as follows: $762 million, $436 million, $535 million, $1.3 billion, $11 million and $2.8 billion.
Long-Term Debt
We had total long-term obligations, including the current portion and other short-term borrowings, of $5.9 billion and $4.7 billion at March 31, 2024 and June 30, 2023, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $32.1 billion and $29.8 billion at March 31, 2024 and June 30, 2023, respectively.
In February 2024, we issued additional debt with the aggregate principal amount of $1.15 billion to fund the repayment of all of the aggregate principal amount outstanding of our 3.5% Notes due 2024 and 3.079% Notes due 2024, at their respective maturities, and for general corporate purposes. The notes issued are $650 million aggregate principal amount of 5.125% Notes that mature on February 15, 2029 and $500 million aggregate principal amount of 5.45% Notes that mature on February 15, 2034. The proceeds of the notes issued, net of discounts, premiums, and debt issuance costs, were $1.14 billion. A portion of the proceeds were invested in short-term time deposits of $550 million with initial effective maturities of more than three months and classified as prepaid

 30
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements

expenses and other in our condensed consolidated balance sheets as of March 31, 2024. The remaining proceeds of $589 million were invested in short-term time deposits classified as cash and equivalents in our condensed consolidated balance sheets as of March 31, 2024.
If we undergo a change of control, as defined in the notes, and if the notes receive specified ratings below investment grade by each of Standard & Poor's Ratings Services, Moody’s Investors Services and Fitch Ratings, any holder of the notes, excluding the debentures, can require with respect to the notes owned by such holder, or we can offer, to repurchase the notes at 101% of the principal amount plus accrued and unpaid interest.
Other Financing Arrangements
In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. During the nine months ended March 31, 2024, under our commercial paper program and our committed receivables program, we had maximum combined total daily amounts outstanding of $1.3 billion and an average combined daily amount outstanding of $25 million. At March 31, 2024, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility.
In February 2023, we extended our $2.0 billion revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2025. In September 2023, Cardinal Health 23 Funding, LLC ("CH-23 Funding") was added as a seller under our committed receivables sales facility. Each of CHF and CH-23 Funding was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, each of CHF and CH-23 Funding is a separate legal entity from Cardinal Health, Inc. and from our respective subsidiary that sells receivables to CHF or CH-23 Funding, as applicable. Each of CHF and CH-23 Funding is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its respective creditors.
Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of March 31, 2024, we were in compliance with this financial covenant.
7. Commitments, Contingent Liabilities and Litigation
Commitments
Generic Sourcing Venture with CVS Health
In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.
Contingencies
New York Opioid Stewardship Act
In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018).
We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. During the fiscal year 2023, we recorded $6 million of income to reduce the previously estimated accrual to the invoiced amount for the calendar year 2018 assessment. At June 30, 2023, we had an outstanding liability of $3 million, which was paid in full during the first quarter of fiscal year 2024.
Legal Proceedings
We become involved from time to time in disputes, litigation and regulatory matters.
From time to time, we determine that products we distribute, source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, restrictions on importation, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.
From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and

 31
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements
abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.
We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.
We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.
We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit.
Opioid Lawsuits and Investigations
Cardinal Health, other Pharmaceutical wholesalers and other participants in the pharmaceutical supply chain have been named as a defendant in lawsuits related to the distribution of opioid pain medications. These lawsuits seek equitable relief and monetary damages based on a variety of legal theories, including various common law claims, such as public nuisance, negligence, unjust enrichment, personal injury, as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organization Act and various other statutes. Plaintiffs in these lawsuits include governmental entities as well as private parties, such as unions and other health and welfare funds, hospital
system and other healthcare providers, businesses and individuals.
Additionally, we have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information, subpoenas and other requests from other DOJ offices. These investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcomes of any of these investigations.
In total, as of March 31, 2024, we have $5.3 billion accrued for these matters, of which $438 million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During the three months ended March 31, 2024, we recognized expense of $193 million in connection with opioid-related matters, which was partially offset by a benefit of $105 million related to prepayments at a prenegotiated discount of certain future payments totaling $344 million.
Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgements about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of the settlements described below is an admission of liability or wrong-doing. Please see below for additional description of these matters.
States & Political Subdivisions
In February 2022, we along with two other national distributors (collectively, the "Distributors") independently approved a settlement agreement (the "National Opioid Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and political subdivisions. This National Opioid Settlement Agreement became effective on April 2, 2022. In addition to the Distributors, parties to the National Opioid Settlement Agreement include 48 states, the District of Columbia and 5 U.S. territories. Over 99 percent of political subdivisions in settling states (by population as calculated under the National Opioid Settlement Agreement) that had brought opioid-related suits against us have chosen to join the National Opioid Settlement Agreement or have had their claims addressed by state legislation (together with settling states and territories, the "Settling Governmental Entities").
In February 2024, we finalized an agreement with the Alabama Attorney General, under which we agreed to pay approximately

 32
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements
$123 million to the State of Alabama over a period of ten years to resolve opioid-related claims brought by the State and its political subdivisions. This agreement is subject to certain contingencies, including subdivision participation. During the nine months ended March 31, 2024, we recognized a $22 million charge in litigation (recoveries)/charge, net in the condensed consolidated statements of earnings related to this agreement.
Through April 2024, we have paid the Settling Governmental Entities approximately $1.5 billion, which includes the January 2024 prepayment of certain future payment amounts described below. We expect to pay Settling Governmental Entities additional amounts up to $4.8 billion through 2038. The National Opioid Settlement Agreement also includes injunctive relief terms related to Distributors' controlled substance anti-diversion programs. A monitor is overseeing compliance with these provisions until 2027. In addition, the Distributors are engaging a third-party vendor to act as a clearinghouse for data aggregation and reporting, which Distributors will fund for 10 years. As a result of the National Opioid Settlement Agreement, the vast majority of lawsuits brought against us by State and other political subdivisions have been dismissed. We continue to engage in resolution discussions with certain nonparticipating political subdivisions. A trial in the case brought by the city of Baltimore, which is the largest remaining nonparticipating subdivision by population, is scheduled to begin in September 2024. We intend to defend ourselves vigorously against all remaining lawsuits.
Other Settlements
West Virginia subdivisions and Native American tribes were not a part of the National Opioid Settlement Agreement, and we had separate settlement negotiations with these groups. In July 2022, a judgment in favor of the Distributors was entered in bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington. Plaintiffs have appealed this decision to the Fourth Circuit Court of Appeals. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $124 million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.
In October 2022, we executed a final settlement agreement with the Native American tribes, pursuant to which we will pay up to approximately $136 million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases.
Prepayment of Future Payment Years
In January 2024, we made payments of approximately $239 million to prepay at a prenegotiated discount of certain future payment amounts totaling approximately $344 million owed under each of the National Opioid Settlement Agreement, West Virginia Subdivisions Settlement Agreement and settlement agreements with Native American tribes and Cherokee Nation. The majority of
the prepayment relates to the seventh annual payment as due under the National Opioid Settlement Agreement. As a result of these prepayments, we recognized income of approximately $105 million in litigation charges/(recoveries), net in our condensed consolidated statements of earnings during the three months ended March 31, 2024.
Private Plaintiffs
The National Opioid Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Lawsuits brought by private plaintiffs that were pending as of April 26, 2024 were approximately 380. Of these, 103 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are engaged in resolution discussions with certain private plaintiffs and have reached agreements in principle with counsel representing classes of third-party payors and acute care hospitals and have accrued $213 million in connection with those matters, which represents our anticipated share of those possible settlements. The agreements in principle remain subject to contingencies. We are vigorously defending ourselves in all these matters.
A trial in a case involving 21 plaintiffs began in state court in Georgia in January 2023 and concluded in March 2023 with a verdict for the company and other defendants on all claims. In July 2023, the judge denied the plaintiffs' motion for a new trial. Plaintiffs have filed a notice of appeal and defendants have filed a notice of cross-appeal. A trial involving eight hospital plaintiffs is scheduled to begin in Alabama in July 2024.
Insurance Litigation
We are involved in ongoing legal proceedings with insurers related to their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. During fiscal year 2023, we received approximately $10 million in insurance recoveries related to these matters.
Department of Justice Civil Investigative Demand
In November 2023, we received a Civil Investigative Demand ("CID") from the Department of Justice focused on potential violations of the Anti-Kickback Statute and False Claims Act in connection with a 2022 transaction in which we purchased a minority ownership interest in a rheumatology managed services organization and a group purchasing organization. We are cooperating with this investigation.
Cordis IVC Filter Matters
We have been named as a defendant in approximately 400 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 4,500 plaintiffs that allege personal injuries associated with the use of inferior vena cava ("IVC") filter products. These lawsuits sought a variety of remedies, including unspecified monetary damages. The divestiture of the Cordis business did not include product liability

 33
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements
related to the IVC filters in the U.S. and Canada, which we retained.
In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve 4,375 claims for $275 million. This settlement agreement is subject to certain conditions, including certain opt-in thresholds. Between May and September 2023, we made settlement payments totaling $275 million into a qualified settlement fund, which will be disbursed to the plaintiffs if required conditions are satisfied. Since July 2021, we have also entered into other agreements to settle approximately 2,800 product liability claims. While these settlements will resolve the vast majority of IVC filter product liability claims, they will not resolve all of them and we intend to continue to vigorously defend ourselves in the remaining lawsuits.
We recognized income of $103 million during fiscal year 2023, primarily related to a reduction of the reserve for the estimated settlement and defense costs for these matters due to the execution of the settlements noted above. At March 31, 2024, we had a total of $296 million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets.
Other Civil Litigation
Generic Pharmaceutical Pricing Antitrust Litigation
In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the amended complaint. We are vigorously defending ourselves in this matter.
Antitrust Litigation Proceeds
We recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $6 million and $77 million during the three and nine months ended March 31, 2024, respectively, and $66 million during the nine months ended March 31, 2023.




8. Income Taxes
Fluctuations in our provision for income taxes as a percentage of pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.
Effective Tax Rate
During the three and nine months ended March 31, 2024, the effective tax rate was 24.2 percent and 23.2 percent, respectively, and reflects any impact of the tax effects of the goodwill impairment charges recognized during the three and nine months ended March 31, 2024.
During the three and nine months ended March 31, 2023, the effective tax rate was 36.3 percent and 36.7 percent, respectively, and reflects the impact of the tax effect of the goodwill impairment charges recognized during the nine months ended March 31, 2023.
Tax Effects of Goodwill Impairment Charges
During the nine months ended March 31, 2024, we recognized pre-tax goodwill impairment charges of $671 million. The net tax benefit related to these charges is $56 million for fiscal 2024.
Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.
The tax effect of the goodwill impairment charges during the nine months ended March 31, 2024 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to the pre-tax income for the nine months ended March 31, 2024 resulted in recognizing an incremental interim tax benefit of approximately $36 million, which impacted the provision for income taxes in the condensed consolidated statements of earnings during the nine months ended March 31, 2024 and prepaid expenses and other assets in the condensed consolidated balance sheet at March 31, 2024. The incremental interim tax benefit will reverse in the fourth quarter of fiscal 2024.
Unrecognized Tax Benefits
We had $937.0 million and $1.0 billion of unrecognized tax benefits, at March 31, 2024 and June 30, 2023, respectively. The March 31, 2024 and June 30, 2023 balances include $850 million and $873 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate.
At March 31, 2024 and June 30, 2023, we had $57 million and $65 million, respectively, accrued for the payment of interest and

 34
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements
penalties related to unrecognized tax benefits, which we recognize in the benefit from income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $20 million, exclusive of penalties and interest.
Other Tax Matters
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.
We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. In December 2023, the estimated tax exposure was updated to reflect adjustments based on settlement discussions with the IRS. Additionally, Cardinal received a partial payment from CareFusion to be applied towards the anticipated liability. The indemnification receivable was $20 million and $82 million at March 31, 2024 and June 30, 2023, respectively, and is included in other assets in the condensed consolidated balance sheets.

9. Fair Value Measurements
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
March 31, 2024
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$2,013 $— $— $2,013 
Other investments (1)105 — — 105 
Liabilities:
Forward contracts (2)— (70)— (70)
June 30, 2023
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,253 $— $— $1,253 
Other investments (1)101 — — 101 
Liabilities:
Forward contracts (2)— (73)— (73)
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2)The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
Assets Measured on a Nonrecurring Basis
As discussed further in Note 3, on July 10, 2023, we closed the transaction to contribute the Outcomes™ business to TDS, a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. We accounted for this investment initially at its fair value using Level 3 unobservable inputs under the discounted cash flow method. Accordingly, we recognized a $147 million equity method investment at closing during the first quarter of fiscal 2024.
10. Financial Instruments
We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk but are not designated as hedging instruments. These derivative instruments are adjusted to current

 35
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements
fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.
Interest Rate Risk Management
We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.
Currency Exchange Risk Management
We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.
Commodity Price Risk Management
We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.
Fair Value Hedges
We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three and nine months ended March 31, 2024 and 2023, there were no gains or losses recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.
During the nine months ended March 31, 2024 and 2023, we entered into pay-floating interest rate swaps with total notional amounts of $500 million and $200 million, respectively. These
swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.
Cash Flow Hedges
We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.
Pre-tax gains recognized in other comprehensive income/(loss) were $1 million and $2 million for the three months ended March 31, 2024 and 2023, respectively, and $2 million and $4 million for the nine months ended March 31, 2024 and 2023, respectively. Gains recognized in accumulated other comprehensive loss and reclassified into earnings were $2 million and $4 million for the three months ended March 31, 2024 and 2023, respectively, and $4 million and $8 million for the nine months ended March 31, 2024 and 2023, respectively. Gains currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are $3 million.
Net Investment Hedges
We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.
In September 2023, we entered into ¥18 billion ($120 million) cross-currency swaps maturing in September 2025 and ¥18 billion ($120 million) cross-currency swaps maturing in June 2027.
In September 2023, we terminated the ¥38 billion ($300 million) cross-currency swaps entered into in January 2023 and received net settlement in cash of $28 million, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows.
In January 2023, we entered into ¥19 billion ($150 million) cross-currency swaps maturing in September 2025 and ¥19 billion ($150 million) cross-currency swaps maturing in June 2027. In March 2023, we entered into €100 million ($107 million) cross-currency swaps maturing in March 2025 and €100 million ($107 million) cross-currency swaps maturing in March 2026.
In January and March 2023, we terminated the ¥48 billion ($400 million) cross-currency swaps entered into in March 2022 and the €200 million ($233 million) cross-currency swap entered into in September 2018, respectively, and received net settlements of $10 million and $19 million in cash, respectively, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows.

 36
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements
Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.
Pre-tax gains and losses from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive income/(loss) were a $19 million gain and an immaterial loss during the three months ended March 31, 2024 and 2023, respectively, and a $14 million gain and a $21 million loss during the nine months ended March 31, 2024 and 2023, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $3 million and $4 million during the three months ended March 31, 2024 and 2023, respectively, and $10 million and $12 million during the nine months ended March 31, 2024 and 2023, respectively.
Economic (Non-Designated) Hedges
We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded an immaterial gain and an immaterial loss during the three months ended March 31, 2024 and 2023, respectively, and an immaterial loss and a $3 million loss during the nine months ended March 31, 2024 and 2023, respectively. The principal currencies managed through foreign currency contracts are Chinese renminbi, Canadian dollar, Indian rupee, Euro and British pound.
Fair Value of Financial Instruments
The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at March 31, 2024 and June 30, 2023 approximate fair value due to their short-term maturities.
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
(in millions)March 31, 2024June 30, 2023
Estimated fair value$5,650 $4,417 
Carrying amount5,854 4,701 
The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.
11. Shareholders' Deficit
We repurchased $750 million and $1.5 billion of our common shares, in the aggregate, through share repurchase programs during the nine months ended March 31, 2024 and 2023, respectively. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.
During the three months ended December 31, 2023, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.0 million common shares using a reference price of $101.66. The program concluded on December 13, 2023 at a volume weighted average price per common share of $103.67 resulting in a final delivery of 0.4 million common shares.
During the three months ended September 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 4.4 million common shares using a reference price of $90.57. The program concluded on October 31, 2023 at a volume weighted average price per common share of $88.22 resulting in a final delivery of 1.3 million common shares.
During the three months ended June 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase of $500 million. We received an initial delivery of 4.6 million common shares using a reference price of $87.18. The program concluded on August 16, 2023 at a volume weighted average price per common share of $91.15 resulting in a final delivery of 0.9 million common shares.
During the three months ended March 31, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.6 million common shares using a reference price of $77.03. The program concluded on February 28, 2023 at a volume weighted average price per common share of $77.27 resulting in a final delivery of 0.6 million common shares.
During the three months ended December 31, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial

 37
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements

delivery of 2.6 million common shares using a reference price of $76.58. The program concluded on January 13, 2023 at a volume weighted average price per common share of $77.50 resulting in a final delivery of 0.6 million common shares.
During the three months ended September 30, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $1.0 billion. We received an initial delivery of 12.0 million common shares using a reference price of $66.74. The program concluded on December 23, 2022 at a volume weighted average price per common share of $73.36 resulting in a final delivery of 1.6 million common shares.
Accumulated Other Comprehensive Loss
The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2023$(137)$(14)$(151)
Other comprehensive income/(loss), before reclassifications(4)1 (3)
Amounts reclassified to earnings— (6)(6)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $4 million
(4)(5)(9)
Balance at March 31, 2024$(141)$(19)$(160)
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2022$(102)$(12)$(114)
Other comprehensive income/(loss), before reclassifications(34)15 (19)
Amounts reclassified to earnings— (9)(9)
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax benefit of $5 million
(34)6 (28)
Balance at March 31, 2023$(136)$(6)$(142)

12. Earnings Per Share Attributable to Cardinal Health, Inc.
The following tables reconcile the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:
Three Months Ended March 31,
(in millions)20242023
Weighted-average common shares–basic243 256 
Effect of dilutive securities:
Employee stock options, restricted share units and performance share units2 2 
Weighted-average common shares–diluted245 258 
Nine Months Ended March 31,
(in millions)20242023
Weighted-average common shares–basic245 263 
Effect of dilutive securities:
Employee stock options, restricted share units and performance share units2 1 
Weighted-average common shares–diluted247 264 
The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were immaterial and 1 million for the three and nine months ended March 31, 2024, respectively, and 2 million for both the three and nine months ended March 31, 2023.

13. Segment Information
Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions segment and GMPD segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change.
Our Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for

 38
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements


specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over the counter healthcare products.
Our GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada.
The remaining three operating segments included in Other are Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics. These operating segments respectively operate nuclear pharmacies and radiopharmaceutical manufacturing facilities, distribute medical products to patients' homes in the United States and provide supply chain services and solutions to our customers.
Revenue
The following tables present revenue for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
Three Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions$50,651 $46,496 
Global Medical Products and Distribution3,113 2,989 
Nuclear and Precision Health Solutions352 313 
at-Home Solutions
743 651 
OptiFreight® Logistics
72 61 
Other
1,167 1,025 
Total segment revenue54,931 50,510 
Corporate (1)
(20)(23)
Total revenue$54,911 $50,487 

Nine Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions$154,524 $139,441 
Global Medical Products and Distribution9,264 9,140 
Nuclear and Precision Health Solutions1,006 875 
at-Home Solutions
2,188 1,986 
OptiFreight® Logistics
198 177 
Other
3,392 3,038 
Total segment revenue167,180 151,619 
Corporate (1)
(61)(60)
Total revenue$167,119 $151,559 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

The following tables present revenue by geographic area:
Three Months Ended March 31,
(in millions)20242023
United States$53,715 $49,343 
International1,216 1,167 
 Total segment revenue54,931 50,510 
Corporate (1)(20)(23)
Total revenue$54,911 $50,487 
Nine Months Ended March 31,
(in millions)20242023
United States$163,548 $148,186 
International3,632 3,433 
Total segment revenue167,180 151,619 
Corporate (1)(61)(60)
Total revenue$167,119 $151,559 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit
We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate technology and shared function expenses, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the operating segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.

 39
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements


We do not allocate the following items to our segments:
•last-in first-out, or ("LIFO"), inventory charges/(credits);
•state opioid assessment related to prior fiscal years;
•shareholder cooperation agreement costs;
•restructuring and employee severance;
•amortization and other acquisition-related costs;
•impairments and (gain)/loss on disposal of assets, net; in connection with goodwill impairment testing for the GMPD segment as discussed further in Note 5, we recognized pre-tax goodwill impairment charges of $90 million during the three months ended March 31, 2024 and $671 million and $863 million during the nine months ended March 31, 2024 and 2023, respectively;
•litigation (recoveries)/charges, net;
•other (income)/expense, net;
•interest expense, net;
•loss on early extinguishment of debt; or
•provision for/(benefit from) income taxes
In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $17 million and $9 million for the three months ended March 31, 2024 and 2023, respectively, and $37 million and $20 million for the nine months ended March 31, 2024 and 2023, respectively.
The following tables present segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
Three Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions
$580 $560 
Global Medical Products and Distribution
20 (46)
Other (1)111 106 
Total segment profit711 620 
Corporate(344)(48)
Total operating earnings
$367 $572 

Nine Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions
$1,541 $1,394 
Global Medical Products and Distribution
18 (175)
Other (1)319 305 
Total segment profit1,878 1,524 
Corporate(1,043)(934)
Total operating earnings
$835 $590 
(1)Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics.
Segment Assets
The following table presents total assets for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
(in millions)March 31,
2024		June 30,
2023
Pharmaceutical and Specialty Solutions
$30,496 $27,615 
Global Medical Products and Distribution
7,357 7,961 
Other (1)2,692 2,621 
Corporate 5,335 5,220 
Total assets$45,880 $43,417 
(1)Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics.

14. Share-Based Compensation
We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees.
The following tables provide total share-based compensation expense by type of award:
Three Months Ended March 31,
(in millions)20242023
Restricted share unit expense$20 $17 
Performance share unit expense11 4 
Total share-based compensation
$31 $21 
Nine Months Ended March 31,
(in millions)20242023
Restricted share unit expense$58 $49 
Performance share unit expense30 20 
Total share-based compensation
$88 $69 
The total tax benefit related to share-based compensation was $4 million and $3 million for the three months ended March 31, 2024 and 2023, respectively, and $12 million and $9 million for the nine months ended March 31, 2024 and 2023, respectively.
Restricted Share Units
Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units

 40
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Notes to Financial Statements

accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)Restricted Share UnitsWeighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20232.2 $57.37 
Granted0.9 90.78 
Vested(1.1)60.83 
Canceled and forfeited(0.1)71.21 
Nonvested at March 31, 20241.9 $69.96 
At March 31, 2024, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $86 million, which is expected to be recognized over a weighted-average period of two years.
Performance Share Units
Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 234 percent of the target award amount for both the fiscal 2022 and 2023 grants and zero to 240 percent of the target award for the fiscal 2024 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)Performance
Share Units		Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20231.2 $82.17 
Granted0.5 94.66 
Vested(0.4)62.26 
Canceled and forfeited— — 
Nonvested at March 31, 20241.3 $96.80 
At March 31, 2024, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $53 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.



 41
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Exhibits
Exhibits
Exhibit
Number		Exhibit Description
3.1
3.2
10.1.1
10.1.2
10.1.3
10.1.4
10.2
31.1
31.2
32.1
99.1
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)
Cardinal Health Website
Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases, SEC filings and certain other information on its website.

 42
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Form 10-Q Cross Reference Index


Form 10-Q Cross Reference Index
N/ANot applicable



 43
Cardinal Health | Q3 Fiscal 2024 Form 10-Q


Additional Information
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Cardinal Health, Inc.
Date:May 2, 2024/s/ JASON M. HOLLAR
Jason M. Hollar
Chief Executive Officer
/s/ AARON E. ALT
Aaron E. Alt
Chief Financial Officer


 44
Cardinal Health | Q3 Fiscal 2024 Form 10-Q

 EX-10.1 1 2 a10-qex1011xltiamendment.htm EX-10.1 1 Document
Exhibit 10.1.1
FIRST AMENDMENT TO THE
CARDINAL HEALTH, INC. 2021 LONG-TERM INCENTIVE PLAN

This First Amendment to the Cardinal Health, Inc. 2021 Long-Term Incentive Plan (the “Plan”) was adopted on January 29, 2024 by the Human Resources and Compensation Committee of the Board of Directors of Cardinal Health, Inc. (the “Company”).

The Plan is hereby amended, effective as of January 29, 2024, as follows:

1.Section 20 of the Plan is hereby deleted in its entirety and in replacement thereof shall be the following:

“20. Clawback Policy.

To the extent applicable, Participants and Awards will be subject to the terms of the Cardinal Health, Inc. Clawback Policy adopted by the Company, as required by New York Stock Exchange listing standards and as may be in effect from time to time. In its discretion, moreover, the Administrator may require repayment to the Company of all or any portion of any Award if the amount of the Award was calculated based upon the achievement of financial results that were subsequently the subject of a restatement of the Company’s financial statements, the Participant engaged in misconduct that caused or contributed to the need for the restatement of the financial statements, and the amount payable to the Participant would have been lower than the amount actually paid to the Participant had the financial results been properly reported. This Section 20 will not be the Company’s exclusive remedy with respect to such matters.

 EX-10.1 2 3 aex1012formofnqsoagreement.htm EX-10.1 2 Document
Exhibit 10.1.2
CARDINAL HEALTH, INC.
NONQUALIFIED STOCK OPTION AGREEMENT
This Nonqualified Stock Option Agreement (this “Agreement”) is entered into in Franklin County, Ohio. On [date of grant] (the “Grant Date”), Cardinal Health, Inc., an Ohio corporation (the “Company”), has awarded to [employee name] (“Awardee”), a Nonqualified Stock Option (the “Option”) to purchase [# of shares] common shares, without par value, of the Company (the “Shares”) for an exercise price of [$X.XX] per share. The Option has been granted under the Cardinal Health, Inc. 2021 Long-Term Incentive Plan, as amended (the “Plan”), and will include and be subject to all provisions of the Plan, all of which are incorporated in this Agreement by reference and will be subject to the provisions of this Agreement. Capitalized terms used in this Agreement which are not specifically defined will have the meanings ascribed to such terms in the Plan. [CLIFF ALTERNATIVE: This Option vests and becomes exercisable on the [ ] anniversary of the Grant Date (the “Vesting Date”), subject to the provisions of this Agreement, including those relating to Awardee’s continued employment with the Company and its Affiliates (collectively, the “Cardinal Group”).] [INSTALLMENT ALTERNATIVE: This Option vests and becomes exercisable in [ ] installments, which will be as nearly equal as possible, on the [ ] anniversaries of the Grant Date (each a “Vesting Date” with respect to the portion of the Option scheduled to vest on such date), subject in each case to the provisions of this Agreement, including those relating to Awardee’s continued employment with the Company and its Affiliates (collectively, the “Cardinal Group”).] This Option will expire on [date of expiration] (the “Grant Expiration Date”), subject to Section 3 hereof.

1.Method of Exercise and Payment of Price.
(a)Method of Exercise. At any time when all or a portion of the Option is exercisable under the Plan and this Agreement, some or all of the exercisable portion of the Option may be exercised from time to time by written notice to the Company, or such other method of exercise as may be specified by the Company, including without limitation, exercise by electronic means on the web site of the Company’s third-party equity plan administrator, which will:
(i)state the number of whole Shares with respect to which the Option is being exercised; and
(ii)if the Option is being exercised by anyone other than Awardee, if not already provided, be accompanied by proof satisfactory to counsel for the Company of the right of such person or persons to exercise the Option under the Plan and all applicable laws and regulations.
(b)Payment of Price. The full exercise price for the portion of the Option being exercised shall be paid to the Company as provided below:
(i)in cash;
(ii)by check acceptable to the Company or wire transfer (denominated in U.S. Dollars);
(iii)subject to any conditions or limitations established by the Administrator, other Shares owned by Awardee that have a Fair Market Value on the date of surrender equal to or greater than the aggregate exercise price of the Shares as to which said Option is exercised (it being agreed that the excess of the Fair Market Value over the aggregate exercise price will be refunded to Awardee);


(iv)if permitted by the Administrator, consideration received by the Company under a broker-assisted sale and remittance program acceptable to the Administrator;
(v)if permitted by the Administrator, and subject to any conditions or limitations established by the Administrator, the Company’s withholding Shares otherwise issuable upon exercise of the Option pursuant to a “net exercise” arrangement; or
(vi)any combination of the foregoing methods of payment.
2.Transferability. The Option is transferable (a) at Awardee’s death, by Awardee by will or pursuant to the laws of descent and distribution, and (b) by Awardee during Awardee’s lifetime, without payment of consideration, to (i) the spouse, former spouse, parents, stepparents, grandparents, parents-in-law, siblings, siblings-in-law, children, stepchildren, children-in-law, grandchildren, nieces or nephews of Awardee, or any other persons sharing Awardee’s household (other than tenants or employees) (collectively, “Family Members”) or (ii) a trust, partnership or other entity controlled by Awardee or Awardee’s Family Members and in which Awardee or Awardee’s Family Members have 100% of the pecuniary interest; provided, however, that subsequent transfers of the transferred Option are prohibited, except (X) if the transferee is an individual, at the transferee’s death by the transferee by will or pursuant to the laws of descent and distribution, and (Y) without payment of consideration to the individuals or entities listed in Paragraphs (b)(i) or (ii) above, with respect to the original Awardee. The Administrator may, in its discretion, permit transfers to other persons and entities as permitted by the Plan. Neither a transfer under a domestic relations order in settlement of marital property rights nor a transfer to an entity in which more than 50% of the voting interests are owned by Awardee or Family Members in exchange for an interest in that entity will be a transfer for consideration. Within 10 days of any transfer, Awardee shall notify the Company in writing of the transfer. Following transfer, the Option continues to be subject to the same terms and conditions as were applicable immediately prior to transfer and, except as otherwise provided in the Plan or this Agreement, references to the original Awardee are deemed to refer to the transferee. The events of a Termination of Employment of Awardee provided in Paragraph 3 continue to be applied with respect to the original Awardee, following which the Option is exercisable by the transferee only to the extent, and for the periods, specified in Paragraph 3. The Company has no obligation to notify any transferee of Awardee’s Termination of Employment with the Cardinal Group for any reason. The conduct prohibited of Awardee in Paragraph 5 continues to be prohibited of Awardee following transfer to the same extent as immediately prior to transfer and the Option (or its economic value, as applicable) is subject to forfeiture by the transferee and recoupment from Awardee to the same extent as would have been the case of Awardee had the Option not been transferred. Awardee remains subject to the recoupment provisions of Paragraph 5 of this Agreement and tax withholding provisions of Section 31 of the Plan following transfer of the Option.
3.Termination of Employment.
(a)Termination of Employment by Reason of Death or Disability. If a Termination of Employment by reason of death occurs after the Grant Date or a Termination of Employment by reason of Disability occurs at least six months after the Grant Date, then any outstanding unvested portion of the Option vests upon and becomes exercisable in full from and after such Termination of Employment. The entire Option (including previously vested but unexercised portions) may thereafter be exercised by Awardee, any transferee of Awardee, if applicable, or by the legal representative of the estate or by the legatee of Awardee under the will of Awardee from the date of such Termination of Employment until the Grant Expiration Date.
    2

(b)Termination of Employment by Reason of Retirement. If a Termination of Employment by reason of Retirement occurs at least six months after the Grant Date, then a Ratable Portion of each unvested installment of the outstanding Option immediately vests and becomes exercisable. Such “Ratable Portion,” with respect to the applicable installment, is an amount (rounded down to the nearest whole Share) equal to such installment of the Option scheduled to vest on a future Vesting Date multiplied by a fraction, the numerator of which is the number of days from the Grant Date through the date of the Termination of Employment, and the denominator of which is the number of days from the Grant Date through such Vesting Date. The Option, to the extent vested, may be exercised by Awardee (or any transferee, if applicable) until the Grant Expiration Date. If Awardee dies after Retirement, but before the Grant Expiration Date, the Option, to the extent vested, may be exercised by any transferee of the Option, if applicable, or by the legal representative of the estate or by the legatee of Awardee under the will of Awardee from and after such death until the Grant Expiration Date.1
(c)Involuntary Termination of Employment with Separation Agreement. If (i) Paragraph 3(b) is not applicable, but Awardee has attained either (A) age 53 and at least eight years of continuous service with the Cardinal Group, or (B) age 59 and at least four years of continuous service with the Cardinal Group, in each case including service with an Affiliate of the Company prior to the time that such Affiliate became an Affiliate of the Company, (ii) a Termination of Employment by the Cardinal Group (other than a Termination for Cause) occurs at least six months after the Grant Date, and (iii) no later than 45 days after the Termination of Employment, Awardee enters into a written separation agreement and general release of claims with the Cardinal Group (in such form as may reasonably be presented by the Cardinal Group) (a “Separation Agreement”), and Awardee does not timely revoke such Separation Agreement, then a Ratable Portion of each unvested installment of the outstanding Option immediately vests and becomes exercisable. The Option, to the extent vested, may be exercised by Awardee (or any transferee, if applicable) until the Grant Expiration Date. If Awardee dies after such Termination of Employment, but before the Grant Expiration Date, the Option, to the extent vested, may be exercised by any transferee of the Option, if applicable, or by the legal representative of the estate or by the legatee of Awardee under the will of Awardee from and after such death until the Grant Expiration Date.
(d)Change of Control. In the event of a Change of Control prior to the Participant’s Termination of Employment, any outstanding unvested portion of the Option vests in full, except to the extent a Replacement Award is provided to the Participant in accordance with Section 16(b) of the Plan.
(e)Other Termination of Employment. Except as set forth in Paragraphs 3(a), (b) and (c) or as provided in a plan or agreement described in Paragraph 14 below, if a Termination of Employment occurs, any unexercised portion of the Option that has not vested on such date of Termination of Employment is automatically immediately forfeited. Unless a longer period is applicable as specified in Section 16(b)(iv) of the Plan or Paragraphs 3(a) through (c), Awardee (or any transferee, if applicable) has 90 days from the date of Termination of Employment or until the Grant Expiration Date, whichever period is shorter, to exercise any portion of the Option that is vested and exercisable on the date of Termination of Employment; provided, however, that if the Termination of Employment was a Termination for Cause, as determined by the Administrator, the Option may be immediately canceled by the Administrator (whether then held by Awardee or any transferee).
4.Restrictions on Exercise. The Option is subject to all restrictions in this Agreement and in the Plan. As a condition of any exercise of the Option, the Company may require Awardee or his or
1 This provision is an alternative that may not be included in every award agreement.
    3

her transferee or successor to make any representation and warranty to comply with any applicable law or regulation or to confirm any factual matters (including Awardee’s compliance with the terms of Paragraph 5 or any employment or severance agreement between the Cardinal Group and Awardee) reasonably requested by the Company. The Option is not exercisable if such exercise would involve a violation of any Applicable Law.
5.Special Forfeiture and Repayment Rules. This Agreement contains special forfeiture and repayment rules intended to encourage conduct that protects the Cardinal Group’s legitimate business assets and discourage conduct that threatens or harms those assets. The Company does not intend to have the benefits of this Agreement reward or subsidize conduct detrimental to the Company, and therefore will require the forfeiture of the benefits offered under this Agreement and the repayment of gains obtained from this Agreement, according to the rules specified below. Activities that trigger the forfeiture and repayment rules are divided into two categories: Misconduct and Competitor Conduct. Awardee also agrees to application of the Company’s Clawback Policy described in Paragraph 5(d) below.
(a)Misconduct. During employment with the Cardinal Group and for three years after the Termination of Employment for any reason, Awardee agrees not to engage in Misconduct. If Awardee engages in Misconduct during employment or with respect to clauses (A), (D), (E), (F) and (G), within three years after the Termination of Employment for any reason, then
(i)Awardee immediately forfeits the Option (or any part of the Option that has not been exercised) which automatically terminates, and
(ii)Awardee shall, within 30 days following written notice from the Company, pay to the Company in cash an amount equal to (A) the gross gain to Awardee or any transferee from each and every exercise of the Option at any time within three years prior to the date the Misconduct first occurred less (B) $1.00. The gross gain is calculated by subtracting the exercise price paid for the Shares from the Fair Market Value of the Shares on the exercise date.
As used in this Agreement, “Misconduct” means
(A)disclosing or using any of the Cardinal Group's confidential information (as defined by the applicable Cardinal Group policies and agreements) without proper authorization from the Cardinal Group or in any capacity other than as necessary for the performance of Awardee's assigned duties for the Cardinal Group;
(B)violation of the Standards of Business Conduct or any successor code of conduct or other applicable Cardinal Group policies, including but not limited to conduct which would constitute a breach of any representation or certificate of compliance signed by Awardee;
(C)fraud, gross negligence or willful misconduct by Awardee, including but not limited to fraud, gross negligence or willful misconduct causing or contributing to a material error resulting in a restatement of the financial statements of any member of the Cardinal Group;
(D)directly or indirectly soliciting or recruiting for employment or contract work on behalf of a person or entity other than a member of the Cardinal Group, any person who is an employee, representative, officer or director in the Cardinal Group or who held one or more of those positions at any time within the 12 months prior to Awardee’s Termination of Employment;
    4

(E)directly or indirectly inducing, encouraging or causing an employee of the Cardinal Group to terminate his/her employment or a contract worker to terminate his/her contract with a member of the Cardinal Group;
(F)any action by Awardee and/or his or her representatives that either does or could reasonably be expected to undermine, diminish or otherwise damage the relationship between the Cardinal Group and any of its customers, prospective customers, vendors, suppliers or employees known to Awardee; or
(G)breaching any provision of any employment or severance agreement with a member of the Cardinal Group.
Nothing in this Agreement will prevent Awardee from testifying truthfully as required by law, prohibit or prevent Awardee from filing a charge with or participating, testifying or assisting in any investigation, hearing, whistleblower proceeding or other proceeding before any federal, state or local government agency (e.g., Equal Employment Opportunity Commission, National Labor Relations Board, Securities and Exchange Commission, etc.), or prevent Awardee from disclosing Cardinal Group’s confidential information in confidence to a federal, state or local government official for the purpose of reporting or investigating a suspected violation of law.
(b)Competitor Conduct. If Awardee engages in Competitor Conduct during employment or within one year after the Termination of Employment for any reason, then
(i)Awardee immediately forfeits the Option (or any part of the Option that has not been exercised) which automatically terminates, and
(ii)Awardee shall, within 30 days following written notice from the Company, pay to the Company in cash an amount equal to (A) the gross gain to Awardee or any transferee from each and every exercise of the Option at any time since the earlier of one year prior to the date the Competitor Conduct first occurred and one year prior to the Termination of Employment, if applicable, less (B) $1.00. The gross gain is calculated by subtracting the exercise price paid for the Shares from the Fair Market Value of the Shares on the exercise date.
As used in this Agreement, “Competitor Conduct” means accepting employment with, or directly or indirectly providing services to, a Competitor in the United States. If Awardee has a Termination of Employment and Awardee’s responsibilities to the Cardinal Group were limited to a specific territory or territories within or outside the United States during the 24 months prior to the Termination of Employment, then Competitor Conduct will be limited to that specific territory or territories. A “Competitor” means any person or business that competes with the products or services provided by a member of the Cardinal Group for which Awardee had business responsibilities within 24 months prior to Termination of Employment or about which Awardee obtained confidential information (as defined by the applicable Cardinal Group policies or agreements).
(c)General.
(i)Nothing in this Paragraph 5 constitutes or is to be construed as a “noncompete” covenant or other restraint on employment or trade. The provisions of this Paragraph 5 do not prevent, nor are they intended to prevent, Awardee from seeking or accepting employment or other work outside the Cardinal Group. The execution of this Agreement is voluntary. Awardee is free to choose to comply with the terms of this Agreement and receive the benefits offered or
    5

else reject this Agreement with no adverse consequences to Awardee’s employment with the Cardinal Group.
(ii)Awardee agrees to provide the Company with at least 10 days’ written notice prior to accepting employment with or providing services to a Competitor prior to one year after Termination of Employment.
(iii)Awardee acknowledges receiving sufficient consideration for the requirements of this Paragraph 5, including Awardee’s receipt of the Option. Awardee further acknowledges that the Company would not provide the Option to Awardee without Awardee's promise to abide by the terms of this Paragraph 5. The parties also acknowledge that the provisions contained in this Paragraph 5 are ancillary to, or part of, an otherwise enforceable agreement at the time this Agreement is made.
(iv)Awardee may be released from the obligations of this Paragraph 5 if and only if the Administrator determines, in writing and in the Administrator's sole discretion, that a release is in the best interests of the Company.
(d)Clawback Policy. Awardee acknowledges and agrees that, in addition to the other provisions of Paragraph 5, Awardee and this Award will be subject to the terms of the Clawback Policy adopted by the Company, as required by New York Stock Exchange listing standards and as may be in effect from time to time, and Awardee agrees to comply with the requirements of such policy. In its discretion, moreover, the Administrator may require repayment to the Company of all or any portion of this Award if the amount of the Award was calculated based upon the achievement of financial results that were subsequently the subject of a restatement of the Company’s financial statements, Awardee engaged in misconduct that caused or contributed to the need for the restatement of the financial statements, and the amount payable to Awardee would have been lower than the amount actually paid to Awardee had the financial results been properly reported. This Paragraph 5(d) is not the Company’s exclusive remedy with respect to such matters.
6.Right of Set-Off. By accepting the Option, Awardee consents to a deduction from, and set-off against, any amounts owed to Awardee that are not treated as “non-qualified deferred compensation” under Section 409A of the Code by any member of the Cardinal Group from time to time (including, but not limited to, amounts owed to Awardee as wages, severance payments or other fringe benefits) to the extent of the amounts owed to the Cardinal Group by Awardee under this Agreement, subject to Applicable Law.
7.Withholding Tax.
(a)Generally. Awardee is liable and responsible for all taxes owed in connection with the exercise of the Option, regardless of any action the Company takes with respect to any tax withholding obligations that arise in connection with the Option. The Company does not make any representation or undertaking regarding the tax treatment or the treatment of any tax withholding in connection with the exercise of the Option. The Company does not commit and is under no obligation to structure the Option or the exercise of the Option to reduce or eliminate Awardee's tax liability.
(b)Payment of Withholding Taxes. Concurrently with the payment of the exercise price pursuant to Paragraph 1, Awardee is required to arrange for the satisfaction of the minimum amount of any domestic or foreign tax withholding obligation, whether national, federal, state, or local, including any employment tax obligation (the “Tax Withholding Obligation”) in a manner acceptable to the
    6

Company. Any manner provided for in Paragraph 1(b) is an acceptable manner to satisfy the Tax Withholding Obligation unless otherwise determined by the Administrator.
8.Governing Law/Venue for Dispute Resolution/Costs and Legal Fees. This Agreement is governed by the laws of the State of Ohio, without regard to principles of conflicts of law, except to the extent superseded by the laws of the United States of America. The parties agree and acknowledge that the laws of the State of Ohio bear a substantial relationship to the parties and/or this Agreement and that the Option and benefits granted in this Agreement would not be granted without the governance of this Agreement by the laws of the State of Ohio. In addition, all legal actions or proceedings relating to this Agreement must be brought exclusively in state or federal courts located in Franklin County, Ohio and the parties executing this Agreement hereby consent to the personal jurisdiction of such courts. Awardee acknowledges that the provisions of Paragraph 5 are reasonable in nature, are fundamental for the protection of the Company’s legitimate business and proprietary interests, and do not adversely affect Awardee’s ability to earn a living. If it becomes necessary for the Company to institute legal proceedings under this Agreement, Awardee is responsible to the Company for all costs and reasonable legal fees incurred by the Company in connection with the proceedings. Any provision of this Agreement which is determined by a court of competent jurisdiction to be invalid or unenforceable or to disqualify the Award under any Applicable Law should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by the provision, without invalidating or rendering unenforceable the remaining provisions of this Agreement.
9.Defend Trade Secrets Act Notice. Under the U.S. Defend Trade Secrets Act of 2016, Awardee will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, and (ii) solely for the purpose of reporting or investigating a suspected violation of law; (b) is made to Awardee’s attorney in relation to a lawsuit for retaliation against Awardee for reporting a suspected violation of law; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
10.Action by the Administrator. The parties agree that the interpretation of this Agreement rests exclusively and completely within the sole discretion of the Administrator. The parties agree to be bound by the decisions of the Administrator regarding the interpretation of this Agreement and regarding all matters set forth in this Agreement. In fulfilling its responsibilities, the Administrator may rely upon documents, written statements of the parties, financial reports or other material as the Administrator deems appropriate. The parties agree that there is no right to be heard or to appear before the Administrator and that any decision of the Administrator relating to this Agreement, including without limitation whether conduct constitutes Misconduct or Competitor Conduct, is final and binding. The Administrator may delegate its functions under this Agreement to an officer of the Cardinal Group designated by the Administrator, to the extent permitted under the Plan.
11.Prompt Acceptance of Agreement. The Option grant evidenced by this Agreement will, at the discretion of the Administrator, be forfeited if this Agreement is not manually executed and returned to the Company, or electronically executed by Awardee by indicating Awardee’s acceptance of this Agreement in accordance with the acceptance procedures set forth on the Company’s third-party equity plan administrator’s web site, within 90 days of the Grant Date.
12.Electronic Delivery and Consent to Electronic Participation. The Company may, in its sole discretion, decide to deliver any documents related to the Option grant under and participation in the
    7

Plan or future options that may be granted under the Plan by electronic means or to request Awardee’s consent to participate in the Plan by electronic means. Awardee hereby consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company, including the acceptance of option grants and the execution of option agreements through electronic signature.
13.Notices. All notices, requests, consents, and other communications required or provided under this Agreement to be delivered by Awardee to the Company will be in writing and will be deemed sufficient if delivered by hand, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to the Company at the address set forth below:
        Cardinal Health, Inc.
        7000 Cardinal Place
        Dublin, Ohio 43017
        Attention: Corporate Secretary

All notices, requests, consents, and other communications required or provided under this Agreement to be delivered by the Company to Awardee may be delivered by e-mail or in writing and will be deemed sufficient if delivered by e-mail, hand, facsimile, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to Awardee.
14.Employment Agreement, Offer Letter or Other Arrangement. To the extent a written employment agreement, offer letter or other arrangement (“Employment Arrangement”) that was approved by the Human Resources and Compensation Committee or the Board of Directors or that was approved in writing by an officer of the Company pursuant to delegated authority of the Human Resources and Compensation Committee provides for greater benefits to Awardee with respect to (a) vesting of the Option on Termination of Employment by reason of specified events or (b) exercisability of the Option following Termination of Employment, than provided in this Agreement or in the Plan, then the terms of such Employment Arrangement with respect to vesting of the Option on Termination of Employment by reason of such specified events or exercisability of the Option following Termination of Employment supersede the terms of this Agreement to the extent permitted by the terms of the Plan. If Awardee is eligible for severance benefits under the Cardinal Health, Inc. Senior Executive Severance Plan, as amended, such plan also constitutes an “Employee Arrangement” for purposes of this section.
15.Amendments. Any amendment to the Plan will be deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto; provided, however, that no amendment will impair the rights of Awardee with respect to an outstanding Award unless agreed to by Awardee and the Company, which agreement must be in writing and signed by Awardee and the Company. Other than following a Change of Control, no such agreement is required if the Administrator determines in its sole discretion that such amendment either (a) is required or advisable in order for the Company, the Plan or the Option to satisfy any Applicable Law or to meet the requirements of any accounting standard or (b) is not reasonably likely to significantly diminish the benefits provided under the Option, or that any such diminishment has been adequately compensated, including pursuant to Section 16(c) of the Plan.
16.Adjustments. The number of Shares issuable subject to the Option and the other terms and conditions of the grant evidenced by this Agreement are subject to adjustment as provided in Section 16 of the Plan.
    8

17.Review. The Awardee agrees and represent that the Awardee has been advised to consult with an attorney prior to executing this Agreement and fully understands the Awardee’s right to discuss all aspects of this Agreement with an attorney of the Awardee’s choice. The Awardee’s execution of this Agreement establishes that, if the Awardee wishes the advice of an attorney, the Awardee has done so by the date the Awardee signed the Agreement, and that the Awardee was given at least 14 days to consider whether to sign. The Awardee may sign this Agreement before the end of the 14-day period and the Awardee agrees that if the Awardee decides to shorten this time period for signing, the Awardee’s decision was knowing and voluntary. The parties agree that a change, whether material or immaterial, does not restart the running of said period.
18.No Right to Future Awards or Employment. The grant of the Option under this Agreement to Awardee is a voluntary, discretionary award being made on a one-time basis and it does not constitute a commitment to make any future awards. The grant of the Option and any related payments made to Awardee will not be considered salary or other compensation for purposes of any severance pay or similar allowance, except as otherwise required by Applicable Law. Nothing contained in this Agreement confers upon Awardee any right with respect to continuance of employment or other service with the Company or any Affiliate, nor interferes in any way with any right the Company or any Affiliate would otherwise have to terminate Awardee’s employment or other service at any time.
19.Successors and Assigns. Without limiting Paragraph 2, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of Awardee, and the successors and assigns of the Company.

CARDINAL HEALTH, INC.


By:                         
Its:                         

    9

ACCEPTANCE OF AGREEMENT AND APPLICATION OF CLAWBACK POLICIES
Awardee hereby: (a) acknowledges that he or she has received a copy of the Plan, a copy of the Company’s most recent annual report to shareholders and other communications routinely distributed to the Company’s shareholders, and a copy of the Plan Description pertaining to the Plan; (b) accepts this Agreement and the Option granted to him or her under this Agreement subject to all provisions of the Plan and this Agreement, including the provisions in the Agreement regarding “Special Forfeiture and Repayment Rules” set forth in Paragraph 5; (c) represents that he or she understands that the acceptance of this Agreement through an on-line or electronic system, if applicable, carries the same legal significance as if he or she manually signed the Agreement; (d) agrees that no transfer of the Shares delivered in respect of the Option may be made unless the Shares have been duly registered under all applicable Federal and state securities laws pursuant to a then-effective registration which contemplates the proposed transfer or unless the Company has received a written opinion of, or satisfactory to, its legal counsel that the proposed transfer is exempt from such registration; and (e) acknowledges that any awards granted to Awardee under any incentive plan, agreement or arrangement of the Company are subject to the forfeiture and repayment rules set forth in such plan, agreement or arrangement and, if applicable, to the Cardinal Health, Inc. Clawback Policy as in effect from time to time and agrees to be bound by these provisions with respect to any such awards.
                        [                        
                        Awardee’s Signature

                                                
                        Date]

    10
 EX-10.1 3 4 aex1013formofpsuagreement.htm EX-10.1 3 Document
Exhibit 10.1.3
CARDINAL HEALTH, INC.
PERFORMANCE SHARE UNITS AGREEMENT
This Performance Share Units Agreement (this “Agreement”) is entered into in Franklin County, Ohio. On [grant date] (the “Grant Date”), Cardinal Health, Inc., an Ohio corporation (the “Company”), has awarded to [employee name] (“Awardee”) [target # of units] performance-based Stock Units (the “Performance Share Units” or “Award”). The Performance Share Units have been granted pursuant to the Cardinal Health, Inc. 2021 Long-Term Incentive Plan, as amended (the “Plan”), and are subject to all provisions of the Plan, all of which are incorporated in this Agreement by reference and are subject to the provisions of this Agreement. Capitalized terms used in this Agreement which are not specifically defined have the meanings ascribed to them in the Plan.
1.Vesting of Performance Share Units. Subject to the provisions of this Agreement, zero to [maximum percentage] of the Performance Share Units vest when the Administrator certifies the payout level (“Payout Level”) as a result of achievement of specific performance criteria (the “Performance Goals”) for a performance period (“Performance Period”) set forth in the Statement of Performance Goals provided to the Awardee with respect to the Award and approved by the Committee (the “Statement of Performance Goals”).
2.Transferability. The Performance Share Units are not transferable other than by beneficiary designation, will, or by the laws of descent or distribution.
3.Termination of Employment.
(a)General. Except to the extent that vesting occurs pursuant to Paragraphs 3(b), (c), (d) or (e) or Paragraph 5 or as provided in a plan or agreement described in Paragraph 17 below, if a Termination of Employment occurs prior to the [applicable payment date in Paragraph 6(a) (the “Payment Date”)]1 / [First Payment Date (as defined in Paragraph 6(a))]2 associated with a Performance Period, any Performance Share Units allocated to that Performance Period, whether vested or unvested, are forfeited by Awardee.
(b)Death or Disability. If a Termination of Employment by reason of Awardee’s death occurs after the Grant Date or a Termination of Employment by reason of Awardee’s Disability occurs at least 6 months after the Grant Date, then the outstanding unvested Performance Share Units for a Performance Period will vest (or in the case of an ongoing Performance Period, be eligible to vest) as if Awardee had remained employed through the [First]2 Payment Date.
(c)[Retirement. If a Termination of Employment by reason of Awardee’s Retirement occurs at least 6 months after the Grant Date, then the outstanding unvested Performance Share Units for a Performance Period will be eligible to vest in an amount equal to the number of Performance Share Units that would have vested if Awardee had remained employed through the [First]2 Payment Date multiplied by a fraction, the numerator of which is the number of days in the Performance Period up to the date of such Termination of Employment, and the denominator of which is the total number of days in such Performance Period.]3
1 For awards without deferred settlement.
2 For awards with deferred settlement.
3 This provision is an alternative that may not be included in every award agreement.


(d)Involuntary Termination with Separation Agreement. If (i) neither Paragraph 3(c) nor Paragraph 3(e) is applicable, but Awardee has attained either (A) age 53 and at least eight years of continuous service with the Company and its Affiliates (collectively, the “Cardinal Group”), or (B) age 59 and at least four years of continuous service with the Cardinal Group, in each case including service with an Affiliate of the Company prior to the time that such Affiliate became an Affiliate of the Company, (ii) a Termination of Employment by the Cardinal Group (other than a Termination for Cause) occurs at least 6 months after the Grant Date, and (iii) no later than 45 days after the Termination of Employment, Awardee enters into a written separation agreement and general release with the Cardinal Group (in such form as may reasonably be presented by the Company) (a “Separation Agreement”), and Awardee does not timely revoke such Separation Agreement, then the outstanding unvested Performance Share Units for a Performance Period will be eligible to vest in an amount equal to the number of Performance Share Units that would have vested if Awardee had remained employed through the [First]2 Payment Date multiplied by a fraction, the numerator of which is the number of days in the Performance Period up to the date of such Termination of Employment, and the denominator of which is the total number of days in such Performance Period.
(e)Involuntary Termination After Completion of a Performance Period. If a Termination of Employment by the Cardinal Group (other than a Termination for Cause) occurs after the completion of a Performance Period but prior to the [First]2 Payment Date, then the Performance Share Units for the applicable Performance Period will vest as if Awardee had remained employed through the [First]2 Payment Date.
4.Special Forfeiture and Repayment Rules. This Agreement contains special forfeiture and repayment rules intended to encourage conduct that protects the Cardinal Group’s legitimate business assets and discourage conduct that threatens or harms those assets. The Company does not intend to have the benefits of this Agreement reward or subsidize conduct detrimental to the Company, and therefore will require the forfeiture of the benefits offered under this Agreement and the repayment of gains obtained from this Agreement, according to the rules specified below. Activities that trigger the forfeiture and repayment rules are divided into two categories: Misconduct and Competitor Conduct. Awardee also agrees to application of the Company’s Clawback Policy described in Section 4(d) below.
(a)Misconduct. During employment with the Cardinal Group and with respect to clauses (A), (D), (E), (F) and (G), for three years after the Termination of Employment for any reason, Awardee agrees not to engage in Misconduct. If Awardee engages in Misconduct during employment or within three years after the Termination of Employment for any reason, then
(i)Awardee immediately forfeits the Performance Share Units that have not yet vested or that vested at any time within three years prior to the date the Misconduct first occurred and have not yet been paid pursuant to Paragraph 6, and those forfeited Performance Share Units automatically terminate, and
(ii)Awardee shall, within 30 days following written notice from the Company, pay to the Company in cash an amount equal to: (A) the gross gain to Awardee resulting from the payment of the Performance Share Units pursuant to Paragraph 6 that had vested at any time within three years prior to the date the Misconduct first occurred less (B) $1.00. The gross gain is the Fair Market Value of the Shares represented by the Performance Share Units on the [Payment Date]1 / [applicable payment date]2.
As used in this Agreement, “Misconduct” means
    -2-    

(A)disclosing or using any of the Cardinal Group’s confidential information (as defined by the applicable Cardinal Group policies and agreements) without proper authorization from the Cardinal Group or in any capacity other than as necessary for the performance of Awardee’s assigned duties for the Cardinal Group;
(B)violation of the Standards of Business Conduct or any successor code of conduct or other applicable Cardinal Group policies, including but not limited to conduct which would constitute a breach of any representation or certificate of compliance signed by Awardee;
(C)fraud, gross negligence or willful misconduct by Awardee, including but not limited to fraud, gross negligence or willful misconduct causing or contributing to a material error resulting in a restatement of the financial statements of any member of the Cardinal Group;
(D)directly or indirectly soliciting or recruiting for employment or contract work on behalf of a person or entity other than a member of the Cardinal Group, any person who is an employee, representative, officer or director in the Cardinal Group or who held one or more of those positions at any time within the 12 months prior to Awardee’s Termination of Employment;
(E)directly or indirectly inducing, encouraging or causing an employee of the Cardinal Group to terminate his/her employment or a contract worker to terminate his/her contract with a member of the Cardinal Group;
(F)any action by Awardee and/or his or her representatives that either does or could reasonably be expected to undermine, diminish or otherwise damage the relationship between the Cardinal Group and any of its customers, prospective customers, vendors, suppliers or employees known to Awardee; or
(G)breaching any provision of any employment or severance agreement with a member of the Cardinal Group.
Nothing in this Agreement will prevent Awardee from testifying truthfully as required by law, prohibit or prevent Awardee from filing a charge with or participating, testifying or assisting in any investigation, hearing, whistleblower proceeding or other proceeding before any federal, state or local government agency (e.g., Equal Employment Opportunity Commission, National Labor Relations Board, Securities and Exchange Commission, etc.), or prevent Awardee from disclosing Cardinal Group’s confidential information in confidence to a federal, state or local government official for the purpose of reporting or investigating a suspected violation of law.
(b)Competitor Conduct. If Awardee engages in Competitor Conduct during employment or within one year after the Termination of Employment for any reason, then
(i)Awardee immediately forfeits the Performance Share Units that have not yet vested or that vested at any time within one year prior to the date the Competitor Conduct first occurred and have not yet been paid pursuant to Paragraph 6, and those forfeited Performance Share Units automatically terminate, and
(ii)Awardee shall, within 30 days following written notice from the Company, pay the Company an amount equal to: (A) the gross gain to Awardee resulting from the payment of Performance Share Units pursuant to Paragraph 6 that had vested at any time since the earlier of one year prior to the date the Competitor Conduct first occurred or one year prior to the
    -3-    

Termination of Employment, if applicable, less (B) $1.00. The gross gain is the Fair Market Value of the Shares represented by the Performance Share Units on the [Payment Date]1 / [applicable payment date]2.
As used in this Agreement, “Competitor Conduct” means accepting employment with, or directly or indirectly providing services to, a Competitor in the United States. If Awardee has a Termination of Employment and Awardee’s responsibilities to the Cardinal Group were limited to a specific territory or territories within or outside the United States during the 24 months prior to the Termination of Employment, then Competitor Conduct is limited to that specific territory or territories. A “Competitor” means any person or business that competes with the products or services provided by a member of the Cardinal Group for which Awardee had business responsibilities within 24 months prior to Termination of Employment or about which Awardee obtained confidential information (as defined by the applicable Cardinal Group policies or agreements).
(c)General.
(i)Nothing in this Paragraph 4 constitutes or is to be construed as a “noncompete” covenant or other restraint on employment or trade. The provisions of this Paragraph 4 do not prevent, nor are they intended to prevent, Awardee from seeking or accepting employment or other work outside the Cardinal Group. The execution of this Agreement is voluntary. Awardee is free to choose to comply with the terms of this Agreement and receive the benefits offered or else reject this Agreement with no adverse consequences to Awardee’s employment with the Cardinal Group.
(ii)Awardee agrees to provide the Company with at least 10 days written notice prior to accepting employment with or providing services to a Competitor within one year after Termination of Employment.
(iii)Awardee acknowledges receiving sufficient consideration for the requirements of this Paragraph 4, including Awardee’s receipt of the Performance Share Units. Awardee further acknowledges that the Company would not provide the Performance Share Units to Awardee without Awardee’s promise to abide by the terms of this Paragraph 4. The parties also acknowledge that the provisions contained in this Paragraph 4 are ancillary to, or part of, an otherwise enforceable agreement at the time this Agreement is made.
(iv)Awardee may be released from the obligations of this Paragraph 4 if and only if the Administrator determines, in writing and in the Administrator’s sole discretion, that a release is in the best interests of the Company.
(d)Clawback Policy. Awardee acknowledges and agrees that, in addition to the other provisions of this Paragraph 4, Awardee and this Award will be subject to the terms of the Clawback Policy adopted by the Company, as required by New York Stock Exchange listing standards and as may be in effect from time to time, and Awardee agrees to comply with the requirements of such policy. In its discretion, moreover, the Administrator may require repayment to the Company of all or any portion of this Award if the amount of the Award was calculated based upon the achievement of financial results that were subsequently the subject of a restatement of the Company’s financial statements, Awardee engaged in misconduct that caused or contributed to the need for the restatement of the financial statements, and the amount payable to Awardee would have been lower than the amount actually paid to
    -4-    

Awardee had the financial results been properly reported. This Paragraph 4(d) is not the Company’s exclusive remedy with respect to such matters.
5.Change of Control.
(a)Valuation. In the event of a Change of Control prior to [a Payment Date]2 / [the First Payment Date]3, the Administrator, as constituted immediately before such Change of Control, shall determine and certify the Payout Level (the “Change of Control Payout Level”) based on (i) actual performance through the most recent date prior to the Change of Control for which achievement of the Performance Goals can reasonably be determined; and (ii) the expected performance for the remainder of the Performance Period based on information reasonably available.
(b)Vesting and Substitute Awards.
(i)In the event of a Change of Control prior to [a Payment Date]1 / [the First Payment Date]2, the percentage of the Performance Share Units determined in accordance with the Statement of Performance Goals at the Change of Control Payout Level vests unless an award meeting the requirements of Paragraph 5(b)(ii) (a “Substitute Award”) is provided to Awardee to replace or adjust the Award. If a Substitute Award is provided, any Performance Share Units that (A) except to the extent that clause (B) applies, would vest in accordance with Paragraphs 3(b) or (c) in connection with Awardee’s Retirement or Disability if Awardee’s Termination of Employment occurred on the date of the Change of Control or (B) are eligible to vest in accordance with Paragraph 3(d) as a result of Awardee’s Termination of Employment that actually occurs prior to the Change of Control, vest at the time of the Change of Control. No Substitute Award will be provided in the event of Awardee’s Termination of Employment by reason of death, Disability, Retirement, or the circumstances described in Paragraph 3(d) prior to a Change of Control.
(ii)An award meets the conditions of this Paragraph 5(b)(ii) (and hence qualifies as a Substitute Award) if, as determined by the Administrator as constituted immediately before the Change of Control, (A) it has a value at the time of grant or adjustment at least equal to the value of the Performance Share Units that would vest under Paragraph 5(b)(i) if there were no Substitute Award; (B) it is paid in publicly traded equity securities of the Company or its successor in the Change of Control or another entity that is affiliated with the Company or its successor following the Change of Control; (C) it is a restricted stock unit award with vesting and payment not conditioned on the achievement of any performance criteria or conditions; (D) it vests in full upon (1) a Termination for Good Reason by Awardee, (2) a Termination of Employment by the Company or its successor in the Change of Control other than a Termination for Cause, or (3) Awardee’s death or Disability, in each case, occurring at or during the period of two years after the Change of Control; (E) if Awardee is subject to U.S. federal income tax under the Code, the tax consequences to Awardee under the Code of the Substitute Award are not less favorable to Awardee than the tax consequences of the Award; and (F) its other terms and conditions are not less favorable to Awardee than the terms and conditions of the Award (including the provisions that would apply in the event of a subsequent Change of Control). Without limiting the generality of the foregoing, the Substitute Award may take the form of a continuation of the Award if the requirements of the preceding sentence are satisfied.
    -5-    

6.Payment.
(a)General. [The Company shall pay Performance Share Units in Shares. Subject to the provisions of Paragraph 4 and Paragraphs 6(b) and (c), Awardee is entitled to receive from the Company (without any payment on behalf of Awardee other than as described in Paragraph 10) one Share for each vested Performance Share Unit not later than the 60th day after the end of a Performance Period, except that if Awardee’s Termination of Employment occurs due to death after the end of the Performance Period, Awardee is entitled to receive, with respect to any Performance Shares Units which are not subject to a “substantial risk of forfeiture” as determined for purposes of Section 409A of the Code on the date of Awardee’s death, the corresponding Shares from the Company on the date of death.]1 / [The Company shall pay Performance Share Units in Shares. Subject to the provisions of Paragraph 4, Awardee is entitled to receive from the Company (without any payment on behalf of Awardee other than as described in Paragraph 10) one Share for each vested Performance Share Unit. Subject to the provisions of Paragraph 6(b) and (c), payment with respect to any vested Performance Share Units shall be made in three installments. The first installment, which shall be with respect to [percentage] of the total number of vested Performance Share Units, shall be paid no later than the 60th day after the end of the Performance Period (the “First Payment Date”). The second installment, which shall be with respect to [percentage] of the total number of vested Performance Share Units, shall be paid on the first anniversary of the last day of the Performance Period. [The third installment, which shall be with respect to [percentage] of the total number of vested Performance Share Units, shall be paid on the second anniversary of the last day of the Performance Period.] Notwithstanding the above, in the event of an Awardee's death after the end of the Performance Period, Awardee is entitled to receive, with respect to any Performance Shares Units which are not subject to a “substantial risk of forfeiture” as determined for purposes of Section 409A of the Code on the date of Awardee’s death, corresponding Shares from the Company on account of any vested Performance Share Units which have not yet been paid as soon as practical following the date of death. Payment shall be made at each of the times specified above unless the Administrator makes a finding that the number of vested Performance Share Units shall be reduced pursuant to Paragraph 4 due to Misconduct or Competitor Conduct.]2
(b)Change of Control. Notwithstanding Paragraph 6(a) but subject to the provisions of Paragraph 4, to the extent that the Performance Share Units are not subject to a “substantial risk of forfeiture” as determined for purposes of Section 409A of the Code on the dates set forth below, payment with respect to such Performance Share Units will be made as follows:
(i)On the date of a Change of Control, Awardee is entitled to receive one Share for each such Performance Share Unit, subject to any adjustments made pursuant to Section 16(a) of the Plan, from the Company; provided, however, that if such Change of Control would not qualify as a permissible date of distribution under Section 409A(a)(2)(A)(v) of the Code and the regulations thereunder, and where Section 409A of the Code applies to such distribution as a deferral of compensation, Awardee is entitled to receive the corresponding Shares from the Company on the date that would have otherwise applied pursuant to Paragraphs 6(a), 6(b)(i), 6(b)(ii), or 6(b)(iii).
(ii)If Awardee’s separation from service occurs during the period of two years following a Change of Control (and such Change of Control constitutes a change of control event as defined in accordance with Section 409A(a)(2)(A)(v) of the Code and the regulations thereunder), Awardee is entitled to receive one Share for each such Performance Share Unit from the Company on the date of Awardee’s separation from service; provided, in such event that if Awardee on the date of separation from service is a “specified employee” (certain employees of
    -6-    

the Cardinal Group within the meaning of Section 409A of the Code determined using the identification methodology selected by the Company from time to time), Awardee is entitled to receive the corresponding Shares from the Company on the first day of the seventh month after the date of Awardee’s separation from service or, if earlier, the date of Awardee’s death.
(iii)On the date of Awardee's Termination of Employment due to death following a Change of Control, Awardee is entitled to receive one Share for each such Performance Share Unit from the Company on the date of death.
(c)Elections to Defer Receipt. Elections to defer receipt of the Shares beyond the [Payment Date]1 / [applicable payment date]2 applicable payment date may be permitted in the discretion of the Administrator pursuant to procedures established by the Administrator in compliance with the requirements of Section 409A of the Code. [Any election to defer will be valid only if the elected payment date is a date that is later than the date payment would have otherwise occurred.]2
7.Dividend Equivalents. Awardee is not entitled to receive cash dividends on the Performance Share Units but will receive a dividend equivalent payment from the Company in an amount equal to the dividends that would have been paid on each Share underlying the Performance Share Units if it had been outstanding between the Grant Date and the [applicable]2 payment date of any such Share (i.e., based on the record date for cash dividends). Subject to an election to defer receipt as permitted under Paragraph 6(c), the Company shall pay dividend equivalent payments in cash (without interest) as soon as reasonably practicable after the [applicable]2 payment date of (and to the same extent as) the Performance Share Units to which such dividend equivalents relate.
8.Right of Set-Off. By accepting the Performance Share Units, Awardee consents to a deduction from, and set-off against, any amounts owed to Awardee that are not treated as “non-qualified deferred compensation” under Section 409A of the Code by any member of the Cardinal Group from time to time (including, but not limited to, amounts owed to Awardee as wages, severance payments or other fringe benefits) to the extent of the amounts owed to the Cardinal Group by Awardee, subject to Applicable Law.
9.No Shareholder Rights. Awardee has no rights of a shareholder with respect to the Performance Share Units, including no right to vote any Shares represented by the Performance Share Units, until such Shares are paid to Awardee.
10.Withholding Tax.
(a)Generally. Awardee is liable and responsible for all taxes owed in connection with the Performance Share Units (including taxes owed with respect to the cash payments described in Paragraph 7), regardless of any action the Company takes with respect to any tax withholding obligations that arise in connection with the Performance Share Units. The Company does not make any representation or undertaking regarding the tax treatment or the treatment of any tax withholding in connection with the grant, vesting or payment of the Performance Share Units or the subsequent sale of Shares issuable pursuant to vested Performance Share Units. The Company does not commit and is under no obligation to structure the Performance Share Units to reduce or eliminate Awardee’s tax liability.
(b)Payment of Withholding Taxes. Prior to any event in connection with the Performance Share Units (e.g., vesting or payment) that the Company determines may result in any domestic or foreign tax withholding amounts being paid by the Company, whether national, federal, state or local, including any employment tax obligation (the “Tax Withholding Obligation”), Awardee is required to arrange for
    -7-    

the satisfaction of the minimum amount of such Tax Withholding Obligation in a manner acceptable to the Company. Awardee’s acceptance of this Agreement constitutes Awardee’s instruction and authorization to the Company to withhold on Awardee’s behalf the number of Shares from those Shares issuable to Awardee under this Award as the Company determines to be sufficient to satisfy the Tax Withholding Obligation. In the case of any amounts withheld for taxes pursuant to this provision in the form of Shares, the amount withheld may not exceed the amount legally required and withholding above the minimum withholding requirements shall be available only if and to the extent that the Administrator has authorized such. The Company has the right to deduct from all cash payments paid pursuant to Paragraph 7 the amount of any taxes which the Company is required to withhold with respect to such payments.
11.Governing Law/Venue for Dispute Resolution/Costs and Legal Fees. This Agreement is governed by the laws of the State of Ohio, without regard to principles of conflicts of law, except to the extent superseded by the laws of the United States of America. The parties agree and acknowledge that the laws of the State of Ohio bear a substantial relationship to the parties and/or this Agreement and that the Performance Share Units and benefits granted in this Agreement would not be granted without the governance of this Agreement by the laws of the State of Ohio. In addition, all legal actions or proceedings relating to this Agreement must be brought exclusively in state or federal courts located in Franklin County, Ohio and the parties executing this Agreement hereby consent to the personal jurisdiction of such courts. Awardee acknowledges that the provisions of Paragraph 4 are reasonable in nature, are fundamental for the protection of the Company’s legitimate business and proprietary interests, and do not adversely affect Awardee’s ability to earn a living. If it becomes necessary for the Company to institute legal proceedings under this Agreement, Awardee is responsible to the Company for all costs and reasonable legal fees incurred by the Company in connection with the proceedings. Any provision of this Agreement which is determined by a court of competent jurisdiction to be invalid or unenforceable or to disqualify the Award under any Applicable Law should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by the provision, without invalidating or rendering unenforceable the remaining provisions of this Agreement.
12.Defend Trade Secrets Act Notice. Under the U.S. Defend Trade Secrets Act of 2016, Awardee will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, and (ii) solely for the purpose of reporting or investigating a suspected violation of law; (b) is made to Awardee’s attorney in relation to a lawsuit for retaliation against Awardee for reporting a suspected violation of law; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
13.Action by the Administrator. The parties agree that the interpretation of this Agreement rests exclusively and completely within the sole discretion of the Administrator. The parties agree to be bound by the decisions of the Administrator regarding the interpretation of this Agreement and regarding all matters set forth in this Agreement. In fulfilling its responsibilities under this Agreement, the Administrator may rely upon documents, written statements of the parties, financial reports or other material as the Administrator deems appropriate. The parties agree that there is no right to be heard or to appear before the Administrator and that any decision of the Administrator relating to this Agreement, including whether conduct constitutes Misconduct or Competitor Conduct, is final and binding. The Administrator may delegate its functions under this Agreement to an officer of the Cardinal Group designated by the Administrator, to the extent permitted under the Plan.
    -8-    

14.Prompt Acceptance of Agreement. The Performance Share Units grant evidenced by this Agreement will, at the discretion of the Administrator, be forfeited if this Agreement is not manually executed and returned to the Company, or electronically executed by Awardee by indicating Awardee’s acceptance of this Agreement in accordance with the acceptance procedures set forth on the Company’s third-party equity plan administrator’s web site, within 90 days of the Grant Date.
15.Electronic Delivery and Consent to Electronic Participation. The Company may, in its sole discretion, decide to deliver any documents related to the Performance Share Unit grant under and participation in the Plan or future Performance Share Units that may be granted under the Plan by electronic means or to request Awardee’s consent to participate in the Plan by electronic means. Awardee hereby consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company, including the acceptance of performance share unit grants and the execution of performance share unit agreements through electronic signature.
16.Notices. All notices, requests, consents, and other communications required or provided under this Agreement to be delivered by Awardee to the Company will be in writing and will be deemed sufficient if delivered by hand, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to the Company at the address set forth below:
Cardinal Health, Inc.
7000 Cardinal Place
Dublin, Ohio 43017
Attention: Corporate Secretary
All notices, requests, consents, and other communications required or provided under this Agreement to be delivered by the Company to Awardee may be delivered by e-mail or in writing and will be deemed sufficient if delivered by e-mail, hand, facsimile, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to Awardee.
17.Employment Agreement, Offer Letter or Other Arrangement. To the extent a written employment agreement, offer letter or other arrangement (“Employment Arrangement”) that was approved by the Human Resources and Compensation Committee or the Board of Directors or that was approved in writing by an officer of the Company pursuant to delegated authority of the Human Resources and Compensation Committee provides for greater benefits to Awardee with respect to vesting of the Award on Termination of Employment by reason of specified events than provided in this Agreement or in the Plan, then the terms of such Employment Arrangement with respect to vesting of the Award on Termination of Employment by reason of such specified events supersede the terms of this Agreement to the extent permitted by the terms of the Plan. If Awardee is eligible for severance benefits under the Cardinal Health, Inc. Senior Executive Severance Plan, as amended, such plan also constitutes an “Employee Arrangement” for purposes of this section.
18.Amendment. Any amendment to the Plan is deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto; provided, however, that no amendment may impair the rights of Awardee with respect to an outstanding Performance Share Unit unless agreed to by Awardee and the Company, which agreement must be in writing and signed by Awardee and the Company. Other than following a Change of Control, no such agreement is required if the Administrator determines in its sole discretion that such amendment either (a) is required or advisable in order for the
    -9-    

Company, the Plan or the Performance Share Units to satisfy any Applicable Law or to meet the requirements of any accounting standard or (b) is not reasonably likely to significantly diminish the benefits provided under the Performance Share Units, or that any such diminishment has been adequately compensated, including pursuant to Section 16(c) of the Plan.
19.Adjustments. The number of Shares issuable for each Performance Share Unit and the other terms and conditions of the Award evidenced by this Agreement are subject to adjustment as provided in Section 16 of the Plan.
20.Compliance with Section 409A of the Code. To the extent applicable, it is intended that this Agreement comply with the provisions of Section 409A of the Code. This Agreement shall be administered in a manner consistent with this intent, and any provision that would cause this Agreement or the Plan to fail to satisfy Section 409A of the Code shall have no force or effect until amended to comply with Section 409A of the Code (which amendment may be retroactive to the extent permitted by Section 409A of the Code and may be made by the Company without the consent of Awardee).
21.Review. The Awardee agrees and represent that the Awardee has been advised to consult with an attorney prior to executing this Agreement and fully understands the Awardee’s right to discuss all aspects of this Agreement with an attorney of the Awardee’s choice. The Awardee’s execution of this Agreement establishes that, if the Awardee wishes the advice of an attorney, the Awardee has done so by the date the Awardee signed the Agreement, and that the Awardee was given at least 14 days to consider whether to sign. The Awardee may sign this Agreement before the end of the 14-day period and the Awardee agrees that if the Awardee decides to shorten this time period for signing, the Awardee’s decision was knowing and voluntary. The parties agree that a change, whether material or immaterial, does not restart the running of said period.
22.No Right to Future Awards or Employment. The grant of the Performance Share Units under this Agreement to Awardee is a voluntary, discretionary award being made on a one-time basis and it does not constitute a commitment to make any future awards. The grant of the Performance Share Units and any payments made under this Agreement will not be considered salary or other compensation for purposes of any severance pay or similar allowance, except as otherwise required by law. Nothing contained in this Agreement confers upon Awardee any right to be employed or remain employed by the Company or any of its Affiliates, nor limits or affects in any manner the right of the Company or any of its Affiliates to terminate the employment or adjust the compensation of Awardee.
23.Successors and Assigns. Without limiting Paragraph 2, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of Awardee, and the successors and assigns of the Company.
CARDINAL HEALTH, INC.


By:                                                                        
Its:                                                                        


    -10-    

ACCEPTANCE OF AGREEMENT AND APPLICATION OF CLAWBACK POLICIES
Awardee hereby: (a) acknowledges that he or she has received a copy of the Plan, a copy of the Company’s most recent annual report to shareholders and other communications routinely distributed to the Company’s shareholders, and a copy of the Plan Description pertaining to the Plan; (b) accepts this Agreement and the Performance Share Units granted to him or her under this Agreement subject to all provisions of the Plan and this Agreement, including the provisions in this Agreement regarding “Special Forfeiture and Repayment Rules” set forth in Paragraph 4; (c) represents that he or she understands that the acceptance of this Agreement through an on-line or electronic system, if applicable, carries the same legal significance as if he or she manually signed the Agreement; (d) agrees that no transfer of the Shares delivered in respect of the Performance Share Units may be made unless the Shares have been duly registered under all applicable Federal and state securities laws pursuant to a then-effective registration which contemplates the proposed transfer or unless the Company has received a written opinion of, or satisfactory to, its legal counsel that the proposed transfer is exempt from such registration; and (e) acknowledges that any awards granted to Awardee under any incentive plan, agreement or arrangement of the Company are subject to the forfeiture and repayment rules set forth in such plan, agreement or arrangement and, if applicable, to the Cardinal Health, Inc. Clawback Policy as in effect from time to time and agrees to be bound by these provisions with respect to any such awards.
                        [                        
                        Awardee’s Signature

                                                
                        Date]

    -11-    
 EX-10.1 4 5 aex1014formofrsuagreement.htm EX-10.1 4 Document
Exhibit 10.1.4
CARDINAL HEALTH, INC.
RESTRICTED SHARE UNITS AGREEMENT
This Restricted Share Units Agreement (this “Agreement”) is entered into in Franklin County, Ohio. On [grant date] (the “Grant Date”), Cardinal Health, Inc., an Ohio corporation (the “Company”), has awarded to [employee name] (“Awardee”) [# of shares] Stock Units (the “Restricted Share Units” or “Award”), representing an unfunded unsecured promise of the Company to deliver common shares, without par value, of the Company (the “Shares”) to Awardee as set forth in this Agreement. The Restricted Share Units have been granted pursuant to the Cardinal Health, Inc. 2021 Long-Term Incentive Plan, as amended (the “Plan”), and are subject to all provisions of the Plan, all of which are incorporated in this Agreement by reference and are subject to the provisions of this Agreement. Capitalized terms used in this Agreement which are not specifically defined have the meanings ascribed to such terms in the Plan.
1.Vesting of Restricted Share Units.
(a)General. [CLIFF ALTERNATIVE: The Restricted Share Units vest on the [ ] anniversary of the Grant Date (the “Vesting Date”), subject to the provisions of this Agreement, including those relating to Awardee’s continued employment with the Company and its Affiliates (collectively, the “Cardinal Group”).] [INSTALLMENT ALTERNATIVE: The Restricted Share Units vest in [ ] installments, which will be as nearly equal as possible, on the [ ] anniversaries of the Grant Date (each a “Vesting Date” with respect to the portion of the Restricted Share Units scheduled to vest on such date), subject in each case to the provisions of this Agreement, including those relating to Awardee’s continued employment with the Company and its Affiliates (collectively, the “Cardinal Group”).]
(b)Change of Control. In the event of a Change of Control prior to a Termination of Employment, the Restricted Share Units (to the extent not previously vested or forfeited) vest in full, except to the extent that a Replacement Award is provided to Awardee in accordance with Section 16(b) of the Plan. Any Replacement Award must vest in full upon (i) a Termination for Good Reason by Awardee, (ii) a Termination of Employment by the Company or its successor in the Change of Control other than a Termination for Cause, or (iii) Awardee’s death or Disability, in each case, occurring at or during the period of two years after the Change of Control. In addition, if a Replacement Award is provided, any Restricted Share Units that would vest in accordance with Paragraphs 3(b) or (c) in connection with Awardee’s Retirement or Disability if Awardee’s Termination of Employment occurred on the date of the Change of Control will for purposes of this Agreement vest at the time of the Change of Control.
2.Transferability. The Restricted Share Units are not transferable other than by beneficiary designation, will, or by the laws of descent or distribution.
3.Termination of Employment.
(a)General. Except as set forth in Paragraphs 1(b) and 3(b), (c) and (d) or as provided in a plan or agreement described in Paragraph 16 below, if a Termination of Employment occurs, then any unvested Restricted Share Units are forfeited by Awardee immediately upon such Termination of Employment.
(b)Death or Disability. If a Termination of Employment by reason of Awardee’s death occurs after the Grant Date or a Termination of Employment by reason of Awardee’s Disability occurs at



least 6 months after the Grant Date, then any outstanding unvested Restricted Share Units immediately vest in full and are not forfeited.
(c)Retirement. If a Termination of Employment by reason of Awardee’s Retirement occurs at least 6 months after the Grant Date, then a Ratable Portion of each unvested installment of the outstanding Restricted Share Units immediately vests and is not forfeited. Such “Ratable Portion,” with respect to the applicable installment, is an amount (rounded down to the nearest whole Share) equal to such installment of the Restricted Share Units scheduled to vest on a future Vesting Date multiplied by a fraction, the numerator of which is the number of days from the Grant Date through the date of the Termination of Employment, and the denominator of which is the number of days from the Grant Date through such Vesting Date.1
(d)Involuntary Termination with Separation Agreement. If (i) Paragraph 3(c) is not applicable, but Awardee has attained either (A) age 53 and at least eight years of continuous service with the Cardinal Group or (B) age 59 and at least four years of continuous service with the Cardinal Group, in each case including service with an Affiliate of the Company prior to the time that such Affiliate became an Affiliate of the Company, (ii) a Termination of Employment by the Cardinal Group (other than a Termination for Cause) occurs at least 6 months after the Grant Date, and (iii) no later than 45 days after the Termination of Employment, Awardee enters into a written separation agreement and general release of claims with the Cardinal Group (in such form as may reasonably be presented by the Company) (a “Separation Agreement”), and Awardee does not timely revoke such Separation Agreement, then a Ratable Portion of each unvested installment of the outstanding Restricted Share Units immediately vests and is not forfeited.
4.Special Forfeiture and Repayment Rules. This Agreement contains special forfeiture and repayment rules intended to encourage conduct that protects the Cardinal Group’s legitimate business assets and discourage conduct that threatens or harms those assets. The Company does not intend to have the benefits of this Agreement reward or subsidize conduct detrimental to the Company, and therefore will require the forfeiture of the benefits offered under this Agreement and the repayment of gains obtained from this Agreement, according to the rules specified below. Activities that trigger the forfeiture and repayment rules are divided into two categories: Misconduct and Competitor Conduct. Awardee also agrees to application of the Company’s Clawback Policy described in Paragraph 4(d) below.
(a)Misconduct. During employment with the Cardinal Group and with respect to clauses (A), (D), (E), (F) and (G), for three years after the Termination of Employment for any reason, Awardee agrees not to engage in Misconduct. If Awardee engages in Misconduct during employment or within three years after the Termination of Employment for any reason, then
(i)Awardee immediately forfeits the Restricted Share Units that have not yet vested or that vested at any time within three years prior to the date the Misconduct first occurred and have not yet been paid pursuant to Paragraph 5, and those forfeited Restricted Share Units automatically terminate, and
(ii)Awardee shall, within 30 days following written notice from the Company, pay to the Company in cash an amount equal to (A) the gross gain to Awardee resulting from the payment of Restricted Share Units pursuant to Paragraph 5 that had vested at any time within three years prior to the date the Misconduct first occurred less (B) $1.00. The gross gain is the Fair Market Value of the Shares represented by the Restricted Share Units on the date of receipt.
1 This provision is an alternative that may not be included in every award agreement.
2


As used in this Agreement, “Misconduct” means
(A)disclosing or using any of the Cardinal Group’s confidential information (as defined by the applicable Cardinal Group policies and agreements) without proper authorization from the Cardinal Group or in any capacity other than as necessary for the performance of Awardee’s assigned duties for the Cardinal Group;
(B)violation of the Standards of Business Conduct or any successor code of conduct or other applicable Cardinal Group policies, including but not limited to conduct which would constitute a breach of any representation or certificate of compliance signed by Awardee;
(C)fraud, gross negligence or willful misconduct by Awardee, including but not limited to fraud, gross negligence or willful misconduct causing or contributing to a material error resulting in a restatement of the financial statements of any member of the Cardinal Group;
(D)directly or indirectly soliciting or recruiting for employment or contract work on behalf of a person or entity other than a member of the Cardinal Group, any person who is an employee, representative, officer or director in the Cardinal Group or who held one or more of those positions at any time within the 12 months prior to Awardee’s Termination of Employment;
(E)directly or indirectly inducing, encouraging or causing an employee of the Cardinal Group to terminate his/her employment or a contract worker to terminate his/her contract with a member of the Cardinal Group;
(F)any action by Awardee and/or his or her representatives that either does or could reasonably be expected to undermine, diminish or otherwise damage the relationship between the Cardinal Group and any of its customers, prospective customers, vendors, suppliers or employees known to Awardee; or
(G)breaching any provision of any employment or severance agreement with a member of the Cardinal Group.
Nothing in this Agreement will prevent Awardee from testifying truthfully as required by law, prohibit or prevent Awardee from filing a charge with or participating, testifying or assisting in any investigation, hearing, whistleblower proceeding or other proceeding before any federal, state or local government agency (e.g., Equal Employment Opportunity Commission, National Labor Relations Board, Securities and Exchange Commission, etc.), or prevent Awardee from disclosing Cardinal Group’s confidential information in confidence to a federal, state or local government official for the purpose of reporting or investigating a suspected violation of law.
(b)Competitor Conduct. If Awardee engages in Competitor Conduct during employment or within one year after the Termination of Employment for any reason, then
(i)Awardee immediately forfeits the Restricted Share Units that have not yet vested or that vested at any time within one year prior to the date the Competitor Conduct first occurred and have not yet been paid pursuant to Paragraph 5, and those forfeited Restricted Share Units automatically terminate, and
(ii)Awardee shall, within 30 days following written notice from the Company, pay to the Company in cash an amount equal to (A) the gross gain to Awardee resulting from the
3


payment of Restricted Share Units pursuant to Paragraph 5 that had vested at any time since the earlier of one year prior to the date the Competitor Conduct first occurred or one year prior to the Termination of Employment, if applicable, less (B) $1.00. The gross gain is the Fair Market Value of the Shares represented by the Restricted Share Units on the date of receipt.
As used in this Agreement, “Competitor Conduct” means accepting employment with, or directly or indirectly providing services to, a Competitor in the United States. If Awardee has a Termination of Employment and Awardee’s responsibilities to the Cardinal Group were limited to a specific territory or territories within or outside the United States during the 24 months prior to the Termination of Employment, then Competitor Conduct will be limited to that specific territory or territories. A “Competitor” means any person or business that competes with the products or services provided by a member of the Cardinal Group for which Awardee had business responsibilities within 24 months prior to Termination of Employment or about which Awardee obtained confidential information (as defined by the applicable Cardinal Group policies or agreements).
(c)General.
(i)Nothing in this Paragraph 4 constitutes or is to be construed as a “noncompete” covenant or other restraint on employment or trade. The provisions of this Paragraph 4 do not prevent, nor are they intended to prevent, Awardee from seeking or accepting employment or other work outside the Cardinal Group. The execution of this Agreement is voluntary. Awardee is free to choose to comply with the terms of this Agreement and receive the benefits offered or else reject this Agreement with no adverse consequences to Awardee’s employment with the Cardinal Group.
(ii)Awardee agrees to provide the Company with at least 10 days’ written notice prior to accepting employment with or providing services to a Competitor within one year after Termination of Employment.
(iii)Awardee acknowledges receiving sufficient consideration for the requirements of this Paragraph 4, including Awardee’s receipt of the Restricted Share Units. Awardee further acknowledges that the Company would not provide the Restricted Share Units to Awardee without Awardee’s promise to abide by the terms of this Paragraph 4. The parties also acknowledge that the provisions contained in this Paragraph 4 are ancillary to, or part of, an otherwise enforceable agreement at the time this Agreement is made.
(iv)Awardee may be released from the obligations of this Paragraph 4 if and only if the Administrator determines, in writing and in the Administrator’s sole discretion, that a release is in the best interests of the Company.
(d)Clawback Policy. Awardee acknowledges and agrees that, in addition to the other provisions of Paragraph 4, Awardee and this Award will be subject to the terms of the Clawback Policy adopted by the Company, as required by New York Stock Exchange listing standards and as may be in effect from time to time, and Awardee agrees to comply with the requirements of such policy. In its discretion, moreover, the Administrator may require repayment to the Company of all or any portion of this Award if the amount of the Award was calculated based upon the achievement of financial results that were subsequently the subject of a restatement of the Company’s financial statements, Awardee engaged in misconduct that caused or contributed to the need for the restatement of the financial statements, and the amount payable to Awardee would have been lower than the amount actually paid to
4


Awardee had the financial results been properly reported. This Paragraph 4(d) is not the Company’s exclusive remedy with respect to such matters.
5.Payment.
    (a)    General. Subject to the provisions of Paragraph 4 and Paragraphs 5(b), (c), (d) and (e), Awardee is entitled to receive from the Company (without any payment by or on behalf of Awardee other than as described in Paragraph 9) the Shares represented by the vested Restricted Share Units on the Vesting Date.
(a)Death. To the extent that Restricted Share Units are vested on the date of Awardee’s Termination of Employment due to death, Awardee’s estate or designated beneficiary is entitled to receive the corresponding Shares from the Company on the date of death.
(b)Disability, Retirement and Other Separations from Service. To the extent that Restricted Share Units are vested as the result of Disability, Retirement or otherwise on the date of Awardee’s “separation from service” (determined in accordance with Section 409A of the Code), Awardee is entitled to receive the corresponding Shares from the Company on the date that is not later than 60 days after Awardee’s “separation from service”; provided, however, that if Awardee on the date of separation from service is a “specified employee” (certain employees of the Cardinal Group within the meaning of Section 409A of the Code determined using the identification methodology selected by the Company from time to time), to the extent necessary to avoid the imposition of tax under Section 409A of the Code, Awardee is entitled to receive the corresponding Shares from the Company six months after the date of Awardee’s separation from service or, if earlier, the date of Awardee’s death.
(c)Change of Control. To the extent that Restricted Share Units are vested on the date of a Change of Control, Awardee is entitled to receive the corresponding Shares from the Company on the date of the Change of Control; provided, however, that if such Change of Control would not qualify as a permissible date of distribution under Section 409A(a)(2)(A)(v) of the Code and the regulations thereunder, and where Section 409A of the Code applies to such distribution as a deferral of compensation, Awardee is entitled to receive the corresponding Shares from the Company on the date that would have otherwise applied pursuant to Paragraphs 5(a), (b) or (c).
(d)Elections to Defer Receipt. Elections to defer receipt of the Shares beyond the date of payment provided in this Agreement may be permitted in the discretion of the Administrator pursuant to procedures established by the Administrator in compliance with the requirements of Section 409A of the Code.
6.Dividend Equivalents. Awardee is not entitled to receive cash dividends on the Restricted Share Units but will receive a dividend equivalent payment from the Company in an amount equal to the dividends that would have been paid on each Share underlying the Restricted Share Units if it had been outstanding between the Grant Date and the payment date of any such Share (i.e., based on the record date for cash dividends). Subject to an election to defer receipt if permitted under Paragraph 5(e), the Company shall pay dividend equivalent payments in cash as soon as reasonably practicable after the payment date of the Restricted Share Units to which such dividend equivalents relate.
7.Right of Set-Off. By accepting the Restricted Share Units, Awardee consents to a deduction from, and set-off against, any amounts owed to Awardee that are not treated as “non-qualified deferred compensation” under Section 409A of the Code by any member of the Cardinal Group from time
5


to time (including, but not limited to, amounts owed to Awardee as wages, severance payments or other fringe benefits) to the extent of the amounts owed to the Cardinal Group by Awardee under this Agreement, subject to Applicable Law.
8.No Shareholder Rights. Awardee has no rights of a shareholder with respect to the Restricted Share Units, including no right to vote the Shares represented by the Restricted Share Units, until such Shares vest and are paid to Awardee.
9.Withholding Tax.
(a)Generally. Awardee is liable and responsible for all taxes owed in connection with the Restricted Share Units (including taxes owed with respect to the cash payments described in Paragraph 6), regardless of any action the Company takes with respect to any tax withholding obligations that arise in connection with the Restricted Share Units. The Company does not make any representation or undertaking regarding the tax treatment or the treatment of any tax withholding in connection with the grant, vesting or payment of the Restricted Share Units or the subsequent sale of Shares issuable pursuant to the Restricted Share Units. The Company does not commit and is under no obligation to structure the Restricted Share Units to reduce or eliminate Awardee’s tax liability.
(b)Payment of Withholding Taxes. Prior to any event in connection with the Restricted Share Units (e.g., vesting or payment) that the Company determines may result in any domestic or foreign tax withholding amounts being paid by the Company, whether national, federal, state or local, including any employment tax obligation (the “Tax Withholding Obligation”), Awardee is required to arrange for the satisfaction of the minimum amount of such Tax Withholding Obligation in a manner acceptable to the Company. Awardee’s acceptance of this Agreement constitutes Awardee’s instruction and authorization to the Company to withhold on Awardee’s behalf the number of Shares from those Shares issuable to Awardee under this Award as the Company determines to be sufficient to satisfy the Tax Withholding Obligation. In the case of any amounts withheld for taxes pursuant to this provision in the form of Shares, the amount withheld may not exceed the amount legally required and withholding above the minimum withholding requirements shall be available only if and to the extent that the Administrator has authorized such. The Company has the right to deduct from all cash payments paid pursuant to Paragraph 6 the amount of any taxes which the Company is required to withhold with respect to such payments.
10.Governing Law/Venue for Dispute Resolution/Costs and Legal Fees. This Agreement is governed by the laws of the State of Ohio, without regard to principles of conflicts of law, except to the extent superseded by the laws of the United States of America. The parties agree and acknowledge that the laws of the State of Ohio bear a substantial relationship to the parties and/or this Agreement and that the Restricted Share Units and benefits granted in this Agreement would not be granted without the governance of this Agreement by the laws of the State of Ohio. In addition, all legal actions or proceedings relating to this Agreement must be brought exclusively in state or federal courts located in Franklin County, Ohio and the parties executing this Agreement hereby consent to the personal jurisdiction of such courts. Awardee acknowledges that the provisions of Paragraph 4 are reasonable in nature, are fundamental for the protection of the Company’s legitimate business and proprietary interests, and do not adversely affect Awardee’s ability to earn a living. If it becomes necessary for the Company to institute legal proceedings under this Agreement, Awardee is responsible to the Company for all costs and reasonable legal fees incurred by the Company in connection with the proceedings. Any provision of this Agreement which is determined by a court of competent jurisdiction to be invalid or unenforceable or to disqualify the Award under any Applicable Law should
6


be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by the provision, without invalidating or rendering unenforceable the remaining provisions of this Agreement.
11.Defend Trade Secrets Act Notice. Under the U.S. Defend Trade Secrets Act of 2016, Awardee will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, and (ii) solely for the purpose of reporting or investigating a suspected violation of law; (b) is made to Awardee’s attorney in relation to a lawsuit for retaliation against Awardee for reporting a suspected violation of law; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
12.Action by the Administrator. The parties agree that the interpretation of this Agreement rests exclusively and completely within the sole discretion of the Administrator. The parties agree to be bound by the decisions of the Administrator regarding the interpretation of this Agreement and regarding any and all matters set forth in this Agreement. In fulfilling its responsibilities under this Agreement, the Administrator may rely upon documents, written statements of the parties, financial reports or other material as the Administrator deems appropriate. The parties agree that there is no right to be heard or to appear before the Administrator and that any decision of the Administrator relating to this Agreement, including whether conduct constitutes Misconduct or Competitor Conduct, is final and binding. The Administrator may delegate its functions under this Agreement to an officer of the Cardinal Group designated by the Administrator, to the extent permitted under the Plan.
13.Prompt Acceptance of Agreement. The Restricted Share Unit grant evidenced by this Agreement will, at the discretion of the Administrator, be forfeited if this Agreement is not manually executed and returned to the Company, or electronically executed by Awardee by indicating Awardee’s acceptance of this Agreement in accordance with the acceptance procedures set forth on the Company’s third-party equity plan administrator’s web site, within 90 days of the Grant Date.
14.Electronic Delivery and Consent to Electronic Participation. The Company may, in its sole discretion, decide to deliver any documents related to the Restricted Share Unit grant under and participation in the Plan or future Restricted Share Units that may be granted under the Plan by electronic means or to request Awardee’s consent to participate in the Plan by electronic means. Awardee hereby consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company, including the acceptance of restricted share unit grants and the execution of restricted share unit agreements through electronic signature.
15.Notices. All notices, requests, consents, and other communications required or provided under this Agreement to be delivered by Awardee to the Company will be in writing and will be deemed sufficient if delivered by hand, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to the Company at the address set forth below:
        Cardinal Health, Inc.
        7000 Cardinal Place
        Dublin, Ohio 43017
        Attention: Corporate Secretary

7


All notices, requests, consents, and other communications required or provided under this Agreement to be delivered by the Company to Awardee may be delivered by e-mail or in writing and will be deemed sufficient if delivered by e-mail, hand, facsimile, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to Awardee.
16.Employment Agreement, Offer Letter or Other Arrangement. To the extent a written employment agreement, offer letter or other arrangement (“Employment Arrangement”) that was approved by the Human Resources and Compensation Committee or the Board of Directors or that was approved in writing by an officer of the Company pursuant to delegated authority of the Human Resources and Compensation Committee provides for greater benefits to Awardee with respect to vesting of the Award on Termination of Employment by reason of specified events than provided in this Agreement or in the Plan, then the terms of such Employment Arrangement with respect to vesting of the Award on Termination of Employment by reason of such specified events supersede the terms of this Agreement to the extent permitted by the terms of the Plan. If Awardee is eligible for severance benefits under the Cardinal Health, Inc. Senior Executive Severance Plan, as amended, such plan also constitutes an “Employee Arrangement” for purposes of this section.
17.Amendment. Any amendment to the Plan is deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto; provided, however, that no amendment may impair the rights of Awardee with respect to an outstanding Restricted Share Unit unless agreed to by Awardee and the Company, which agreement must be in writing and signed by Awardee and the Company. Other than following a Change of Control, no such agreement is required if the Administrator determines in its sole discretion that such amendment either (a) is required or advisable in order for the Company, the Plan or the Restricted Share Units to satisfy any Applicable Law or to meet the requirements of any accounting standard or (b) is not reasonably likely to significantly diminish the benefits provided under the Restricted Share Units, or that any such diminishment has been adequately compensated, including pursuant to Section 16(c) of the Plan.
18.Adjustments. The number of Shares issuable for each Restricted Share Unit and the other terms and conditions of the Award evidenced by this Agreement are subject to adjustment as provided in Section 16 of the Plan.
19.Compliance with Section 409A of the Code. To the extent applicable, it is intended that this Agreement comply with the provisions of Section 409A of the Code. This Agreement shall be administered in a manner consistent with this intent, and any provision that would cause this Agreement or the Plan to fail to satisfy Section 409A of the Code shall have no force or effect until amended to comply with Section 409A of the Code (which amendment may be retroactive to the extent permitted by Section 409A of the Code and may be made by the Company without the consent of Awardee).
20.No Right to Future Awards or Employment. The grant of the Restricted Share Units under this Agreement to Awardee is a voluntary, discretionary award being made on a one-time basis and it does not constitute a commitment to make any future awards. The grant of the Restricted Share Units and any payments made under this Agreement will not be considered salary or other compensation for purposes of any severance pay or similar allowance, except as otherwise required by law. Nothing contained in this Agreement confers upon Awardee any right to be employed or remain employed by the Company or any of its Affiliates, nor limits or affects in any manner the right of the Company or any of its Affiliates to terminate the employment or adjust the compensation of Awardee.
8


21.Review. The Awardee agrees and represent that the Awardee has been advised to consult with an attorney prior to executing this Agreement and fully understands the Awardee’s right to discuss all aspects of this Agreement with an attorney of the Awardee’s choice. The Awardee’s execution of this Agreement establishes that, if the Awardee wishes the advice of an attorney, the Awardee has done so by the date the Awardee signed the Agreement, and that the Awardee was given at least 14 days to consider whether to sign. The Awardee may sign this Agreement before the end of the 14-day period and the Awardee agrees that if the Awardee decides to shorten this time period for signing, the Awardee’s decision was knowing and voluntary. The parties agree that a change, whether material or immaterial, does not restart the running of said period.
22.Successors and Assigns. Without limiting Paragraph 2, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of Awardee, and the successors and assigns of the Company.

                    CARDINAL HEALTH, INC.

                    By:                         
                    Its:                         



9


ACCEPTANCE OF AGREEMENT AND APPLICATION OF CLAWBACK POLICIES
Awardee hereby: (a) acknowledges that he or she has received a copy of the Plan, a copy of the Company’s most recent annual report to shareholders and other communications routinely distributed to the Company’s shareholders, and a copy of the Plan Description pertaining to the Plan; (b) accepts this Agreement and the Restricted Share Units granted to him or her under this Agreement subject to all provisions of the Plan and this Agreement, including the provisions in the Agreement regarding “Special Forfeiture and Repayment Rules” set forth in Paragraph 4; (c) represents that he or she understands that the acceptance of this Agreement through an on-line or electronic system, if applicable, carries the same legal significance as if he or she manually signed the Agreement; (d) agrees that no transfer of the Shares delivered in respect of the Restricted Share Units may be made unless the Shares have been duly registered under all applicable Federal and state securities laws pursuant to a then-effective registration which contemplates the proposed transfer or unless the Company has received a written opinion of, or satisfactory to, its legal counsel that the proposed transfer is exempt from such registration; and (e) acknowledges that any awards granted to Awardee under any incentive plan, agreement or arrangement of the Company are subject to the forfeiture and repayment rules set forth in such plan, agreement or arrangement and, if applicable, to the Cardinal Health, Inc. Clawback Policy as in effect from time to time and agrees to be bound by these provisions with respect to such awards.
                        [                        
                        Awardee’s Signature

                                                
                        Date]

10
 EX-10.2 6 a10-qex102amendmentno1tomip.htm EX-10.2 Document
Exhibit 10.2
FIRST AMENDMENT TO THE
CARDINAL HEALTH, INC. MANAGEMENT INCENTIVE PLAN
This First Amendment to the Cardinal Health, Inc. Management Incentive Plan (the “Plan”) was adopted on January 29, 2024 by the Human Resources and Compensation Committee of the Board of Directors of Cardinal Health, Inc. (the “Company”).

The Plan is hereby amended, effective as of January 29, 2024, as follows:

1.Section 5(b)(ii) of the Plan is hereby deleted in its entirety and in replacement thereof shall be the following:
“(ii)    Mandatory Deferral. The Administrator additionally or alternatively may establish one or more programs under the Plan to require the deferral of payment of any Award for any specified period after the end of the applicable Performance Period, during which time the amount payable under the deferred Award may be reduced if and to the extent that the Administrator determines that the Participant whose Award is subject to reduction under Section 7 of the Plan. In such case, the Administrator will establish the conditions and mechanisms for payments of, and accrual of interest or other earnings, if any, on amounts so deferred, and such other terms, conditions, rules, and procedures that the Administrator deems advisable for the administration of any such deferral program.
2.The title of Section 7 of the Plan is changed to “Clawback Policy; Other Special Repayment and Forfeiture Events.”
3.Section 7(a) of the Plan is hereby deleted in its entirety and in replacement thereof shall be the following:
“(a)    Clawback Policy. In addition to the other provisions of this Section 7, to the extent applicable, Participants and Awards will be subject to the terms of the Cardinal Health, Inc. Clawback Policy adopted by the Company, as required by New York Stock Exchange listing standards and as may be in effect from time to time. In its discretion, moreover, the Administrator may require repayment to the Company of all or any portion of any Award if the amount of the Award was calculated based upon the achievement of financial results that were subsequently the subject of a restatement of the Company’s financial statements, the Participant engaged in misconduct that caused or contributed to the need for the restatement of the financial statements, and the amount payable to the Participant would have been lower than the amount actually paid to the Participant had the financial results been properly reported. This Section 7(a) will not be the Company’s exclusive remedy with respect to such matters.

 EX-31.1 7 a24q3_10qx33124xexhibit311.htm EX-31.1 Document
Exhibit 31.1

I, Jason M. Hollar, certify that:
1.I have reviewed this Form 10-Q of Cardinal Health, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 2, 2024
/s/ JASON M. HOLLAR
Jason M. Hollar
Chief Executive Officer


 EX-31.2 8 a24q3_10qx33124xexhibit312.htm EX-31.2 Document
Exhibit 31.2

I, Aaron E. Alt, certify that:
1.I have reviewed this Form 10-Q of Cardinal Health, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 2, 2024
/s/ AARON E. ALT
Aaron E. Alt
Chief Financial Officer


 EX-32.1 9 a24q3_10qx33124xexhibit321.htm EX-32.1 Document
Exhibit 32.1

Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Jason M. Hollar, Chief Executive Officer of Cardinal Health, Inc. (the “Company”) and Aaron E. Alt, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that:
(1)the Periodic Report on Form 10-Q for the quarter ended March 31, 2024 containing the financial statements of the Company (the “Periodic Report”), which this statement accompanies, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
(2)the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: May 2, 2024
/s/ JASON M. HOLLAR
Jason M. Hollar
Chief Executive Officer
/s/ AARON E. ALT
Aaron E. Alt
Chief Financial Officer


 EX-99.1 10 a24q3_10qx33124xexhibit991.htm EX-99.1 Document
Exhibit 99.1



Statement Regarding Forward-Looking Information
As used in this exhibit, “we,” “our,” “us” and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (the “2023 Form 10-K”), and our quarterly reports on Form 10-Q, including this one, and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include:
•competitive pressures in the markets in which we operate, including pricing pressures;
•uncertainties relating to the pricing of and demand for generic pharmaceuticals;
•significantly increased costs for commodities and other materials used in the Global Medical Products and Distribution segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities and the possibility that we may not successfully offset or mitigate these increases;
•uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches or other components of our pharmaceutical generics program;
•changes in the timing or frequency of the introduction of branded pharmaceuticals;
•uncertainties related to the timing, magnitude and profit impact of the distribution of commercially available COVID-19 vaccines;
•material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers;
•Risks associated with the nonrenewal of a large Pharmaceutical and Specialty Solutions segment customer at the end of fiscal year 2024, including the adverse impact of unwinding the negative net working capital associated with this customer and the risk that we may not be successful in mitigating the negative impact to segment profit;
•costs or claims resulting from quality issues, or other potential or alleged errors or defects in our manufacturing or sourcing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls, remediation efforts, and related product liability claims and lawsuits, including class action lawsuits;
•any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption;
•continuing risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including the investigations by the U.S. Department of Justice which concerns our anti-diversion program, our anti-diversion policies and procedures and our distribution of certain controlled substances;
•risks associated with the national opioid settlement agreement, including the risk that the maintenance of the required changes to distributors' controlled substance anti-diversion programs may result in unforeseen costs or operational challenges and the risk that if we fail to or are alleged to have failed to comply with the terms of the settlement agreement, we could incur monetary or other penalties or result in additional lawsuits being filed against us;
•uncertainties related to Cardinal Health Brand products, including our ability to manage cost and infrastructure, retain margin, increase volume and improve performance;
•risks arising from acquisitions, including possible liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions;
•risks associated with the tax benefit from our self-insurance loss claims, including, certain state courts' interpretation of laws and insurance policies in ways that may impact our self-insurance loss, which could negatively impact our financial position;
•disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks;
•risks associated with our Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services, including the risk that failure to comply with the requirements set forth therein could result in monetary or other penalties;
•our high sales concentration with certain key customers, including CVS Health Corporation and OptumRx;
•our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation;
•actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or


governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions;
•shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes;
•the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available;
•uncertainties with respect to certain business process initiatives, including IT infrastructure activities and outsourcing relationships, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel;
•difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties', or approvals associated with those activities;
•manufacturing disruptions, whether due to regulatory action, including regulatory action to reduce ethylene oxide ("EtO") emissions, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities;
•risks associated with industry reliance on EtO to sterilize certain medical products that we manufacture or distribute, including the possibility that regulatory actions to reduce EtO emissions could become more widespread, which may result in increased costs or supply shortages; and risks that the lawsuits against us alleging personal injury resulting from EtO exposure could become more widespread;
•the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased;
•risks arising from possible violations of healthcare fraud and abuse laws;
•risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws;
•risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information;
•risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements;
•risks arising from pharmaceutical manufacturers' restriction of sales under the 340B drug pricing program to contract pharmacies, which may adversely impact our customers;
•risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations;
•changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications;
•unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix;
•risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments;
•uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All;
•reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services;
•changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices;
•changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits;
•uncertainties arising as a result of the Supreme Court decision on Dobbs vs. Jackson, including uncertainties associated with states' proposed and adopted laws which may impact our ability to distribute or store certain pharmaceutical products and the risk that we could incur unforeseen costs to comply with these new laws in various jurisdictions;
•changes in hospital buying groups or hospital buying practices;
•changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution;


•changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid;
•continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers;
•risks to our business and information and controls systems in the event that business process improvements, infrastructure modernization or initiatives to use third-party service providers for key systems and processes are not effectively implemented;
•the risk that we may not effectively implement and maintain data governance structures across businesses to allow us to access and interpret our data, which could put us at a competitive disadvantage relative to our peers;
•the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, qui tam actions, government investigations, shareholder lawsuits or other legal proceedings;
•the possibility that our business performance or internal control over financial reporting may be adversely impacted if we are not successful at attracting, retaining and developing talent;
•losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products;
•risks associated with the importation of products or source materials used in products that we manufacture or distribute, including risks associated with our country-of-origin determinations and the possibility that we could experience additional supply disruptions as a result of the Uyghur Forced Labor Prevention Act or other similar regulations;
•our ability to maintain adequate intellectual property protections;
•our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives;
•bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount;
•risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations;
•uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business;
•risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures;
•our ability to introduce and market new products and our ability to keep pace with advances in technology;
•significant charges to earnings if goodwill or intangible assets become impaired;
•uncertainties relating to general political, business, industry, regulatory and market conditions; and
•other factors described in the “Risk Factors” section of the 2023 Form 10-K.
The words “expect,” “anticipate,” “intend,” “plan,” “believe,” “will,” “should,” “could,” “would,” “project,” “continue,” “likely,” and similar expressions generally identify “forward-looking statements,” which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.ted, anticipated or implied in or by such statements. These risks and uncertainties include:


 EX-101.SCH 11 cah-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Statements of Earnings link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Business Combinations and Asset Acquisitions link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Divestitures link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Restructuring and Employee Severance link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Commitments, Contingent Liabilities and Litigation link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Business Combinations and Asset Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Discontinued Operations and Disposal Groups (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Restructuring and Employee Severance (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Business Combinations and Asset Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Discontinued Operations and Disposal Groups (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Restructuring and Employee Severance Narative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Financial Instruments (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Shareholders' Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Segment Information (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Segment Information (Assets by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Share-Based Compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 cah-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 cah-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 cah-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stockholders' Equity, Other Shares Stockholders' Equity, Other Shares 4.9% Notes due 2045 4.9% Notes due 2045 [Member] 4.9% Notes due 2045 5.45% Notes due 2034 5.45% Notes due 2034 [Member] 5.45% Notes due 2034 Adjustments to reconcile net earnings to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Goodwill acquired, net of purchase price adjustments Goodwill, Acquired During Period Statistical Measurement [Domain] Statistical Measurement [Domain] OptiFreight Logistics [Member] OptiFreight Logistics [Member] OptiFreight Logistics Reduction of long-term obligations Repayments of Long-Term Debt Cover [Abstract] Cover [Abstract] Net decrease in cash and equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Indefinite-Lived Intangible Assets [Table] Intangible Asset, Indefinite-Lived [Table] Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Equity Method Investment, Ownership Percentage Equity Method Investment, Ownership Percentage Fair Value Hedging Fair Value Hedging [Member] Total comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest All Trading Arrangements All Trading Arrangements [Member] Long-term obligations, less current portion Long-Term Debt and Lease Obligation Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Award vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Tax benefit related to share-based compensation Share-Based Payment Arrangement, Expense, Tax Benefit Segment Revenue from External Customers by Geographic Area [Table] Segment Revenue from External Customers by Geographic Area [Table] Segment Revenue from External Customers by Geographic Area [Table] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash dividends declared per common share Common Stock, Dividends, Per Share, Declared Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Schedule of Total Share-based Compensation Expense by Type of Award Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Disposal Group Name [Domain] Disposal Group Name [Domain] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Vesting Period in years for Shares Vesting Period in years for Shares Vesting Period in years for Shares Derivative [Table] Derivative [Table] Currency Swap [Member] Currency Swap [Member] Product Liability Lawsuits Product Liability Lawsuits [Member] Product Liability Lawsuits [Member] Goodwill and other intangibles, net Intangible Assets, Net (Including Goodwill) Class Action Lawsuits [Member] Class Action Lawsuits [Member] Class Action Lawsuits [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Hedging Relationship [Domain] Hedging Relationship [Domain] Fair Value Disclosures Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Net Investment Hedging [Member] Net Investment Hedging [Member] Other accrued liabilities and operating items, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Other Borrowings Other Borrowings Common shares, without par value: Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Investment, Name [Domain] Investment, Name [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Estimated annual amortization of intangible assets - Year Three Finite-Lived Intangible Asset, Expected Amortization, Year Three Goodwill [Line Items] Goodwill [Line Items] Debt and Lease Obligation Debt and Lease Obligation Loss Contingency, Pending Claims, Number Loss Contingency, Pending Claims, Number Cash Flow Hedging [Member] Cash Flow Hedging [Member] Restructuring Charges [Abstract] Restructuring Charges [Abstract] Maturity Date Maturity Date [Axis] Maturity Date Purchase of noncontrolling interests Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Updated Segment Reporting Structure Segment Reporting, Policy [Policy Text Block] UNITED STATES UNITED STATES Employee stock options, restricted share units, and performance share units (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Outcomes divestiture [Axis] Outcomes divestiture [Axis] Outcomes divestiture Gross Intangible Finite-Lived Intangible Assets, Gross Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Treasury shares acquired (in shares) Treasury Stock, Shares, Acquired Treasury Stock, Shares, Acquired Payments for Legal Settlements Payments for Legal Settlements Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] Operating Segments Operating Segments [Member] June 2027 June 2027 [Member] June 2027 Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Treasury Stock, Common Treasury Shares Treasury Stock, Common [Member] Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Other Stockholders' Equity, Other Equity Components [Axis] Equity Components [Axis] Loss Contingency Accrual, Period Increase (Decrease) Loss Contingency Accrual, Period Increase (Decrease) Prepaid expenses and other Other Assets, Current Award Timing Method Award Timing Method [Text Block] Facility Exit and Other Costs Facility Closing [Member] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Restructuring Type [Axis] Restructuring Type [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Committed Receivables Sales Facility Program [Member] Committed Receivables Sales Facility Program [Member] Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Proceeds from divestitures, net of cash sold Proceeds from Divestiture of Businesses Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Project costs on investment and other spending Project Costs On Investment And Other Spending Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses. 3.079% Notes due 2024 3.079% Notes due 2024 [Member] 3.079% Notes due 2024 Adjustment to Compensation, Amount Adjustment to Compensation Amount September 2025 September 2025 [Member] September 2025 Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Developed Technology Rights [Member] Developed technology and other Developed Technology Rights [Member] Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Summary of Restructuring and Employee Severance Restructuring and Related Costs [Table Text Block] Tabular List, Table Tabular List [Table Text Block] Indemnification Receivable Indemnification Receivable Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes. Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Award Date [Axis] Award Date [Axis] Net tax proceeds from share-based compensation Net proceeds/(tax withholdings) from share-based compensation The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Trade receivables, net Receivables, Net, Current Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Loss Contingency Accrual Loss Contingency Accrual Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Estimated Litigation Liability Estimated Litigation Liability Plaintiff Type [Domain] Plaintiff Type [Domain] [Domain] for Plaintiff Type [Axis] Payments and other adjustments Payments for Restructuring WEST VIRGINIA WEST VIRGINIA Credit Facility [Domain] Credit Facility [Domain] Cash and equivalents at beginning of period Cash and equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Remaining Cash from Debt Proceeds [Axis] Remaining Cash from Debt Proceeds [Axis] Remaining Cash from Debt Proceeds Current assets: Assets, Current [Abstract] Goodwill Beginning balance Ending balance Goodwill Pharmaceutical and Specialty Solutions Pharmaceutical and Specialty Solutions [Member] Pharmaceutical and Specialty Solutions Consolidation Items [Axis] Consolidation Items [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Other comprehensive income/(loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Settling U.S Territories Settling U.S Territories Settling U.S Territories Common shares in treasury Treasury, balance at beginning of period (in shares) Treasury, balance at end of period (in shares) Treasury Stock, Common, Shares Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Employee Stock Option Employee Stock Option [Member] Schedule of Segment Reporting Information, by Segment [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Vested (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Goodwill [Roll Forward] Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] 4.368% Notes due 2047 4.368% Notes due 2047 [Member] 4.368% Notes due 2047 Total comprehensive income attributable to Cardinal Health, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent 7.0% Debentures due fiscal 2027 7.0% Debentures due fiscal 2027 [Member] 7.0% Debentures due fiscal 2027 Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] Proceeds from investments Proceeds from sale of available-for-sale securities and other investments The cash inflow from sales of available-for-sale securities and other investments. Foreign currency translation adjustments and other Goodwill, Foreign Currency Translation Gain (Loss) Earnings per common share attributable to Cardinal Health, Inc.: Earnings Per Share, Basic [Abstract] Outcomes divestiture [Domain] Outcomes divestiture [Domain] Outcomes divestiture [Domain] Restricted Share Units Performance Share Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property and equipment, net Property, Plant and Equipment, Net Noncontrolling interests Equity, Attributable to Noncontrolling Interest Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revolving Credit Facility [Member] Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date Fair Value, Nonrecurring Fair Value, Nonrecurring [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Reclassification out of Accumulated Other Comprehensive Loss [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Facility Exit and Other Costs Facility Exit and Other Costs Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services. Subsegments [Axis] Subsegments [Axis] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Equity Method Investments, Fair Value Disclosure Equity Method Investments, Fair Value Disclosure Income As A Result Of Prepayments Income As A Result Of Prepayments Income as a result of prepayments at a pre-negotiated discount certain future payment amounts Total Shareholder Return Amount Total Shareholder Return Amount Common shares, issued Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Issued Remaining Cash from Debt Proceeds Remaining Cash from Debt Proceeds [Member] Remaining Cash from Debt Proceeds Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Concentration Risk, Percentage Concentration Risk, Percentage Long-term Purchase Commitment, Period Long-Term Purchase Commitment, Period Assets held for sale Disposal Group, Including Discontinued Operation, Assets Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Line of Credit Facility, Average Outstanding Amount Line of Credit Facility, Average Outstanding Amount Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Common shares, authorized Common Stock, Shares Authorized Forward Contract Derivative Assets (Liabilities), at Fair Value, Net Acquisition of subsidiaries, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Amortization and other acquisition-related costs Amortization and other acquisition-related costs The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Fiscal 2022 Fiscal 2022 [Member] Fiscal 2022 Diluted (in shares) Weighted-average common shares–diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Agreements [Axis] Agreements [Axis] Agreement Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member] Derivative Liability, Notional Amount Derivative Liability, Notional Amount Goodwill Impairment [Axis] Goodwill Impairment [Axis] Goodwill Impairment Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] Additions Restructuring Costs MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Estimated annual amortization of intangible assets - Remainder of Fiscal Year Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Total Cardinal Health, Inc. shareholders' deficit Equity, Attributable to Parent Common shares in treasury, at cost: 83 million shares and 76 million shares at March 31, 2024 and June 30, 2023, respectively Treasury, balance at beginning of period Treasury, balance at end of period Treasury Stock, Value Proceeds from long-term obligations, net of issuance costs Proceeds from Issuance of Debt Financial Instruments Financial Instruments Disclosure [Text Block] Litigation Case [Axis] Litigation Case [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Schedule of Goodwill by Reportable Segment Schedule of Goodwill [Table Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Distribution, selling, general and administrative expenses Selling, General and Administrative Expense Accounts Payable Accounts Payable Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Recurring Fair Value, Recurring [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Estimated Litigation Liability, Current Estimated Litigation Liability, Current Long-Term Debt, Maturity, Year Four Long-Term Debt, Maturity, Year Four Business Combination, Acquisition Related Costs Business Combination, Acquisition Related Costs All Executive Categories All Executive Categories [Member] Long-Term Debt, Maturity, after Year Five Long-Term Debt, Maturity, after Year Five OptumRx OptumRx [Member] OptumRx Terminal Growth Rate, Fair Value Input Terminal Growth Rate, Fair Value Input Terminal Growth Rate, Fair Value Input Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Estimated annual amortization of intangible assets - Year Two Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Assets Assets [Abstract] Total other comprehensive income/(loss), net of tax Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Document Type Document Type Derivative, Name [Domain] Derivative Contract [Domain] Commercial Paper [Member] Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Treasury shares acquired, average price per share (in usd per share) Shares Acquired, Average Cost Per Share Effective March 2022 March 2022 [Member] March 2022 Outcomes Divestiture [Member] Outcomes Divestiture [Member] Outcomes Divestiture Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Short Term Credit Facilities Member Short Term Credit Facilities Member Other short-term credit facilities and an unsecured line of credit Net Intangible Indefinite-Lived Intangible Assets (Excluding Goodwill) Maximum Maximum [Member] Amortization of intangible assets Amortization of Intangible Assets Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Goodwill, Impaired, Accumulated Impairment Loss Goodwill, Impaired, Accumulated Impairment Loss Net Intangible Finite-Lived Intangible Assets, Net Non-US [Member] Non-US [Member] Accounts payable Accounts Payable, Current Liabilities: Liabilities [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Litigation (recoveries)/charges, net Gain (Loss) from Litigation Settlement Business Combination Disclosure Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Effect of dilutive securities: Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Earnings/(loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Cash and equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Loss Contingency, Claims Settled, Number Loss Contingency, Claims Settled, Number Goodwill impairment Goodwill, Impairment Loss Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Total net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Non-PEO NEO Non-PEO NEO [Member] Trademarks, trade names and patents Trademarks And Patents Member The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law. Other investments Investments, Fair Value Disclosure 4.6% Notes due 2043 4.6% Notes due 2043 [Member] 4.6% Notes due 2043 Hedging Relationship [Axis] Hedging Relationship [Axis] Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Total Long-Term and Short-Term Obligations Total Long-Term and Short-Term Obligations Total Long-Term and Short-Term Obligations Dividends on common shares Payments of Ordinary Dividends, Common Stock Notes Payable Notes Payable Class of Stock [Line Items] Class of Stock [Line Items] Investment, Name [Axis] Investment, Name [Axis] Customer relationships Customer Relationships [Member] Recent Financial Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Forecast [Member] Forecast [Member] Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share Schedule of Weighted Average Number of Shares [Table Text Block] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Schedule of Transactions Related to Performance Share Units Under the Plans Schedule of Nonvested Performance-Based Units Activity [Table Text Block] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Target performance goal (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Number of operating segments Number of Operating Segments Trademarks and patents IPR&D,TrademarksandOther [Member] Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style. Preferred shares, issued Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Employee- Related Costs Employee Severance [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Transaction Data System Investment Transaction Data System Investment [Member] Transaction Data System Investment Restructuring and Employee Severance Restructuring and Related Activities Disclosure [Text Block] Increase in trade receivables Increase (Decrease) in Receivables Share-based compensation Share-Based Payment Arrangement, Noncash Expense Nuclear Precision Health Services [Member] Nuclear Precision Health Solutions [Member] Nuclear Precision Health Solutions Net earnings/(loss) Net earnings/(loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Proceeds from disposal of property and equipment Proceeds from Sale of Property, Plant, and Equipment Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Income from Settlements of Class Action Lawsuits Income from Settlements of Class Action Lawsuits Income from Settlements of Class Action Lawsuits Provision for income taxes Income Tax Expense (Benefit) Income Tax Expense (Benefit) Fiscal 2023 Fiscal 2023 [Member] Fiscal 2023 Derivative, Notional Amount Derivative, Notional Amount Corporate Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] 4.5% Notes due 2044 4.5% Notes due 2044 [Member] 4.5% Notes due 2044 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Tax Matter [Domain] Tax Matter [Domain] [Domain] for Tax Matter [Axis] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Percent 5.125% Notes due 2029 5.125% Notes due 2029 [Member] 5.125% Notes due 2029 Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating earnings Total operating earnings Operating Income (Loss) AOCI, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Interest expense, net Interest Expense, Operating and Nonoperating Settling States Settling States Settling States Business Acquisition [Line Items] Business Acquisition [Line Items] Number of reportable segments Number of Reportable Segments Total liabilities and shareholders’ deficit Liabilities and Equity Dividends Dividends Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Hedging Designation [Axis] Hedging Designation [Axis] Restructuring and employee severance Total restructuring and employee severance Restructuring Charges Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] March 2026 March 2026 [Member] March 2026 Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Interest Income (Expense), Nonoperating, Net Interest Income (Expense), Nonoperating Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] Current portion of long-term obligations and other short-term borrowings Long-Term Debt and Lease Obligation, Current 3.5% Notes due 2024 3.5% Notes due 2024 [Member] 3.5% Notes due 2024 $300 million share repurchase program $300 million share repurchase program [Member] $300 million share repurchase program Underlying Security Market Price Change Underlying Security Market Price Change, Percent Scenario [Domain] Scenario [Domain] Proceeds from net investment hedge terminations Proceeds from Hedge, Investing Activities Individual: Individual [Axis] Accumulated Other Comprehensive Income/(Loss) AOCI Attributable to Parent AOCI Attributable to Parent [Member] Inventories, net Inventory, Net Liabilities related to assets held for sale Disposal Group, Including Discontinued Operation, Liabilities Carrying Amount of Long-Term and other Short-Term Borrowings Carrying Amount of Long-Term and other Short-Term Borrowings Carrying Amount of Long-Term and other Short-Term Borrowings Entity Address, State or Province Entity Address, State or Province Statement of Stockholders' Equity Statement [Line Items] Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Lawsuit Type [Domain] Lawsuit Type [Domain] [Domain] for Lawsuit Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Opioid Litigation [Domain] Opioid Litigation [Domain] Opioid Litigation [Domain] March 2025 March 2025 [Member] March 2025 Segment Profit by Reportable Segment Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Fiscal 2024 Fiscal 2024 [Member] Fiscal 2024 Operating expenses: Operating Expenses [Abstract] $500 million share repurchase program [Domain] $500 million share repurchase program [Member] $500 million share repurchase program [Domain] Total identifiable net assets/(liabilities) acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Date Initiated [Domain] Date Initiated [Domain] Date Initiated [Domain] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] January 2023 January 2023 [Member] January 2023 CareFusion [Member] CareFusion [Member] CareFusion [Member] Goodwill Impairment [Domain] Goodwill Impairment [Domain] Goodwill Impairment [Domain] Nonvested at beginning of period (in usd per share) Nonvested at end of period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Shareholders’ Deficit Liabilities and Equity [Abstract] Loss Contingency, Estimate of Possible Loss Loss Contingency, Estimate of Possible Loss Loss Contingency, Number of Plaintiffs Loss Contingency, Number of Plaintiffs Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Concentration Risk [Table] Concentration Risk [Table] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Provision for bad debts Accounts Receivable, Credit Loss Expense (Reversal) Deferred income taxes and other liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Segments [Axis] Operating and Reportable Segment Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Exercise Price Award Exercise Price Earnings Per Share [Text Block] Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Subsequent Event Subsequent Event [Member] Goodwill and Other Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Basic (in shares) Income (Loss) from Continuing Operations, Per Basic Share Shareholders’ deficit: Equity, Attributable to Parent [Abstract] Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Subsegments [Domain] Subsegments [Domain] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Restructuring Plan [Axis] Restructuring Plan [Axis] Segments [Domain] Segments [Domain] Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Maturity Date [Domain] Maturity Date [Domain] Maturity Date [Domain] Estimated annual amortization of intangible assets - Year Four Finite-Lived Intangible Asset, Expected Amortization, Year Four Deferred income taxes and other liabilities Deferred Tax and Other Liabilities, Noncurrent All Individuals All Individuals [Member] Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Reporting Unit [Axis] Reporting Unit [Axis] PEO PEO [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Estimated fair value Debt Instrument, Fair Value Disclosure Name Trading Arrangement, Individual Name Other (income)/expense, net Other Nonoperating Income (Expense) Net Intangible, Total other intangible assets Intangible Assets, Net (Excluding Goodwill) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Impairments and (gain)/loss on disposal of assets, net Gain (Loss) on Sale of Assets and Asset Impairment Charges Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Disposal Group Name [Axis] Disposal Group Name [Axis] ALABAMA ALABAMA Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Other Segments Other Operating Segment [Member] Assets: Assets, Fair Value Disclosure [Abstract] Schedule of Assets and Liabilities Held for Sale [Table] Disposal Groups, Including Discontinued Operations [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Estimated range of decrease in unrecognized tax benefits within the next 12 months Decrease in Unrecognized Tax Benefits is Reasonably Possible Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Effective Date [Axis] Date Initiated [Axis] Date Initiated Local Phone Number Local Phone Number Gross Intangible, Total other intangible assets Intangible Assets, Gross (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Income Taxes Tax Credit Carryforward [Line Items] Total Opioid Litigation [Member] Total Opioid Litigation [Member] Total Opioid Litigation Schedule of Transactions Related to Restricted Share Units Under the Plans Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Change in operating assets and liabilities, net of effects from acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Goodwill, Transfers Goodwill, Transfers Total identifiable intangible assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Specialty Networks Specialty Networks [Member] Specialty Networks Share Repurchase Program [Domain] Share Repurchase Program [Domain] Lawsuit Type [Axis] Lawsuit Type [Axis] Lawsuit Type [Axis] Commitments, Contingent Liabilities and Litigation Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Effective September 2018 September 2018 [Member] September 2018 Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Line of Credit Facility, Maximum Amount Outstanding During Period Line of Credit Facility, Maximum Amount Outstanding During Period Preferred shares, authorized Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Prepaid expenses and other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] 3.75% Notes due 2025 3.75% Notes due 2025 [Member] 3.75% Notes due 2025 Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Long-Term Debt, Maturity, Year Five Long-Term Debt, Maturity, Year Five Scenario [Axis] Scenario [Axis] Major Customers Major Customers, Policy [Policy Text Block] Unrecognized tax benefits, interest and penalties accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Discontinued Operations and Disposal Groups [Abstract] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Product Liability Accrual, Period Expense Product Liability Accrual, Period Expense Shareholders' Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Segment Information Segment Reporting Disclosure [Text Block] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Foreign Currency Translation Adjustments Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Measurement Frequency [Domain] Measurement Frequency [Domain] Unrecognized tax benefits Unrecognized Tax Benefits Consolidation Items [Domain] Consolidation Items [Domain] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Foreign currency translation adjustments and other Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] GEORGIA GEORGIA Global Medical Products and Distribution GMPD [Member] GMPD CVS Health CVS Health [Member] CVS Health [Member] New York Opioid Stewardship Act [Member] New York Opioid Stewardship Act [Member] New York Opioid Stewardship Act Purchase of treasury shares Purchase of treasury shares Payments for Repurchase of Common Stock Long-Term Debt, Maturity, Year Three Long-Term Debt, Maturity, Year Three Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Other Short-term Borrowings Other Short-Term Borrowings Weighted-Average Grant Date Fair Value per Share Weighted-Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] at-Home Solutions [Member] at-Home Solutions [Member] at-Home Solutions Other Agreements [Member] Other Agreements [Member] Other Agreements Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Income Taxes Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Increase in inventories Increase (Decrease) in Inventories Schedule of Debt [Table Text Block] Schedule of Debt [Table Text Block] Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Two Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Net cash provided by/(used in) financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Performance Share Units Performance Share Unit Performance Shares [Member] Credit Facility [Axis] Credit Facility [Axis] Preferred shares, without par value: Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Amendment Flag Amendment Flag Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Entity Registrant Name Entity Registrant Name Payments to Acquire Businesses, Gross Payments to Acquire Businesses, Gross Remaining Cash from Debt Proceeds [Domain] Remaining Cash from Debt Proceeds [Domain] Remaining Cash from Debt Proceeds [Domain] Trade receivables, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation, Depletion and Amortization Gross margin Gross Profit Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Assets by Reportable Segment Reconciliation of Assets from Segment to Consolidated [Table Text Block] Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Level 2 Level 2 Fair Value, Inputs, Level 2 [Member] Long-Term Obligations and Other Short-Term Borrowings Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Weighted- Average Remaining Amortization Period (Years) Finite-Lived Intangible Assets, Remaining Amortization Period Geographical [Domain] Geographical [Domain] Agreements [Domain] Agreements [Domain] Agreements [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Interest Rate Swap Interest Rate Swap [Member] Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Authorized—755 million shares, Issued—327 million shares at March 31, 2024 and June 30, 2023 Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Plaintiff Type [Axis] Plaintiff Type [Axis] Plaintiff Type [Axis] Cash and equivalents Cash and Cash Equivalents, at Carrying Value Purchases of short-term time deposits Purchases of short-term time deposits Payments to Acquire Restricted Certificates of Deposit Narative [Abstract] Narative [Abstract] Narative [Abstract] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] 3.41% Notes due 2027 3.41% Notes due 2027 [Member] 3.41% Notes due 2027 Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Canceled and forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Authorized—500 thousand shares, Issued—none Preferred Stock, Value, Issued Native American tribes Native American tribes [Member] Native American tribes Reporting Unit [Domain] Reporting Unit [Domain] Increase in accounts payable Increase (Decrease) in Accounts Payable Tax Matter [Axis] Tax Matter [Axis] Tax Matter [Axis] Opioid Lawsuits [Member] Opioid Lawsuits [Member] Opioid Lawsuits [Member] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Alameda County [Member] Alameda County [Member] Alameda County [Member] Debt Instrument, Issued, Principal Debt Instrument, Issued, Principal Private Parties [Member] Private Parties [Member] Private Parties [Member] Income Taxes Tax Credit Carryforward [Table] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Goodwill [Table] Goodwill [Table] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Discount Rate, Fair Value Input Discount Rate, Fair Value Input Discount Rate, Fair Value Input Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted Average Number of Shares Outstanding, Diluted [Abstract] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Total assets Total assets Assets Estimated annual amortization of intangible assets - Year One Finite-Lived Intangible Asset, Expected Amortization, Year One Cost of products sold Cost of Goods and Services Sold Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Additions to property and equipment Payments to Acquire Property, Plant, and Equipment Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Opioid Litigation [Axis] Opioid Litigation [Axis] Opioid Litigation Termination Date Trading Arrangement Termination Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Revenue Total revenue Revenues Long-Term Debt, Maturity, Year One Long-Term Debt, Maturity, Year One Share-Based Compensation Share-Based Payment Arrangement [Text Block] Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount Aggregate Annual Assessment Aggregate Annual Assessment Aggregate Annual Assessment Not Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Revenue from External Customers by Geographic Areas [Table Text Block] Revenue from External Customers by Geographic Areas [Table Text Block] Entity Address, City or Town Entity Address, City or Town Proceeds from Issuance of Long-Term Debt Proceeds from Issuance of Long-Term Debt Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Purchases of investments Purchase of available-for-sale securities and other investments The cash outflow from purchases of available-for-sale securities and other investments. Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Total share-based compensation Share-Based Payment Arrangement, Expense Disposal Groups, Including Discontinued Operations, Disclosure Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Net earnings attributable to Cardinal Health, Inc. Net Income (Loss) Attributable to Parent Net Income (Loss) Trading Arrangement: Trading Arrangement [Axis] Loss Contingency, Lawsuits, Number Loss Contingency, Lawsuits, Number Loss Contingency, Lawsuits, Number Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Canceled and forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Loss Contingencies Loss Contingencies [Table] Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Insurance Recoveries Insurance Recoveries Net unrealized gain/(loss) on derivative instruments, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Document Fiscal Year Focus Document Fiscal Year Focus Noncontrolling Interest Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Value, Acquired, Cost Method Weighted-average number of common shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Segment Revenue from External Customers by Geographic Area [Line Items] Segment Revenue from External Customers by Geographic Area [Line Items] [Line Items] for Segment Revenue from External Customers by Geographic Area [Table] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Employee-related costs Severance Costs Restructuring Plan [Domain] Restructuring Plan [Domain] Other accrued liabilities Other Accrued Liabilities, Current Name Forgone Recovery, Individual Name Award Date [Domain] Award Date [Domain] Document Period End Date Document Period End Date IVC April 2023 Agreement IVC April 2023 Agreement [Member] IVC April 2023 Agreement Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Nonvested at beginning of period (in shares) Nonvested at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Insider Trading Arrangements [Line Items] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Diluted (in shares) Income (Loss) from Continuing Operations, Per Diluted Share Adjustment to Compensation: Adjustment to Compensation [Axis] Less: Net earnings attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Foreign Exchange Contract [Member] Foreign Exchange Contract [Member] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Litigation Case [Domain] Litigation Case [Domain] Fair Value Measurements, Recurring and Nonrecurring Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Customer [Domain] Customer [Domain] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained Earnings Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Basic (in shares) Weighted-average common shares–basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] $250 million share repurchase program [Member] $250 million share repurchase program [Member] $250 million share repurchase program Tax Matters Agreement [Domain] Tax Matters Agreement [Domain] [Domain] for Tax Matters Agreement [Axis] Tax Matters Agreement [Axis] Tax Matters Agreement [Axis] Tax Matters Agreement [Axis] Total shareholders’ deficit Balance at beginning of period Balance at end of period Equity, Including Portion Attributable to Noncontrolling Interest Restricted Share Units Restricted Share Unit Restricted Stock Units (RSUs) [Member] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Other accrued liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Revenue Benchmark Revenue Benchmark [Member] Litigation Settlement, Loss Litigation Settlement, Loss Entity Filer Category Entity Filer Category Beginning Balance Ending Balance Restructuring Reserve Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 15 cah-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 16 cah-20240331_g1.jpg begin 644 cah-20240331_g1.jpg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end GRAPHIC 17 cah-20240331_g2.jpg begin 644 cah-20240331_g2.jpg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end GRAPHIC 18 cah-20240331_g3.jpg begin 644 cah-20240331_g3.jpg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g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end GRAPHIC 19 cah-20240331_g4.jpg begin 644 cah-20240331_g4.jpg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end GRAPHIC 20 cah-20240331_g5.jpg begin 644 cah-20240331_g5.jpg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æ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�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end XML 22 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover Page - shares
 9 Months Ended
Mar. 31, 2024
Apr. 26, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 1-11373  
Entity Registrant Name Cardinal Health, Inc.  
Entity Central Index Key 0000721371  
Current Fiscal Year End Date --06-30  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Incorporation, State or Country Code OH  
Entity Tax Identification Number 31-0958666  
Entity Address, Address Line One 7000 Cardinal Place  
Entity Address, City or Town Dublin  
Entity Address, State or Province OH  
Entity Address, Postal Zip Code 43017  
City Area Code 614  
Local Phone Number 757-5000  
Title of 12(b) Security Common shares (without par value)  
Trading Symbol CAH  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   243,566,952
XML 23 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]        
Revenue $ 54,911 $ 50,487 $ 167,119 $ 151,559
Cost of products sold 52,964 48,702 161,558 146,497
Gross margin 1,947 1,785 5,561 5,062
Operating expenses:        
Distribution, selling, general and administrative expenses 1,282 1,179 3,762 3,567
Restructuring and employee severance 53 16 106 62
Amortization and other acquisition-related costs 80 74 207 216
Impairments and (gain)/loss on disposal of assets, net 84 20 622 883
Litigation (recoveries)/charges, net 81 (76) 29 (256)
Operating earnings 367 572 835 590
Other (income)/expense, net (7) 0 (25) (5)
Interest expense, net 33 28 55 78
Earnings/(loss) before income taxes 341 544 805 517
Provision for income taxes 82 197 186 189
Net earnings/(loss) 259 347 619 328
Less: Net earnings attributable to noncontrolling interests (1) (2) (3) (3)
Net earnings attributable to Cardinal Health, Inc. $ 258 $ 345 $ 616 $ 325
Earnings per common share attributable to Cardinal Health, Inc.:        
Basic (in shares) $ 1.06 $ 1.35 $ 2.51 $ 1.24
Diluted (in shares) $ 1.05 $ 1.34 $ 2.49 $ 1.23
Weighted-average number of common shares outstanding:        
Basic (in shares) 243 256 245 263
Diluted (in shares) 245 258 247 264
Cash dividends declared per common share $ 0.5006 $ 0.4957 $ 1.5018 $ 1.4871
XML 24 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]        
Net earnings/(loss) $ 259 $ 347 $ 619 $ 328
Other comprehensive income/(loss):        
Foreign currency translation adjustments and other 1 4 (4) (34)
Net unrealized gain/(loss) on derivative instruments, net of tax (6) 0 (5) 6
Total other comprehensive income/(loss), net of tax (5) 4 (9) (28)
Total comprehensive income 254 351 610 300
Less: Net earnings attributable to noncontrolling interests (1) (2) (3) (3)
Total comprehensive income attributable to Cardinal Health, Inc. $ 253 $ 349 $ 607 $ 297
XML 25 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets - USD ($)
shares in Thousands, $ in Millions
Mar. 31, 2024
Jun. 30, 2023
Current assets:    
Cash and equivalents $ 3,718 $ 4,043
Trade receivables, net 11,566 11,344
Inventories, net 17,277 15,940
Prepaid expenses and other 3,161 2,362
Assets held for sale 12 144
Total current assets 35,734 33,833
Property and equipment, net 2,470 2,462
Goodwill and other intangibles, net 6,507 6,081
Other assets 1,169 1,041
Total assets 45,880 43,417
Current liabilities:    
Accounts payable 32,089 29,813
Current portion of long-term obligations and other short-term borrowings 1,187 792
Other accrued liabilities 3,030 3,059
Liabilities related to assets held for sale 0 42
Total current liabilities 36,306 33,706
Long-term obligations, less current portion 4,667 3,909
Deferred income taxes and other liabilities 8,169 8,653
Preferred shares, without par value:    
Authorized—500 thousand shares, Issued—none 0 0
Common shares, without par value:    
Authorized—755 million shares, Issued—327 million shares at March 31, 2024 and June 30, 2023 2,887 2,747
Accumulated deficit (289) (534)
Common shares in treasury, at cost: 83 million shares and 76 million shares at March 31, 2024 and June 30, 2023, respectively (5,703) (4,914)
Accumulated other comprehensive loss (160) (151)
Total Cardinal Health, Inc. shareholders' deficit (3,265) (2,852)
Noncontrolling interests 3 1
Total shareholders’ deficit (3,262) (2,851)
Total liabilities and shareholders’ deficit $ 45,880 $ 43,417
Preferred shares, authorized 500 500
Preferred shares, issued 0 0
Common shares, authorized 755,000 755,000
Common shares, issued 327,000 327,000
Common shares in treasury 83,000 76,000
XML 26 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets (Parenthetical) - shares
shares in Thousands
Mar. 31, 2024
Jun. 30, 2023
Statement of Financial Position [Abstract]    
Preferred shares, authorized 500 500
Preferred shares, issued 0 0
Common shares, authorized 755,000 755,000
Common shares, issued 327,000 327,000
Common shares in treasury 83,000 76,000
XML 27 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
shares in Thousands, $ in Millions
Total
Common Stock
Retained Earnings
Treasury Stock, Common
Accumulated Other Comprehensive Income/(Loss)
Noncontrolling Interest
Common shares in treasury       54,000    
Balance at beginning of period (in shares) at Jun. 30, 2022   327,000        
Balance at beginning of period at Jun. 30, 2022 $ (706) $ 2,813 $ (280)   $ (114) $ 3
Treasury, balance at beginning of period (in shares) at Jun. 30, 2022       (54,000)    
Treasury, balance at beginning of period at Jun. 30, 2022       $ (3,128)    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 328         3
Net Income (Loss) Attributable to Parent 325          
Other Comprehensive Income (Loss), Net of Tax (28)          
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (28)       (28)  
Purchase of noncontrolling interests (2)         2
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture   0   2,000    
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 82 $ 5   $ 77    
Purchase of treasury shares (1,500)   $ (1,500)    
Treasury shares acquired (in shares)       (20,000)    
Dividends (388)   (388)      
Stockholders' Equity, Other Shares          
Other 1   1     2
Balance at end of period (in shares) at Mar. 31, 2023   327,000        
Balance at end of period at Mar. 31, 2023 (2,218) $ 2,818 (342)   (142) 2
Treasury, balance at end of period (in shares) at Mar. 31, 2023       (72,000)    
Treasury, balance at end of period at Mar. 31, 2023       $ (4,554)    
Treasury Stock, Value, Acquired, Cost Method (1,503)     $ (1,503)    
Common shares in treasury       68,000    
Balance at beginning of period (in shares) at Dec. 31, 2022   327,000        
Balance at beginning of period at Dec. 31, 2022 (2,212) $ 2,747 (560)   (146) 1
Treasury, balance at beginning of period (in shares) at Dec. 31, 2022       (68,000)    
Treasury, balance at beginning of period at Dec. 31, 2022       $ (4,254)    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 347         2
Net Income (Loss) Attributable to Parent 345          
Other Comprehensive Income (Loss), Net of Tax 4          
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 4       4  
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture   0   0    
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 24 $ 21   $ 3    
Purchase of treasury shares   (50)        
Treasury shares acquired (in shares)       (4,000)    
Dividends (128)   (128)      
Stockholders' Equity, Other Shares          
Other 0 1     1
Balance at end of period (in shares) at Mar. 31, 2023   327,000        
Balance at end of period at Mar. 31, 2023 (2,218) $ 2,818 (342)   (142) 2
Treasury, balance at end of period (in shares) at Mar. 31, 2023       (72,000)    
Treasury, balance at end of period at Mar. 31, 2023       $ (4,554)    
Treasury Stock, Value, Acquired, Cost Method $ (253)     $ (303)    
Common shares in treasury       72,000    
Balance at end of period (in shares) at Jun. 30, 2023 327,000 327,000        
Balance at end of period at Jun. 30, 2023 $ (2,851) $ 2,747 (534)   (151) 1
Treasury, balance at end of period (in shares) at Jun. 30, 2023 (76,000)     76,000    
Treasury, balance at end of period at Jun. 30, 2023 $ (4,914)     $ 4,914    
Common shares in treasury 76,000     (76,000)    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $ 619         3
Net Income (Loss) Attributable to Parent 616          
Other Comprehensive Income (Loss), Net of Tax (9)          
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent $ (9)       (9)  
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture 1,000 0        
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture $ 110 $ 40   $ 70    
Purchase of treasury shares (750) $ (100)   $ (750)    
Treasury shares acquired (in shares)       (9,000)    
Dividends (372)   (372)      
Stockholders' Equity, Other Shares       (1,000)    
Other $ 0   (1)     1
Balance at end of period (in shares) at Mar. 31, 2024 327,000 327,000        
Balance at end of period at Mar. 31, 2024 $ (3,262) $ 2,887 (289)   (160) 3
Treasury, balance at end of period (in shares) at Mar. 31, 2024 (83,000)     (83,000)    
Treasury, balance at end of period at Mar. 31, 2024 $ (5,703)     $ (5,703)    
Treasury Stock, Value, Acquired, Cost Method (759)     $ (859)    
Common shares in treasury       (83,000)    
Balance at beginning of period (in shares) at Dec. 31, 2023   327,000        
Balance at beginning of period at Dec. 31, 2023 (3,447) $ 2,855 (425)   (155) 2
Treasury, balance at beginning of period (in shares) at Dec. 31, 2023       83,000    
Treasury, balance at beginning of period at Dec. 31, 2023       $ 5,724    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 259         1
Net Income (Loss) Attributable to Parent 258          
Other Comprehensive Income (Loss), Net of Tax (5)          
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (5)          
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture   0   0    
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 53 $ 32   $ 21    
Dividends (123)   (123)      
Stockholders' Equity, Other Shares          
Other $ (1) 1    
Balance at end of period (in shares) at Mar. 31, 2024 327,000 327,000        
Balance at end of period at Mar. 31, 2024 $ (3,262) $ 2,887 $ (289)   $ (160) $ 3
Treasury, balance at end of period (in shares) at Mar. 31, 2024 (83,000)     (83,000)    
Treasury, balance at end of period at Mar. 31, 2024 $ (5,703)     $ (5,703)    
Common shares in treasury 83,000     83,000    
XML 28 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net earnings/(loss) $ 619 $ 328
Adjustments to reconcile net earnings to net cash provided by operating activities:    
Depreciation and amortization 524 516
Impairments and (gain)/loss on disposal of assets, net 622 883
Share-based compensation 88 69
Provision for bad debts 59 79
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:    
Increase in trade receivables (262) (510)
Increase in inventories (1,371) (1,012)
Increase in accounts payable 2,276 2,473
Other accrued liabilities and operating items, net (870) (845)
Net cash provided by operating activities 1,685 1,981
Cash flows from investing activities:    
Acquisition of subsidiaries, net of cash acquired 1,192 10
Proceeds from divestitures, net of cash sold 9 0
Additions to property and equipment (318) (264)
Proceeds from disposal of property and equipment 10 2
Purchases of investments (3) (6)
Proceeds from investments 1 1
Proceeds from net investment hedge terminations 28 29
Purchases of short-term time deposits (550) 0
Net cash used in investing activities (2,015) (248)
Cash flows from financing activities:    
Proceeds from long-term obligations, net of issuance costs 1,139 0
Reduction of long-term obligations (23) (571)
Net tax proceeds from share-based compensation 23 11
Dividends on common shares (377) (399)
Purchase of treasury shares (750) (1,500)
Net cash provided by/(used in) financing activities 12 (2,459)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations (7) (1)
Net decrease in cash and equivalents (325) (727)
Cash and equivalents at beginning of period 4,043 4,717
Cash and equivalents at end of period $ 3,718 $ 3,990
XML 29 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of Presentation and Summary of Significant Accounting Policies
 9 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies
1. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.
References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2024 and 2023 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts.
In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2024 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2024. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (our "2023 Form 10-K").
Major Customers
On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. Sales to OptumRx generated 16% of our consolidated revenue in fiscal 2023.
Recently Issued Financial Accounting Standards
and Disclosure Rules Not Yet Adopted
We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2023 Form 10-K.
Segment Reporting
In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in our fiscal 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Income Tax Disclosure
In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in our fiscal 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Climate-Related Disclosures
In March 2024, the SEC issued final rules on climate-related disclosures that will require annual disclosure of material climate-related risks and material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the rules require disclosure in the notes to the financial statements of the effects of severe weather events and other natural conditions, subject to certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates. These rules also require disclosure of climate risk oversight practices of the Board of Directors and management, and the disclosure of governance, risk management and strategy related to material climate-related risks. In April 2024, the SEC voluntarily stayed the new rules pending the completion of judicial review. The disclosure requirements, if ultimately upheld as adopted, will begin phasing in for reports and registration statements including financial information with respect to annual periods beginning in our fiscal 2026. We are currently evaluating the impact of adoption of these final rules on our disclosures.
Recently Adopted Financial Accounting Standards
There were no new material accounting standards adopted during the nine months ended March 31, 2024.
Updated Segment Reporting Structure
Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions segment and Global Medical Products and Distribution ("GMPD") segment. The remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics, are not significant enough to require separate reportable disclosures and are included in Other. The Pharmaceutical and Specialty Solutions reportable segment consists of all businesses formerly within our Pharmaceutical segment, excluding Nuclear and Precision Health Solutions. The Global Medical Products and Distribution reportable segment consists of all businesses formerly within our Medical segment, excluding at-Home Solutions and OptiFreight® Logistics. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change. See Note 13 for segment results under the new reporting structure.
XML 30 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Combinations and Asset Acquisitions
 9 Months Ended
Mar. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Business Combination Disclosure
2. Acquisitions
On March 18, 2024, we completed the acquisition of Specialty Networks for a purchase price of $1.2 billion in cash, subject to certain adjustments. Specialty Networks creates clinical and economic value for providers and partners across multiple specialty group purchasing organizations ("GPOs"): UroGPO, Gastrologix and GastroGPO, and United Rheumatology.
Specialty Networks’ PPS Analytics platform analyzes data from electronic medical records, practice management, imaging, and dispensing systems and transforms it into meaningful and actionable insights for providers and other stakeholders by using artificial intelligence and modern data analytics capabilities. The acquisition further expands our offering in key therapeutic areas, accelerates our upstream data and research opportunities with biopharma manufacturers, and creates a platform for our expansion across therapeutic areas.
The pro forma results of operations and the results of operations for Specialty Networks have not been separately disclosed because the effects were not significant compared to the condensed consolidated financial statements.
Transaction costs associated with the Specialty Networks acquisition were $15 million during the three and nine months ended March 31, 2024, and are included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings.
Fair Value of Assets Acquired and Liabilities Assumed
The allocation of the purchase price for the acquisition of Specialty Networks is not yet finalized and is subject to adjustment as we complete the valuation analysis of the acquisition. The purchase price is also subject to adjustment based on working capital requirements as set forth in the acquisition agreement.
The valuation of identifiable intangible assets utilizes significant unobservable inputs and thus represents a Level 3 nonrecurring fair value measurement. The estimated fair value of the identifiable intangible assets was determined using an income-based approach, which includes market participant expectations of the cash flows that an asset could generate over its remaining useful life, discounted back to present value using an appropriate rate of return. The discount rate used to arrive at the present value of the identifiable intangible assets was 10 percent, and reflects the internal rate of return and uncertainty in the cash flow projections.
The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date for Specialty Networks:
(in millions)
Specialty Networks
Identifiable intangible assets:
Customer relationships (1)
$404 
Trade names (2)
15 
Developed technology (3)
20 
Total identifiable intangible assets acquired
439 
Identifiable net assets/(liabilities):
Cash and equivalents
23 
Trade receivables, net
19 
Prepaid expenses and other
2 
Other accrued liabilities
(15)
Deferred income taxes and other liabilities
(109)
Total identifiable net assets/(liabilities) acquired
359 
Goodwill
856 
Total net assets acquired
$1,215 
(1)    The weighted-average useful life of customer relationships is 14 years.
(2)    The weighted-average useful life of trade names is 8 years.
(3)    The weighted-average useful life of developed technology is 9 years.
XML 31 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Divestitures
 9 Months Ended
Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Disposal Groups, Including Discontinued Operations, Disclosure
3. Divestitures
On June 5, 2023 we signed a definitive agreement to contribute the OutcomesTM business to Transaction Data Systems ("TDS"), a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. The transaction closed on July 10, 2023 and we recognized a pre-tax gain of $53 million during the nine months ended March 31, 2024, which was included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This gain includes our initial recognition of an equity method investment in the combined entity for $147 million.
We determined that the divestiture of the OutcomesTM business does not meet the criteria to be classified as discontinued operations. The OutcomesTM business operated within our former Pharmaceutical segment.
XML 32 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring and Employee Severance
 9 Months Ended
Mar. 31, 2024
Restructuring Charges [Abstract]  
Restructuring and Employee Severance
4. Restructuring and Employee Severance
The following tables summarize restructuring and employee severance:
Three Months Ended March 31,
(in millions)20242023
Employee-related$36 $3 
Facility exit and other17 13 
Total restructuring and employee severance$53 $16 
Nine Months Ended March 31,
(in millions)20242023
Employee-related$51 $32 
Facility exit and other55 30 
Total restructuring and employee severance$106 $62 

Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional, project management and other service fees to support divestitures, costs associated with vacant facilities, and certain other divestiture-related costs.
Restructuring and employee severance costs during the three and nine months ended March 31, 2024 and 2023 include costs related to the implementation of certain enterprise-wide cost-savings measures, which include certain initiatives to rationalize our manufacturing operations. The increase in restructuring costs during the three and nine months ended March 31, 2024 was primarily due to these initiatives and certain projects resulting from the review of our strategy portfolio, capital-allocation framework and operations. During the three and nine months ended March 31, 2023, restructuring and employee severance costs also included costs related to the divestiture of the Cordis business.
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)Employee-
Related Costs		Facility Exit
and Other Costs		Total
Balance at June 30, 2023$44 $2 $46 
Additions38 13 51 
Payments and other adjustments(21)(6)(27)
Balance at March 31, 2024$61 $9 $70 
XML 33 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets
 9 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets
5. Goodwill and Other Intangible Assets
Goodwill
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions)Pharmaceutical and Specialty SolutionsGlobal Medical Products and Distribution (1)
Other (2) (3)
Total
Balance at June 30, 2023 (4)
$2,762 $677 $1,170 $4,609 
Goodwill acquired, net of purchase price adjustments856 (3)— 853 
Foreign currency translation adjustments and other— (3)— (3)
Goodwill impairment— (671)— (671)
Balance at March 31, 2024$3,618 $— $1,170 $4,788 
(1) Prior-period goodwill impairment charges related to the former Medical segment were allocated to the GMPD segment. At March 31, 2024 and June 30, 2023, the GMPD segment accumulated goodwill impairment loss was $5.4 billion and $4.7 billion, respectively.
(2) Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics.
(3) Reflects $48 million allocated to OptiFreight® Logistics.
(4) Reflects a $110 million reclassification between Pharmaceutical and Specialty Solutions and Other, which does not impact our previously reported condensed consolidated financial statements or results of our impairment tests.
The increase in the Pharmaceutical and Specialty Solutions segment goodwill is due to the Specialty Networks acquisition. Goodwill recognized in connection with this acquisition primarily represents the expected benefits from anticipated growth from new technology capabilities, synergies of integrating this business and the existing workforce of the acquired entity.
As a result of the segment change discussed in Note 1, we allocated $90 million and $48 million of goodwill from the former Medical Unit to GMPD and OptiFreight® Logistics, respectively, based on the estimated relative fair values of the reporting units. We also assessed goodwill for impairment for these reporting units before and after the reallocation and determined there was no impairment for the Medical Unit and OptiFreight® Logistics during the three months ended March 31, 2024 as their fair values substantially exceeded their carrying values. However, the quantitative test resulted in an impairment of GMPD’s remaining goodwill balance of $90 million.
Our determination of the estimated fair value of the GMPD reporting unit is based on a combination of the income-based approach (using a discount rate of 11 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public
company method, and 10 percent to the guideline transaction method.
During the three months ended December 31, 2023, we did not identify any indicators of impairment within our reporting units. During the three months ended September 30, 2023, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the former Medical Unit due to an increase in the risk-free interest rate used in the discount rate. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $581 million for the former Medical Unit, which was recognized during the three months ended September 30, 2023 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This impairment charge was driven by an increase of 1 percent in the discount rate primarily due to an increase in the risk-free interest rate.
During the three months ended December 31, 2022 and September 30, 2022, we performed quantitative goodwill impairment testing for the former Medical Unit. This quantitative testing resulted in the carrying amount of the former Medical Unit exceeding the fair value, resulting in pre-tax goodwill impairment charges of $709 million and $154 million recorded during the three months ended December 31, 2022 and September 30, 2022, respectively. We also performed interim quantitative goodwill impairment testing at March 31, 2023 and concluded that there was no impairment as of March 31, 2023 as the estimated fair value of the former Medical Unit exceeded its carrying value by approximately 4 percent. The impairment charge recognized in the second quarter of fiscal 2023 was driven by certain reductions in our long-term financial plan assumptions, and the impairment charge recognized in the first quarter of fiscal 2023 was driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate.
Other Intangible Assets
The following tables summarize other intangible assets by class at:
March 31, 2024
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible		Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents$11 $— $11 N/A
Total indefinite-life intangibles11 — 11 N/A
Definite-life intangibles:
Customer relationships3,564 2,387 1,177 10
Trademarks, trade names and patents561 401 160 7
Developed technology and other1,043 672 371 7
Total definite-life intangibles5,168 3,460 1,708 9
Total other intangible assets$5,179 $3,460 $1,719 N/A
June 30, 2023
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible
Indefinite-life intangibles:
Trademarks and patents$11 $— $11 
Total indefinite-life intangibles11 — 11 
Definite-life intangibles:
Customer relationships3,174 2,274 900 
Trademarks, trade names and patents546 380 166 
Developed technology and other1,021 626 395 
Total definite-life intangibles4,741 3,280 1,461 
Total other intangible assets$4,752 $3,280 $1,472 
The increase in definite-life intangibles is due to the Specialty Networks acquisition. Total amortization of intangible assets was $64 million and $69 million for the three months ended March 31, 2024 and 2023, respectively, and $191 million and $211 million for the nine months ended March 31, 2024 and 2023, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2024 through 2028 is as follows: $69 million, $256 million, $241 million, $213 million and $186 million.
XML 34 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Long-Term Obligations and Other Short-Term Borrowings
 9 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Long-Term Obligations and Other Short-Term Borrowings
6. Long-Term Obligations and Other Short-Term Borrowings
The following table summarizes long-term obligations and other short-term borrowings at:
(in millions) (1)March 31, 2024June 30, 2023
3.079% Notes due 2024$753 $764 
3.5% Notes due 2024402 404 
3.75% Notes due 2025508 513 
3.41% Notes due 20271,192 1,184 
5.125% Notes due 2029644 — 
5.45% Notes due 2034494 — 
4.6% Notes due 2043311 306 
4.5% Notes due 2044330 331 
4.9% Notes due 2045428 428 
4.368% Notes due 2047564 561 
7.0% Debentures due 2026124 124 
Other Obligations104 86 
Total5,854 4,701 
Less: current portion of long-term obligations and other short-term borrowings1,187 792 
Long-term obligations, less current portion$4,667 $3,909 
(1)    Maturities are presented on a calendar year basis.
Maturities of existing long-term obligations and other short-term borrowings for the remainder of fiscal 2024 through 2028 and thereafter are as follows: $762 million, $436 million, $535 million, $1.3 billion, $11 million and $2.8 billion.
Long-Term Debt
We had total long-term obligations, including the current portion and other short-term borrowings, of $5.9 billion and $4.7 billion at March 31, 2024 and June 30, 2023, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $32.1 billion and $29.8 billion at March 31, 2024 and June 30, 2023, respectively.
In February 2024, we issued additional debt with the aggregate principal amount of $1.15 billion to fund the repayment of all of the aggregate principal amount outstanding of our 3.5% Notes due 2024 and 3.079% Notes due 2024, at their respective maturities, and for general corporate purposes. The notes issued are $650 million aggregate principal amount of 5.125% Notes that mature on February 15, 2029 and $500 million aggregate principal amount of 5.45% Notes that mature on February 15, 2034. The proceeds of the notes issued, net of discounts, premiums, and debt issuance costs, were $1.14 billion. A portion of the proceeds were invested in short-term time deposits of $550 million with initial effective maturities of more than three months and classified as prepaid
expenses and other in our condensed consolidated balance sheets as of March 31, 2024. The remaining proceeds of $589 million were invested in short-term time deposits classified as cash and equivalents in our condensed consolidated balance sheets as of March 31, 2024.
If we undergo a change of control, as defined in the notes, and if the notes receive specified ratings below investment grade by each of Standard & Poor's Ratings Services, Moody’s Investors Services and Fitch Ratings, any holder of the notes, excluding the debentures, can require with respect to the notes owned by such holder, or we can offer, to repurchase the notes at 101% of the principal amount plus accrued and unpaid interest.
Other Financing Arrangements
In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. During the nine months ended March 31, 2024, under our commercial paper program and our committed receivables program, we had maximum combined total daily amounts outstanding of $1.3 billion and an average combined daily amount outstanding of $25 million. At March 31, 2024, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility.
In February 2023, we extended our $2.0 billion revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2025. In September 2023, Cardinal Health 23 Funding, LLC ("CH-23 Funding") was added as a seller under our committed receivables sales facility. Each of CHF and CH-23 Funding was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, each of CHF and CH-23 Funding is a separate legal entity from Cardinal Health, Inc. and from our respective subsidiary that sells receivables to CHF or CH-23 Funding, as applicable. Each of CHF and CH-23 Funding is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its respective creditors.
Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of March 31, 2024, we were in compliance with this financial covenant.
XML 35 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments, Contingent Liabilities and Litigation
 9 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments, Contingent Liabilities and Litigation
7. Commitments, Contingent Liabilities and Litigation
Commitments
Generic Sourcing Venture with CVS Health
In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.
Contingencies
New York Opioid Stewardship Act
In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018).
We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. During the fiscal year 2023, we recorded $6 million of income to reduce the previously estimated accrual to the invoiced amount for the calendar year 2018 assessment. At June 30, 2023, we had an outstanding liability of $3 million, which was paid in full during the first quarter of fiscal year 2024.
Legal Proceedings
We become involved from time to time in disputes, litigation and regulatory matters.
From time to time, we determine that products we distribute, source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, restrictions on importation, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.
From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and
abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.
We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.
We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.
We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit.
Opioid Lawsuits and Investigations
Cardinal Health, other Pharmaceutical wholesalers and other participants in the pharmaceutical supply chain have been named as a defendant in lawsuits related to the distribution of opioid pain medications. These lawsuits seek equitable relief and monetary damages based on a variety of legal theories, including various common law claims, such as public nuisance, negligence, unjust enrichment, personal injury, as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organization Act and various other statutes. Plaintiffs in these lawsuits include governmental entities as well as private parties, such as unions and other health and welfare funds, hospital
system and other healthcare providers, businesses and individuals.
Additionally, we have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information, subpoenas and other requests from other DOJ offices. These investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcomes of any of these investigations.
In total, as of March 31, 2024, we have $5.3 billion accrued for these matters, of which $438 million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During the three months ended March 31, 2024, we recognized expense of $193 million in connection with opioid-related matters, which was partially offset by a benefit of $105 million related to prepayments at a prenegotiated discount of certain future payments totaling $344 million.
Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgements about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of the settlements described below is an admission of liability or wrong-doing. Please see below for additional description of these matters.
States & Political Subdivisions
In February 2022, we along with two other national distributors (collectively, the "Distributors") independently approved a settlement agreement (the "National Opioid Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and political subdivisions. This National Opioid Settlement Agreement became effective on April 2, 2022. In addition to the Distributors, parties to the National Opioid Settlement Agreement include 48 states, the District of Columbia and 5 U.S. territories. Over 99 percent of political subdivisions in settling states (by population as calculated under the National Opioid Settlement Agreement) that had brought opioid-related suits against us have chosen to join the National Opioid Settlement Agreement or have had their claims addressed by state legislation (together with settling states and territories, the "Settling Governmental Entities").
In February 2024, we finalized an agreement with the Alabama Attorney General, under which we agreed to pay approximately
$123 million to the State of Alabama over a period of ten years to resolve opioid-related claims brought by the State and its political subdivisions. This agreement is subject to certain contingencies, including subdivision participation. During the nine months ended March 31, 2024, we recognized a $22 million charge in litigation (recoveries)/charge, net in the condensed consolidated statements of earnings related to this agreement.
Through April 2024, we have paid the Settling Governmental Entities approximately $1.5 billion, which includes the January 2024 prepayment of certain future payment amounts described below. We expect to pay Settling Governmental Entities additional amounts up to $4.8 billion through 2038. The National Opioid Settlement Agreement also includes injunctive relief terms related to Distributors' controlled substance anti-diversion programs. A monitor is overseeing compliance with these provisions until 2027. In addition, the Distributors are engaging a third-party vendor to act as a clearinghouse for data aggregation and reporting, which Distributors will fund for 10 years. As a result of the National Opioid Settlement Agreement, the vast majority of lawsuits brought against us by State and other political subdivisions have been dismissed. We continue to engage in resolution discussions with certain nonparticipating political subdivisions. A trial in the case brought by the city of Baltimore, which is the largest remaining nonparticipating subdivision by population, is scheduled to begin in September 2024. We intend to defend ourselves vigorously against all remaining lawsuits.
Other Settlements
West Virginia subdivisions and Native American tribes were not a part of the National Opioid Settlement Agreement, and we had separate settlement negotiations with these groups. In July 2022, a judgment in favor of the Distributors was entered in bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington. Plaintiffs have appealed this decision to the Fourth Circuit Court of Appeals. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $124 million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.
In October 2022, we executed a final settlement agreement with the Native American tribes, pursuant to which we will pay up to approximately $136 million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases.
Prepayment of Future Payment Years
In January 2024, we made payments of approximately $239 million to prepay at a prenegotiated discount of certain future payment amounts totaling approximately $344 million owed under each of the National Opioid Settlement Agreement, West Virginia Subdivisions Settlement Agreement and settlement agreements with Native American tribes and Cherokee Nation. The majority of
the prepayment relates to the seventh annual payment as due under the National Opioid Settlement Agreement. As a result of these prepayments, we recognized income of approximately $105 million in litigation charges/(recoveries), net in our condensed consolidated statements of earnings during the three months ended March 31, 2024.
Private Plaintiffs
The National Opioid Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Lawsuits brought by private plaintiffs that were pending as of April 26, 2024 were approximately 380. Of these, 103 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are engaged in resolution discussions with certain private plaintiffs and have reached agreements in principle with counsel representing classes of third-party payors and acute care hospitals and have accrued $213 million in connection with those matters, which represents our anticipated share of those possible settlements. The agreements in principle remain subject to contingencies. We are vigorously defending ourselves in all these matters.
A trial in a case involving 21 plaintiffs began in state court in Georgia in January 2023 and concluded in March 2023 with a verdict for the company and other defendants on all claims. In July 2023, the judge denied the plaintiffs' motion for a new trial. Plaintiffs have filed a notice of appeal and defendants have filed a notice of cross-appeal. A trial involving eight hospital plaintiffs is scheduled to begin in Alabama in July 2024.
Insurance Litigation
We are involved in ongoing legal proceedings with insurers related to their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. During fiscal year 2023, we received approximately $10 million in insurance recoveries related to these matters.
Department of Justice Civil Investigative Demand
In November 2023, we received a Civil Investigative Demand ("CID") from the Department of Justice focused on potential violations of the Anti-Kickback Statute and False Claims Act in connection with a 2022 transaction in which we purchased a minority ownership interest in a rheumatology managed services organization and a group purchasing organization. We are cooperating with this investigation.
Cordis IVC Filter Matters
We have been named as a defendant in approximately 400 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 4,500 plaintiffs that allege personal injuries associated with the use of inferior vena cava ("IVC") filter products. These lawsuits sought a variety of remedies, including unspecified monetary damages. The divestiture of the Cordis business did not include product liability
related to the IVC filters in the U.S. and Canada, which we retained.
In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve 4,375 claims for $275 million. This settlement agreement is subject to certain conditions, including certain opt-in thresholds. Between May and September 2023, we made settlement payments totaling $275 million into a qualified settlement fund, which will be disbursed to the plaintiffs if required conditions are satisfied. Since July 2021, we have also entered into other agreements to settle approximately 2,800 product liability claims. While these settlements will resolve the vast majority of IVC filter product liability claims, they will not resolve all of them and we intend to continue to vigorously defend ourselves in the remaining lawsuits.
We recognized income of $103 million during fiscal year 2023, primarily related to a reduction of the reserve for the estimated settlement and defense costs for these matters due to the execution of the settlements noted above. At March 31, 2024, we had a total of $296 million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets.
Other Civil Litigation
Generic Pharmaceutical Pricing Antitrust Litigation
In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the amended complaint. We are vigorously defending ourselves in this matter.
Antitrust Litigation Proceeds
We recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $6 million and $77 million during the three and nine months ended March 31, 2024, respectively, and $66 million during the nine months ended March 31, 2023.
XML 36 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes
 9 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes
8. Income Taxes
Fluctuations in our provision for income taxes as a percentage of pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.
Effective Tax Rate
During the three and nine months ended March 31, 2024, the effective tax rate was 24.2 percent and 23.2 percent, respectively, and reflects any impact of the tax effects of the goodwill impairment charges recognized during the three and nine months ended March 31, 2024.
During the three and nine months ended March 31, 2023, the effective tax rate was 36.3 percent and 36.7 percent, respectively, and reflects the impact of the tax effect of the goodwill impairment charges recognized during the nine months ended March 31, 2023.
Tax Effects of Goodwill Impairment Charges
During the nine months ended March 31, 2024, we recognized pre-tax goodwill impairment charges of $671 million. The net tax benefit related to these charges is $56 million for fiscal 2024.
Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.
The tax effect of the goodwill impairment charges during the nine months ended March 31, 2024 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to the pre-tax income for the nine months ended March 31, 2024 resulted in recognizing an incremental interim tax benefit of approximately $36 million, which impacted the provision for income taxes in the condensed consolidated statements of earnings during the nine months ended March 31, 2024 and prepaid expenses and other assets in the condensed consolidated balance sheet at March 31, 2024. The incremental interim tax benefit will reverse in the fourth quarter of fiscal 2024.
Unrecognized Tax Benefits
We had $937.0 million and $1.0 billion of unrecognized tax benefits, at March 31, 2024 and June 30, 2023, respectively. The March 31, 2024 and June 30, 2023 balances include $850 million and $873 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate.
At March 31, 2024 and June 30, 2023, we had $57 million and $65 million, respectively, accrued for the payment of interest and
penalties related to unrecognized tax benefits, which we recognize in the benefit from income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $20 million, exclusive of penalties and interest.
Other Tax Matters
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.
We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. In December 2023, the estimated tax exposure was updated to reflect adjustments based on settlement discussions with the IRS. Additionally, Cardinal received a partial payment from CareFusion to be applied towards the anticipated liability. The indemnification receivable was $20 million and $82 million at March 31, 2024 and June 30, 2023, respectively, and is included in other assets in the condensed consolidated balance sheets.
XML 37 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements
 9 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Disclosures
9. Fair Value Measurements
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
March 31, 2024
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$2,013 $— $— $2,013 
Other investments (1)105 — — 105 
Liabilities:
Forward contracts (2)— (70)— (70)
June 30, 2023
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,253 $— $— $1,253 
Other investments (1)101 — — 101 
Liabilities:
Forward contracts (2)— (73)— (73)
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2)The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
Assets Measured on a Nonrecurring Basis
As discussed further in Note 3, on July 10, 2023, we closed the transaction to contribute the Outcomes™ business to TDS, a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. We accounted for this investment initially at its fair value using Level 3 unobservable inputs under the discounted cash flow method. Accordingly, we recognized a $147 million equity method investment at closing during the first quarter of fiscal 2024.
XML 38 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments
 9 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments
10. Financial Instruments
We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk but are not designated as hedging instruments. These derivative instruments are adjusted to current
fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.
Interest Rate Risk Management
We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.
Currency Exchange Risk Management
We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.
Commodity Price Risk Management
We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.
Fair Value Hedges
We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three and nine months ended March 31, 2024 and 2023, there were no gains or losses recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.
During the nine months ended March 31, 2024 and 2023, we entered into pay-floating interest rate swaps with total notional amounts of $500 million and $200 million, respectively. These
swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.
Cash Flow Hedges
We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.
Pre-tax gains recognized in other comprehensive income/(loss) were $1 million and $2 million for the three months ended March 31, 2024 and 2023, respectively, and $2 million and $4 million for the nine months ended March 31, 2024 and 2023, respectively. Gains recognized in accumulated other comprehensive loss and reclassified into earnings were $2 million and $4 million for the three months ended March 31, 2024 and 2023, respectively, and $4 million and $8 million for the nine months ended March 31, 2024 and 2023, respectively. Gains currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are $3 million.
Net Investment Hedges
We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.
In September 2023, we entered into ¥18 billion ($120 million) cross-currency swaps maturing in September 2025 and ¥18 billion ($120 million) cross-currency swaps maturing in June 2027.
In September 2023, we terminated the ¥38 billion ($300 million) cross-currency swaps entered into in January 2023 and received net settlement in cash of $28 million, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows.
In January 2023, we entered into ¥19 billion ($150 million) cross-currency swaps maturing in September 2025 and ¥19 billion ($150 million) cross-currency swaps maturing in June 2027. In March 2023, we entered into €100 million ($107 million) cross-currency swaps maturing in March 2025 and €100 million ($107 million) cross-currency swaps maturing in March 2026.
In January and March 2023, we terminated the ¥48 billion ($400 million) cross-currency swaps entered into in March 2022 and the €200 million ($233 million) cross-currency swap entered into in September 2018, respectively, and received net settlements of $10 million and $19 million in cash, respectively, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows.
Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.
Pre-tax gains and losses from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive income/(loss) were a $19 million gain and an immaterial loss during the three months ended March 31, 2024 and 2023, respectively, and a $14 million gain and a $21 million loss during the nine months ended March 31, 2024 and 2023, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $3 million and $4 million during the three months ended March 31, 2024 and 2023, respectively, and $10 million and $12 million during the nine months ended March 31, 2024 and 2023, respectively.
Economic (Non-Designated) Hedges
We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded an immaterial gain and an immaterial loss during the three months ended March 31, 2024 and 2023, respectively, and an immaterial loss and a $3 million loss during the nine months ended March 31, 2024 and 2023, respectively. The principal currencies managed through foreign currency contracts are Chinese renminbi, Canadian dollar, Indian rupee, Euro and British pound.
Fair Value of Financial Instruments
The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at March 31, 2024 and June 30, 2023 approximate fair value due to their short-term maturities.
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
(in millions)March 31, 2024June 30, 2023
Estimated fair value$5,650 $4,417 
Carrying amount5,854 4,701 
The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.
XML 39 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Shareholders' Equity
 9 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Shareholders' Equity
11. Shareholders' Deficit
We repurchased $750 million and $1.5 billion of our common shares, in the aggregate, through share repurchase programs during the nine months ended March 31, 2024 and 2023, respectively. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.
During the three months ended December 31, 2023, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.0 million common shares using a reference price of $101.66. The program concluded on December 13, 2023 at a volume weighted average price per common share of $103.67 resulting in a final delivery of 0.4 million common shares.
During the three months ended September 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 4.4 million common shares using a reference price of $90.57. The program concluded on October 31, 2023 at a volume weighted average price per common share of $88.22 resulting in a final delivery of 1.3 million common shares.
During the three months ended June 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase of $500 million. We received an initial delivery of 4.6 million common shares using a reference price of $87.18. The program concluded on August 16, 2023 at a volume weighted average price per common share of $91.15 resulting in a final delivery of 0.9 million common shares.
During the three months ended March 31, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.6 million common shares using a reference price of $77.03. The program concluded on February 28, 2023 at a volume weighted average price per common share of $77.27 resulting in a final delivery of 0.6 million common shares.
During the three months ended December 31, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial
delivery of 2.6 million common shares using a reference price of $76.58. The program concluded on January 13, 2023 at a volume weighted average price per common share of $77.50 resulting in a final delivery of 0.6 million common shares.
During the three months ended September 30, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $1.0 billion. We received an initial delivery of 12.0 million common shares using a reference price of $66.74. The program concluded on December 23, 2022 at a volume weighted average price per common share of $73.36 resulting in a final delivery of 1.6 million common shares.
Accumulated Other Comprehensive Loss
The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2023$(137)$(14)$(151)
Other comprehensive income/(loss), before reclassifications(4)1 (3)
Amounts reclassified to earnings— (6)(6)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $4 million
(4)(5)(9)
Balance at March 31, 2024$(141)$(19)$(160)
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2022$(102)$(12)$(114)
Other comprehensive income/(loss), before reclassifications(34)15 (19)
Amounts reclassified to earnings— (9)(9)
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax benefit of $5 million
(34)6 (28)
Balance at March 31, 2023$(136)$(6)$(142)
XML 40 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings Per Share Attributable to Cardinal Health, Inc.
 9 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block]
12. Earnings Per Share Attributable to Cardinal Health, Inc.
The following tables reconcile the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:
Three Months Ended March 31,
(in millions)20242023
Weighted-average common shares–basic243 256 
Effect of dilutive securities:
Employee stock options, restricted share units and performance share units2 2 
Weighted-average common shares–diluted245 258 
Nine Months Ended March 31,
(in millions)20242023
Weighted-average common shares–basic245 263 
Effect of dilutive securities:
Employee stock options, restricted share units and performance share units2 1 
Weighted-average common shares–diluted247 264 
The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were immaterial and 1 million for the three and nine months ended March 31, 2024, respectively, and 2 million for both the three and nine months ended March 31, 2023.
XML 41 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information
 9 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Segment Information
13. Segment Information
Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions segment and GMPD segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change.
Our Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for
specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over the counter healthcare products.
Our GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada.
The remaining three operating segments included in Other are Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics. These operating segments respectively operate nuclear pharmacies and radiopharmaceutical manufacturing facilities, distribute medical products to patients' homes in the United States and provide supply chain services and solutions to our customers.
Revenue
The following tables present revenue for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
Three Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions$50,651 $46,496 
Global Medical Products and Distribution3,113 2,989 
Nuclear and Precision Health Solutions352 313 
at-Home Solutions
743 651 
OptiFreight® Logistics
72 61 
Other
1,167 1,025 
Total segment revenue54,931 50,510 
Corporate (1)
(20)(23)
Total revenue$54,911 $50,487 

Nine Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions$154,524 $139,441 
Global Medical Products and Distribution9,264 9,140 
Nuclear and Precision Health Solutions1,006 875 
at-Home Solutions
2,188 1,986 
OptiFreight® Logistics
198 177 
Other
3,392 3,038 
Total segment revenue167,180 151,619 
Corporate (1)
(61)(60)
Total revenue$167,119 $151,559 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

The following tables present revenue by geographic area:
Three Months Ended March 31,
(in millions)20242023
United States$53,715 $49,343 
International1,216 1,167 
 Total segment revenue54,931 50,510 
Corporate (1)(20)(23)
Total revenue$54,911 $50,487 
Nine Months Ended March 31,
(in millions)20242023
United States$163,548 $148,186 
International3,632 3,433 
Total segment revenue167,180 151,619 
Corporate (1)(61)(60)
Total revenue$167,119 $151,559 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit
We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate technology and shared function expenses, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the operating segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.
We do not allocate the following items to our segments:
•last-in first-out, or ("LIFO"), inventory charges/(credits);
•state opioid assessment related to prior fiscal years;
•shareholder cooperation agreement costs;
•restructuring and employee severance;
•amortization and other acquisition-related costs;
•impairments and (gain)/loss on disposal of assets, net; in connection with goodwill impairment testing for the GMPD segment as discussed further in Note 5, we recognized pre-tax goodwill impairment charges of $90 million during the three months ended March 31, 2024 and $671 million and $863 million during the nine months ended March 31, 2024 and 2023, respectively;
•litigation (recoveries)/charges, net;
•other (income)/expense, net;
•interest expense, net;
•loss on early extinguishment of debt; or
•provision for/(benefit from) income taxes
In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $17 million and $9 million for the three months ended March 31, 2024 and 2023, respectively, and $37 million and $20 million for the nine months ended March 31, 2024 and 2023, respectively.
The following tables present segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
Three Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions
$580 $560 
Global Medical Products and Distribution
20 (46)
Other (1)111 106 
Total segment profit711 620 
Corporate(344)(48)
Total operating earnings
$367 $572 

Nine Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions
$1,541 $1,394 
Global Medical Products and Distribution
18 (175)
Other (1)319 305 
Total segment profit1,878 1,524 
Corporate(1,043)(934)
Total operating earnings
$835 $590 
(1)Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics.
Segment Assets
The following table presents total assets for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
(in millions)March 31,
2024		June 30,
2023
Pharmaceutical and Specialty Solutions
$30,496 $27,615 
Global Medical Products and Distribution
7,357 7,961 
Other (1)2,692 2,621 
Corporate 5,335 5,220 
Total assets$45,880 $43,417 
(1)Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics.
XML 42 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation
 9 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation
14. Share-Based Compensation
We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees.
The following tables provide total share-based compensation expense by type of award:
Three Months Ended March 31,
(in millions)20242023
Restricted share unit expense$20 $17 
Performance share unit expense11 4 
Total share-based compensation
$31 $21 
Nine Months Ended March 31,
(in millions)20242023
Restricted share unit expense$58 $49 
Performance share unit expense30 20 
Total share-based compensation
$88 $69 
The total tax benefit related to share-based compensation was $4 million and $3 million for the three months ended March 31, 2024 and 2023, respectively, and $12 million and $9 million for the nine months ended March 31, 2024 and 2023, respectively.
Restricted Share Units
Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units
accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)Restricted Share UnitsWeighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20232.2 $57.37 
Granted0.9 90.78 
Vested(1.1)60.83 
Canceled and forfeited(0.1)71.21 
Nonvested at March 31, 20241.9 $69.96 
At March 31, 2024, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $86 million, which is expected to be recognized over a weighted-average period of two years.
Performance Share Units
Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 234 percent of the target award amount for both the fiscal 2022 and 2023 grants and zero to 240 percent of the target award for the fiscal 2024 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)Performance
Share Units		Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20231.2 $82.17 
Granted0.5 94.66 
Vested(0.4)62.26 
Canceled and forfeited— — 
Nonvested at March 31, 20241.3 $96.80 
At March 31, 2024, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $53 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.
XML 43 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure        
Net Income (Loss) Attributable to Parent $ 258 $ 345 $ 616 $ 325
XML 44 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 45 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.
References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2024 and 2023 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts.
In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2024 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2024. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (our "2023 Form 10-K").
Major Customers
Major Customers
On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. Sales to OptumRx generated 16% of our consolidated revenue in fiscal 2023.
Recent Financial Accounting Standards
Recently Issued Financial Accounting Standards
and Disclosure Rules Not Yet Adopted
We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2023 Form 10-K.
Segment Reporting
In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in our fiscal 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Income Tax Disclosure
In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in our fiscal 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Climate-Related Disclosures
In March 2024, the SEC issued final rules on climate-related disclosures that will require annual disclosure of material climate-related risks and material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the rules require disclosure in the notes to the financial statements of the effects of severe weather events and other natural conditions, subject to certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates. These rules also require disclosure of climate risk oversight practices of the Board of Directors and management, and the disclosure of governance, risk management and strategy related to material climate-related risks. In April 2024, the SEC voluntarily stayed the new rules pending the completion of judicial review. The disclosure requirements, if ultimately upheld as adopted, will begin phasing in for reports and registration statements including financial information with respect to annual periods beginning in our fiscal 2026. We are currently evaluating the impact of adoption of these final rules on our disclosures.
Recently Adopted Financial Accounting Standards
There were no new material accounting standards adopted during the nine months ended March 31, 2024.
Updated Segment Reporting Structure
Updated Segment Reporting Structure
Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions segment and Global Medical Products and Distribution ("GMPD") segment. The remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics, are not significant enough to require separate reportable disclosures and are included in Other. The Pharmaceutical and Specialty Solutions reportable segment consists of all businesses formerly within our Pharmaceutical segment, excluding Nuclear and Precision Health Solutions. The Global Medical Products and Distribution reportable segment consists of all businesses formerly within our Medical segment, excluding at-Home Solutions and OptiFreight® Logistics. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change. See Note 13 for segment results under the new reporting structure.
XML 46 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Combinations and Asset Acquisitions (Tables)
 9 Months Ended
Mar. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date for Specialty Networks:
(in millions)
Specialty Networks
Identifiable intangible assets:
Customer relationships (1)
$404 
Trade names (2)
15 
Developed technology (3)
20 
Total identifiable intangible assets acquired
439 
Identifiable net assets/(liabilities):
Cash and equivalents
23 
Trade receivables, net
19 
Prepaid expenses and other
2 
Other accrued liabilities
(15)
Deferred income taxes and other liabilities
(109)
Total identifiable net assets/(liabilities) acquired
359 
Goodwill
856 
Total net assets acquired
$1,215 
(1)    The weighted-average useful life of customer relationships is 14 years.
(2)    The weighted-average useful life of trade names is 8 years.
(3)    The weighted-average useful life of developed technology is 9 years.
XML 47 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring and Employee Severance (Tables)
 9 Months Ended
Mar. 31, 2024
Restructuring Charges [Abstract]  
Summary of Restructuring and Employee Severance
The following tables summarize restructuring and employee severance:
Three Months Ended March 31,
(in millions)20242023
Employee-related$36 $3 
Facility exit and other17 13 
Total restructuring and employee severance$53 $16 
Nine Months Ended March 31,
(in millions)20242023
Employee-related$51 $32 
Facility exit and other55 30 
Total restructuring and employee severance$106 $62 
Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)Employee-
Related Costs		Facility Exit
and Other Costs		Total
Balance at June 30, 2023$44 $2 $46 
Additions38 13 51 
Payments and other adjustments(21)(6)(27)
Balance at March 31, 2024$61 $9 $70 
XML 48 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets (Tables)
 9 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill by Reportable Segment
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions)Pharmaceutical and Specialty SolutionsGlobal Medical Products and Distribution (1)
Other (2) (3)
Total
Balance at June 30, 2023 (4)
$2,762 $677 $1,170 $4,609 
Goodwill acquired, net of purchase price adjustments856 (3)— 853 
Foreign currency translation adjustments and other— (3)— (3)
Goodwill impairment— (671)— (671)
Balance at March 31, 2024$3,618 $— $1,170 $4,788 
(1) Prior-period goodwill impairment charges related to the former Medical segment were allocated to the GMPD segment. At March 31, 2024 and June 30, 2023, the GMPD segment accumulated goodwill impairment loss was $5.4 billion and $4.7 billion, respectively.
(2) Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics.
(3) Reflects $48 million allocated to OptiFreight® Logistics.
(4) Reflects a $110 million reclassification between Pharmaceutical and Specialty Solutions and Other, which does not impact our previously reported condensed consolidated financial statements or results of our impairment tests.
Schedule of Finite-Lived Intangible Assets
The following tables summarize other intangible assets by class at:
March 31, 2024
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible		Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents$11 $— $11 N/A
Total indefinite-life intangibles11 — 11 N/A
Definite-life intangibles:
Customer relationships3,564 2,387 1,177 10
Trademarks, trade names and patents561 401 160 7
Developed technology and other1,043 672 371 7
Total definite-life intangibles5,168 3,460 1,708 9
Total other intangible assets$5,179 $3,460 $1,719 N/A
June 30, 2023
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible
Indefinite-life intangibles:
Trademarks and patents$11 $— $11 
Total indefinite-life intangibles11 — 11 
Definite-life intangibles:
Customer relationships3,174 2,274 900 
Trademarks, trade names and patents546 380 166 
Developed technology and other1,021 626 395 
Total definite-life intangibles4,741 3,280 1,461 
Total other intangible assets$4,752 $3,280 $1,472 
XML 49 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Long-Term Obligations and Other Short-Term Borrowings (Tables)
 9 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Debt [Table Text Block]
The following table summarizes long-term obligations and other short-term borrowings at:
(in millions) (1)March 31, 2024June 30, 2023
3.079% Notes due 2024$753 $764 
3.5% Notes due 2024402 404 
3.75% Notes due 2025508 513 
3.41% Notes due 20271,192 1,184 
5.125% Notes due 2029644 — 
5.45% Notes due 2034494 — 
4.6% Notes due 2043311 306 
4.5% Notes due 2044330 331 
4.9% Notes due 2045428 428 
4.368% Notes due 2047564 561 
7.0% Debentures due 2026124 124 
Other Obligations104 86 
Total5,854 4,701 
Less: current portion of long-term obligations and other short-term borrowings1,187 792 
Long-term obligations, less current portion$4,667 $3,909 
(1)    Maturities are presented on a calendar year basis.
XML 50 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements (Tables)
 9 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value, Assets and Liabilities Measured on Recurring Basis
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
March 31, 2024
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$2,013 $— $— $2,013 
Other investments (1)105 — — 105 
Liabilities:
Forward contracts (2)— (70)— (70)
June 30, 2023
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,253 $— $— $1,253 
Other investments (1)101 — — 101 
Liabilities:
Forward contracts (2)— (73)— (73)
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2)The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
XML 51 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments (Tables)
 9 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
(in millions)March 31, 2024June 30, 2023
Estimated fair value$5,650 $4,417 
Carrying amount5,854 4,701 
XML 52 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Shareholders' Equity (Tables)
 9 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total
The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2023$(137)$(14)$(151)
Other comprehensive income/(loss), before reclassifications(4)1 (3)
Amounts reclassified to earnings— (6)(6)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $4 million
(4)(5)(9)
Balance at March 31, 2024$(141)$(19)$(160)
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2022$(102)$(12)$(114)
Other comprehensive income/(loss), before reclassifications(34)15 (19)
Amounts reclassified to earnings— (9)(9)
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax benefit of $5 million
(34)6 (28)
Balance at March 31, 2023$(136)$(6)$(142)
XML 53 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)
 9 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share
The following tables reconcile the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:
Three Months Ended March 31,
(in millions)20242023
Weighted-average common shares–basic243 256 
Effect of dilutive securities:
Employee stock options, restricted share units and performance share units2 2 
Weighted-average common shares–diluted245 258 
Nine Months Ended March 31,
(in millions)20242023
Weighted-average common shares–basic245 263 
Effect of dilutive securities:
Employee stock options, restricted share units and performance share units2 1 
Weighted-average common shares–diluted247 264 
XML 54 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information (Tables)
 9 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Disaggregation of Revenue [Table Text Block]
The following tables present revenue for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
Three Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions$50,651 $46,496 
Global Medical Products and Distribution3,113 2,989 
Nuclear and Precision Health Solutions352 313 
at-Home Solutions
743 651 
OptiFreight® Logistics
72 61 
Other
1,167 1,025 
Total segment revenue54,931 50,510 
Corporate (1)
(20)(23)
Total revenue$54,911 $50,487 
Nine Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions$154,524 $139,441 
Global Medical Products and Distribution9,264 9,140 
Nuclear and Precision Health Solutions1,006 875 
at-Home Solutions
2,188 1,986 
OptiFreight® Logistics
198 177 
Other
3,392 3,038 
Total segment revenue167,180 151,619 
Corporate (1)
(61)(60)
Total revenue$167,119 $151,559 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Revenue from External Customers by Geographic Areas [Table Text Block]
The following tables present revenue by geographic area:
Three Months Ended March 31,
(in millions)20242023
United States$53,715 $49,343 
International1,216 1,167 
 Total segment revenue54,931 50,510 
Corporate (1)(20)(23)
Total revenue$54,911 $50,487 
Nine Months Ended March 31,
(in millions)20242023
United States$163,548 $148,186 
International3,632 3,433 
Total segment revenue167,180 151,619 
Corporate (1)(61)(60)
Total revenue$167,119 $151,559 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment
The following tables present segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
Three Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions
$580 $560 
Global Medical Products and Distribution
20 (46)
Other (1)111 106 
Total segment profit711 620 
Corporate(344)(48)
Total operating earnings
$367 $572 
Nine Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions
$1,541 $1,394 
Global Medical Products and Distribution
18 (175)
Other (1)319 305 
Total segment profit1,878 1,524 
Corporate(1,043)(934)
Total operating earnings
$835 $590 
(1)Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics.
Assets by Reportable Segment
The following table presents total assets for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
(in millions)March 31,
2024		June 30,
2023
Pharmaceutical and Specialty Solutions
$30,496 $27,615 
Global Medical Products and Distribution
7,357 7,961 
Other (1)2,692 2,621 
Corporate 5,335 5,220 
Total assets$45,880 $43,417 
(1)Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics.
XML 55 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation (Tables)
 9 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Total Share-based Compensation Expense by Type of Award
The following tables provide total share-based compensation expense by type of award:
Three Months Ended March 31,
(in millions)20242023
Restricted share unit expense$20 $17 
Performance share unit expense11 4 
Total share-based compensation
$31 $21 
Nine Months Ended March 31,
(in millions)20242023
Restricted share unit expense$58 $49 
Performance share unit expense30 20 
Total share-based compensation
$88 $69 
Schedule of Transactions Related to Restricted Share Units Under the Plans
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)Restricted Share UnitsWeighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20232.2 $57.37 
Granted0.9 90.78 
Vested(1.1)60.83 
Canceled and forfeited(0.1)71.21 
Nonvested at March 31, 20241.9 $69.96 
Schedule of Transactions Related to Performance Share Units Under the Plans
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)Performance
Share Units		Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20231.2 $82.17 
Granted0.5 94.66 
Vested(0.4)62.26 
Canceled and forfeited— — 
Nonvested at March 31, 20241.3 $96.80 
XML 56 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details)
 12 Months Ended
Jun. 30, 2023
OptumRx | Revenue Benchmark | Customer Concentration Risk | Pharmaceutical and Specialty Solutions  
Concentration Risk [Line Items]  
Concentration Risk, Percentage 16.00%
XML 57 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Combinations and Asset Acquisitions (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 18, 2024
Jun. 30, 2023
Business Acquisition [Line Items]      
Net Intangible $ 1,708   $ 1,461
Goodwill $ 4,788   4,609
Weighted- Average Remaining Amortization Period (Years) 9 years    
Specialty Networks      
Business Acquisition [Line Items]      
Total identifiable intangible assets acquired   $ 439  
Cash and equivalents   23  
Trade receivables, net   19  
Prepaid expenses and other   2  
Other accrued liabilities   (15)  
Deferred income taxes and other liabilities   (109)  
Total identifiable net assets/(liabilities) acquired   359  
Goodwill   856  
Total net assets acquired   1,215  
Business Combination, Acquisition Related Costs $ 15    
Payments to Acquire Businesses, Gross 1,200    
Customer relationships      
Business Acquisition [Line Items]      
Net Intangible $ 1,177   900
Weighted- Average Remaining Amortization Period (Years) 10 years    
Customer relationships | Specialty Networks      
Business Acquisition [Line Items]      
Net Intangible   $ 404  
Weighted- Average Remaining Amortization Period (Years)   14 years  
Developed Technology Rights [Member]      
Business Acquisition [Line Items]      
Net Intangible $ 371   395
Weighted- Average Remaining Amortization Period (Years) 7 years    
Developed Technology Rights [Member] | Specialty Networks      
Business Acquisition [Line Items]      
Net Intangible   $ 20  
Weighted- Average Remaining Amortization Period (Years)   9 years  
Trademarks, trade names and patents      
Business Acquisition [Line Items]      
Net Intangible $ 160   $ 166
Weighted- Average Remaining Amortization Period (Years) 7 years    
Trademarks, trade names and patents | Specialty Networks      
Business Acquisition [Line Items]      
Net Intangible   $ 15  
Weighted- Average Remaining Amortization Period (Years)   8 years  
XML 58 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Discontinued Operations and Disposal Groups (Details)
$ in Millions
 9 Months Ended
Mar. 31, 2024
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Gain (Loss) on Sale of Assets and Asset Impairment Charges
Outcomes Divestiture [Member]  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal $ 53
Transaction Data System Investment  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Equity Method Investment, Ownership Percentage 16.00%
XML 59 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Restructuring Charges [Abstract]        
Employee-related costs $ 36 $ 3 $ 51 $ 32
Facility Exit and Other Costs 17 13 55 30
Total restructuring and employee severance $ 53 $ 16 $ 106 $ 62
XML 60 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)
$ in Millions
 9 Months Ended
Mar. 31, 2024
USD ($)
Restructuring Reserve [Roll Forward]  
Beginning Balance $ 46
Additions 51
Payments and other adjustments (27)
Ending Balance 70
Employee- Related Costs  
Restructuring Reserve [Roll Forward]  
Beginning Balance 44
Additions 38
Payments and other adjustments (21)
Ending Balance 61
Facility Exit and Other Costs  
Restructuring Reserve [Roll Forward]  
Beginning Balance 2
Additions 13
Payments and other adjustments (6)
Ending Balance $ 9
XML 61 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring and Employee Severance Narative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Restructuring Cost and Reserve [Line Items]        
Employee-related costs $ 36 $ 3 $ 51 $ 32
Facility Exit and Other Costs $ 17 $ 13 $ 55 $ 30
XML 62 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2024
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Mar. 31, 2024
Mar. 31, 2023
Jun. 30, 2023
Goodwill [Roll Forward]              
Beginning balance   $ 4,609     $ 4,609    
Goodwill acquired, net of purchase price adjustments         853    
Foreign currency translation adjustments and other         3    
Goodwill impairment         671    
Ending balance $ 4,788       4,788   $ 4,609
OptiFreight Logistics [Member]              
Goodwill [Roll Forward]              
Ending balance 48       48    
Pharmaceutical and Specialty Solutions              
Goodwill [Roll Forward]              
Beginning balance   2,762     2,762    
Goodwill acquired, net of purchase price adjustments         856    
Foreign currency translation adjustments and other         0    
Goodwill impairment         0    
Ending balance 3,618       3,618   2,762
Goodwill, Transfers             110
Global Medical Products and Distribution              
Goodwill [Roll Forward]              
Beginning balance   677     677    
Goodwill acquired, net of purchase price adjustments         (3)    
Foreign currency translation adjustments and other         3    
Goodwill impairment 90 581 $ 709 $ 154 671 $ 863  
Ending balance 0       0   677
Goodwill, Impaired, Accumulated Impairment Loss 5,400       5,400   4,700
Other Segments              
Goodwill [Roll Forward]              
Beginning balance   $ 1,170     1,170    
Goodwill acquired, net of purchase price adjustments         0    
Foreign currency translation adjustments and other         0    
Goodwill impairment         0    
Ending balance 1,170       1,170   1,170
Goodwill, Transfers             $ (110)
Other Segments | OptiFreight Logistics [Member]              
Goodwill [Roll Forward]              
Ending balance $ 48       $ 48    
XML 63 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Jun. 30, 2023
Indefinite-lived Intangible Assets [Line Items]    
Net Intangible $ 11 $ 11
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible 5,168 4,741
Accumulated Amortization 3,460 3,280
Net Intangible $ 1,708 1,461
Weighted- Average Remaining Amortization Period (Years) 9 years  
Gross Intangible, Total other intangible assets $ 5,179 4,752
Net Intangible, Total other intangible assets 1,719 1,472
Trademarks and patents    
Indefinite-lived Intangible Assets [Line Items]    
Net Intangible 11 11
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible 3,564 3,174
Accumulated Amortization 2,387 2,274
Net Intangible $ 1,177 900
Weighted- Average Remaining Amortization Period (Years) 10 years  
Trademarks, trade names and patents    
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible $ 561 546
Accumulated Amortization 401 380
Net Intangible $ 160 166
Weighted- Average Remaining Amortization Period (Years) 7 years  
Developed technology and other    
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible $ 1,043 1,021
Accumulated Amortization 672 626
Net Intangible $ 371 $ 395
Weighted- Average Remaining Amortization Period (Years) 7 years  
XML 64 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Sep. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Mar. 31, 2024
Mar. 31, 2023
Jan. 01, 2024
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]                  
Amortization of intangible assets $ 64   $ 69     $ 191 $ 211    
Estimated annual amortization of intangible assets - Remainder of Fiscal Year 69         69      
Estimated annual amortization of intangible assets - Year One 256         256      
Estimated annual amortization of intangible assets - Year Two 241         241      
Estimated annual amortization of intangible assets - Year Three 213         213      
Estimated annual amortization of intangible assets - Year Four 186         186      
Goodwill [Line Items]                  
Goodwill 4,788         4,788     $ 4,609
Goodwill impairment           671      
Global Medical Products and Distribution                  
Goodwill [Line Items]                  
Goodwill 0         0     $ 677
Goodwill impairment 90 $ 581   $ 709 $ 154 671 $ 863    
OptiFreight Logistics [Member]                  
Goodwill [Line Items]                  
Goodwill $ 48         $ 48      
Global Medical Products and Distribution                  
Goodwill [Line Items]                  
Goodwill               $ 90  
Discount Rate, Fair Value Input 11.00%         11.00%      
Terminal Growth Rate, Fair Value Input 2.00%         2.00%      
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount     4.00%       4.00%    
XML 65 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Long-Term Obligations and Other Short-Term Borrowings (Details) - USD ($)
$ in Millions
 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Jun. 30, 2023
Jun. 30, 2022
Debt Instrument [Line Items]        
Other Borrowings $ 104   $ 86  
Debt and Lease Obligation 5,854   4,701  
Current portion of long-term obligations and other short-term borrowings 1,187   792  
Long-term obligations, less current portion 4,667   3,909  
Long-Term Debt, Maturity, Year One 762      
Long-Term Debt, Maturity, Year Two 436      
Long-Term Debt, Maturity, Year Three 535      
Long-Term Debt, Maturity, Year Four 1,300      
Long-Term Debt, Maturity, Year Five 11      
Long-Term Debt, Maturity, after Year Five 2,800      
Total Long-Term and Short-Term Obligations 5,900   4,700  
Accounts Payable 32,100   29,800  
Debt Instrument, Issued, Principal 1,150      
Proceeds from Issuance of Long-Term Debt 1,140      
Purchases of short-term time deposits 550 $ 0    
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 3,718 $ 3,990 4,043 $ 4,717
Line of Credit Facility, Average Outstanding Amount 25      
Remaining Cash from Debt Proceeds        
Debt Instrument [Line Items]        
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 589      
Commercial Paper [Member]        
Debt Instrument [Line Items]        
Line of Credit Facility, Maximum Borrowing Capacity 2,000      
Revolving Credit Facility [Member]        
Debt Instrument [Line Items]        
Line of Credit Facility, Maximum Borrowing Capacity 2,000      
Short Term Credit Facilities Member        
Debt Instrument [Line Items]        
Other Short-term Borrowings 0      
Committed Receivables Sales Facility Program [Member]        
Debt Instrument [Line Items]        
Line of Credit Facility, Maximum Amount Outstanding During Period 1,300      
Committed Receivables Sales Facility Program [Member] | Short Term Credit Facilities Member        
Debt Instrument [Line Items]        
Line of Credit Facility, Maximum Borrowing Capacity 1,000      
3.079% Notes due 2024        
Debt Instrument [Line Items]        
Notes Payable 753   764  
3.5% Notes due 2024        
Debt Instrument [Line Items]        
Notes Payable 402   404  
3.75% Notes due 2025        
Debt Instrument [Line Items]        
Notes Payable 508   513  
3.41% Notes due 2027        
Debt Instrument [Line Items]        
Notes Payable 1,192   1,184  
5.125% Notes due 2029        
Debt Instrument [Line Items]        
Notes Payable 644   0  
Debt Instrument, Issued, Principal 650      
5.45% Notes due 2034        
Debt Instrument [Line Items]        
Notes Payable 494   0  
Debt Instrument, Issued, Principal 500      
4.6% Notes due 2043        
Debt Instrument [Line Items]        
Notes Payable 311   306  
4.5% Notes due 2044        
Debt Instrument [Line Items]        
Notes Payable 330   331  
4.9% Notes due 2045        
Debt Instrument [Line Items]        
Notes Payable 428   428  
4.368% Notes due 2047        
Debt Instrument [Line Items]        
Notes Payable 564   561  
7.0% Debentures due fiscal 2027        
Debt Instrument [Line Items]        
Notes Payable $ 124   $ 124  
XML 66 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments, Contingent Liabilities and Litigation (Details)
$ in Thousands
 3 Months Ended 5 Months Ended 9 Months Ended 12 Months Ended 34 Months Ended 176 Months Ended
Jul. 01, 2024
plaintiff
Apr. 26, 2024
lawsuit
plaintiff
Apr. 30, 2023
USD ($)
lawsuit
Jul. 31, 2014
Mar. 31, 2024
USD ($)
states
numberOfUSTerritories
Mar. 31, 2023
plaintiff
Sep. 30, 2023
USD ($)
Mar. 31, 2024
USD ($)
states
numberOfUSTerritories
Mar. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Apr. 30, 2024
USD ($)
Apr. 26, 2024
lawsuit
Dec. 31, 2038
USD ($)
Nov. 30, 2023
USD ($)
Oct. 31, 2022
USD ($)
Jul. 31, 2022
USD ($)
Apr. 30, 2018
USD ($)
Loss Contingencies [Line Items]                                  
Income from Settlements of Class Action Lawsuits         $ 6,000     $ 77,000 $ 66,000                
Product Liability Lawsuits | Subsequent Event                                  
Loss Contingencies [Line Items]                                  
Loss Contingency, Pending Claims, Number | lawsuit   400                   400          
Product Liability Lawsuits | IVC April 2023 Agreement                                  
Loss Contingencies [Line Items]                                  
Loss Contingency, Claims Settled, Number | lawsuit     4,375                            
Product Liability Lawsuits | Subsequent Event | Other Agreements [Member]                                  
Loss Contingencies [Line Items]                                  
Loss Contingency, Claims Settled, Number | lawsuit                       2,800          
Product Liability Lawsuits | Minimum                                  
Loss Contingencies [Line Items]                                  
Loss Contingency Accrual         296,000     296,000                  
Total Opioid Litigation [Member]                                  
Loss Contingencies [Line Items]                                  
Loss Contingency Accrual, Period Increase (Decrease)         (344,000)                        
Estimated Litigation Liability         5,300,000     5,300,000                  
Estimated Litigation Liability, Current         438,000     $ 438,000                  
Litigation Settlement, Loss         193,000                        
Income As A Result Of Prepayments         $ 105,000                        
New York Opioid Stewardship Act [Member]                                  
Loss Contingencies [Line Items]                                  
Aggregate Annual Assessment                                 $ 100,000
Loss Contingency Accrual                   $ 3,000              
Loss Contingency Accrual, Period Increase (Decrease)                   (6,000)              
Opioid Lawsuits [Member]                                  
Loss Contingencies [Line Items]                                  
Settling States | states         48     48                  
Settling U.S Territories | numberOfUSTerritories         5     5                  
Payments for Legal Settlements         $ 239,000                        
Insurance Recoveries                   10,000              
Opioid Lawsuits [Member] | Subsequent Event                                  
Loss Contingencies [Line Items]                                  
Payments for Legal Settlements                     $ 1,500,000   $ 4,800,000        
Opioid Lawsuits [Member] | WEST VIRGINIA                                  
Loss Contingencies [Line Items]                                  
Loss Contingency, Estimate of Possible Loss                               $ 124,000  
Opioid Lawsuits [Member] | ALABAMA                                  
Loss Contingencies [Line Items]                                  
Loss Contingency, Estimate of Possible Loss                           $ 123,000      
Litigation Settlement, Loss               $ 22,000                  
Opioid Lawsuits [Member] | Native American tribes                                  
Loss Contingencies [Line Items]                                  
Loss Contingency, Estimate of Possible Loss                             $ 136,000    
Opioid Lawsuits [Member] | Private Parties [Member] | Subsequent Event                                  
Loss Contingencies [Line Items]                                  
Loss Contingency, Lawsuits, Number | lawsuit   380                   380          
Opioid Lawsuits [Member] | Private Parties [Member] | GEORGIA                                  
Loss Contingencies [Line Items]                                  
Loss Contingency, Number of Plaintiffs | plaintiff           21                      
Opioid Lawsuits [Member] | Private Parties [Member] | ALABAMA | Subsequent Event                                  
Loss Contingencies [Line Items]                                  
Loss Contingency, Number of Plaintiffs | plaintiff 8                                
Opioid Lawsuits [Member] | Class Action Lawsuits [Member] | Private Parties [Member]                                  
Loss Contingencies [Line Items]                                  
Estimated Litigation Liability         $ 213,000     $ 213,000                  
Opioid Lawsuits [Member] | Class Action Lawsuits [Member] | Private Parties [Member] | Subsequent Event                                  
Loss Contingencies [Line Items]                                  
Loss Contingency, Lawsuits, Number | lawsuit   103                   103          
Product Liability Lawsuits                                  
Loss Contingencies [Line Items]                                  
Product Liability Accrual, Period Expense                   $ (103,000)              
Product Liability Lawsuits | IVC April 2023 Agreement                                  
Loss Contingencies [Line Items]                                  
Loss Contingency, Estimate of Possible Loss     $ 275,000                            
Payments for Legal Settlements             $ 275,000                    
Product Liability Lawsuits | Alameda County [Member] | Subsequent Event                                  
Loss Contingencies [Line Items]                                  
Loss Contingency, Number of Plaintiffs | plaintiff   4,500                              
CVS Health                                  
Loss Contingencies [Line Items]                                  
Long-term Purchase Commitment, Period       10 years                          
XML 67 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2024
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Taxes              
Effective Income Tax Rate Reconciliation, Percent   24.20% 36.30% 23.20% 36.70%    
Goodwill impairment       $ 671      
Income Tax Expense (Benefit)   $ (82) $ (197) (186) $ (189)    
Unrecognized tax benefits   937   937     $ 1,000
Unrecognized tax benefits that would impact effective tax rate   850   850     873
Unrecognized tax benefits, interest and penalties accrued   57   57     65
Global Medical Products and Distribution | Subsequent Event              
Income Taxes              
Income Tax Expense (Benefit) $ 36            
Forecast [Member] | Global Medical Products and Distribution              
Income Taxes              
Income Tax Expense (Benefit)           $ 56  
Minimum              
Income Taxes              
Estimated range of decrease in unrecognized tax benefits within the next 12 months   0   0      
Maximum              
Income Taxes              
Estimated range of decrease in unrecognized tax benefits within the next 12 months   20   20      
CareFusion [Member]              
Income Taxes              
Indemnification Receivable   $ 20   $ 20     $ 82
XML 68 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Jul. 10, 2023
Jun. 30, 2023
Transaction Data System Investment      
Assets:      
Equity Method Investment, Ownership Percentage 16.00%    
Recurring      
Assets:      
Cash equivalents $ 2,013   $ 1,253
Other investments 105   101
Forward Contract (70)   (73)
Liabilities:      
Forward Contract (70)   (73)
Level 1 | Recurring      
Assets:      
Cash equivalents 2,013   1,253
Other investments 105   101
Forward Contract 0   0
Liabilities:      
Forward Contract 0   0
Level 2 | Recurring      
Assets:      
Cash equivalents 0   0
Other investments 0   0
Forward Contract (70)   (73)
Liabilities:      
Forward Contract (70)   (73)
Level 3 | Recurring      
Assets:      
Cash equivalents 0   0
Other investments 0   0
Forward Contract 0   0
Liabilities:      
Forward Contract $ 0   $ 0
Level 3 | Fair Value, Nonrecurring | Transaction Data System Investment      
Assets:      
Equity Method Investments, Fair Value Disclosure   $ 147  
XML 69 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments (Narrative) (Details)
€ in Millions, ¥ in Millions, $ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2024
JPY (¥)
Mar. 31, 2023
JPY (¥)
Mar. 31, 2023
EUR (€)
Derivative [Line Items]                
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments $ 0 $ 0 $ 0 $ 0        
Proceeds from net investment hedge terminations     28 29        
Effective March 2022                
Derivative [Line Items]                
Proceeds from net investment hedge terminations   10            
Effective September 2018                
Derivative [Line Items]                
Proceeds from net investment hedge terminations   19            
January 2023                
Derivative [Line Items]                
Proceeds from net investment hedge terminations     28          
Cash Flow Hedging [Member]                
Derivative [Line Items]                
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 1 2 2 4        
Foreign Exchange Contract [Member]                
Derivative [Line Items]                
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax 19   14 21        
Interest Income (Expense), Nonoperating, Net 3 4 10 12        
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member]                
Derivative [Line Items]                
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net 2 4 4 8        
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Forecast [Member] | Subsequent Event                
Derivative [Line Items]                
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net         $ 3      
Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap                
Derivative [Line Items]                
Derivative Liability, Notional Amount 500 200 500 200        
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | Effective March 2022                
Derivative [Line Items]                
Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount   400   400     ¥ 48,000  
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | Effective September 2018                
Derivative [Line Items]                
Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount   233   233       € 200
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | January 2023                
Derivative [Line Items]                
Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount 300   300     ¥ 38,000    
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | September 2025                
Derivative [Line Items]                
Derivative, Notional Amount 120 150 120 150   18,000 19,000  
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | June 2027                
Derivative [Line Items]                
Derivative, Notional Amount $ 120 150 $ 120 150   ¥ 18,000 ¥ 19,000  
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | March 2025                
Derivative [Line Items]                
Derivative, Notional Amount   107   107       100
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | March 2026                
Derivative [Line Items]                
Derivative, Notional Amount   $ 107   107       € 100
Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]                
Derivative [Line Items]                
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net       $ 3        
XML 70 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Jun. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Carrying Amount of Long-Term and other Short-Term Borrowings $ 5,854 $ 4,701
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Estimated fair value $ 5,650 $ 4,417
XML 71 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Shareholders' Equity (Narrative) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 2 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Dec. 13, 2023
Nov. 02, 2023
Oct. 31, 2023
Aug. 16, 2023
Feb. 28, 2023
Jan. 13, 2023
Dec. 23, 2022
Feb. 28, 2023
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Dec. 31, 2023
Sep. 30, 2023
Mar. 31, 2023
Dec. 23, 2022
Mar. 31, 2024
Mar. 31, 2023
Class of Stock [Line Items]                                        
Purchase of treasury shares                                     $ 750 $ 1,500
$250 million share repurchase program [Member]                                        
Class of Stock [Line Items]                                        
Purchase of treasury shares                 $ 250     $ 250                
$300 million share repurchase program                                        
Class of Stock [Line Items]                                        
Purchase of treasury shares                         $ 250              
$500 million share repurchase program [Domain]                                        
Class of Stock [Line Items]                                        
Purchase of treasury shares                   $ 500 $ 500     $ 1,000            
Treasury Stock, Common                                        
Class of Stock [Line Items]                                        
Purchase of treasury shares                                     $ 750 $ 1,500
Treasury Stock, Shares, Acquired                       (4.0)             (9.0) (20.0)
Treasury Stock, Common | $250 million share repurchase program [Member]                                        
Class of Stock [Line Items]                                        
Treasury Stock, Shares, Acquired (0.4)       (0.6)       (2.0)     (2.6)                
Treasury shares acquired, average price per share (in usd per share)   $ 101.66           $ 77.27 $ 103.67     $ 77.03                
Treasury Stock, Common | $300 million share repurchase program                                        
Class of Stock [Line Items]                                        
Treasury Stock, Shares, Acquired           (0.6)             (2.6)              
Treasury shares acquired, average price per share (in usd per share)                         $ 76.58       $ 77.50      
Treasury Stock, Common | $500 million share repurchase program [Domain]                                        
Class of Stock [Line Items]                                        
Treasury Stock, Shares, Acquired     (1.3) (0.9)     (1.6)     (4.4) (4.6)     (12.0)            
Treasury shares acquired, average price per share (in usd per share)                   $ 90.57 $ 87.18     $ 66.74 $ 88.22 $ 91.15   $ 73.36    
XML 72 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
AOCI, Net of Tax [Roll Forward]        
Balance at beginning of period $ (3,447) $ (2,212) $ (2,851) $ (706)
Other Comprehensive Income (Loss), Tax     4 (5)
Total other comprehensive income/(loss), net of tax (5) 4 (9) (28)
Balance at end of period (3,262) (2,218) (3,262) (2,218)
Foreign Currency Translation Adjustments        
AOCI, Net of Tax [Roll Forward]        
Balance at beginning of period     (137) (102)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax     (4) (34)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax     0 0
Total other comprehensive income/(loss), net of tax     (4) (34)
Balance at end of period (141) (136) (141) (136)
Unrealized Gain/(Loss) on Derivatives, net of tax        
AOCI, Net of Tax [Roll Forward]        
Balance at beginning of period     (14) (12)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax     1 15
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax     (6) (9)
Total other comprehensive income/(loss), net of tax     (5) 6
Balance at end of period (19) (6) (19) (6)
Accumulated Other Comprehensive Loss        
AOCI, Net of Tax [Roll Forward]        
Balance at beginning of period     (151) (114)
Total other comprehensive income/(loss), net of tax     (9) (28)
Balance at end of period (160) (142) (160) (142)
AOCI Attributable to Parent        
AOCI, Net of Tax [Roll Forward]        
Balance at beginning of period (155) (146) (151) (114)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax     (3) (19)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax     (6) (9)
Balance at end of period $ (160) $ (142) $ (160) $ (142)
XML 73 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share [Abstract]        
Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares) 1,000 2,000 1,000 2,000
XML 74 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares
shares in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share [Abstract]        
Weighted-average common shares–basic (in shares) 243 256 245 263
Effect of dilutive securities:        
Employee stock options, restricted share units, and performance share units (in shares) 2 2 2 1
Weighted-average common shares–diluted (in shares) 245 258 247 264
XML 75 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information (Narrative) (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2024
USD ($)
Sep. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Mar. 31, 2024
USD ($)
Segments
segment
Mar. 31, 2023
USD ($)
Segment Reporting Information [Line Items]              
Number of reportable segments | segment           2  
Goodwill impairment           $ 671  
Project costs on investment and other spending $ 17   $ 9     37 $ 20
Global Medical Products and Distribution              
Segment Reporting Information [Line Items]              
Goodwill impairment $ 90 $ 581   $ 709 $ 154 $ 671 $ 863
Other Segments              
Segment Reporting Information [Line Items]              
Number of operating segments | Segments           3  
Goodwill impairment           $ 0  
XML 76 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information (Revenue by Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting Information [Line Items]        
Total revenue $ 54,911 $ 50,487 $ 167,119 $ 151,559
Operating Segments        
Segment Reporting Information [Line Items]        
Total revenue 54,931 50,510 167,180 151,619
Operating Segments | Pharmaceutical and Specialty Solutions        
Segment Reporting Information [Line Items]        
Total revenue 50,651 46,496 154,524 139,441
Operating Segments | Global Medical Products and Distribution        
Segment Reporting Information [Line Items]        
Total revenue 3,113 2,989 9,264 9,140
Operating Segments | Other Segments        
Segment Reporting Information [Line Items]        
Total revenue 1,167 1,025 3,392 3,038
Corporate        
Segment Reporting Information [Line Items]        
Total revenue (20) (23) (61) (60)
Nuclear Precision Health Services [Member] | Operating Segments | Other Segments        
Segment Reporting Information [Line Items]        
Total revenue 352 313 1,006 875
OptiFreight Logistics [Member] | Operating Segments | Other Segments        
Segment Reporting Information [Line Items]        
Total revenue 72 61 198 177
at-Home Solutions [Member] | Operating Segments | Other Segments        
Segment Reporting Information [Line Items]        
Total revenue $ 743 $ 651 $ 2,188 $ 1,986
XML 77 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information Revenue From External Customers By Geographic Areas (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Segment Revenue from External Customers by Geographic Area [Line Items]        
Revenue $ 54,911 $ 50,487 $ 167,119 $ 151,559
UNITED STATES        
Segment Revenue from External Customers by Geographic Area [Line Items]        
Revenue 53,715 49,343 163,548 148,186
Non-US [Member]        
Segment Revenue from External Customers by Geographic Area [Line Items]        
Revenue 1,216 1,167 3,632 3,433
Operating Segments        
Segment Revenue from External Customers by Geographic Area [Line Items]        
Revenue 54,931 50,510 167,180 151,619
Corporate        
Segment Revenue from External Customers by Geographic Area [Line Items]        
Revenue $ (20) $ (23) $ (61) $ (60)
XML 78 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings $ 367 $ 572 $ 835 $ 590
Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings 711 620 1,878 1,524
Operating Segments | Pharmaceutical and Specialty Solutions        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings 580 560 1,541 1,394
Operating Segments | Global Medical Products and Distribution        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings 20 (46) 18 (175)
Operating Segments | Other Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings 111 106 319 305
Corporate        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings $ (344) $ (48) $ (1,043) $ (934)
XML 79 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information (Assets by Reportable Segment) (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Jun. 30, 2023
Segment Reporting Information [Line Items]    
Total assets $ 45,880 $ 43,417
Operating Segments | Pharmaceutical and Specialty Solutions    
Segment Reporting Information [Line Items]    
Total assets 30,496 27,615
Operating Segments | Global Medical Products and Distribution    
Segment Reporting Information [Line Items]    
Total assets 7,357 7,961
Operating Segments | Other Segments    
Segment Reporting Information [Line Items]    
Total assets 2,692 2,621
Corporate    
Segment Reporting Information [Line Items]    
Total assets $ 5,335 $ 5,220
XML 80 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation (Narrative) (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Tax benefit related to share-based compensation $ 4 $ 3 $ 12 $ 9
Restricted Share Units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period (in years)     3 years  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount 86   $ 86  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition     2 years  
Performance Share Units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 53   $ 53  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition     2 years  
Vesting Period in years for Shares     3  
Performance Share Units | Minimum | Fiscal 2024        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target performance goal (as a percent)     0.00%  
Performance Share Units | Minimum | Fiscal 2023        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target performance goal (as a percent)     0.00%  
Performance Share Units | Minimum | Fiscal 2022        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target performance goal (as a percent)     0.00%  
Performance Share Units | Maximum | Fiscal 2024        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target performance goal (as a percent)     240.00%  
Performance Share Units | Maximum | Fiscal 2023        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target performance goal (as a percent)     234.00%  
Performance Share Units | Maximum | Fiscal 2022        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target performance goal (as a percent)     234.00%  
XML 81 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation $ 31 $ 21 $ 88 $ 69
Restricted Share Unit        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation 20 17 58 49
Performance Share Unit        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation $ 11 $ 4 $ 30 $ 20
XML 82 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units
$ / shares in Units, shares in Millions, $ in Millions
 9 Months Ended
Mar. 31, 2024
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ $ 86
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2 years
Restricted Share Units  
Nonvested at beginning of period (in shares) | shares 2.2
Granted (in shares) | shares 0.9
Vested (in shares) | shares (1.1)
Canceled and forfeited (in shares) | shares (0.1)
Nonvested at end of period (in shares) | shares 1.9
Weighted-Average Grant Date Fair Value per Share  
Nonvested at beginning of period (in usd per share) | $ / shares $ 57.37
Granted (in usd per share) | $ / shares 90.78
Vested (in usd per share) | $ / shares 60.83
Canceled and forfeited (in usd per share) | $ / shares 71.21
Nonvested at end of period (in usd per share) | $ / shares $ 69.96
XML 83 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units
$ / shares in Units, shares in Millions, $ in Millions
 9 Months Ended
Mar. 31, 2024
USD ($)
$ / shares
shares
Performance Share Units  
Nonvested at beginning of period (in shares) | shares 1.2
Granted (in shares) | shares 0.5
Vested (in shares) | shares (0.4)
Canceled and forfeited (in shares) | shares 0.0
Nonvested at end of period (in shares) | shares 1.3
Weighted-Average Grant Date Fair Value per Share  
Nonvested at beginning of period (in usd per share) | $ / shares $ 82.17
Granted (in usd per share) | $ / shares 94.66
Vested (in usd per share) | $ / shares 62.26
Canceled and forfeited (in usd per share) | $ / shares 0
Nonvested at end of period (in usd per share) | $ / shares $ 96.80
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ $ 53
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2 years
EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 85 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 314 282 1 false 101 0 false 13 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.cardinal.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Statements of Earnings Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings Condensed Consolidated Statements of Earnings Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity Condensed Consolidated Statements of Shareholders' Equity Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 0000009 - Disclosure - Business Combinations and Asset Acquisitions Sheet http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitions Business Combinations and Asset Acquisitions Notes 9 false false R10.htm 0000010 - Disclosure - Divestitures Sheet http://www.cardinal.com/role/Divestitures Divestitures Notes 10 false false R11.htm 0000011 - Disclosure - Restructuring and Employee Severance Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeverance Restructuring and Employee Severance Notes 11 false false R12.htm 0000012 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 12 false false R13.htm 0000013 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Sheet http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings Long-Term Obligations and Other Short-Term Borrowings Notes 13 false false R14.htm 0000014 - Disclosure - Commitments, Contingent Liabilities and Litigation Sheet http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation Commitments, Contingent Liabilities and Litigation Notes 14 false false R15.htm 0000015 - Disclosure - Income Taxes Sheet http://www.cardinal.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 0000016 - Disclosure - Fair Value Measurements Sheet http://www.cardinal.com/role/FairValueMeasurements Fair Value Measurements Notes 16 false false R17.htm 0000017 - Disclosure - Financial Instruments Sheet http://www.cardinal.com/role/FinancialInstruments Financial Instruments Notes 17 false false R18.htm 0000018 - Disclosure - Shareholders' Equity Sheet http://www.cardinal.com/role/ShareholdersEquity Shareholders' Equity Notes 18 false false R19.htm 0000019 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc Earnings Per Share Attributable to Cardinal Health, Inc. Notes 19 false false R20.htm 0000020 - Disclosure - Segment Information Sheet http://www.cardinal.com/role/SegmentInformation Segment Information Notes 20 false false R21.htm 0000021 - Disclosure - Share-Based Compensation Sheet http://www.cardinal.com/role/ShareBasedCompensation Share-Based Compensation Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 24 false false R25.htm 9954472 - Disclosure - Business Combinations and Asset Acquisitions (Tables) Sheet http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsTables Business Combinations and Asset Acquisitions (Tables) Tables http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitions 25 false false R26.htm 9954474 - Disclosure - Restructuring and Employee Severance (Tables) Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables Restructuring and Employee Severance (Tables) Tables http://www.cardinal.com/role/RestructuringandEmployeeSeverance 26 false false R27.htm 9954475 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets 27 false false R28.htm 9954476 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables) Sheet http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables Long-Term Obligations and Other Short-Term Borrowings (Tables) Tables http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings 28 false false R29.htm 9954477 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.cardinal.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.cardinal.com/role/FairValueMeasurements 29 false false R30.htm 9954478 - Disclosure - Financial Instruments (Tables) Sheet http://www.cardinal.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.cardinal.com/role/FinancialInstruments 30 false false R31.htm 9954479 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.cardinal.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.cardinal.com/role/ShareholdersEquity 31 false false R32.htm 9954480 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) Tables http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc 32 false false R33.htm 9954481 - Disclosure - Segment Information (Tables) Sheet http://www.cardinal.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.cardinal.com/role/SegmentInformation 33 false false R34.htm 9954482 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.cardinal.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.cardinal.com/role/ShareBasedCompensation 34 false false R35.htm 9954483 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details) Details http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies 35 false false R36.htm 9954484 - Disclosure - Business Combinations and Asset Acquisitions (Details) Sheet http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails Business Combinations and Asset Acquisitions (Details) Details http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsTables 36 false false R37.htm 9954485 - Disclosure - Discontinued Operations and Disposal Groups (Details) Sheet http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails Discontinued Operations and Disposal Groups (Details) Details 37 false false R38.htm 9954486 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) Details http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables 38 false false R39.htm 9954487 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) Details http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables 39 false false R40.htm 9954488 - Disclosure - Restructuring and Employee Severance Narative (Details) Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails Restructuring and Employee Severance Narative (Details) Details http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables 40 false false R41.htm 9954489 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) Details http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables 41 false false R42.htm 9954490 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) Details http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables 42 false false R43.htm 9954491 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails Goodwill and Other Intangible Assets (Narrative) (Details) Details http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables 43 false false R44.htm 9954492 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details) Sheet http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails Long-Term Obligations and Other Short-Term Borrowings (Details) Details http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables 44 false false R45.htm 9954493 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details) Sheet http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails Commitments, Contingent Liabilities and Litigation (Details) Details http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation 45 false false R46.htm 9954494 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://www.cardinal.com/role/IncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) Details http://www.cardinal.com/role/IncomeTaxes 46 false false R47.htm 9954495 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) Sheet http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) Details http://www.cardinal.com/role/FairValueMeasurementsTables 47 false false R48.htm 9954496 - Disclosure - Financial Instruments (Narrative) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments (Narrative) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 48 false false R49.htm 9954497 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) Details 49 false false R50.htm 9954498 - Disclosure - Shareholders' Equity (Narrative) (Details) Sheet http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails Shareholders' Equity (Narrative) (Details) Details http://www.cardinal.com/role/ShareholdersEquityTables 50 false false R51.htm 9954499 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) Sheet http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) Details http://www.cardinal.com/role/ShareholdersEquityTables 51 false false R52.htm 9954500 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) Details http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables 52 false false R53.htm 9954501 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) Details http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables 53 false false R54.htm 9954502 - Disclosure - Segment Information (Narrative) (Details) Sheet http://www.cardinal.com/role/SegmentInformationNarrativeDetails Segment Information (Narrative) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 54 false false R55.htm 9954503 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails Segment Information (Revenue by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 55 false false R56.htm 9954504 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details) Sheet http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails Segment Information Revenue From External Customers By Geographic Areas (Details) Details 56 false false R57.htm 9954505 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails Segment Information (Segment Profit by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 57 false false R58.htm 9954506 - Disclosure - Segment Information (Assets by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails Segment Information (Assets by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 58 false false R59.htm 9954507 - Disclosure - Share-Based Compensation (Narrative) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails Share-Based Compensation (Narrative) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 59 false false R60.htm 9954508 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 60 false false R61.htm 9954509 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 61 false false R62.htm 9954510 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 62 false false All Reports Book All Reports cah-20240331.htm cah-20240331.xsd cah-20240331_cal.xml cah-20240331_def.xml cah-20240331_lab.xml cah-20240331_pre.xml cah-20240331_g1.jpg cah-20240331_g2.jpg cah-20240331_g3.jpg cah-20240331_g4.jpg cah-20240331_g5.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 90 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cah-20240331.htm": { "nsprefix": "cah", "nsuri": "http://www.cardinal.com/20240331", "dts": { "inline": { "local": [ "cah-20240331.htm" ] }, "schema": { "local": [ "cah-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "cah-20240331_cal.xml" ] }, "definitionLink": { "local": [ "cah-20240331_def.xml" ] }, "labelLink": { "local": [ "cah-20240331_lab.xml" ] }, "presentationLink": { "local": [ "cah-20240331_pre.xml" ] } }, "keyStandard": 263, "keyCustom": 19, "axisStandard": 30, "axisCustom": 10, "memberStandard": 44, "memberCustom": 50, "hidden": { "total": 6, "http://fasb.org/us-gaap/2024": 1, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 314, "entityCount": 1, "segmentCount": 101, "elementCount": 649, "unitCount": 13, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 907, "http://xbrl.sec.gov/dei/2024": 31, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.cardinal.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "longName": "0000002 - Statement - Condensed Consolidated Statements of Earnings", "shortName": "Condensed Consolidated Statements of Earnings", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "unique": true } }, "R3": { "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "longName": "0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "unique": true } }, "R4": { "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "longName": "0000004 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": null }, "R6": { "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "longName": "0000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity", "shortName": "Condensed Consolidated Statements of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-52", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-50", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "unique": true } }, "R7": { "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "unique": true } }, "R8": { "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "longName": "0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitions", "longName": "0000009 - Disclosure - Business Combinations and Asset Acquisitions", "shortName": "Business Combinations and Asset Acquisitions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.cardinal.com/role/Divestitures", "longName": "0000010 - Disclosure - Divestitures", "shortName": "Divestitures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeverance", "longName": "0000011 - Disclosure - Restructuring and Employee Severance", "shortName": "Restructuring and Employee Severance", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets", "longName": "0000012 - Disclosure - Goodwill and Other Intangible Assets", "shortName": "Goodwill and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings", "longName": "0000013 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings", "shortName": "Long-Term Obligations and Other Short-Term Borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation", "longName": "0000014 - Disclosure - Commitments, Contingent Liabilities and Litigation", "shortName": "Commitments, Contingent Liabilities and Litigation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.cardinal.com/role/IncomeTaxes", "longName": "0000015 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.cardinal.com/role/FairValueMeasurements", "longName": "0000016 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.cardinal.com/role/FinancialInstruments", "longName": "0000017 - Disclosure - Financial Instruments", "shortName": "Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.cardinal.com/role/ShareholdersEquity", "longName": "0000018 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc", "longName": "0000019 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.cardinal.com/role/SegmentInformation", "longName": "0000020 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.cardinal.com/role/ShareBasedCompensation", "longName": "0000021 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsTables", "longName": "9954472 - Disclosure - Business Combinations and Asset Acquisitions (Tables)", "shortName": "Business Combinations and Asset Acquisitions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables", "longName": "9954474 - Disclosure - Restructuring and Employee Severance (Tables)", "shortName": "Restructuring and Employee Severance (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables", "longName": "9954475 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "shortName": "Goodwill and Other Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables", "longName": "9954476 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables)", "shortName": "Long-Term Obligations and Other Short-Term Borrowings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.cardinal.com/role/FairValueMeasurementsTables", "longName": "9954477 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.cardinal.com/role/FinancialInstrumentsTables", "longName": "9954478 - Disclosure - Financial Instruments (Tables)", "shortName": "Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.cardinal.com/role/ShareholdersEquityTables", "longName": "9954479 - Disclosure - Shareholders' Equity (Tables)", "shortName": "Shareholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables", "longName": "9954480 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.cardinal.com/role/SegmentInformationTables", "longName": "9954481 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.cardinal.com/role/ShareBasedCompensationTables", "longName": "9954482 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails", "longName": "9954483 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-61", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "us-gaap:MajorCustomersPolicyPolicyTextBlock", "div", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-61", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "us-gaap:MajorCustomersPolicyPolicyTextBlock", "div", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails", "longName": "9954484 - Disclosure - Business Combinations and Asset Acquisitions (Details)", "shortName": "Business Combinations and Asset Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-66", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "unique": true } }, "R37": { "role": "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "longName": "9954485 - Disclosure - Discontinued Operations and Disposal Groups (Details)", "shortName": "Discontinued Operations and Disposal Groups (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-68", "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-68", "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails", "longName": "9954486 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)", "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": null }, "R39": { "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails", "longName": "9954487 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)", "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails", "longName": "9954488 - Disclosure - Restructuring and Employee Severance Narative (Details)", "shortName": "Restructuring and Employee Severance Narative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "longName": "9954489 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)", "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "unique": true } }, "R42": { "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails", "longName": "9954490 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)", "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "longName": "9954491 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)", "shortName": "Goodwill and Other Intangible Assets (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails", "longName": "9954492 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)", "shortName": "Long-Term Obligations and Other Short-Term Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:OtherBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:OtherBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "longName": "9954493 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)", "shortName": "Commitments, Contingent Liabilities and Litigation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "cah:IncomefromSettlementsofClassActionLawsuits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "cah:IncomefromSettlementsofClassActionLawsuits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "longName": "9954494 - Disclosure - Income Taxes (Narrative) (Details)", "shortName": "Income Taxes (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "longName": "9954495 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)", "shortName": "Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-67", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-171", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "unique": true } }, "R48": { "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "longName": "9954496 - Disclosure - Financial Instruments (Narrative) (Details)", "shortName": "Financial Instruments (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "span", "div", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "span", "div", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails", "longName": "9954497 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)", "shortName": "Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-6", "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails", "longName": "9954498 - Disclosure - Shareholders' Equity (Narrative) (Details)", "shortName": "Shareholders' Equity (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsForRepurchaseOfCommonStock", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-206", "name": "us-gaap:PaymentsForRepurchaseOfCommonStock", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "unique": true } }, "R51": { "role": "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails", "longName": "9954499 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)", "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "unique": true } }, "R52": { "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails", "longName": "9954500 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails", "longName": "9954501 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "unique": true } }, "R54": { "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "longName": "9954502 - Disclosure - Segment Information (Narrative) (Details)", "shortName": "Segment Information (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "longName": "9954503 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)", "shortName": "Segment Information (Revenue by Reportable Segment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-248", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "unique": true } }, "R56": { "role": "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "longName": "9954504 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)", "shortName": "Segment Information Revenue From External Customers By Geographic Areas (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-280", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "unique": true } }, "R57": { "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails", "longName": "9954505 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)", "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-260", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "unique": true } }, "R58": { "role": "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "longName": "9954506 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)", "shortName": "Segment Information (Assets by Reportable Segment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-289", "name": "us-gaap:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "unique": true } }, "R59": { "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "longName": "9954507 - Disclosure - Share-Based Compensation (Narrative) (Details)", "shortName": "Share-Based Compensation (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails", "longName": "9954508 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)", "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "longName": "9954509 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)", "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-306", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-305", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "unique": true } }, "R62": { "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "longName": "9954510 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)", "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-313", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-313", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "div", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240331.htm", "first": true, "unique": true } } }, "tag": { "cah_A250MillionShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "A250MillionShareRepurchaseProgramMember", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$250 million share repurchase program [Member]", "label": "$250 million share repurchase program [Member]", "documentation": "$250 million share repurchase program" } } }, "auth_ref": [] }, "cah_A3.079Notesdue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "A3.079Notesdue2024Member", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.079% Notes due 2024", "label": "3.079% Notes due 2024 [Member]", "documentation": "3.079% Notes due 2024" } } }, "auth_ref": [] }, "cah_A3.41Notesdue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "A3.41Notesdue2027Member", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.41% Notes due 2027", "label": "3.41% Notes due 2027 [Member]", "documentation": "3.41% Notes due 2027" } } }, "auth_ref": [] }, "cah_A3.5NotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "A3.5NotesDue2024Member", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.5% Notes due 2024", "label": "3.5% Notes due 2024 [Member]", "documentation": "3.5% Notes due 2024" } } }, "auth_ref": [] }, "cah_A3.75NotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "A3.75NotesDue2025Member", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.75% Notes due 2025", "label": "3.75% Notes due 2025 [Member]", "documentation": "3.75% Notes due 2025" } } }, "auth_ref": [] }, "cah_A300MillionShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "A300MillionShareRepurchaseProgramMember", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$300 million share repurchase program", "label": "$300 million share repurchase program [Member]", "documentation": "$300 million share repurchase program" } } }, "auth_ref": [] }, "cah_A4.368Notesdue2047Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "A4.368Notesdue2047Member", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.368% Notes due 2047", "label": "4.368% Notes due 2047 [Member]", "documentation": "4.368% Notes due 2047" } } }, "auth_ref": [] }, "cah_A4.5Notesdue2044Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "A4.5Notesdue2044Member", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.5% Notes due 2044", "label": "4.5% Notes due 2044 [Member]", "documentation": "4.5% Notes due 2044" } } }, "auth_ref": [] }, "cah_A4.6Notesdue2043Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "A4.6Notesdue2043Member", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.6% Notes due 2043", "label": "4.6% Notes due 2043 [Member]", "documentation": "4.6% Notes due 2043" } } }, "auth_ref": [] }, "cah_A4.9Notesdue2045Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "A4.9Notesdue2045Member", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.9% Notes due 2045", "label": "4.9% Notes due 2045 [Member]", "documentation": "4.9% Notes due 2045" } } }, "auth_ref": [] }, "cah_A5.125NotesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "A5.125NotesDue2029Member", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.125% Notes due 2029", "label": "5.125% Notes due 2029 [Member]", "documentation": "5.125% Notes due 2029" } } }, "auth_ref": [] }, "cah_A5.45NotesDue2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "A5.45NotesDue2034Member", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.45% Notes due 2034", "label": "5.45% Notes due 2034 [Member]", "documentation": "5.45% Notes due 2034" } } }, "auth_ref": [] }, "cah_A500MillionShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "A500MillionShareRepurchaseProgramMember", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$500 million share repurchase program [Domain]", "label": "$500 million share repurchase program [Member]", "documentation": "$500 million share repurchase program [Domain]" } } }, "auth_ref": [] }, "cah_A7.0Debenturesduefiscal2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "A7.0Debenturesduefiscal2027Member", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "7.0% Debentures due fiscal 2027", "label": "7.0% Debentures due fiscal 2027 [Member]", "documentation": "7.0% Debentures due fiscal 2027" } } }, "auth_ref": [] }, "stpr_AL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "AL", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ALABAMA", "label": "ALABAMA" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r97", "r793" ] }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable", "label": "Accounts Payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r164", "r1046" ] }, "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Adjustments", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r3", "r15", "r25", "r110", "r111", "r204", "r616", "r918", "r919" ] }, "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r4", "r15", "r25" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r24", "r25", "r112", "r193", "r607", "r639", "r640" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income/(Loss)", "verboseLabel": "AOCI Attributable to Parent", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r15", "r25", "r509", "r512", "r554", "r635", "r636", "r917", "r918", "r919", "r927", "r928", "r929", "r931" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r856" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r869" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r869" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r869" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r869" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net earnings to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "cah_AggregateAnnualAssessment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "AggregateAnnualAssessment", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Annual Assessment", "label": "Aggregate Annual Assessment", "documentation": "Aggregate Annual Assessment" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r902" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r828", "r838", "r848", "r880" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r831", "r841", "r851", "r883" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r903" ] }, "cah_AgreementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "AgreementsAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreements [Axis]", "label": "Agreements [Axis]", "documentation": "Agreement" } } }, "auth_ref": [] }, "cah_AgreementsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "AgreementsDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreements [Domain]", "label": "Agreements [Domain]", "documentation": "Agreements [Domain]" } } }, "auth_ref": [] }, "cah_AlamedaCountyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "AlamedaCountyMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alameda County [Member]", "label": "Alameda County [Member]", "documentation": "Alameda County [Member]" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r869" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r876" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r832", "r842", "r852", "r876", "r884", "r888", "r896" ] }, "us-gaap_AllOtherSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllOtherSegmentsMember", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Segments", "label": "Other Operating Segment [Member]", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r251", "r278", "r279", "r280", "r281", "r282", "r285", "r755", "r756" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r894" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total share-based compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r456", "r461" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r10", "r316", "r323", "r763" ] }, "cah_Amortizationandotheracquisitionrelatedcosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "Amortizationandotheracquisitionrelatedcosts", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization and other acquisition-related costs", "label": "Amortization and other acquisition-related costs", "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r244" ] }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r15", "r25", "r917", "r918", "r919" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r162", "r174", "r189", "r219", "r247", "r254", "r280", "r284", "r297", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r497", "r501", "r538", "r603", "r679", "r755", "r756", "r793", "r819", "r978", "r979", "r1038" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r183", "r196", "r219", "r297", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r497", "r501", "r538", "r793", "r978", "r979", "r1038" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r86", "r92", "r137", "r181", "r182" ] }, "cah_AtHomeSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "AtHomeSolutionsMember", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "at-Home Solutions [Member]", "label": "at-Home Solutions [Member]", "documentation": "at-Home Solutions" } } }, "auth_ref": [] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Date [Axis]", "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009" ] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Date [Domain]", "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r891" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r892" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r887" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r887" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r887" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r887" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r887" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r887" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r890" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r889" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r888" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r888" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r131" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r317", "r318", "r319", "r320", "r321", "r491", "r776", "r777" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r56", "r57", "r317", "r318", "r319", "r320", "r321", "r491", "r776", "r777" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r491" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Acquisition Related Costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r55" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitions" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination Disclosure", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r152", "r492" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other accrued liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total identifiable intangible assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r58", "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total identifiable net assets/(liabilities) acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r58", "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred income taxes and other liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total net assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r59" ] }, "cah_CVSHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "CVSHealthMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CVS Health", "label": "CVS Health [Member]", "documentation": "CVS Health [Member]" } } }, "auth_ref": [] }, "cah_CareFusionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "CareFusionMember", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CareFusion [Member]", "label": "CareFusion [Member]", "documentation": "CareFusion [Member]" } } }, "auth_ref": [] }, "cah_CarryingAmountofLongTermandotherShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "CarryingAmountofLongTermandotherShortTermBorrowings", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount of Long-Term and other Short-Term Borrowings", "label": "Carrying Amount of Long-Term and other Short-Term Borrowings", "documentation": "Carrying Amount of Long-Term and other Short-Term Borrowings" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r30", "r185", "r746" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1018", "r1019" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and equivalents at beginning of period", "periodEndLabel": "Cash and equivalents at end of period", "terseLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r30", "r128", "r216" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r128" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging [Member]", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r71" ] }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement." } } }, "auth_ref": [ "r160" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r867" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r864" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r862" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "cah_ClassActionLawsuitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "ClassActionLawsuitsMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class Action Lawsuits [Member]", "label": "Class Action Lawsuits [Member]", "documentation": "Class Action Lawsuits [Member]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r190", "r191", "r192", "r249", "r401", "r402", "r403", "r405", "r408", "r413", "r415", "r644", "r645", "r646", "r647", "r770", "r906", "r924" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r868" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r868" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper [Member]", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r144", "r361", "r811", "r812", "r813", "r816" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments, Contingent Liabilities and Litigation", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r142", "r351", "r352", "r731", "r966", "r972" ] }, "cah_CommittedReceivablesSalesFacilityProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "CommittedReceivablesSalesFacilityProgramMember", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Committed Receivables Sales Facility Program [Member]", "label": "Committed Receivables Sales Facility Program [Member]", "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables." } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividends declared per common share", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r149" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r807", "r808", "r809", "r811", "r812", "r813", "r816", "r927", "r928", "r931", "r1017", "r1080", "r1081" ] }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, without par value:", "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r105", "r667" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, issued", "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r105" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized\u2014755 million shares, Issued\u2014327 million shares at March\u00a031, 2024 and June 30, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r105", "r606", "r793" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r873" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r872" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r874" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r871" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r26", "r201", "r203", "r210", "r599", "r617", "r618" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r66", "r155", "r201", "r203", "r209", "r598", "r617" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r33", "r34", "r82", "r83", "r292", "r730" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r33", "r34", "r82", "r83", "r292", "r642", "r730" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r33", "r34", "r82", "r83", "r292", "r730", "r914" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r730" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk, Percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r33", "r34", "r82", "r83", "r292" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r32", "r33", "r34", "r35", "r82", "r161", "r730" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r33", "r34", "r82", "r83", "r292", "r730" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r172", "r221", "r247", "r256", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r755", "r756", "r978", "r979" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r172", "r221", "r247", "r256", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r755", "r756", "r978", "r979" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r19", "r279", "r280", "r281", "r282", "r285", "r936" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r116", "r117", "r562" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r361", "r976" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r361", "r976", "r977" ] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrencySwapMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency Swap [Member]", "label": "Currency Swap [Member]", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r132", "r292" ] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r60", "r955", "r956", "r957", "r958", "r959", "r961", "r963", "r964" ] }, "cah_DateInitiatedAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "DateInitiatedAxis", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective Date [Axis]", "label": "Date Initiated [Axis]", "documentation": "Date Initiated" } } }, "auth_ref": [] }, "cah_DateInitiatedDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "DateInitiatedDomain", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Date Initiated [Domain]", "label": "Date Initiated [Domain]", "documentation": "Date Initiated [Domain]" } } }, "auth_ref": [] }, "us-gaap_DebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Debt and Lease Obligation", "label": "Debt and Lease Obligation", "documentation": "Amount of short-term and long-term debt and lease obligation." } } }, "auth_ref": [ "r163", "r165" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r143", "r217", "r333", "r334", "r335", "r336", "r337", "r360", "r361", "r373", "r379", "r380", "r381", "r382", "r383", "r384", "r389", "r396", "r397", "r399", "r549" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r22", "r99", "r100", "r163", "r165", "r221", "r374", "r375", "r376", "r377", "r378", "r380", "r385", "r386", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r765", "r766", "r767", "r768", "r769", "r792", "r925", "r967", "r968", "r969", "r1036", "r1037" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r387", "r537", "r766", "r767", "r1019", "r1020", "r1021", "r1022", "r1029" ] }, "us-gaap_DebtInstrumentIssuedPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIssuedPrincipal", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Issued, Principal", "label": "Debt Instrument, Issued, Principal", "documentation": "Amount of principal of debt issued." } } }, "auth_ref": [ "r644" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r221", "r374", "r375", "r376", "r377", "r378", "r380", "r385", "r386", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r398", "r765", "r766", "r767", "r768", "r769", "r792", "r925", "r1036", "r1037" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r22", "r221", "r374", "r375", "r376", "r377", "r378", "r380", "r385", "r386", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r765", "r766", "r767", "r768", "r769", "r792", "r925", "r967", "r968", "r969", "r1036", "r1037" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r22", "r47", "r50", "r84", "r147", "r148", "r221", "r374", "r375", "r376", "r377", "r378", "r380", "r385", "r386", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r398", "r765", "r766", "r767", "r768", "r769", "r792", "r925", "r1036", "r1037" ] }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit." } } }, "auth_ref": [ "r175" ] }, "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes and other liabilities", "label": "Deferred Tax and Other Liabilities, Noncurrent", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other." } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r10", "r247", "r259", "r284", "r755", "r756" ] }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward Contract", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments." } } }, "auth_ref": [ "r11", "r1020", "r1021", "r1022" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Name [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r657", "r659", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r680", "r681", "r682", "r683", "r693", "r694", "r695", "r696", "r699", "r700", "r701", "r702", "r717", "r719", "r722", "r724", "r807", "r809", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1030", "r1031" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r74", "r76", "r78", "r158", "r657", "r659", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r680", "r681", "r682", "r683", "r693", "r694", "r695", "r696", "r699", "r700", "r701", "r702", "r717", "r719", "r722", "r724", "r748", "r807", "r809", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1030", "r1031" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r17", "r74", "r76" ] }, "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments." } } }, "auth_ref": [ "r20", "r159" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r77", "r915" ] }, "us-gaap_DerivativeLiabilityNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityNotionalAmount", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Notional Amount", "label": "Derivative Liability, Notional Amount", "documentation": "Nominal or face amount used to calculate payments on the derivative liability." } } }, "auth_ref": [ "r718", "r720", "r721", "r723", "r1014", "r1015", "r1016" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r514" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Notional Amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1015", "r1016" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r17", "r67", "r68", "r69", "r73", "r75", "r76", "r79", "r80", "r81", "r514" ] }, "cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount", "label": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount", "documentation": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount" } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r17" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed Technology Rights [Member]", "verboseLabel": "Developed technology and other", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r154", "r955", "r956", "r957", "r958", "r959", "r961", "r963", "r964" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table Text Block]", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r983" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensation" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r426", "r429", "r457", "r458", "r460", "r779" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "cah_DiscountRateFairValueInput": { "xbrltype": "percentItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "DiscountRateFairValueInput", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount Rate, Fair Value Input", "label": "Discount Rate, Fair Value Input", "documentation": "Discount Rate, Fair Value Input" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r330", "r923", "r965" ] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation." } } }, "auth_ref": [ "r331" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/Divestitures" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations, Disclosure", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r85", "r136" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r776", "r777" ] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r6", "r149" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r823" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r855" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r866" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per common share attributable to Cardinal Health, Inc.:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Text Block]", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r236", "r244", "r245", "r246" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r539" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective Income Tax Rate Reconciliation, Percent", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r466", "r781" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r459" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r459" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax benefit related to share-based compensation", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r456" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee- Related Costs", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r821" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r821" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r821" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r905" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r821" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r821" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r821" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r821" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r860" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r901" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r901" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r901" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r16", "r178", "r204", "r205", "r206", "r222", "r223", "r224", "r226", "r231", "r232", "r234", "r248", "r298", "r299", "r329", "r416", "r476", "r477", "r486", "r487", "r488", "r490", "r494", "r495", "r508", "r509", "r510", "r511", "r512", "r513", "r516", "r540", "r542", "r543", "r544", "r545", "r546", "r550", "r552", "r554", "r616", "r635", "r636", "r637", "r652", "r705" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r294", "r295", "r296", "r485", "r908", "r909", "r910", "r1010", "r1011", "r1012", "r1013" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Ownership Percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r294" ] }, "us-gaap_EquityMethodInvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments, Fair Value Disclosure", "label": "Equity Method Investments, Fair Value Disclosure", "documentation": "Fair value portion of investments accounted under the equity method." } } }, "auth_ref": [ "r916", "r1018", "r1019", "r1029" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r870" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r828", "r838", "r848", "r880" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r825", "r835", "r845", "r877" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r876" ] }, "us-gaap_FacilityClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FacilityClosingMember", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility Exit and Other Costs", "label": "Facility Closing [Member]", "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "cah_FacilityExitAndOtherCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "FacilityExitAndOtherCosts", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": { "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility Exit and Other Costs", "label": "Facility Exit and Other Costs", "documentation": "Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r519", "r520", "r530", "r785" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring", "verboseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r519", "r520", "r530", "r785" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r387", "r418", "r419", "r420", "r421", "r422", "r423", "r518", "r520", "r521", "r522", "r523", "r529", "r530", "r532", "r556", "r557", "r558", "r766", "r767", "r773", "r774", "r775", "r785", "r788" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r519", "r520", "r521", "r523", "r785", "r1021", "r1032" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r525", "r527", "r528", "r529", "r532", "r533", "r534", "r535", "r536", "r595", "r785", "r789" ] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueHedgingMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hedging", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": [ "r70" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a01", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r387", "r418", "r423", "r520", "r530", "r556", "r773", "r774", "r775", "r785" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Level\u00a02", "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r387", "r418", "r423", "r520", "r521", "r530", "r557", "r766", "r767", "r773", "r774", "r775", "r785" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a03", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r387", "r418", "r419", "r420", "r421", "r422", "r423", "r520", "r521", "r522", "r523", "r530", "r558", "r766", "r767", "r773", "r774", "r775", "r785", "r788" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r519", "r520", "r521", "r523", "r785", "r1021", "r1032" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r387", "r418", "r419", "r420", "r421", "r422", "r423", "r518", "r520", "r521", "r522", "r523", "r529", "r530", "r532", "r556", "r557", "r558", "r766", "r767", "r773", "r774", "r775", "r785", "r788" ] }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsNonrecurringMember", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Nonrecurring", "label": "Fair Value, Nonrecurring [Member]", "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value." } } }, "auth_ref": [ "r519", "r520", "r521", "r523", "r785", "r1021" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r785", "r1018", "r1019", "r1020", "r1021", "r1022", "r1032" ] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/FinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r187", "r301", "r322", "r763" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization of intangible assets - Year One", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r324", "r743", "r763" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization of intangible assets - Remainder of Fiscal Year", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [ "r1086" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization of intangible assets - Year Four", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r324", "r743", "r763" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization of intangible assets - Year Three", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r324", "r743", "r763" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization of intangible assets - Year Two", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r324", "r743", "r763" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r315", "r317", "r318", "r319", "r321", "r322", "r326", "r327", "r563", "r564", "r743" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Intangible", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r301", "r322", "r564", "r763" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r315", "r322", "r326", "r327", "r328", "r563", "r743", "r763" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r315", "r317", "r318", "r319", "r321", "r322", "r326", "r327", "r743" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Intangible", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r563", "r961" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Amortization Period (Years)", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r563" ] }, "cah_Fiscal2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "Fiscal2022Member", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2022", "label": "Fiscal 2022 [Member]", "documentation": "Fiscal 2022" } } }, "auth_ref": [] }, "cah_Fiscal2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "Fiscal2023Member", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2023", "label": "Fiscal 2023 [Member]", "documentation": "Fiscal 2023" } } }, "auth_ref": [] }, "cah_Fiscal2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "Fiscal2024Member", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2024", "label": "Fiscal 2024 [Member]", "documentation": "Fiscal 2024" } } }, "auth_ref": [] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Contract [Member]", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r748", "r773", "r784", "r785" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r832", "r842", "r852", "r884" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r832", "r842", "r852", "r884" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r832", "r842", "r852", "r884" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r832", "r842", "r852", "r884" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r832", "r842", "r852", "r884" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r865" ] }, "stpr_GA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "GA", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GEORGIA", "label": "GEORGIA" } } }, "auth_ref": [] }, "cah_GMPDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "GMPDMember", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global Medical Products and Distribution", "label": "GMPD [Member]", "documentation": "GMPD" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value." } } }, "auth_ref": [ "r923" ] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Litigation (recoveries)/charges, net", "label": "Gain (Loss) from Litigation Settlement", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": [ "r755", "r973" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r186", "r302", "r596", "r756", "r762", "r786", "r793", "r944", "r951" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill acquired, net of purchase price adjustments", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r306", "r762" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r942", "r954" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign currency translation adjustments and other", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r310" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Impaired, Accumulated Impairment Loss", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r305", "r312", "r762" ] }, "cah_GoodwillImpairmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "GoodwillImpairmentAxis", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill Impairment [Axis]", "label": "Goodwill Impairment [Axis]", "documentation": "Goodwill Impairment" } } }, "auth_ref": [] }, "cah_GoodwillImpairmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "GoodwillImpairmentDomain", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill Impairment [Domain]", "label": "Goodwill Impairment [Domain]", "documentation": "Goodwill Impairment [Domain]" } } }, "auth_ref": [] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill impairment", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r10", "r303", "r309", "r314", "r762", "r786" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r762" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GoodwillTransfers": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillTransfers", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Transfers", "label": "Goodwill, Transfers", "documentation": "Amount of increase (decrease) from transfer into (out of) asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r950" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "totalLabel": "Gross margin", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r113", "r118", "r173", "r219", "r297", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r538", "r749", "r755", "r933", "r935", "r937", "r938", "r939", "r978" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r17", "r506" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r17" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r17" ] }, "cah_IPRDTrademarksandOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "IPRDTrademarksandOtherMember", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks and patents", "label": "IPR&D,TrademarksandOther [Member]", "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": [] }, "cah_IVCApril2023AgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "IVCApril2023AgreementMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IVC April 2023 Agreement", "label": "IVC April 2023 Agreement [Member]", "documentation": "IVC April 2023 Agreement" } } }, "auth_ref": [] }, "cah_IncomeAsAResultOfPrepayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "IncomeAsAResultOfPrepayments", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income As A Result Of Prepayments", "label": "Income As A Result Of Prepayments", "documentation": "Income as a result of prepayments at a pre-negotiated discount certain future payment amounts" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings/(loss) before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r114", "r168", "r173", "r601", "r612", "r749", "r755", "r933", "r935", "r937", "r938", "r939" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r115", "r169", "r211", "r225", "r227", "r228", "r229", "r230", "r231", "r239", "r241", "r242", "r489", "r495", "r517", "r600", "r1049" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r115", "r211", "r225", "r227", "r228", "r229", "r230", "r231", "r239", "r241", "r242", "r243", "r495", "r517", "r600", "r1049" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r776", "r777" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities Held for Sale [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r14", "r18", "r23", "r86", "r87", "r88", "r89", "r90", "r91", "r93", "r94", "r95", "r138" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r331", "r338", "r343", "r524", "r526", "r531", "r632", "r634", "r690", "r743", "r787", "r1051" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r338", "r343", "r524", "r526", "r531", "r632", "r634", "r690", "r743", "r787", "r1051" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r220", "r463", "r466", "r467", "r468", "r469", "r473", "r474", "r478", "r480", "r483", "r484", "r649", "r781" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Provision for income taxes", "negatedTerseLabel": "Income Tax Expense (Benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r176", "r177", "r233", "r234", "r247", "r262", "r284", "r465", "r466", "r479", "r619", "r781" ] }, "cah_IncomefromSettlementsofClassActionLawsuits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "IncomefromSettlementsofClassActionLawsuits", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income from Settlements of Class Action Lawsuits", "label": "Income from Settlements of Class Action Lawsuits", "documentation": "Income from Settlements of Class Action Lawsuits" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase in inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other accrued liabilities and operating items, net", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase in trade receivables", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r315", "r320", "r325", "r763" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r315", "r325", "r328", "r763" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Intangible", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r301", "r325", "r763" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r315", "r320", "r325", "r763" ] }, "cah_IndemnificationReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "IndemnificationReceivable", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indemnification Receivable", "label": "Indemnification Receivable", "documentation": "Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r832", "r842", "r852", "r876", "r884", "r888", "r896" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r894" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r824", "r900" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r824", "r900" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r824", "r900" ] }, "us-gaap_InsuranceRecoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InsuranceRecoveries", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance Recoveries", "label": "Insurance Recoveries", "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses." } } }, "auth_ref": [ "r120" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Intangible, Total other intangible assets", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r186" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Intangible, Total other intangible assets", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r315", "r961", "r962" ] }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetIncludingGoodwill", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and other intangibles, net", "label": "Intangible Assets, Net (Including Goodwill)", "documentation": "Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets." } } }, "auth_ref": [ "r941" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r247", "r254", "r258", "r264", "r284", "r548", "r755", "r756" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Income (Expense), Nonoperating, Net", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": [ "r755", "r920", "r935" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r744", "r814", "r815" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r194", "r747", "r793" ] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other investments", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r1018", "r1019", "r1029" ] }, "cah_January2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "January2023Member", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "January 2023", "label": "January 2023 [Member]", "documentation": "January 2023" } } }, "auth_ref": [] }, "cah_June2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "June2027Member", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "June 2027", "label": "June 2027 [Member]", "documentation": "June 2027" } } }, "auth_ref": [] }, "cah_LawsuitTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "LawsuitTypeAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lawsuit Type [Axis]", "label": "Lawsuit Type [Axis]", "documentation": "Lawsuit Type [Axis]" } } }, "auth_ref": [] }, "cah_LawsuitTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "LawsuitTypeDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lawsuit Type [Domain]", "label": "Lawsuit Type [Domain]", "documentation": "[Domain] for Lawsuit Type [Axis]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r109", "r167", "r610", "r793", "r926", "r940", "r1033" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Shareholders\u2019 Deficit", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r101", "r184", "r219", "r297", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r498", "r501", "r502", "r538", "r793", "r978", "r1038", "r1039" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities related to assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r86", "r92", "r137", "r181", "r182" ] }, "us-gaap_LineOfCreditFacilityAverageOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAverageOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Average Outstanding Amount", "label": "Line of Credit Facility, Average Outstanding Amount", "documentation": "Average amount borrowed under the credit facility during the period." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Maximum Amount Outstanding During Period", "label": "Line of Credit Facility, Maximum Amount Outstanding During Period", "documentation": "Maximum amount borrowed under the credit facility at any time during the period." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r98", "r102" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationReserve", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Litigation Liability", "label": "Estimated Litigation Liability", "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs." } } }, "auth_ref": [ "r103", "r973" ] }, "us-gaap_LitigationReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationReserveCurrent", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Litigation Liability, Current", "label": "Estimated Litigation Liability, Current", "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position." } } }, "auth_ref": [ "r103", "r973" ] }, "us-gaap_LitigationSettlementLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementLoss", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Settlement, Loss", "label": "Litigation Settlement, Loss", "documentation": "Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": [ "r973" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 }, "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails": { "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term obligations, less current portion", "label": "Long-Term Debt and Lease Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": [ "r22", "r604" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails": { "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0, "order": 1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term obligations and other short-term borrowings", "label": "Long-Term Debt and Lease Obligation, Current", "documentation": "Amount of long-term debt and lease obligation, classified as current." } } }, "auth_ref": [ "r100" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Maturity, after Year Five", "label": "Long-Term Debt, Maturity, after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r221", "r981" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Maturity, Year One", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r221", "r391" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Maturity, Year Five", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r221", "r391" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Maturity, Year Four", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r221", "r391" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Maturity, Year Three", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r221", "r391" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Maturity, Year Two", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r221", "r391" ] }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermPurchaseCommitmentPeriod", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Purchase Commitment, Period", "label": "Long-Term Purchase Commitment, Period", "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r353", "r354", "r355", "r359", "r462", "r641", "r764", "r974", "r975" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r353", "r354", "r355", "r359", "r462", "r764", "r974", "r975" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r353", "r354", "r355", "r359", "r462", "r764", "r974", "r975" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Accrual", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r353", "r907" ] }, "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Accrual, Period Increase (Decrease)", "label": "Loss Contingency Accrual, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in loss contingency liability." } } }, "auth_ref": [ "r973" ] }, "us-gaap_LossContingencyClaimsSettledNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyClaimsSettledNumber", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Claims Settled, Number", "label": "Loss Contingency, Claims Settled, Number", "documentation": "Number of claims settled." } } }, "auth_ref": [ "r974", "r975" ] }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyEstimateOfPossibleLoss", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Estimate of Possible Loss", "label": "Loss Contingency, Estimate of Possible Loss", "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date." } } }, "auth_ref": [ "r354", "r355", "r358", "r359", "r462", "r764" ] }, "cah_LossContingencyLawsuitsNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "LossContingencyLawsuitsNumber", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Loss Contingency, Lawsuits, Number", "label": "Loss Contingency, Lawsuits, Number", "documentation": "Loss Contingency, Lawsuits, Number" } } }, "auth_ref": [] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r353", "r354", "r355", "r359", "r462", "r641", "r764", "r974", "r975" ] }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNumberOfPlaintiffs", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Number of Plaintiffs", "label": "Loss Contingency, Number of Plaintiffs", "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency." } } }, "auth_ref": [ "r974", "r975" ] }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Pending Claims, Number", "label": "Loss Contingency, Pending Claims, Number", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": [ "r974", "r975" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r292", "r772", "r802", "r806", "r983", "r1050", "r1052", "r1053", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079" ] }, "us-gaap_MajorCustomersPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MajorCustomersPolicyPolicyTextBlock", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Major Customers", "label": "Major Customers, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity." } } }, "auth_ref": [ "r32", "r33", "r34", "r134" ] }, "cah_March2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "March2022Member", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective March 2022", "label": "March 2022 [Member]", "documentation": "March 2022" } } }, "auth_ref": [] }, "cah_March2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "March2025Member", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2025", "label": "March 2025 [Member]", "documentation": "March 2025" } } }, "auth_ref": [] }, "cah_March2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "March2026Member", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2026", "label": "March 2026 [Member]", "documentation": "March 2026" } } }, "auth_ref": [] }, "cah_MaturityDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "MaturityDateAxis", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity Date", "label": "Maturity Date [Axis]", "documentation": "Maturity Date" } } }, "auth_ref": [] }, "cah_MaturityDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "MaturityDateDomain", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity Date [Domain]", "label": "Maturity Date [Domain]", "documentation": "Maturity Date [Domain]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r354", "r355", "r356", "r357", "r424", "r462", "r523", "r561", "r631", "r633", "r641", "r658", "r659", "r710", "r712", "r714", "r715", "r725", "r741", "r742", "r761", "r770", "r778", "r788", "r789", "r790", "r791", "r803", "r980", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r868" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r868" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r354", "r355", "r356", "r357", "r424", "r462", "r523", "r561", "r631", "r633", "r641", "r658", "r659", "r710", "r712", "r714", "r715", "r725", "r741", "r742", "r761", "r770", "r778", "r788", "r789", "r790", "r803", "r980", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r108", "r166", "r219", "r297", "r362", "r365", "r366", "r367", "r371", "r372", "r538", "r609", "r669" ] }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromRedemptions", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of noncontrolling interests", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)." } } }, "auth_ref": [ "r63", "r149", "r156" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r887" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r895" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r292", "r772", "r802", "r806", "r983", "r1050", "r1052", "r1053", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r869" ] }, "cah_NarativeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "NarativeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Narative [Abstract]", "label": "Narative [Abstract]", "documentation": "Narative [Abstract]" } } }, "auth_ref": [] }, "cah_NativeAmericanTribesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "NativeAmericanTribesMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Native American tribes", "label": "Native American tribes [Member]", "documentation": "Native American tribes" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by/(used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r214" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r214" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r128", "r129", "r130" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net earnings attributable to Cardinal Health, Inc.", "terseLabel": "Net Income (Loss) Attributable to Parent", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r119", "r130", "r170", "r182", "r199", "r202", "r206", "r219", "r225", "r227", "r228", "r229", "r230", "r231", "r233", "r234", "r240", "r297", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r489", "r495", "r517", "r538", "r615", "r687", "r703", "r704", "r817", "r978" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r65", "r157", "r199", "r202", "r231", "r233", "r234", "r614", "r919" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedging [Member]", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r72" ] }, "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net tax proceeds from share-based compensation", "label": "Net proceeds/(tax withholdings) from share-based compensation", "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Financial Accounting Standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "cah_NewYorkOpioidStewardshipActMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "NewYorkOpioidStewardshipActMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New York Opioid Stewardship Act [Member]", "label": "New York Opioid Stewardship Act [Member]", "documentation": "New York Opioid Stewardship Act" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r868" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r832", "r842", "r852", "r876", "r884" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r859" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r858" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r876" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r895" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r895" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-US [Member]", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1082", "r1083", "r1084", "r1085" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r61", "r416", "r927", "r928", "r929", "r931", "r1081" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument [Member]", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r17" ] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Payable", "label": "Notes Payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r22", "r165", "r1047", "r1048" ] }, "cah_NuclearPrecisionHealthSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "NuclearPrecisionHealthSolutionsMember", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nuclear Precision Health Services [Member]", "label": "Nuclear Precision Health Solutions [Member]", "documentation": "Nuclear Precision Health Solutions" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r756", "r934" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r750", "r760", "r934" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating earnings", "terseLabel": "Total operating earnings", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r173", "r749", "r933", "r935", "r937", "r938", "r939" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r278", "r279", "r280", "r281", "r282", "r285", "r755", "r756" ] }, "cah_OpioidLawsuitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "OpioidLawsuitsMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Opioid Lawsuits [Member]", "label": "Opioid Lawsuits [Member]", "documentation": "Opioid Lawsuits [Member]" } } }, "auth_ref": [] }, "cah_OpioidLitigationAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "OpioidLitigationAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Opioid Litigation [Axis]", "label": "Opioid Litigation [Axis]", "documentation": "Opioid Litigation" } } }, "auth_ref": [] }, "cah_OpioidLitigationDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "OpioidLitigationDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Opioid Litigation [Domain]", "label": "Opioid Litigation [Domain]", "documentation": "Opioid Litigation [Domain]" } } }, "auth_ref": [] }, "cah_OptiFreightLogisticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "OptiFreightLogisticsMember", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OptiFreight Logistics [Member]", "label": "OptiFreight Logistics [Member]", "documentation": "OptiFreight Logistics" } } }, "auth_ref": [] }, "cah_OptumRxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "OptumRxMember", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OptumRx", "label": "OptumRx [Member]", "documentation": "OptumRx" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r100" ] }, "cah_OtherAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "OtherAgreementsMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Agreements [Member]", "label": "Other Agreements [Member]", "documentation": "Other Agreements" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r195", "r793" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r188" ] }, "us-gaap_OtherBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherBorrowings", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Borrowings", "label": "Other Borrowings", "documentation": "The carrying amount as of the balance sheet date for the aggregate of other miscellaneous borrowings owed by the reporting entity." } } }, "auth_ref": [ "r163", "r165" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r21", "r25", "r205", "r540", "r543", "r546", "r616", "r917" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized gain/(loss) on derivative instruments, net of tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r197", "r198", "r616" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r197", "r198", "r503", "r504", "r507" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments and other", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r3", "r616" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r505" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income/(loss), net of tax", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r16", "r21", "r200", "r203", "r208", "r231", "r540", "r541", "r546", "r597", "r616", "r917", "r918" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income/(loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r7", "r15", "r155", "r200", "r203", "r231" ] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive Income (Loss), Tax", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": [ "r5", "r204", "r208", "r465", "r481", "r482", "r540", "r544", "r546", "r597", "r616" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "negatedLabel": "Other (income)/expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r122" ] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Nonoperating Income (Expense) [Member]", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r868" ] }, "us-gaap_OtherShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherShortTermBorrowings", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Short-term Borrowings", "label": "Other Short-Term Borrowings", "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r96", "r666" ] }, "cah_OutcomesDivestitureAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "OutcomesDivestitureAxis", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outcomes divestiture [Axis]", "label": "Outcomes divestiture [Axis]", "documentation": "Outcomes divestiture" } } }, "auth_ref": [] }, "cah_OutcomesDivestitureDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "OutcomesDivestitureDomain", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outcomes divestiture [Domain]", "label": "Outcomes divestiture [Domain]", "documentation": "Outcomes divestiture [Domain]" } } }, "auth_ref": [] }, "cah_OutcomesDivestitureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "OutcomesDivestitureMember", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outcomes Divestiture [Member]", "label": "Outcomes Divestiture [Member]", "documentation": "Outcomes Divestiture" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r830", "r840", "r850", "r882" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r833", "r843", "r853", "r885" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r833", "r843", "r853", "r885" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r857" ] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for Legal Settlements", "label": "Payments for Legal Settlements", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of treasury shares", "terseLabel": "Purchase of treasury shares", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r126" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments and other adjustments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r342", "r922" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends on common shares", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r126" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to Acquire Businesses, Gross", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r28", "r493" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition of subsidiaries, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r28" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Additions to property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r125" ] }, "us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireRestrictedCertificatesOfDeposit", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of short-term time deposits", "terseLabel": "Purchases of short-term time deposits", "label": "Payments to Acquire Restricted Certificates of Deposit", "documentation": "The cash outflow from temporary investment with specific maturity and interest rate that are prohibited for current use." } } }, "auth_ref": [ "r124" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r867" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r867" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r859" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r876" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r869" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r858" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Share Units", "verboseLabel": "Performance Share Unit", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "cah_PharmaceuticalAndSpecialtySolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "PharmaceuticalAndSpecialtySolutionsMember", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pharmaceutical and Specialty Solutions", "label": "Pharmaceutical and Specialty Solutions [Member]", "documentation": "Pharmaceutical and Specialty Solutions" } } }, "auth_ref": [] }, "cah_PlaintiffTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "PlaintiffTypeAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plaintiff Type [Axis]", "label": "Plaintiff Type [Axis]", "documentation": "Plaintiff Type [Axis]" } } }, "auth_ref": [] }, "cah_PlaintiffTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "PlaintiffTypeDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plaintiff Type [Domain]", "label": "Plaintiff Type [Domain]", "documentation": "[Domain] for Plaintiff Type [Axis]" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r860" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r904" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r859" ] }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, without par value:", "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r104", "r667" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r104", "r401" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized\u2014500 thousand shares, Issued\u2014none", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r104", "r605", "r793" ] }, "cah_PrivatePartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "PrivatePartiesMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Parties [Member]", "label": "Private Parties [Member]", "documentation": "Private Parties [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from divestitures, net of cash sold", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ProceedsFromHedgeInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromHedgeInvestingActivities", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from net investment hedge terminations", "label": "Proceeds from Hedge, Investing Activities", "documentation": "The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation." } } }, "auth_ref": [ "r215", "r912" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from long-term obligations, net of issuance costs", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r921" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Issuance of Long-Term Debt", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r29", "r644" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from disposal of property and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r123" ] }, "cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from investments", "label": "Proceeds from sale of available-for-sale securities and other investments", "documentation": "The cash inflow from sales of available-for-sale securities and other investments." } } }, "auth_ref": [] }, "us-gaap_ProductLiabilityAccrualPeriodExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductLiabilityAccrualPeriodExpense", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Liability Accrual, Period Expense", "label": "Product Liability Accrual, Period Expense", "documentation": "The amount of loss reported during the period pertaining to product liability." } } }, "auth_ref": [] }, "cah_ProductLiabilityLawsuitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "ProductLiabilityLawsuitsMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Liability Lawsuits", "label": "Product Liability Lawsuits [Member]", "documentation": "Product Liability Lawsuits [Member]" } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Net earnings/(loss)", "terseLabel": "Net earnings/(loss)", "verboseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r182", "r199", "r202", "r213", "r219", "r225", "r231", "r233", "r234", "r297", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r489", "r495", "r496", "r499", "r500", "r517", "r538", "r601", "r613", "r651", "r687", "r703", "r704", "r782", "r783", "r818", "r919", "r978" ] }, "cah_ProjectCostsOnInvestmentAndOtherSpending": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "ProjectCostsOnInvestmentAndOtherSpending", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Project costs on investment and other spending", "label": "Project Costs On Investment And Other Spending", "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r12", "r553", "r602", "r611", "r793" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for bad debts", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r212", "r300" ] }, "cah_Purchaseofavailableforsalesecuritiesandotherinvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "Purchaseofavailableforsalesecuritiesandotherinvestments", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of investments", "label": "Purchase of available-for-sale securities and other investments", "documentation": "The cash outflow from purchases of available-for-sale securities and other investments." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r857" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r857" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r354", "r355", "r356", "r357", "r417", "r424", "r452", "r453", "r454", "r462", "r523", "r559", "r560", "r561", "r631", "r633", "r641", "r658", "r659", "r710", "r712", "r714", "r715", "r725", "r741", "r742", "r761", "r770", "r778", "r788", "r789", "r790", "r791", "r803", "r809", "r970", "r980", "r1021", "r1041", "r1042", "r1043", "r1044", "r1045" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r354", "r355", "r356", "r357", "r417", "r424", "r452", "r453", "r454", "r462", "r523", "r559", "r560", "r561", "r631", "r633", "r641", "r658", "r659", "r710", "r712", "r714", "r715", "r725", "r741", "r742", "r761", "r770", "r778", "r788", "r789", "r790", "r791", "r803", "r809", "r970", "r980", "r1021", "r1041", "r1042", "r1043", "r1044", "r1045" ] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables, net", "label": "Receivables, Net, Current", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r793" ] }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r206" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r21", "r25", "r205", "r540", "r545", "r546", "r616", "r917" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI, Net of Tax [Roll Forward]", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r206" ] }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Assets by Reportable Segment", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." } } }, "auth_ref": [ "r41", "r42" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": [ "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r40", "r42" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Profit by Reportable Segment", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r40", "r42" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r39", "r42" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r825", "r835", "r845", "r877" ] }, "cah_RemainingCashFromDebtProceedsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "RemainingCashFromDebtProceedsAxis", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Cash from Debt Proceeds [Axis]", "label": "Remaining Cash from Debt Proceeds [Axis]", "documentation": "Remaining Cash from Debt Proceeds" } } }, "auth_ref": [] }, "cah_RemainingCashFromDebtProceedsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "RemainingCashFromDebtProceedsDomain", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Cash from Debt Proceeds [Domain]", "label": "Remaining Cash from Debt Proceeds [Domain]", "documentation": "Remaining Cash from Debt Proceeds [Domain]" } } }, "auth_ref": [] }, "cah_RemainingCashFromDebtProceedsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "RemainingCashFromDebtProceedsMember", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Cash from Debt Proceeds", "label": "Remaining Cash from Debt Proceeds [Member]", "documentation": "Remaining Cash from Debt Proceeds" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reduction of long-term obligations", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r127", "r647" ] }, "us-gaap_ReportingUnitAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitAxis", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Axis]", "label": "Reporting Unit [Axis]", "documentation": "Information by reporting unit." } } }, "auth_ref": [ "r313", "r314", "r762" ] }, "us-gaap_ReportingUnitDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitDomain", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Domain]", "label": "Reporting Unit [Domain]", "documentation": "Level of reporting at which goodwill is tested for impairment." } } }, "auth_ref": [ "r313", "r314", "r762" ] }, "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "documentation": "Percentage of fair value of reporting unit in excess of carrying amount." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r826", "r836", "r846", "r878" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r827", "r837", "r847", "r879" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r834", "r844", "r854", "r886" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Share Units", "verboseLabel": "Restricted Share Unit", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeverance" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Employee Severance", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r339", "r340", "r342", "r345", "r350" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 }, "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and employee severance", "totalLabel": "Total restructuring and employee severance", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r10", "r346", "r347", "r971" ] }, "us-gaap_RestructuringChargesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringChargesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring Charges [Abstract]", "label": "Restructuring Charges [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r341", "r342", "r347", "r348" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r347", "r348", "r349" ] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCosts", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Restructuring Costs", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r342", "r348" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r106", "r149", "r608", "r638", "r640", "r648", "r668", "r793" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r178", "r222", "r223", "r224", "r226", "r231", "r232", "r234", "r298", "r299", "r329", "r476", "r477", "r486", "r487", "r488", "r490", "r494", "r495", "r508", "r510", "r511", "r513", "r516", "r550", "r552", "r635", "r637", "r652", "r1081" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r133" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "verboseLabel": "Total revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r171", "r172", "r207", "r219", "r247", "r255", "r256", "r278", "r284", "r288", "r290", "r292", "r297", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r538", "r601", "r755", "r978" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility [Member]", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r895" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r895" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r292", "r913" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast [Member]", "label": "Forecast [Member]" } } }, "auth_ref": [ "r425", "r930" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r235", "r425", "r907", "r930" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r25", "r1034", "r1035" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r56", "r57", "r491" ] }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r54" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt [Table Text Block]", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r294", "r295", "r296", "r485", "r908", "r909", "r910", "r1010", "r1011", "r1012", "r1013" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1018", "r1019" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r315", "r322", "r326", "r327", "r328", "r563", "r743", "r763" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r763", "r960" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r762" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill by Reportable Segment", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r762", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Indefinite-Lived [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": [ "r315", "r325", "r328", "r763" ] }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans", "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units." } } }, "auth_ref": [ "r151" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r153" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r347", "r348", "r349" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restructuring and Employee Severance", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r43", "r139", "r140" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r44", "r141" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r36", "r37", "r38" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r427", "r428", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r150" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r45", "r46", "r47", "r48", "r49", "r50", "r145", "r147", "r148", "r149", "r190", "r191", "r192", "r249", "r401", "r402", "r403", "r405", "r408", "r413", "r415", "r644", "r645", "r646", "r647", "r770", "r906", "r924" ] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": [ "r31" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r820" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r822" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r171", "r172", "r173", "r174", "r247", "r251", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r268", "r269", "r270", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r292", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r328", "r344", "r349", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r752", "r755", "r756", "r762", "r805", "r1050", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r290", "r291", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r654", "r655", "r656", "r711", "r713", "r716", "r726", "r729", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r745", "r771", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r804", "r809", "r983", "r1050", "r1052", "r1053", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r174", "r247", "r250", "r251", "r252", "r253", "r254", "r267", "r269", "r270", "r282", "r283", "r284", "r285", "r286", "r288", "r289", "r292", "r750", "r753", "r754", "r755", "r757", "r759", "r760" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Updated Segment Reporting Structure", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r287", "r290", "r751", "r752", "r758" ] }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "presentation": [ "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Revenue from External Customers by Geographic Area [Line Items]", "label": "Segment Revenue from External Customers by Geographic Area [Line Items]", "documentation": "[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]" } } }, "auth_ref": [] }, "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaTable", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Revenue from External Customers by Geographic Area [Table]", "label": "Segment Revenue from External Customers by Geographic Area [Table]", "documentation": "Segment Revenue from External Customers by Geographic Area [Table]" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Distribution, selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r121" ] }, "cah_September2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "September2018Member", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective September 2018", "label": "September 2018 [Member]", "documentation": "September 2018" } } }, "auth_ref": [] }, "cah_September2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "September2025Member", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "September 2025", "label": "September 2025 [Member]", "documentation": "September 2025" } } }, "auth_ref": [] }, "cah_SettlingStates": { "xbrltype": "integerItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "SettlingStates", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settling States", "label": "Settling States", "documentation": "Settling States" } } }, "auth_ref": [] }, "cah_SettlingUSTerritories": { "xbrltype": "integerItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "SettlingUSTerritories", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settling U.S Territories", "label": "Settling U.S Territories", "documentation": "Settling U.S Territories" } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": { "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee-related costs", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r779" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Canceled and forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r446" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canceled and forfeited (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r446" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r444" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r444" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested at beginning of period (in shares)", "periodEndLabel": "Nonvested at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r441", "r442" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Share Units", "verboseLabel": "Performance Share Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested at beginning of period (in usd per share)", "periodEndLabel": "Nonvested at end of period (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r441", "r442" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value per Share", "verboseLabel": "Weighted-Average Grant Date Fair Value per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r445" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r445" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r427", "r428", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455" ] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]" } } }, "auth_ref": [ "r982" ] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]" } } }, "auth_ref": [ "r982" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Target performance goal (as a percent)", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r984" ] }, "cah_ShortTermCreditFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "ShortTermCreditFacilitiesMember", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short Term Credit Facilities Member", "label": "Short Term Credit Facilities Member", "documentation": "Other short-term credit facilities and an unsecured line of credit" } } }, "auth_ref": [] }, "cah_SpecialtyNetworksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "SpecialtyNetworksMember", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Specialty Networks", "label": "Specialty Networks [Member]", "documentation": "Specialty Networks" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "verboseLabel": "Operating and Reportable Segment", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r171", "r172", "r173", "r174", "r180", "r247", "r251", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r268", "r269", "r270", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r292", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r328", "r332", "r344", "r349", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r752", "r755", "r756", "r762", "r805", "r1050", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r16", "r105", "r107", "r108", "r178", "r204", "r205", "r206", "r222", "r223", "r224", "r226", "r231", "r232", "r234", "r248", "r298", "r299", "r329", "r416", "r476", "r477", "r486", "r487", "r488", "r490", "r494", "r495", "r508", "r509", "r510", "r511", "r512", "r513", "r516", "r540", "r542", "r543", "r544", "r545", "r546", "r550", "r552", "r554", "r616", "r635", "r636", "r637", "r652", "r705" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r290", "r291", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r654", "r655", "r656", "r711", "r713", "r716", "r726", "r729", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r745", "r771", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r804", "r809", "r983", "r1050", "r1052", "r1053", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Statement of Stockholders' Equity", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r222", "r223", "r224", "r248", "r552", "r562", "r643", "r653", "r660", "r661", "r662", "r663", "r664", "r665", "r667", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r680", "r681", "r682", "r683", "r684", "r686", "r688", "r689", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r705", "r810" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r235", "r425", "r907", "r911", "r930" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r222", "r223", "r224", "r248", "r293", "r552", "r562", "r643", "r653", "r660", "r661", "r662", "r663", "r664", "r665", "r667", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r680", "r681", "r682", "r683", "r684", "r686", "r688", "r689", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r705", "r810" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r829", "r839", "r849", "r881" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r16", "r104", "r105", "r149" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r53", "r104", "r105", "r149" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Cardinal Health, Inc. shareholders' deficit", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r105", "r107", "r108", "r135", "r669", "r685", "r706", "r707", "r793", "r819", "r926", "r940", "r1033", "r1081" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 deficit:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 deficit", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r61", "r62", "r64", "r178", "r179", "r205", "r222", "r223", "r224", "r226", "r231", "r232", "r298", "r299", "r329", "r416", "r476", "r477", "r486", "r487", "r488", "r490", "r494", "r495", "r508", "r509", "r510", "r511", "r512", "r513", "r516", "r540", "r542", "r546", "r551", "r554", "r636", "r637", "r650", "r669", "r685", "r706", "r707", "r727", "r818", "r926", "r940", "r1033", "r1081" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r146", "r218", "r400", "r402", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r414", "r416", "r515", "r708", "r709", "r728" ] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityOtherShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityOtherShares", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity, Other Shares", "label": "Stockholders' Equity, Other Shares", "documentation": "Number of increase (decrease) in shares of stock classified as other." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsAxis", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Axis]", "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsDomain", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Domain]", "label": "Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r547", "r555" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r547", "r555" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r547", "r555" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r875" ] }, "us-gaap_TaxCreditCarryforwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardLineItems", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Tax Credit Carryforward [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r475" ] }, "us-gaap_TaxCreditCarryforwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardTable", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Tax Credit Carryforward [Table]", "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance." } } }, "auth_ref": [ "r475" ] }, "cah_TaxMatterAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "TaxMatterAxis", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Matter [Axis]", "label": "Tax Matter [Axis]", "documentation": "Tax Matter [Axis]" } } }, "auth_ref": [] }, "cah_TaxMatterDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "TaxMatterDomain", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Matter [Domain]", "label": "Tax Matter [Domain]", "documentation": "[Domain] for Tax Matter [Axis]" } } }, "auth_ref": [] }, "cah_TaxMattersAgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "TaxMattersAgreementAxis", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Matters Agreement [Axis]", "label": "Tax Matters Agreement [Axis]", "documentation": "Tax Matters Agreement [Axis]" } } }, "auth_ref": [] }, "cah_TaxMattersAgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "TaxMattersAgreementDomain", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Matters Agreement [Domain]", "label": "Tax Matters Agreement [Domain]", "documentation": "[Domain] for Tax Matters Agreement [Axis]" } } }, "auth_ref": [] }, "cah_TerminalGrowthRateFairValueInput": { "xbrltype": "percentItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "TerminalGrowthRateFairValueInput", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Terminal Growth Rate, Fair Value Input", "label": "Terminal Growth Rate, Fair Value Input", "documentation": "Terminal Growth Rate, Fair Value Input" } } }, "auth_ref": [] }, "cah_TotalLongTermandShortTermObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "TotalLongTermandShortTermObligations", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Long-Term and Short-Term Obligations", "label": "Total Long-Term and Short-Term Obligations", "documentation": "Total Long-Term and Short-Term Obligations" } } }, "auth_ref": [] }, "cah_TotalOpioidLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "TotalOpioidLitigationMember", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Opioid Litigation [Member]", "label": "Total Opioid Litigation [Member]", "documentation": "Total Opioid Litigation" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r867" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r874" ] }, "cah_TrademarksAndPatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "TrademarksAndPatentsMember", "presentation": [ "http://www.cardinal.com/role/BusinessCombinationsandAssetAcquisitionsDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks, trade names and patents", "label": "Trademarks And Patents Member", "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r894" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r896" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "cah_TransactionDataSystemInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "TransactionDataSystemInvestmentMember", "presentation": [ "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction Data System Investment", "label": "Transaction Data System Investment [Member]", "documentation": "Transaction Data System Investment" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r897" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r898" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r898" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r896" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r896" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r899" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r897" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares acquired, average price per share (in usd per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r51" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock, Common", "verboseLabel": "Treasury Shares", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r51" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares in treasury", "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)", "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r51" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury shares acquired (in shares)", "negatedTerseLabel": "Treasury Stock, Shares, Acquired", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r16", "r105", "r149" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Common shares in treasury, at cost: 83 million shares and 76 million shares at March\u00a031, 2024 and June 30, 2023, respectively", "negatedPeriodStartLabel": "Treasury, balance at beginning of period", "negatedPeriodEndLabel": "Treasury, balance at end of period", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r51", "r52", "r105", "r107" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury Stock, Value, Acquired, Cost Method", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r16", "r51", "r149" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r341", "r342", "r347", "r348" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UNITED STATES", "label": "UNITED STATES" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r893" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r464", "r471", "r780" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, interest and penalties accrued", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r470", "r780" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits that would impact effective tax rate", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r472", "r780" ] }, "cah_VestingPeriodinyearsforShares": { "xbrltype": "integerItemType", "nsuri": "http://www.cardinal.com/20240331", "localname": "VestingPeriodinyearsforShares", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Period in years for Shares", "label": "Vesting Period in years for Shares", "documentation": "Vesting Period in years for Shares" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r863" ] }, "stpr_WV": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "WV", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "WEST VIRGINIA", "label": "WEST VIRGINIA" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock options, restricted share units, and performance share units (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r932" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities:", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average common shares\u2013diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r238", "r243" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average common shares\u2013basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r237", "r243" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of common shares outstanding:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r861" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480463/815-10-45-5" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-24" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r906": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r907": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r908": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r909": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r910": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r911": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 91 0000721371-24-000038-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000721371-24-000038-xbrl.zip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�/XD\CWLWAF]U@+QNRK"@!7GMK2;,&"16TN9!^F0)W%+@P?IV (B]E33IL M9K?"[@,M8"$T!X"(.X")LT4B2\HF,> 8['C32&,:*PN+4S!:0$L\9-T0-P8. M&LJ8*2'O,+YF@L03H<#>44/2D_T26_N/"=6GSFX70DUV=B:8AEAI+#*1O16\ MI>6NII( \C54;B.XN4?%\8:'$G.S_DGSM).XD2@_Y)KP*XE.;: =\>D:/;,@ MFF0W FMDDQG$A\=A?2Q.E(DX)'F+A%M>,YQ!W;\"0ARQG@>7I'9)/GYP27X= M>ZN!(:*JK-V0OIII4C&8?O'TU="=S'W*_ &+K:!+19]@RZ=RH!X$O!#_>QP&,]")"1==J NCF\O6K[#4OYH2%(^QI("+5PC M#";&7!02>/48[IH+ N[;LO3^#WW]@(AW>'48] X6".?X:/38W4P40*=E/%+3 MHX+,K"EC6$=P3>+_:E^"X]A&E$+<8Q*O"!\T4-072GWV M4EBJI"Q\[7'L2C M]=./IT]?!'MBWZ"D!7O)_N\L3Q3:^G&=@-QA8,R$@8!S 5K.F@4*1)DDP*YT M_0=6..)P_;W)/B>9F6EVH'F:T>#TC0+ DT=!NDJXC VL'/ /_E'''#GX/OK= M#//V47%@NEUZXHP4V MDF$#?*\S"+Y[."363D =M#LEICV5 M.*RA'2'7\4*U;$UK;2UMPBG*A<($&E+O,!!W$U44.F[GI?A%P>(1G4+FB4,0H*8IF T M,L8D% 2N%Z"]-[%$+1"N/-QE4*ZU@:1K>_6M9HLW=T9]^E -':RAF1K;#/[& MGSZE(ALH!W\T) [^J0#B@=N]YM^RN[T#3+S3QLCFPD#>L/BFR:Q5=C0TD+FW M,.@0#[NKKY9TX;AS;$;&X'YLJ-.>)&BX(CMVW>P2MR+"W.8)T5\@.QQ36D,\ ](:6A# M[4*=7#*D0WQNJ0PTLQ1$EH(O^S-G+_8> M^>1JXN;9#IQP8V:$FXCP9O$2:F$:XXT::Z @FJ&.@M"BA,ZUL6=P$]RBJQ$;N)--Z MNW-X/+0A7Q08$^6SC()1.-8 52#TRQ#("9KI$.**$L98#P5I@!J#%!CNEJ$ \(IT!+NQ)B)3/,5 M&?=Z7 F[@KO9]]=J33]+D2+XW?LL:K.48C)P.=R!A-*QP2A 9P.%#%$EFLL=B+8GUW']Q?V#OZY,$[^I7!']NY M-AM1%8W"+;5'Y0'>8.QL^3]BI;[@@T0S/.XXHW&..>)]%^QN-?.LL&9Z+^A?N-E0W<$@M;/A$RW< M;((]G0[@KX;[V:0"L$Z-Y4G(:'_C3O//%9PCUD6NC>VS]\]-A5:PHVKK<^KO95T>ET:%>"L^X'KS@V KZ!*&)3 M'!V&@-TT9__IE.Q![,HP?>B<[0\W*(>9-GAID3(7%-P3ZB![LK]BZ3G?^P/? MU0X4C*Y]G&B0.K3 K8;B(+Y!,OX= J6Y@V<<]W$'6/F84F_T6,P1(%L>A6*2 M=,,R%&%5U1[<<'JL,]V]DBB_>C=:(LM\,XXD5J&UKZ-XE@"S30J7^:+\B@?M MQ-P:P%6WQ;?**.F7;BN>J#.K&'N@EPR'(:JB%?;=D W1_%4BBPQUS.R\O-V@76 4LZ#LJ7L$5\@UC9 M'&>=%\C$&M')8OW0LI2AQ[6P?PX+SO""'F_:!N%$$UL MX2(/Q"M-/F-4 78*>T*(S52,+$YHN=@;9MES2Y'H![HPLH*%03,M;G.2BJ)5C%':%4!3Q94(# M C9Z/'B:W2&(E]MI]JR!@=H'QK9M@JXKC);KAYC[DG@QZUIN:*1/URMJUN/0 M>Q%>6RF%+C57WY9D0O%#\:GXM2JM7D(#H;&5;#H1M206#YR3*DYV:$;.,YH' M4S0E>1=@+W >#Y3P/N'VIW!\L9[[62V0>)1'P\J.?@B9_@RW-RW'+% BT_V M#J=%;YL_S'64Q"T0,GTF7D\)%\%-GL(9$05(I4[DQ90Z0?<=HUT0L6+X.OR1 M!X0;.!$JX:L2F)*')F.S[H2&EC&]6B@>'0I"[:M[3,>R%).H[X6H=X2KF3P) M8E,Q<2\EJ%B\M:KY,)TM#9^D51_:D+(GT!PM* $P7^$/-C<:KG@'-.]74T[% M"B9YD6-8UZRCJ'T-^6**D<1D8';:T+H61:M+MFC;]L*KXM(=#4+6-%R^\12# M^S$;&]4DG5U%A,UIF,J H=A,*X.8T+#>]35+'%$;GMAVY%DX23%">4@S-V_A M'8?K9W!_-2_9T\%[R7;F AI4WMHEZ!=RM0/W2Z-4.T?F:@@U9Z_R83:U#@_2 MGA&T,H)8(DG+2]U"L DV7?0FZ&-OTPI]?;0T9+I0?H=NGB248 C+EOAX6'0XT08_*22'SD M1I5=B[">=P"?88CX#P-6^.B8-YK="UXY3SP+[?E5]47V'O4-]_>*AQI&%-@? M]?=L?/GF_<7X0_#S^?C#]<]A\/[B[&&]^O^^7G/8W6[6@-W6JMQ6FOXO2BSO M2Z6#-!_(Y7>0RSUUPH=XUTY-_MEWHLEO=25O.U'CL[/S3]?CB[/SX./;8/SN M\OS\E_.+ZV!\\288?_KTX?W9^/K]QPO\\>S#^+?7X[/_#CY]A*_?GU_=0R+? M5N1O+1_- ;"T8>#FY/H #9,T1YVL%I,I=KGV?8UAX[MF]NHB5R6]3]HXYNEJ MP #6QVP%#;4AZCA'W5Y2 (&N"-K*ZG4E@KTFM?.H->;@#4'2+TGU7G(%:YOW MSX]8Z!:=R::Z+ L;3,PF]Q":G"<+7$N<6*>)V7?TIFE+?M=#YO[Z0 D:@K\. M#/2A,PS@A(Y0N\)8/40@Y>QJ,J-##Y?28,I?5JE4)F:MADCAX0'J58KVG=S? MHI^ZX<6$)VU*G[YC-B-91'R?9B2*(M$F$246!D//Q:!$5&P(WG*CLZGC7<8/ M/;UXOV9>R'+$,LK4U(6CZE !%X!.,#X<$K79%>'[\'10E->@JST85Q2O;B/0 M=;(LVJA<+,];#-M?LYLI.F&'BFYH7$,FF6O:K&N9T & M$UB*X%,.+U =:/3[L(O;584S-;V(?VK:;P'CJ!K/Z42CUJZYO[@:T?_WV>C% M@V;QH(A^]=^FF?K*I, _6("^FL0>#N+#0;SW7P34 7;^J+T^MRJ!#U8.W\HQ M.NHW<_Q]DL=K^&=>+M)7_P]02P,$% @ [T6B6!Q/6Y+QFP$ EG<8 ! M !C86@M,C R-# S,S$N:'1M['UK<^)(LNCW\RMTF=Y9=P302+S=,[[A<;M[ M>D]WVV-[9L_>+QN%5("FA<24)-MLG!]_,ZLD(4" P *5L#;BS&DCJ1[YJLRL M?/ST?Y\GEO)(F6LZ]L]_5^N-ORO4UAW#M$<___WR_NKSY[__WXO_^NG_U&K_ M\\O=%^6#H_L3:GO*%:/$HX;R9'ICQ1M3Y9\.^VX^$N76(M[089-:37QVY4QG MS!R-/45K:*WPM? I.]>&#:/3:ZBU5F/0KK4TJM>(2ENU;EMK-]M&K]_4FM71 M^:"M]@ZOA+W6&C M=UJCT7QGVJY';)U6@O<-.G^;O^E2O3YR'M_!@W>XP?#%9W=QV*=F.*CZ[G^^ M?KG7QW1":LO#6Z;]?<-J\/& N-'KYK-7@P4L?!$NR+3A;8I(>^EJ=U-L!=OA!]0 MW4@&/3R(@SX)[&J_WW_WC'B/\+,"ZH57\6GXJLOFVQT2=\!?@Q\7\*V3\<)H M.F' 0\2JZ\Z$O]AHSN&M.[[ML5GR=H*'B]0$+QA+E!? J?-./ Q?]3VV%J;] M=_ T>M&MC0B9KFXM>+"P ->;LN3EXI/YJ^<6 <%1H7;M]_O*Q4]C2HR+GR;4 M(PI^6Z-_^>;CSY4KQ_9 B-0>9E.@95W\]7/%H\_>.XZD=Q?_]5__]9-G>A:] M ,C60@#^]$[\]M,[,?+ ,687/QGFH^)Z,XO^7#%,=VJ1V;GMV!3F-Y_/\47* MQ#]-PZ V_R<\_P:"C)FZF/[9NZ/#GRMZ#7!DDPF.1,WS:QNFFUW!XABQ/ML& M??YO.JLH)A#BL*:U*Q<-^%]74YM=6-G"J#M,0 MK=$\G,Q2EZE8O?FOM/ M< FC&WP&BXRB0?N5BR&Q7+K?N &EGW\ JG%<8GUBCC_]YGCP-WYAVCXU;J:4 M<1GVB9CV%\=U;^SP]7L/T(1+NAE^AC-S0J^?@9!=.FZU',O;8/_X_-D2DR&$UV-"1M1=V6W[Q:IF]$A!9K2J9O MDRC:SEU^_@ \%"[JSCW@Q)\KKCF96GBZ\-_&C(,KQG[U9]< WN33S><(IG0= MG_&_^)EZ'H"6WYXXOPI\71 MIYP,P[_@J&4>K/6Z-8:T5#S9]$RC?#55JW1K#75^13B2?AW.,F[A7TG M@T&3 Q"Y_""G;5 OD0#!4_2[I,WL>+ M M&QBT]*+H16"(4Q8"/<1?Y8<+\1RV)Q&N?(\_?J"V,P&].&'8 MM/)B88AWBZO?R@,="9"_*(#C^-Q- "_NK"O7SIJAQOKRG?4.O;. \N@(52SQ MIP&3/4\M4S>]KW0R@"D,>&/*\#U&QSC:(Q4&:F%P M<7!#Z<"X^.;8N"/F6&!*CS[#WD"K\0H#?AFLKP-M[>!6T(E05B[&[Q*N#FZJ M%5GSDP%!!S>G3D%=D0%1![<."Z_0RX"ETM(]NMM$+4W=? "OE:9N?K O35UY M<%&:NKF"_^"F[HF/<".2&HZ#;M M\>\%/HHL<5'TR^!<0N"R __!#?G M"^2!H*+;M+G<"^2!J*)?8Q__7B '++5+0SYM@$=FBER[-.1S GQIR.<'^]*0 MEP<7I2&?*_AE*!]UH*T5W>[-Q4=QK.I=2[@JNJF;OX\B)\05W00^GH\B)P05 MW?0]OH\B'T1UBF[]'ME'D1.6Y+>7?_%=0(/KWHLA BSI9'Q^.R9L0G3J>Z9. MK$O;N)]2W226-[MW+!^+0F]#6NK57('N0K'..(YZ9[K??YEA=?0EV>N['AR, M;.7E Z[B%VKKXPEAWQ>7P@M5W]%':OOT&]VF9&U=@,N\\Z_D3X>%6XQAX6;J M^9.[9ZG8(ZYS[UF%U?9QX6O*)D_AG^$ Z2O\=J3UD80\=JF#2'1-)*\Y@B.N M D)ZNF !2 *WE@Q*!X%F%KA%N"74.*@WQI M(T *@/RH40V8SFCV1WVEBH.%4CK8\O[A#X0O*7SDZ&FB]V_ M#-^B-T-A(7ZEWM@!-GBDKC>W&^._4OJ-3.B")+1=HB.60"$A]S-X93(?X/#H MR284O2.=-XP;'+Z'_D?W@XGP-#U0OF/6R.K#DPPNZ$CK!_M(3/8'L7SZRRSZ MYZ\P(F'Z>/8%3XC%0R-ZZ;,]]3V7O]',PF#-FXWW@=A784SBZ!\9_@D.V*ZT_B!Y6$0&-$GKM)&)GP[4TTI:GXD\+'(@R$OKISC*M9T\I[ET_HL= M\/#IZ^V'P@!:.D]$2D!' 566Q0.IPJ>% ;RT?@99)8T$2E%/6M,Z-[$D U:D M-;JED6$R8$E: UU6@7<8%;%]:LSU'\;8_R4<)%@P0LI)> MX7OL_ X>A!^G3Z[H%]ENE\OG!:_V,](-^J45OT5C4QLIL;+4!NE%6"FJR7\T MK*3F%2U#7BF:/^ 8%XB9Z5;2VO^?;8,.=TVU^7Q[]V&>;D-L4:5!WE-_"1G2 MVO5%RGK+"!?26N\%R3_+" W2VOE%RP3+!A]J0UICO"@'1H91*&I#6B.\("=& MILB0UM26_\C(% _2&M<%.C,R18BT=O4'.O ^VQ@4C1_.Z?^R66]T^]\W=@*3'0!Z@()Z^*9C<<$=994K17/:FS58^[45G&< M(5KQC,9C@CI3JBZ>S=BJ-SN]&+"+XPS1BF*:T7SXX\@C-*@G(9JE8\L_/PWA0I$".=D8K OZ,3 M8F(_K2OBCC\R9X)8NF6.3JD1B\O:^%IQS@IIC=D1*7WBI.%"7UI1-@CKOEC%VF/= V63A!9-FEJ:^ M[N!!QC(]CQIW5*?F(QE8U.6-VL(U@H ;,3(I#NZEM:W7X3X_%,B@$C2E-<^S MYE6)>$0Z*WU3,\>K/^Y_I<3RQH=E +6%#-!,PP#+K[Z, :0SWA$97X"B1SP/ M!+3=6/N1;_3I7P[[?C,U'=.X]^@3809FBESJWB')7^W5&JVL#/>F=(:[-!"7 MH'03P+1$SW$]64TIS7(!TCG<8QE2CD>LYR<5**NY*@273/\_?YA_F::N9;)0SJ_ N\I%]:G^4313IR.>4%.3B6N-V7GEU_V=Q](0G[- MFJIF==BUI',0G#(297 QM*1U,=S[ Y=W5/2N'^$_#[/I4B^@I1=>Z@V4AA+4 MG2BAE95IT9+.\?'J*0'0VTY'"=M7FU):47I=MI\ __R@FQF-'N;;H.GO9 M42ZE(V<#$KG# .#_2"\GL%&=V _,'+S\ED<:W*J-S'!;*"_0L45F+L:QE%ZB M6XN8.,!P?F3RGYGY"#N]!=!D>(OZFD[I1>N_5=,Z+[3^+;'41 L]>+:/32ZE M-^TH5(DC!OA?G$84,N(]XE/21\D!!^2 )8IM2^=D/$F*E8=R,KLY:$OG?SP: MY:2QCCY=%I-:EGUD:96[YDN4N^A8GH;H2SR8HZ=[',WM5^=I+172(]I .S@0 MXZ^^R 9J2^=*E@8C.46+M$N7[M*\7QS7O0(@F?:(VCH(FU]FWPCF6=T,YS_/ MXI+),7S=^V*2 8]T+)Y"731?+L_XLVMD?72DMPFX7,\LEH^&.*$ MM?5F:?[JR\20=*[HM;;6GHA)->'EB%%.]/$R[W]<74Z9BCYX;7H^*7A MEL,HL_O%=J&EI;2D]SE*(>M[ M8_Y 4K7FI72W:_!*1BI&1SJ_L83J7TY6:$=*S^Q190(2PQT!XS+PI6%&EVF; M$[\XN:,=N1V6]SJU"6QG#N#PEX\.HSIQ7VS/\0Z*CF,\F9;U>3(E)L-Y9>T) MV\J2@:5S[&6 BZ(>L/S4S($&I',EGH),E=(YMPQ4\EPLH$KI;7H@SU^)YX$% M,+_7)XQ^]-TBI>=UI//AY O;+!--.]+Y4*+N<'"^_D$LG_XRB_[Y*XQ(F#Z> M?<$N<(L'8O329WOJ>RY_0\WJ.(XMYJNX;L?=?&3\!-9G:U82>]6]H[K/F&F/ MBL-VTGE5LB0-K22-_4FC*YWC(TO2V%9BOB2-3:0AG=_E56-#.O])>;Q+HOEU MI?.OE,>[+*0AG=NE/-YE(0WIG$>O&AO2>9U" /]*C1% \@-US9$=*U\TKWXJ M'E#CT@W>G1=#S8I!/U >XFT^TOG8[B=BVAB0^.6GR!O$98,I4$;QYR M77>F^WUQ]L^ :D9=[PZ@=/]$IL51.J7SUY5464RJ;&9)E=)Z.M,!GM>XMYRG M=%C/X,(OCXSVKK0^1QF1=*S,M"4D]:3U_DF*I#Q*;/6D]G\F4<.]Y:<9/-*H)>9578(C6YGR2K2.5DQ O(KEC6 MQ>"^8OV9Z-3CKR,,CDL35SYC>/V3PE69>N:3\")_H]YG^Y&Z'GYX,",[\X8% M?TYG*U613-=I:6KW_!^W_PH_WZ$F4J_H?N&2PC.C\!?(N'_X-BU4B_)>T5WM M)=T?E^Z1WC^#'#7Y_N>$3VR?L!E: H6A_;YT-QAY 5@&ST%?NJN*4I4]<8'W M,E&495A"OU!70"55YGX,YZA^9DKWA;JV*NE>4KK_BI'?*<[B' D_\EU0GZWU M75S_?K>'[Z)?J'N[DHDD9Z*.O$RT3/B%NFPL"3]WPE]C6X>4ORU=3"+*E^Z* MM*3\(E)^S)&A]HI#_5+>>AY?N,@0--:7[N(L/W*7 A\%O]!Y35&[6D.Z&X@B M("N?"PH0&26RBA)#"*.5R"K*F:4UI/4";[,IOCFV$9D56=D0GVW=F= HWO2+ MHR?,S$NZP_0.0)IXW);!KZZ?IS Z=Y.N2+-)Z6X]1,>=E1F"&T1M:0UKG MG_QXR+#ZB-:0SA7%0_+'A-$[.O4!YL2EMPQ[?4UB;;ZT=N.K:5GP0?*K!S]I MU49JX:5JF0DOZ3PGQT!6:LZ-SMSKOWP SI4SF3HVC5JIA*\],'XY-[OW'/T[ MO#0Y1*E?*"TEN<1??1FY2.=[*LDE);EH-;696KK,7WT1 MN:C2>;]2D4N[D;/FL(O9DU5W-4V5SOMU#&2= F_G0R[2^=]*SF:_/04M_<:UEZ$_4I/,G'IRM2G)Y M ;E(YT\LR25CY%),?V))+KN0"RB:6D9'03$]FB6Y+-+ LJZ/_$M MS(X+DL3"RA^7QI^^J'+QV=8MWS#MT:W#>)Z;YS%SX'MD8-$'YYMC(U"8 ^2' M26ZB[V3VZ#Y0=DQ3.B?C_AC\1KVPDLE'YDSBW26H>]I8E,[WMRL6'=T\;0P5 MW>%7'$DI0RV&9M$==L42JU*@O.A.-WEDL!3HE,XI=K("^T )^$WI/&4G+8,/ MA47I'%B%%:N'PI!T/J/7("FU#(V3U@FY<8HE*3/%8N%=.3)*RDPQ5'@W36$D MI0R5N%HGY/,I@%B5 N6%]_M((X.E0&?A?3J%$=B'*<6NM4[(C5, &7PH+!;> ME2.-6,V\7U0P^4K/* S,")Z%0VSJ&;4\GILXX'WP,,V(RS0DOR/I%]\U;>JZ MX2[G$2ZW8\(F1*>^9^K$NK2-^RG536)YLWO'\GFKCBP"9*]@',_8&[0O'??-VBA-TR.![Q]5\I M')+CM(=D4664_#[)DB[SI,N\Y*7\CM/73I>7WJ_8]N7$Y:/\'M^2#H])AWG) M0WG]UDDXN9EZYD>\7QA[7YR1Z7JFGAT1G [A%U4HRNM^+XGQU5G61?7COR;: MR$M0%=5Q_YIH(R>YT9'.4R\CO+BGJ)[-UQU,D$?.::>HSL=73"HY129WY/4/ONI8@US$ MAKSNN==+"WG)A=([)OO]5>[W^[G(J-(S5]*EA/*R*YU7L*3+O._[\Y"/7>D< MH"4=YDJ'>DK&H?OS71!MY":JB.NY? M$VWD)3>D\]3+B)R\&%=,Z]_%&14S163SK_UA94 MA'(+Q-7O)QK\VY/.S2,13O+B$^F\'5*(K#STK)YTSH7\49&73B6E+2^/I,J% M/:0TX27!25Y\(IWEGFU$8E'1(IW%7L:7)Y#*@?JT]*5S")38WXS]+!M0]J7S M0;S.(/%#,;=T?HU7C]Y,N5FB635$V'&PVQ*%X%]1UV/F;I'C7O/T;__;IN>>W?_^VE>P?2E M==A(A9V<+F/ZTOIMUF#GEK*A _:ZK=-[,-SI:5Y<-AO2>E0DP4L^_-)L2.OK MD$V:Y7!ATVQ(ZZJ0"COYW!$T&])Z&N21:;EPC;0N 4GPDA>_2&>[RR+-#F-( M-AO2F>X2 CQ#7TFS(;?ECJP[OTKX:+HZL9#DLG YWA%[% R.?WXU;7/B3UXZ MLF2",Z\#36Z7PQJRTDJRDIRLI/.5)&&.\4/)P9*LD*Q4N5T]QY16!Z#= MUTM6TGFJCG0^K2'85DE6F9"5="ZV? _!DJRR(:O2-W@L+X=:NOL.X-]X9SZ? MP](@SS\>(G^ _'@&FHK8[6[Q+2[;9;#=KH#P9T2(:#AMY2 M-=KJ_1L/[ODWKC>S !,3TZZ->0&H\U:CWIYZ[Y],PQN?JXW&WRJ+;Q(V@I<' MCN_N.]8;I3B\Q@SY9ITQK_Z/WB M<#CQ(V4\5+I&+'-DG^/^@\?S-=4;8ET>[-\SPIF#QW5X]&[U]Z96UYK-Q$>- MNIKX^[&&:FT4H,P[1'Y]KT65$!?AQ@ G86':[ M4X!2X/3B)QPL' C&=MCY#\A\P^'[(9!>;4@FIC4[__LE,XFE?".,.4]_K[K$ M=FLN4&KPEFO^AY[W8&K^UU-(1HWW',\!62$EB;495,=8(.#-<]\&4L&W8#U$ MBG4H8T:'/U=^V,Y'W'G92Z-DX4.2Z6L*'S;[]7[C>1'2QP2/@PP'/R:PJD.*"9X[CG3A(=I,+(S+M9P(DRW*P>HG246Z":P0.7B]V^?'ZX_ M*/;;#CL*?D%D=PZ_0375!O])W#'0F.?8U1]_4#N-]Q_J5W5%:[1;_90[ZR_N MK"\!ZC3G+JP=\K/:;K07X['*,'D&<+0-FA<9"<:9X8ZK\%5*.(FPXA8).:>PAZ&[Y MY]?"W;% @.<&_%*;P!!C_*QFD%EM1@FK43NDQ&;EXBMA^EAIJE4%S3Q M3OIT\'58*=5+J?XRJ?[ 8#H3+;V=Q'HK$.NMTQ7K#W>7W^X_<^$MAUSO+&JM MJBQB*!3S7D1*H9P?,F>B_#OXG^(YT;_WLT"D$;Q7SF1BNNA"53Z:($2!]@>4 MG0MK)#T/7G._*(X@!@B9JPTZ?$U5F]VFO$>4UDIET>P*C#N*-?:!D+QO\"0$ M2 = 3AC(#%B5Z&!453[;>EU>\$2N-C[:N>G!3'H*>)U=/Q/=XV!!YQF+P*$0 M5W&Q/,;0!-7)M!73R 52OWFQL5NL2=3&UG4:'$(2\3'D3TS LFHI]/9". B4'%_]Z.* _6,DZ8"RI^# M52&4/WUFNH:I&X^<[,!0F4\N9 M4<:AMDA[RC>G_C:)JG:XT]GW/NT$7MO?J&<(UN(*L4O#8-1U@__W!<930P'6 MKUS ' TE4JIO+:+3;"UYV-#7,65 E>84IJ+/5/<]\Q%=(* %4;?4% 6T@'X4)* $=5">$)NM?"0<7>D9 M"4^M2T;) NLT*Q<==>4*[^VN+M@O#F#Z=NS82RY8#-7MMKNU-H!@+7?F?0V[ M!QT)V,^]K#_^T-/4[GM7\:A%IP@'Q>: J"K C9:/O*(0 #X ,4YW^VW]R)[% M=KW9W3T6MEWO-W=SC&UR4C:SN;WDJ]H<5IMX3O2E$GPIS]A[$/_,]$SJ!@YP MRJBA3'WF^N@)]QP%WN"FL:J=#=[BX8'W3Y>Z=[[]Y)3K*)A#9,>SX,'T1'PM M)?I8T2WBNH73V'?=,B-<'-W/)@/'.MM)*RCDAK\%MT ,Z!AOB\M:@)G+$UB4LR?3&SN^ITP)4QZ)Y>.A M=LJ6;WH@!OPEV"N"(-Z]7OY:PFB1T*X#;A2WU,N&-/+JD@W=!7:F3\J_'/9= MX25CE'"([<;??G%_?_JN9PYG><1'?+8-=%Y393!3]#&%S<)*OX/8HORF _K MV,WVF1JH[6/B*D/3@K.>6!:\@?%(J +\Y9NH ,"Y/Z#!"S!PH .(3]4FWBZ( M,)Q '8AI$2&H447 QQB&HQCP%$X3?'7*J$[YV:)J8CP>20C2 @8%Y"JN#_+6 M'3MXVQX&MWACXBUOY8DLKA<7*SX.=O.VJA#;4,ZTV)8'0"?PTN!/V!!^Q-^' M+W$]P6"\]#5?"5\N<3VEWQ C&&3FUL4_5_^[J[?BRF<,IA*A8"@+/.+Y;D3$ MO!\P/YK3N,U#.$*O=]UI3JP&.3!P=-,3CH*().+#H2 M7=1]FYE,B@$-81:(J$@F]4N95,JD0\ND9D%E$H@!HEBP%:H070>9A(T&#,ZA M##61Q%\5X*-:X@-W L(,9F&A?@#<.P$(S*JH?<%PH*@@V$;*"#;JCFS6.$N<\?W8\:;'/-"OEC]7WXVM87UJXO? ]UK\J:158PJA+%;*!1 M:H.:%NJ2<06RGC;*='.XY9R&"I&(H7;K[?9NP8UKW:+U5C.+/0(D[-63O>BQR$(5M_-*FZ*M9)'/N*DQRB0J6GL2O M%VV3DK9CM!W"YA,'S55HM:6C<2U[&M\OY"I/W\%P@XV. 3^)K@5SF.3IY/Y- M.&)MA[LG?5?8][!/4=PA(1G887PN:X:3XS4LK&:FV/0)G0>,/IHN/[)M8F,3 M<-3-,>T)7\9"@ 9AAJM@=*IIK(L&:9Z1MXDF>Z:.L SH7TLZR$_3+Y']15TKD[GQP(X1VE&G-K3+MZ+2Q#A>R.7X7 M/?);6$^5AO4>QF%\9L@E;#644X\'O%25E8"7J@)_Z("TE M^YG5Y8JX6V:.*#A3T9\.#;\U%5'ZG@MGA9>*Q$J/2O[_2RCKNZD0;PZ%-1.J M$6^62<&%W?%S%KKU3D>J.L!+=7X#3MO1(I8@&:1;US0M!MB$'8=S@=I =RHM M!P]ZV=P==NI=[44'2\(>CI@L=PS'6;)XO"4829L^#'XW..5<0#Z5\_ 8%>1? MNI#T)>157J[3!JQB[.O?7>4#''Z^J+F&41R7H)',7),;+Q\CGQ&(=T,XG?"= M.^KZEL=?N9E2L9C=ZM"GJG6^!W%LDHL'))LDULF%;'9W,:'PE1+79W2_#A0E<\O#W$@! M:J?D[E/D[A8([M_P0L?TN->-LS?\8(5_X_EO.9R1%3) A^97PKY33[DSW>\E M:Q>(+'6%Y M0&18GC=6 [N8FG^DH-/ MDH.;C.4=U"DP*^*SU=K$K&D"D[>GWV0=NYZNA>HE#W98DX4A?^/O M?J^N88VF$XMHES7'.[%/+B_UABU\E'@[/DRO$QFX:K_;KXI,W9'E#.#K,?]: M)PP(A;)';,+"/8%3YAB^[KE1+J](R.:EUF#3S@26:B@\"X[7>,.D[['C3K'F MN5M=&';F>G0"OTW'A$V(;F*N(ID,L+*EPV:*Z[,1ULP49 O/=-@L4IIBD0%N MP6'\D^EXYIJZ2>RP68Q8)VR1U\R%W6$*X]B9T+KR3QHFD(>S4I]3K_@(H,$G MB#:)/^J.Z]7H<$A%V<[YUGA93&J/":I]KC^=6I@.36!"B@N!Z?49GU)W;!M+ M^X9KJH:+P%U-R4S\_P *;C#MA-C^D.AX0C$!1A/@,!)U;3@ =S6(K^O,[>_ ,QM/?D!$^%L*$C7L+X7+E=@#L?_A[;&@-=S)3["+AGE=O[ M^\K;\$/^WB=!FE\#+-W&L?0!DV#- ?\:/O[T]?;#_.NZ^7M%VU$L../QEAE("AW"M],":(A87^*$0]2@W=%#Q7!9#>8 M'5\-:O>;@H,8KWF 8:N^;E'"@O 8@ #U=-KSA,2DV OF\MA3H6N M/W!!F!#!V;YM86LH9-\@JSC$@2M:CCX!].K*#2=)GADW0Q!2VW"Q2<(_?)LJ MS48],6]P0/3O(P9K-VJ!6![R_[T_BI".S$57% F?I_4A2.9_-_G?\,K'?P7/ MX!]-3EGP(T_-GF_@L-H7Q_G.6X$$[NW4"7VE0O3:%*('E'F_P8D(N(836I2V M1_DP]^&$=?7_$F\%W/.5,#THP-0,SE+EC$O02O0IG#%G\SY9IBTJ%J#HGG<^ M%MT*6,CR;\-# <89!N1L!>3L1N1<48CHC(<_TV=D4!(< 2!T.8+ M=![1AAG^1GUI?J(9=(H;@M/)GZ+6Y_-CFC[RQ,N3$S<\U01<5ZH,PV?8A]!;.1A1 [.-Y5\Q M(V7YMP&U3 #K\L]/IF6MU"P>.[ZU,JB>].-3TH] #G\F[ )/3-/V5Y9@F=]! MSB>>Y@ .3G%"T< C6Q!J'/U QECX"8DB("06(I I(Q_.<2#Q:OP+0"S8KTA) M?$R$N>WRRJO,!\6[KCR,*?P=DBTW#>:],$!!^BZHVX>!0=L"'&!4 J=N#B10 MAGT^GN=SC52L!CXUS.%0\ -%80*\/V3.!+YT^'0&Y:STIRACA?KU9 I(,_B" ME EH_0MZH"BW E^N6Y%@-5<'+32F;,6HI=^OJR&DE4H\<(O7HD9= M^]*V<5NK4NN_(ZFUI/O0I0->.<-Q NSS'Z(A B)X6^53X<]NHD",-(M[.@6T M8O69:'2N?%,]^%4-E8JY/+J_O@J:F;@\ M#$"IJ%[#*XOS9O1![P/#T7VA^5\_Z[#H4%WBY><"D P@T"Q ,6H %GGB MUA(W83SR':T!Q1G "29D.M8YFQI!TWM1L$S9*"YE5ZXD"Q$H5!]V(,HSNK($]5WD9'6[A#X;6Q773]P-<5 M.V2_56A40C\*@/IWV\3)N*WC+H?F157RL)26*72OLPH(75!-F0_+$><9@W%1 ML0K +XZR#?,+PY-_&,^P=0-!:C)Q0AH@174/'5_H#F2<[]>.N.0/P=^E% M:;VA*A.26U2M+**ZU2-D0P^'@-C;O<-7 UMW$[1KV2P9A'"_WFLW=^ZUJ]75 M9C;]&[#YD=;+:BBUV=WC:&AG=C3(,L:!"L-G?9&6KK;RT7H?)5>H426]9#X< MP)>K#PN"W9FZ[SF_3B87J=B;_9$4YY68>S GH'-AR]7M&SW3K%BIY@U_6TG0OH::VM==?2#M5NU/N]?C;M MGV"H_N9.4EL.Z-5K+MI2A\WV^P /\P+'D28@GF?82""X6#N0D MU_!15_ ^U MYV3G2"?BF:-J&:%9OFN)LZU0V>2V2"4'LCO_MA>,Y1+@0.7C7T!.FP.'2>"3MS+32;H M&PF": )'^0Q?UXD[5H:P C=P\.@F 5KTF8[! /J/6&?;-[% MEC>4<-$/K(L;GLW^G@&Q1)#.F%)C2_,NX$HXCG##FBYJ[P!!TBUKE7JG/\/C.).D8A_%1[=IXI'56EHRK+ M/1_9&26G&VHXW \(W51NJ&V!,C+D&-X)>UO6KC@';],E18Q71YH8KP\^0]?( M'LZK:N2Z,6T=@X[@M3ZZHO0PBTMM1']ZCO*FW:KWE8%I6:&KY8W:Z=;5\*?% M]!2,V#4!:+!=Q?!Y$LR $;X6[@:*$LD6L_L4EY[,-M=]?J0&>FK4R$*N>^36,&KLO+WK<3FV2$ M@3KRP<&P[;+E9&"<[.?%&]42QH>EXRM^5_X2*)> + 5"*1 *"./4 F%GE[_. M_[>K>WMB&H9%L[^_3[=O[HV9%Q2BB=Z8D.BV[3PU+32478%S;+B\66:X[/8> MWS/#*:79=+/3S?YV.YV,6PPCR1SH^'0GX.\@")?8/BY(3Y)ADA%XX@R3O.EV M5SM-PHV^U[9__S(BEDL"GC4[*V9^?K@\_O[_MI>>^=HD8*DR1)ON-=NERE"J M#*7*D%IEZ#=.DW!?J\K0TDH!*(>ZDF-#R?*M'-IT;O7-RWX \I)8BC,U'6!! MXKK4=8/T08M'6'J.2(A<*).\5D/?)'<3 %, T/,D1,@^WY=*\(F]=6+7T< M8:R ,78LK!FK.U%%%86,&.6E27@?HVT-H%-X'J058%N*+DI^FB73G.QN*&F) M(4O=5T+4Y/U]D4FCE!,E,6S!2:_X2-GG^U/W%M[1L-87+T^'S6@F4\N94>S? M!XO$&G&OR#G8WE0#1B:9)Z%A661J2,:)VBD^5O+^OLA4L48M:G1*(?$:R2$9 M)YU=HS4EQ,H!?(*9NY".C=?+"19#_<^\ 8]HW4;TOWQ3E VMA5>JBVZDTW<@ M]1H%$8 2&B%%IH9DG'1;Q<=*WM\7F2K6Y7 6+.U')G(L,CFL23?=V9:2$"VE M VD5L9\G4V*RH \V:$EG(V+:;]]9CNMB:UZ\>'1_OBTP5R3*BHQ4EWE]"T MBM@OIF>.A$?I#)M(P[I,ZKY]IX\)&]$7J$:R&P5K5*,RPJ T$>=QM=W=T^1E MPDC>WQ>9(M;XD/JE?'B-U+!&/FCMUR<@RLC[$WNK1.B)O;6O@W>QN8NVDC6_ M-J4^4:9UZ]VV%(;/FMK/88^6!4]JXV+C/B!7R74,J$6) M/LN7=O,NG%0>01*@Y#4?06ND1[7;+XI;\74??J^/ATLU,F5>5K75[Y:\5"J2 M+PU1+L\!*1&34(%SOY:CAV@7O!7#FNC^1Q77GV#8*W8,UIW)U+&C(%D= $U, MF__L>SP@Q%4F9*8P.K2H[BD<_3PCV\ ]\/#:K#E"V3_TF5,3&4-8Y? MA,V;9J<;]L(3G8[;72WZP5ANN;RMTS(? CL;+;=(YD/WFNVEN?J-I+E2-75> M,U5][6Y7-I.Z?[3R1!E5AN318< $,\6<3(F.>6>#F?+IZ^T'/M+M8G=G_.D^ M:OU\[UB^(#*7CGCEHRESAJ:W?K7$I[GX:V:HO8?5 M5:Z8*4!\J>O I1QLMR!J=9,*YKZG-N8'/M+X&]? A!, B0OG+PX(R^*BP725 MKQ]^))/I^TO^\983:3@\#*]N:E?Y$Y%C(0I0Q_#GR@^FH;8Z6K]+2+?;;C5H MHS\8T"$9#AIZ2]5HJ_?OOHHW3AY5VC^](Q?9'_(IQ5\H_"NX%A=YXJ/UF)$0 TM8\MG(NA71G9,,R#84?MK8=L-Z3Z8V#$LE1$B^ UJ/,K2I/ M8U,?"YD[): 0$0MDKC,!$P_$C=0-C=4=>W/'Y4WX3U\TH1 M=@01!HIP(,.ZI0R30X9MB&%XB7)GVCJC!.&I-A08&7M8!AI(^.>R-FOX%#$1 M?NDB#[]0$=RJ 14!W"]^&K!W%VN_"<#6!1/U_=01Q1+.N2R$#;P/.LES M2R_^58#PQOP3,G!QO>L_66G]F6Y]&RDL&HA;G//%<=L:",TB4Y>>A_]X'X8# MF3:G&/[1^\4),#!GR;3F\XG'P>;Z_7JOW<3]!;%$P<3!UNNP]7>KOS>UNMIL M)SYJU-7$WS<,U=)Z60VE-KL;APJBII8HILTI;(VG+-&[0:G6U5JIXRZ//L:! MFMEG7$]WNP1,<%L=;U*M @(\ M$.C_=YM6=S@8_+:I)-]A=YW?IC^*WBQ<0?@(*A/H!K7?=B;_12D4NE!3;N;! MG(!F\8T^*7?.A-@O5".ST/:23O7X?\=L#H 1K0U .?I>(T/@W7-B/9&9BZ"( M3PWSQE65=5I&.G5A'[WCZ%H&;*[>$!O<1_U,AM)@ MJ'[R)TMJ1OK;-]I2A\WVTE5+_)P7S_<]8!)X+[C<.9 ("RWS-*$YQ]OS8?6$ M&UC)HTF?,MQSLB2-"Y]M)E-&$&AM@\#NSBR MJ=^K]QN;95.RL=',S-A8((JCFXW=AK8KS%J]>J>Q67*F':I3[W1V&VG][^U6 MIUQ3N28IU]1ZB9ZQT;6@MM/8K4+//,(AFRY$XX%[.;\*Y^;UXL5$BG/W] #R M#9V]*>!Q((?0<2.8-MVUG+U!M[7B8O.EE73MU$=ML/CBX!]-]:QVNY<'ZO6]H"X--!IU+?)Y+X-2ZGI5J8TE)>F MDNV\=WDCT<$B;!DD.>:EB5N%Y)@UN5GUYI[](&2GW%0Y5)E0 ML5PR\$S3=BZ[=CA22?M_J7^N[>#CRK^!8OG6M,AU>:I$++]K MRDR'*4,1I3FCA.W7_E'V]A3)'/[C#SU-U0X0!UYV+)&?)-;AA)-$\5&3]_=% M)HU26I32(A5.&O5&V31;3MVN?.O NK#B GAP14.2.)*=PM"53GNPW*=*21):*L(2HR?O[(I-&*2U*:9$*)V>H M"9<]K4[,?WA'78_YNB=JPF :'IU,+6=&J>)26"2Q]?41ND6V]I+E7J.N%JQO MBTQ69I'I8:WUWRX^7O+^OLATL4Y.-,LNZ*^2'M;)";57?+R4;=!7,7LY<6 A M_PF<2* ?.=Z8,H7H?_FF",^/*F\OR\R7:R3$YVB*$L2TF.1Z6&=G.B\4CEQ;&]2+C=PGZ,6"Z* ]]F(F/;; M=Y;CN@IV.##=J>/"5,Z0!ZQY;E6QJ7>4-,O$^A![IEEJ:](L3\+*62?(6T51 M^"2TKHI,#^L$>;/TCKUJNEB75*26L2_S;BQG\[XM M;]\%76VX9O>J/&)JP;(I9;*HBDP/:V,F-/75Q4R4-+%91A2M3(M,]%AD>E@K M(SJ-5R:?>;6?LUC-I M_GQL(&#DA:V;%F[&].@$ ,"H,F74Q98RAO)D>F. !/S'543+3PRX1;"1Y[IR M3ZGRET]LV 0)H_E$(\4.APBH. O2O3QRC0*C.GX3.%.4,^9-W"]"U\,H,[G MIDKE^GEJ$7N>2K7X'LX3#?'1M D\ AA]I<3U82OUR@ZH6? 0J[U$9(F?3-L M()W7\*4-=2I@-C]QY!XS![Z@'L#U%6'P-2SD M5THL;UQ5/MMZ73FKQ'SAE;?UD\28)A'&/CJ,LY;'6UPB3]G8VW'B\-Z.=+&W MHX*=Q:J*N5]\OFGKEF]0%^5*#:7#R'&,)].R8@,J0=P7?ONFWU!@_U;([&\Z M737\H0JRQ)V";#$?J36KQJO5XFX^?;W]H+ATA$/6E8_SZK5B _@*!8*8\&]P M;;B< ;7IT/26QXKO%L3?FW9G856F&V[,",44L6T?YA+"#Q;(1VDMD@:1@VZ;P>H6"3>@66,]T<; L0O!'I@\ M4::F5+ETWAV/JS8K=\ Q\*67R\H3Y3H;2#4&ZX5!:$171/<U_75M2!ZB,'1 8.*$>#18+:1T#?(XZKR-#9AW6-B*$1Y@Q&._;=Q M16&(*$;"$I.M0F,5",(@FY]0""\<6ZLWVV_%X0'_[G;2SK,&UHO3\'$%/\8/ M(Z$/5ZZ8RT\WJ1 U]]3&"W=@L]@;U\&IY((UCP,&JC3J MW5\__$@FT_>78G=;-(CA\#"TNZD7\D]$CH4H0"3#GRL_F(;:ZFC]+B'=;KO5 MH(W^8$"'9#AHZ"U5HZW>O_LJ!F%X5&G_](Y<9*^4I10')4*S0JC:: )&.3*+ MN7:GP&OW"KQV6N"U*P5>>R]?P1M8/Q4\!%SNE7#0-X":)_R+NV>Y&C-W)O%V M*=Q>J*"ZKJ !A"" 1P;UB&FYQ5-'/^R@;BYK6G92#".W% A"46N@QH6-J?F@ MS6;T)P#[#4:/">T,KT?GNMFR=1^HLF-8,[P23;FJOP:*G^4\16H>5ZTRPN<(NR+NF&_U^B_??"06-U]3;K$-,P2_8'RGB'P57KGP M D/<4\!.+#)UZ7GXC_=A@*]I\R7QC]ZOCKYT0<'A*1Z_?S(-;XSW!_4&OT,( MPX.#F8/'=7CT;O7W?J_>;R0_:M35O\5"CL.' =":8H_)EW&);<@HU;I::TW2 M@3RW'"GY^\9GBAZ2#(V1S(!86)Y5F.#->E<9A#:XEVCPX$T(\!0WZ]ZTZHWX M^__P;1J\WA"6?5WYL*-%)9PK?*E3YCR:AC TYWR.UNLCR%L0UGS-ZGS-H5D9 M>1E#)XBX?\!KAL"_,24S;JNB,Z;9#:KNQ;T/4T:#=X3'1FOV%U^:&]E+=NZ\ M1P#\X%+/0U\W_/Y(7$^9D#\=, IGX:D3]-RRR)/KFS#5T+3$?ET\8X0LLQPT M(4>8%FL'KA?XKX# F3BZ2'#\W(CA[OFL? V7X6HJ;Q=PD=:*?@( NJX/CV.G MG.78HQI8SA,X[P9>X*W1*4AJX4D%Q.F4&@)R:EUMS1$$OP@Z M15S7')HXH9M,L<&%D1X=TWK\F [IV1U3B@X]OHB$K0E_%J,38N*Q,5\S7X9I M/U+7$\XG=^PP3VP7#',*>^9A\BZ_$8,7 "H+'C.PW7TFT -33QR&T";V(LCY MY>+"7CG% ?+H\Q2WY<[K!-:5SW8$_NK./@J.1%@T%F0V$!]:Q+/#P$EZ#P/Q+G*JS8A^G@E'>KR$?=A7@2RN#'_A R M7D!36?M)3&:CHD+9YN,_E?"/!CKN0=OOUWOMYJ[G;%.KJ\WVQG-VAZ%:6B^K MH=1F=X_3OYW9Z2_+&%L2JW;,CQ(4DWVMK^W*24(LS0&G3XYB:2TR](:@WQ> M=9MH.2K ER[>-SD> P(\$.C_]P"Y;BEA\-NFT+'#[CJ_37^<7X'CC>)$41NU MWW8F_V1;*.5F'D"'%+NG FQ7^B].911'__OF,T!,**U :/D>XU?'9T3 MZXG,7 1%?&J8-ZZJK-,RTJD+^^@=13'G00WO:IO-^;1#M1OU?J^?R5 :#-5/ M_F1)S4@?WDM;ZK#97HK_C)_SXOF^!TP"[P41IP<28>%-9)I,F>/M^;!ZP@VL MY-&D3QGN>9-7*4/?TG"X'URZJ5R1]S _#_NT/>4#?:26,YV$EGK\P$$+\(&A M,2B# _5F[E'B-_$\,$&Y ^.>\5_O@Y9&5+D*PC12RM_.BG0Z\@?]@]@^83,E[HX9T!&L9^[4Y)=G0(B*/Q5N+(?!"T''" P#BXA1.-O$ M_O ]'\/"PILI%E'O_ ,QM/?D!$\%U0ER=\^5VS%A$Z)37T2J<%Z(O$'WZ";A MT=?!!_SY8F3E)8\O#-UH\RV%4Z#SR^.QY+8#N([)"FH[_FB,;E*&_CV&RYH2 M##9+6"K&X>F6PZ.X^6CQR+4;X29[X&%BEN4\\>AR&T/HO, -',9:#9DSX3^X M&#=N),>3M4)GK@UJ:@)0S_>-CVQV\HA)3DFRV*]1ZQS##D\1F=RNJUR$[$:? MYT #IIM$/O K7ETP$SW&&,H)9#OP75B$B\Y6$79IS<(T!^2KI:G#D>BS3D%J M??-UBQ+&5W3+8$4N.C4#@SI:V-Z1M))02O+9*26EQ,52IG2P%(L;$@#Q:K\Z M$QHC0B2%FZEG?F1\L=F#IU-OIX)/\LSQ>(8?G &S+'.&MW _MGJP5U.*P&K)*42>FF VAXSTYJ%^@G:$PQG^B$%ZCB07ZL$C&C,73 M\_0>RYR8=I06R/,5:O.I'ZGMB^_A#'#TH/L:FSI< _6H/K8!1J,9?X5?>!K* MT+=%1'9X2QN&'*!&:C @(!MO[P7KK"Y6+' 5:[(%%Z54N@*C^:4^V-(0/@U# M>)V?Q?,G=\\83.DQHGNKSA]Y=K!&BMG*)1R+8!EJ,1.>V&"^VCH&_J"!BS)J MNL@V0+$BWQ4%AAYN7X2-!% )Q0>($Y,GR K!9?,#&,.IPODPQP;MYP$*%I"% MU*@K]\02$:LAB$?PA'$YIG;^%D8\+43'A%(/)&0\>TIY<# *PUTWH$*4"26H M!PQ]"P2Y"*ZQ#&'#+@_# MF1(4+[Y%&">"<+7.'%0"-AP4!,$PHC% 1:,M8J =S]3R[2=3U!0(=FW3D4@O MQ-@JC,X1(XG(&>*Z#BP[S- /BA@(\,@#MK)8=(T%-[ M,<@@Q@O.]X<(3X CS%7PE KC#S4:1!:-P_EPB(50%Q5Q?4'?P8T M&5:O6*A-D3 !1FJCGTR''42,BNXQ9V+JRB.Q?)Z7BAXUBG%:R#=N-$P0ILF$ M5H\,8O,_=(89M!-@0W.*YWOT =Z,3W]\JE3:P9 M*M *J!0>5S,)_O0? ((2B*\A!252N8 2$#Z"1< YK/I\/9=30Y,(,E5X@$)!.NM!U)PZ\:XM= MD@@,($T(4!*/6A1^U#A9#C'S%F8#:4 MM6&"=I^N PP9IRW\QI\"XBB9A+/C>>12SB#.%+5EWPX">U&2#4Q''*@(8Q_S M5T&%9JZ ;DBR9(Y!A!'.PE?)+=& !%=6MGS0; Y_1$X2=N)C[)#9T6\>-S?$ MD8,GOT7#/ F.MAV[1,3?"+L2#8AJ1 0 >01+--!/ %[KVQEI"U>Y*&&6EH-_Z4,@ Y(Z/T MCNLB/-K?GN%]E6ES/Q \B/1:&KXSH0RW &LCC\2TN.R*\/8H\.;&KF9^K]]C M10/'X"OZP/R1ZE$ 3?+QLY\)0A@]O6 18 M88Q#Z4 1#I8Q$6S%]2701]!L$2XZ,?(=;.R&?(=E@B[(6??+ERL%#DKN+#NK M+#^OO!6:P=4?]Z&7^2IPV/'F<97Y@XHH^;!FQ:&!%-,LPD 0-YA+'+%E+D*9 MBU#F(I2Y"$>+,6SO'(Q=YB*4N0AE+D*9BU#F(I2Y"&4N0IF+('LNPN$= D,, M)Z:V/JNF=0FM,Q.WF['1*Y%)&5Q9PK,UH\:]V!$ZOT37$PMA M%5IU(5.R'F8B:-3 M(B[S##@F,&@3CR=<^MLJOSEQ#''ER2O]$* X<;\Y$@SN^M,I3 6G V]"8>/] MB"FN\4WT=_/0(ZQ*PP,+>!@EW@C;P24RCX_A(2O\'21 ^( (.PH)N8JD4CL1'OD%_?H@)61W>!D4'5E1>AT?8XXK$3;;B M!S>](WZ9.Q]G:-%GDU]'SY9KW]!P$5B8!V.* ^?STLWH0D!I6)&:B$P@44*N MAB_R.C^VYP"")\XC=_(SGI.$NUJ ?5@OFU&0!Z*"N&K!)1( M>,OED9?N!A8CM<8;!N>UBRR \T*>U?Y7#/Q-4:0YO'Z>[TH\^U8 MLE19"!+8A%,1K0QT+BY.!5XW8723IE)5X.CFP\21B$%WR#\8WN#QXF(88+88 MQA?HMB;&BL".'<,-KW*1G /F%W$103B M,32AI%Y4* =F$"4:]EB)R_QY)&' P\$M?S +QL^(^$T\49 ?1)QK M.)/,')RLW/PA[+;UGKGA4OPT139C)N41SVF_#B**1P A>&MEW>)\"5@]##(+7MXA M$F.GZ ]>1W].T\;B$N'9=ILW!&C,MDW 7O&XY5/0S$'BA6_KI<'5P@ -L1PA MEV>/^RYFMH&._4@#L2RRQT/?2RSFR9D'Y HA'N;R8(0B, 6V:T 6&&%I8A22 MO!HB3V(W1$)[F%/$AYRWR;"7QUHP/^:)ZF$DIQ*&%( "9K(@%I<'1V$S->ZG M0:W:G4_! W7GW3@ 6<"?=.@$N5)!RPO.6<$:8:,RM:S;MV)UJCJ8\U2OE=92 MK7EI2G0)1O ,"P8D=^;!;.#0UD/58R75$2M@\FA44:LU_!RCEBMO%YJC+%*& MB!8620]AGJ1(/)SG_RU]LMR$Y)^X7]<)2(2*R@U_7T\KW$RE6.G4M(59PD1A M8%0UYZ\!='"@(*#:C26)1@.'55@76W@=NBU*V43CU+JB'* X_XEY@N\Q,55D M !((A-C7O@Y7&3IQCT--VXRIWQ>"HG61'H:WMMS)8=;E8GT$9Q+B<_"@,MK M%-^>IUR&R6:@ W^IW]9% X+@X6>7O:89@D'D]2,L+QXCY.U*F" MMK:!9H4G?+ ZX7T]T]Z*XQX#U-$$,UWT$?X2U E1[BC>O0(\)V!>>Y2&:8&.\:#CVB@?+] V T<$:)9XN ^!7)UJF.]7 MF^MLL&XRH9BN(N+Z(^\"]YE^!>-$-"9["@Q\(_ T\DKFP8*3*0)/7(L_MTA0 M&^D?/EB@:CMP"X)<%>\$4/N[NPQ37;B/> E\ALX6K/W.O2' **(*4W4.,KYB MW;'MX& /,AD!@GSE+O?]1F^#/>JNW])Z)(DE+^Q$9B-MO:U#T0R8IPE%3ONH MU &F;(1.,'2 3R8"5H&)L1Y$HFV 28G!!X82I;*+*_E+W MAF2&",$2ZSVQC=K*R/$R;%R6XG"LBVAZQY2U47[*)+6^ULPE3U]1ZMY]*$2ECRU]3;/G= MW%"[B0PU:0+-\ZAPOQDB:Y:,.G GZUJCZ9S"=Z+:2)H5EC&^1W(.1WJR.1DI M+M.!%,BXACI,H]E4_SU2ZW].1Q4%-%E87J>RM 6MUYL^[P-K36M,GW'I:Z;5 MXM-VCS9M,S9MI]'J-M5F'R#>;6>_@A>U:\C)W[$GA[3Z=8!E)LI!I][N:SN- MM/[W=C.;9+AR3>6:LE[39I]>2@=5HE-,;:?QN @!6DO5*ULN!]7;V>>K\ M?Q+X]](12;H\_&4RVK;[U/304.0!4#)-O#G.(\D[SI5J?:ZG=.DW:C[[7MW[^, MCN62@_U2!.8%^K^E45U?O?PM=99HTVJ[56W/;<37SK&ETE(J+=LWK3;[U59+ M/4WB?:U:BUI:;I*H+3M[CX+XM:)XC])6'ERKRVWBS 18%(#YFE55W12&+1/_ M)5/;P43UTG0[BVK9"6*-&[[:[_5+Q,C'J44Q%;(@AKP/PI(2-[J9JEKG-5%C M*9JVX*1?55N-$C'R<6I1+*M3.#-._>K]!FL/[&49)6RT"+Q353O=@O!/,BG) M[L22EB#6.!^K#:U=(D9"3BV*,IH%->1]S)6DN-F=UNQKKX@:2]FT!2?-:J/9 M*Q$C'Z>JKXE-\SXT]KU8VOFJK5OOMB6VH1X<+U9]F2UENN]QVW1*]\#M5K7? M+)C'0HJ8@EW6LJ_CJYB$EHSJ=J/:5O?T5Y8(EQKAQ8Z+/3B-Y:T'E 1^(&6V MTZVJO49)YJ4H/;03M*U6.^J> 2(EQJ7&^!K94HH524[/4[]AO'+8%(MW[&<1 M%],-=:8U5@J2E([!/*GP3&L6&B,O$PAR<<>W^M=Z>?N47IATU$*3;I$QLD:8 M=(HMWD]:F+SP5B*HB:FM*)FI-5!Q6Y%$Q4%Y=&E@)RXNUEQ8' U>,F5EOC25 M.7/8R,MX>+%3F"2_K/%R/%?&R]::*HWZE!GZI6G6)\G0:R_06KUNR5C'\"$> MB,GD.B&*>4&7 PWG[8+,FX%>Y/&I\S484E594I T.,J%6/CKT.+M= @+UP#;E8A8TG$!+UZP?MFY4[2J18O, MDI1#^1<(-:(SQW5C SFB(2@,'A"?>ZX0K_8K4/55;[YN4<+XO+<,Q*>+ M4CKH7#Z7_/CX9NJ9'QG?%2REVWJO?'%&R"]Z-K)SUR;+!Z>_=$U-KQS7PPZL MD?@%J!EEBU,!HGQ:G':D.4!;UL(Y:[X0_+2M2N@.RG\&@\"VN"LX,A]5F*!5@5-,QW%#6X-,A M'!,. XDP'.(0@?#2>;\:%U88"3F<>,2%DD!.ZJ-E(_9V$A(O&2G>+G[JN%P% M.&<43\Q'NK:!?#!Q8_X)&;@H1==_DM35]:7B,*?VL+P+?7-7X=+4ZFJSG4GG M3!BJI6UNG;G3JE)UH5^BF'9F(D^6,0[40Y)3]#$E@#YAB[^%/ XD+?MN %18ED&U1VAS9Z#Q4(9OE6Y.#-M92*N(MR5 M#-K4BDQR$)3$^$>])*O=[N7>E1AB:_I5-;1F";%=:.R*7\.]5+R>'%A*UBM9 M+P?6V[>HT[:HX&*H *''9K+HL=FM$^MIY89DVR/]1')#UK7HZ;<*UJ*G$!DI M.XJ8/3JPGQ;+9MNA_418=ET3I6YOSR9*I\XZJ?*UCL)&:=K ME<=+J1'F76JJVNX4I=)4[O*BU A+C3!_H+2KC8Y6LDZI$9Y@!G_N=)JW2KC% MNQD&L-B.3=?S5/F6/&]E5I)!ND3.E%GG,7=U-BFZ4V;"<+#,> +=@-IT:&*= M@B#SSG0=&T,_EW+O;.HEIFACCAV^NI!8CFOBWU,V=-B$V#K%(1V?*2.8CYFZ MBSF((T8FX?>[U7RH*PO@(9;K),-HI^3E^0@Z?!'6*Q"Y^&%AA^GJ.M?6>8C2 M+/?:8U5Y&IOZ&%=E^09U@WS'1X?QD#T!?P3KU-KG-:4L\K])Y$!4'FK7#]/J>U2MXSWSC/>6T6+(0;IM3D!A0!^&=I< MKJE<4QG:7(8VEZ'-96AS&5]9QE=*!K$RM+EDO9+U)**Q,K1Y!22ACT*ARQZ* M,KZYO!I/%=^L];3RJE.F*_E7R;)E-,L.\UV2HU0JF/M5;)LJ1&F!DJSVN[LVBOWE;!.J1&NR6(I);RLJ)&[ M05FZ4+X/+VB-M.+3C(>W+4>RFO8C=3T>>SIESI]4]]QJV%))=UR/MQIR_>G4 M8=Y"^ZTJ7Q+&[\$<_ *UQN,,>0PH?"=9*YERI'*D0HY4]B\I^Y>4_4O*_B49 MERKOE?U+ROXEQ]QUV;^D[%^2M,2R?TG9OV0_/VG9O^05]2^1IT_L?9"J>\N< MH>F5&6W'S6B3PSWW3ZK01V+YV'X[3-V.IVP/N+/-L>UE4Q;$3T2.A2AC1H<_5WXP#;75T?I=0KK==JM! M&_W!@ [)<-#06ZI&6[U_JVJO.; ? M&\D"_L59@/M*/X))8O-4Z'L/?N -OBN\L3")^M5C$C12%D]"7B&J/1VMNQIB MN:BPG<6$U0()TE:_KO:S<2;)FDU8KJE<4W9KVF;;E-FI979JF9U:9J=FL]M3 M2_@J4^3*[-22]4K6*P3$#IZ=6HPCOG*1KJS=GK%^Q8I6SC;!H"#1R&M"2WO% MK)TK18SS"\+_B\4PV8;W%X1AUI0G[S1.DW#W"+X_B>#Z5BG_Y B>+X5OJ:UL M+8#1;A6SG8NT8O\D6:;45V(LT^RW3I-T7ZO&HI8B4!*596>?41!&6!2?T2?+ M&,V<68"+ K ?%I1_"7)I'8P.;TTWQF4ITZZ:[2(7BG(7B,UK!%D:K==2C)) M6'-%DIWZW>0-QJCOI40F;%0J;EMGP17,A"N8M2\M.:SQT30Z)5KDX]*"E5TJ MM">EI,1-L&JJ!2L*6PJF0^*DV6B7:)&/2\OS0G[/^\YW$=UZMRVQY?3@>##0 M8I+F2[SQIW1/UBV,E;4O<1[0V;)_L/C)4EDRJCO:K@&!);:+@.TUGINB'/(' M)[*\-8"2P@\58]?K%NQJJ)2D4M/9NL"TMK9K8%J)[R+@>TW@S*9RD*]*J.1] M*5PZ98R6!]:O7I^9[.FJU6^OO[TAUXE-BP7J$Q\C*)(!=[[!T;=NJD MNT::J-5&JUEHZBTR4M;(DWZSV"+^I 7*"R\D,FF6M$^Y_&"(&KY_WN&7'7G4 M'^/7&'J\6*4CB@+;(X429L/_G]>F6"BC?C0 RY3@]M* MI+H8/L<#<9A<9\-9<_?TK=?;W3)O M*GZ59T.IZ:4&2J]9S,OYUWDFO4IN+C6]])I>_V5Q5:^3JTI-;YVFIY::WFXW MQ"MMD3)M;:-M6Y:V1]':_-MZI6M)DVY;2V'=L<[JQMX=VU>;LN,@\792SE!Q M?*:,J U[TUVXV6.?]1A[G#XC/*D#D39< ( M7\AT=4XWFG/IX32H9U-5GL:F/L;Q+=_ %DHPV9 \.HQW_S$G4Z)[")BKFS\^ M?ZBI?>61Z#K"P(@5P:DJ4P+,3"R K3,WKF739/"IC[EP9*/^- MI6/-Y(VM[.LXO#D )AR:O&.7[@ 5,M.%J4.F9:;#:C-*&/;LLGCG#L)F ;D" M4=O4"UN#T>&0ZJ+9XL3TS)%H[P6O(0/NV=0K1^KC]0)D8IJMM*5JT;+SDNHW M4\_\R/AZLC>3._5V"A"\GSHN[S-WSB@2["-]C]I3K5E/:(^&?0U%#QK8;+=U MC/;ER6A3OC@C8'TX#'?@E#S88C7PK0"4\&%QA"B3:2DB<$-R0P MAOCKB3(:9XPA"#Z'N7AZZ[Z+K =S\@Z*@D.O0-8Z-G9'Y(=^_%;Z)KJ5O@YN MI<'.HER.P@C$4X:.93E/[H8C/=ZY>I4?UO6R#E#6F']"!BZJ4.L_6=> <=?V MUXF=''-HB-W)EJ,"_(HPV <,]BL%ZVZ\J:MQ0( ' OW_ M;FNH?#@8_+8IJ^*PN\YOTQ_AW(:AN.;[$31<16W4?MN9_).;@*?<3"X=BC?J M:TFG>OR_8S8'P(C6!F!T?*^1(?#N.;&>R,Q%4,2GAGGCJLHZ+6.=YKNKEI&/ M3J'MJE-HK7H+-9$,%(%V8VLCVM2K4NO=?BJ=(OT5!6VIPV9[R0L>/]3%\PRS M@@*_^X'DU=5 MY5$W[&1M(+=V\!OM9-YM$V %:Q7?[]7[C53-KY>,CV9FQD?RY9+L'HK/MH(; M$8:^HS#Z2&V?5M&#[[J*6+6XX?@DQ(Q"GZ?4=FGC.Z-?P(;U#]P[FJ)C_2N!QS?T$:< QX%<4,>-EA++,JCN"!7O'-1X MRL3ER1F<2S"9A9K?2@A,ZL,\.:I%8OR77<1W#;A+V47\5(%2DM&!R.C4RXV MC>TQ7_?$326: '0RM9P9',B=/MFF*9C4XIZ$N&*05]^FK9$M+M2?B *A>7$P<6 M\I\@MAOL$(=?=Q']+]\4,8,U'F;(\R=<;_T]H):X]0)D>?7D;,Y[&+F:,OU/ M6A0F [*[N29P"^"1>#8B MIOWVG867]G!*XHVVX\)4SE AKDN#M*E75#BXUY)21A2BH&61J6&=\[[$BGP\ MVM&TDDE?(SDDXZ37:^:#EFW*PH9Z&851&+[,TZ//&-4=6)=)W;?O]#%A(YI> M/=A2.T1:DENC)4C:26\'*&3T?QO.[<&9>! NGQQ03^A26\8*5 FA' M,P6+3@V!59VJHI.IZ7'>LQR=!"6TR(0^.>R[N#>*;?[##AM3@CTUJTLPVDA/ M8;TO1):13!$&0L S830:5C2Z D%DNLK =V$M[J9Z&U((C96[.9&*=AF[F[L+ M]GRU<#=7% &RL$'TIB;<.IK TO;(Q%0CX6SEM/^FTPH#U#EDWG3ZT=]#A\5( M;SW%S44+)[TI5F1YI)AFQ4=4^^KB%)JJKLRQFPA;G$=V\EMQ@W_B;O O@1O\ M0\P-?AFXP;_%[-RB$.$_4?SISLB&;PR%*&_ZC0C-4X89:\^*#02I$W>LC!S' M>(*'/,E. $<15OZR^/GT]?9#5+9K1=*G(IG ?8 ?M/IJN*-!9+L=9J+OQH[ MUEM73%3%$.\U'7'M_E9<@OGA&X&9\X]M9&-'VG\C6M M\01 %*M^Q.4R2.0PS9I_O,76R"+9.XD2-N7#_$3D6(@"Q#/\N?*#::BMCM;O M$M+MMEL-VN@/!G1(AH.&WE(UVNK]NZ]6+KXY'E7:/[TC%]F;;VFK5 0G;P77 MPE6H*P=V8[O\S(HELWXT;3C><=I[4.&X)N?6*S*7ZTL6FG%7X%W,%7@5N@*+ M*")7]+GM95R?%J1JD-;,)9G:;T;R%02*[MAV( V>3&\,>J3IF$9T_(/ /4] MTL_Q[)_7225!L4M/#-QH1P/'A#'(\"F9!<>8!]_ #S8=.:@D8P%%D'(HH>(F MP]#G6F/PF4(F^ )2+VC "(@WS5:D?J2I<:LLP(7KKHM'CJ8MBO'5(P4P3D8 M>KX@KLV#]FN"S2.@AI-?6F1 )D2Y!.IA-ITIG[ <+['J((YI*56SD*IJHQ&( MU6YQQ6J%:Z]A80)X9-J\Y"?^)5-9UWW4-V *9T+Y!K&2[?PRAHL:"RR(H( M M,!38A@S6K5CDR?5Y4=50R%!12($$7TSH9 #:#XPYM4 \P$Z'0B=+T,BZW;4* MV8XV?J)1TNDH>ZIZS>*A=AE\^?@"P0:=TEJZX?'1K+ )_[5^)R&/[ MXLZ1]HKSP/X>:603TD#/-4#-]3SAE>)S&73(3T'AK@A?#YP2-U/O&GU%^.(# M(]-KX3@:4JS8K#Q2&ZB1/!+EK/+YCZO*V[ .N6*99&!:IK=0Q9<^4]U?=H3% M5Q,>)5+5<=Z9*K:[E-:204P)">"&\@* JE-JN'//6 QHZ*!07#B9Z=BQX.P M?#+SD7O: N1VBIFKO)2SDDF7>8(KO]SV Y9) W^I?ZVDTEE _R'%#F[\,C.13=.D]2T7DEJ122UHM&9>D)T]C(B.S[L M_[:7F5Q2^&Y0;K=+"B_%Z*'+S/9*9)\@LM=YJ_KI3?^3/[>V6,QA_*SMV'0] M499OR?-6B= 3>VMS3D' VEV02>^GCBBQ<<[3FLQ'.@]>Q\#UV%>!(&O,/R$# MD&B^M_Z3I$;!0HX,V+LH87*WG(><.@[W^_5>N[EK+']3JZO-=B9QSC!42]L< MZ+S3JE(UOUVBF'9F22^RC'&@B%].T=D=TMMSVCQ[/=MMMV[\3[:X.2H!+'%*DFJ2K7 MQ'[XEPF AT1*(B52 BGLOM=;IG@ B=ZK8(O M%&"2XI9]BE$A*R3 OCKJ6.0O 9@71=;?19'UAH,]9? 5F+F9"U9B;Z45*#/" MT$]IC;!XMKCYT J=\HHG$TUD+!I%<*FZ1PVC:*F M-7/\HW8BOG6KP&87:3\N9JO!UJN\2_3%+Y&^2$"/%0[9*?#4C@7(V@_6.5TO MURPP$.,?[U.GN>C$>\"0&38^HFWAFR, S\T'$"2-O]X.E)_,P0;P]CSQQ)3! MT!9D>?YP'8(PA"[=9G!^4Y!?&[021R.E6]"$3*TU(L"%>,?:70=KA-I&#.:Y M#Y8P$+(;;WR;6V'TVA@>'S>XM9_"I;-<%]^6M2UZRC\7Q.6P3I:_P1:@&[SU MPZ+HJQC4Z6H%=G[!)V+PNGWH41%JWC/S_HM$ 9_*1OPJ;&G54-XN2!-8^MGFK9^@MCF MP2_'FN0H6'P*'&W'X-4,V9Z=%'@GBOUCF5@.[5@2+ AL=L!,.1]*-8K90T3* M*#ZV0&'-9!AB'H+RQ[H+9IOFB9W*1"8"R$0 F0@@$P&J3@1092* 3 20B0 R M$6!'(@"^U9[]K7/8V:9IG;-G#^0:&7NLE0M8(-K@F*R!0;\:"\3L]X9F-0C% MFMK3]9/@6V760!NS!GZU_US;,VQD@.>L-ZS?I/*%!'#0F9*SYP\A3[JF*NP-SQGJCW<6'!6ZT9@3-RF/>6T%/F:SS3K_U4^U*6 M:_!CQ=[-6T'1%[NT-01VQB/!U+,8G\+&>\F&.WYN1*3:8A=<2]P$V+.JH M<@FZEY;HR$RUM\00I+*TGND[:5^1Z12]PM$@8>&^$]XD)!6WF;/@COO0A8^M MB#NC;6>90P#I3\<>VDMZ>:X$:W0Q^K!0K.G-X;P)WI7B$AD2;Z(\CW=)GH=L M/7'>3(C,[%*_;=%NXGC3[QE*>2M.(6/4TU2CC-UU077T"11 7II1[,*C+6?U MWE"91*V#YQV9FA>\*A];Q$ ?I2WUZ:LG=["5]8%:FSO)HT9]&(K4HRK==)>G= ] O$G3 MQYLWY?9ZPN]]Y!V_E4^T+Z'R->D'=!\U4%THYFH'P1H]_8E^=SSWX09. M'TM0[Q.67>.3*;$?X;:-_D2TWV%/-1):P15&KI_,T=;D:,<5VLK,GMOXP2"? MVWE_)F%GC%Q>[SE@ M+0U9'_-T!&1I86MPRBOP:;JE@LW@;I*<-L[=F.MN/SYLW$E/FR[;PFG#\1DC M$.T79O8W@L^T 11,;P4VQ )LE:"+/#?C MFM$VY4*E-1;4G"[OJZ".4HR-:M A43 G9?8@1;^"906?!UOV(PFQ?3RW91 MEVTO>5L/W1L6Q)E%8AYM!I[_C&CYF=_;T+Z'#/*>[M*H-=EQE^XAFR'T_./P%$;[: $Q Y@&;(WP M;SQ[;YPBY_"TYP?LV&@Q>RLY3$YAZMZ2^)&U%70I/5VZ1*G=,#:T0$SAYQF^ MD1Y+K1_);SR([9.'M6.AR;'V67OHR3J F0=!-YVF.W?6TW#-YK0U=WXHG_DT M9P-,RWB8W$= FV0N[1\--+;1CMI[+-EQ"HD-YI\&*>,%EQ!?1J4," 7;:&#/ M;(MVQ_76(2;%1(KV#["]0*2H$@VJH=PILK7+.$A8 XCWD0M( MN?=]U B\L[F;WOT^N$'HKY?2A=)^%TJUG*@5<]7Y!*PIY;TUQ<[#-C]2O?&6 MH'+'5CE.TD[>9='E& MU-'QE:Q"ULD>+FD\Z]\E3_P;18@;+5;\I>TDF/=KNMY=Y==?WR@O.F_^_K[S M,KXY&0#W@)K9<<'DM]^IZ9NO13\AR"ES[L"A&HQ$>':3PPYR2>.8!'W4F96G MSJ[#T[5I[C6H(SADK:EACLXYYCG9=/*AD]'!1%,,7U'7 :HR$.K$VZ;WAB9F MR*N@$';Y "ES<7\?\P;9S(^.![AP80=1) N(,_6PN3UZ4>LUZ>2Q_N1]_U=T M3W_# _7;R#W-C-*O]*A-?_G9P^]@UG7C1.R?; L+O7##%>]-8& L-MSEFW;D M[(\J2%8P_2C6P V!Q/DPB2F"7GJ^!9N]<1(<0O^P<3BZA/=EHTA;-;.-H_K6 M[K4N/2]$6E N6Z<[_>3Q.RI6CQH6MI"1T#0[Q.37V7F MPIAQI-DO_G*CX+MU'AY*![+"K:FQF"&OL:*F9!=C.$M[O>3$HKR -]--9>H% MD0=Q(R8&^U,LF/PS1\2BD)U,L[\543M3@*KND!R=7&ZXL!!MSA=3+.2CD;4M MLK9%UK;(VI:J:ULT6=LB:UMD;8NL;=EA@L@R%5FF(LM49)F* &4J/']?$-## MB#IO:58ENEUD-+K=T6A!'-4\6?M7.,\SSVUNWG;C7*7<0?V3V=/9F2AV&$^G M/G4*YCN.4SGM,>(AHY 34X@F7,T14P21$.,")_1TP>TRG[82&,$^3Z<=-C>= MMM?!G )6'T??0O,Q<3_D;TVY&;FK/4H(@ ]1J*LX(*SU]=%&\41QO+JE-6,H M7\">_JQ0(0B+$!_%- BOID]G\.K*=(8=3/'*9 <0XIE M7SAP,)@]TZ$W,DSS#\O=C-+014C%:-(U-ENH3YF*&V &5I6#2LO"OUWRX(4V M9;S(\T^3%KG&XO3/,A58&+22: MFRC"2U,H61@D/UC1#SQ]^2-#5KQ?PC)@4FZ(>I8G4('J M];Z3:&", [?%*REEXFH]B$J5 H+9N(MM6< X5%G6O\?$"H;ZQ;\;I+\<;$-& MQ;8,O#* MMS;H2%J+07Z)%^2$E*!9E CQ'1< M6XLUM9O&(,^KP51&SV6<0W.M-G-SNMR.0:P,!U.PT3C8*L=57G3NOW[IO(PR M50.: HWY/[P:%7Z-?V,661IH)%C(^M'JSKNJQL^[" _8U -OB?K1!DAN*F57 MV4K>?T3KJF=N>I:2TWR28$U^V $M?\@(G[4.%W!:^;=PQ"FHF+.EZ?=)\;I MTY'%^5*Y7F=QODSZDTE_,NE/)OW5GO2GE\YZDDE_,NE/)OU=2]+?K#B@M2D^ MH+70ULJHIX]5F54HLPK;FU7(RF@_8"^Q,V40UA@-.]X?4B^*=AZ1M\5M"_C;GRL-%82J%I&/%[.6,1O9'%D[8UB3=JST.?>Q@DA+F(+(!(5 MZ[V&%92$4G'*T0V=S7EA6SZ]A4[ 2HJYU=1\B=0SFRH*->"^H-HAN@G7#/ M(%DQ"/@9&'T:87D.:(=A+NHZ"*)\,PND]3FP*6I# M@ =BW@0$.RZ#*EVO5D[4RA.?=+P LU9YBN8THI^54&>5IE\0TR]U1]04-E P MZX7A+20IDWL:CN:U'/B&Z$N[YA0LO#6B@V)0UV)8O)[[K[5+NX)Y&O0W1@EFI$_C<+D<^Y"U'<#D7WI,V&J-\\*&=T=H8K@H M:V:'L[CR#\;&+ J,#) P+^OLLUYANP4K"&E:J&\3"F0+SRR!"QF:Z7_^9:2I MP]>!\J_UC+>,9Z>/%?'@$ZRK.,X9&R?#[HG.J.C6.!G:PB['M%LW/0/9_G2] M1!P?1&><4BZ?D4<0W!7/WL=GX['VE)]YX^AD^!9%15D0WK4(A(+%M[L*/W=% M)$LJ M)P49B&SN[-\ "2.C-0UT)L4AM1^>0DF+UA;_P)MK'S4/6&>%9-N#@\: MF"$GT=;E<:MXGGP+F@,N/RT(YLS,@ (TRQ?49^I.FE_54W[)]INGKT9M8KN( M!(E:B?<4E")AZ!B: MX8K.&Z!QVGQ6WP SAG[ O\7]CN_0@8)K\]]1] M$> \JM:Y[<.>P.YDI8HS@I!3F%YJ WG0A\0@M1S[.U;X4%>4ZX5LPZ,^K(W9 M6EOSQ><=ZB?"!RE\U>9L:1LW=E_\Z1E[>\FOSSQ8&?R1_)@2GFB5(6V(/&!M M$@J7%[\44YK5 &W<\["#+8[C"0Z*EZ;30;9 8+4L;6=D3@F&H*QN"B,Y(&QC M1@Q?6$M$%W6XR9Q[WPN*5_S=]9Y8$VZ[F_,!,V_M[YH2GG1L6DN [V!$9_-$,G$;,K%S68XB(CQ&5 36 MW$D3:G]Z 2VI@V]BU1PVE&":.9E!5P$&6R@L9^R1?=+%U'3X!TU7CPA+&U4L M"(/P.X/F$M>0*YR5O&'B(DT^ ?T?;?($BF&:,!20(@J,=%/(BW%-2KJ]VI(? MQ6GUC MOHO'K%>A%DNY 1X_=#[RB,J([]D^88L4:T\#K552+R"_CFJ!BPI?1 M.ISPR>./,X.2O3&X53XO+']I3!Q'2[YBSB$]6D5#P-]_<3PXRRN_ MD1E]Y#/K8L+8]"W(GV]/Z%/10Z"0'2>5JIU1JOQ4B/LL\EWZ.$A<6HH-6J%U MWCPA63TZ.0<$=F@$5,TR3\2@,^Z8=#4M45,R[RB^_?7[;53ZNIPZ&6O&VSS[<1GUQ//$N=7=V M\!1T>Q7:[WU*WO_\BSHT7BN_>@]8DS$->O0#A^Y*JZXL-9$,S>,P]#1B=/C! M>:;J'_9^;TJ5]D_C_F;)L#%*=T6*#>H8OR&''LB+12B[69N8:F>]:81'">JI MG3_(-\>#I(='?#A*1KQYQ.1NTB#S#K"WY[0#-3I[,=V,?XC3*"+,QK$'P_38 M:L'U>=BR#29BK@:U'T.!>^6!#>^N M-K]%MDES&)]ID,K8 '6%[ENL\/%HU#+2TVABI>RFS[[M^3?HX_5FN:=6#@BQ MW7(W3_I8A7+KEB>I2O,GT@F=M\ MC:R5J(Y(ZA, C9Q@H-^PF6K:/^ O,#L)C) $TH8:??",JB+C3B.;WU+XF!SE 28) M9D!THQ;=]Y+'2?SO)-SZ#AJ*X;:U L>".,& ;XJRI$J65,F2*EE2=9&2*D.6 M5,F2*EE2)4NJ=I@@9ZN..M+,N$3ETT@KG2P AM]0VY\L4*+R:3P:5U/Y!*\: MYS\B*Y_$J7S*\C_/0!6E*NJ0[JP%7?WLZ2U"'IVQV=<##?'S^"MOB3?JQR=9 M[L*)#KMDEK1(5I8D7'BS+FR%V[<_K.T9P>\IJ_7$L:$7G(^R//[)N0=Z;3HT]]=$X"M&&.LUG M]HR&.WD& '9L>-Z==;7?2=V"G.+]_+4]08TG!>T2_!]AZL'6=![E6*XV,D#88]@3?@/_VHB4Y;8B;$9<7WHFI6=2>B:E M9_),GDE3>B:E9U)Z)J5G\F2P)]TX/]A34]R91Q8_F?#4<%"-$U+KC8;5N$;A M! @L(/V9^[3&RR'3M.G/CHN3>_W-]_3H$D_$:L8*/=286^ MOO,W9#P?"))V<$VTZM:D*3X/]$]UXDH"F-P&,L<75K';B4L,>+>[-/02+3E( M*M$1:,FRW2"56K;DQ-G,L0?YFZY97IM-&_0!D]$,-5J5B_1MG@?I@QM#EJ## MD<(&T"I 3"*.<9CB-*F$1"ET$]9&RM]-%NI@PM)KELGJ1MR80W#JRZ')33@< M7BS$VL*E<@*["G$?+)9WGKR$EDQ'E>T\01"3/+N;F;"8UH7>PT>6AD[<@,UB MPNO#GS!QT+$)II5R1Q!(S5OLK29IQ(\+ZY@,TM*A -.\MZJ2?,+JAK 8 M )TZ0*PD5[*;R7WDN?$,4^>9SL5S'SQ1!*Q*,]B$ MMUB2T,?LWI!F)MLTI]:B%5JVR[W.D;^1%>HPCRM&356!H@@M3*TQI\# M$:"W&.');K!WV T%*J--;.C]%*F"UCQR;DS3A88+K##5961%0AOGM)4EO)<4 MO)4?+CJOATV)>(PA *N$:>2,BZA7D"9>XQ.H%2:$CY,:7KB(@0U2:F%7'QB2 M Z^*O[A&,9H\\Z)^%A*Q,;/YVX&A\O(1]O0Z1O6(O\\*Z6@13CT?+>/CIV!N<[$HI;+?DC:FV< &AB>GP E97 MFL"83$&&6$YOI!W*18;JC($."N[74V?-V@W2^H0V[+DD\#XL M&]7JM)"'<*^X \M+:V>I%HD+-F)I2"G>")TGVL-9;CLKF4!]\N3& (BQCN,Y M_^F8&7?(Q[M;%,=@V"-!NKR4,M]MB57@AN4-6NVW>C[,$[MD([)8>'NCCNJ. MQ.>O%!)&&YS#0Y<+&[=!*-7LJ3$/YX/:_?KA_:D3#-:#N8-4OB/[GDXB5 M9['QP *D# .![B^TKD%QK !7G$$BW'AK+%'#&75>4DYUX?[G)#;F1Y/#YBO3 M!6[3J\U:--@%U_@9$ R?]V_!8!$6IS&;'S/BYTYR)J#;+*';:O0Y6K8?*"]8 M#!>AA2;4S$&3B2E8L/&<-59BTVUG"MSK80AKLJ9AJ@E96(\V+5=:PFA9D K' M0&;1EIV"(,6/O^Q2HCDX343-6*#F[I\7[.PM7#\WID]#2/X!!*I M4'S!+M9@RB2E2)AQ W2S:2B=!%NH"G0D:Y\"!V7W.>QU##> X@'RT57(WD-W M28^;*T J= :LDHT^4D:9!S>"VW$75AK=WIA=PAKIX#8KR$EIR%(;HE19-:DL MB@T9M65/]I^-ZJ@5MV"SH2Z*ZH[8YIWP*S-*4TR,/S.%1 \9V&8VH)7Y<&A#R9QQ MN+MHD/!GK(,WQ3W'SHV4-#-(?- '7I)9P$ LV*H$ED//HCG+P\\FD?IYHF:I M-PFFK),X1]WC)D:B3!(HYC0,V\&CW5:US\*FOEU47?\%:O2)(9-%]>=KJJ.6 MUO=4NW+6)31^,6L1NK7*%,$C,8]2W+E%AVC=4(FCQB;+57SK!(^^Y":TEW Z MAT4 )0:3CPV[GO*!-92FBQ0<)1EH[S$-AW\BEH?E,-3KZ=1?X]\! M)V!O$483Q;>+B;[Q=@H,RCA^I M;^O2MTE[6F#/V!.4]&N'J\$E+48.^A"P<<2VG4,>+*=+3_&@&2( $^8CX!HP MT7_(U"P]AGGL6#O5:((O*'SQF]3DXQ;P8&K2T#1+F/(PM0\1/#''*@R5^R#P MT'C$)JV_]C[WNO$O'YA'CFDA]B-\QGN@4#A=I/!LS+SJ)GG MH75+T1]1M,T$(&=CJJ$/MPNIKUX'W.8Z0P%DJ=J]$_)IBTXS)DS!S;%7- M$))KG01='!ODF'O'F92E; 3@54*=G;2Y-'I((^HE*,HT4Y4=^6QZ%QH'T E]5UEZC_ADB>U@,A:GN"(>CF[9'^'W\C!Y/ M'RY/J4ROPP ^.:7O1>40_:N;QP_,K4J%;Y/24J9%D.G[)=K8_TZ<,(PO4GU6 M;B)>OJQD1SLA%\"-V@LZLBZ-RSWX5OH2%;.$L[.@=WA$ 'HQPXM%*+AW*FEG MTZU=JX!$)AZ?@MH!/^_-,GQE4!1[6$P@Y]/U13/'$P()C M5 RMAT;:YOC04^EQV)[$-[?;TY;0M!LO '?=4R@:,MOA(Z.I_U$ X8 \I:DP MHU8?Q<.)=P^$CTGU/,)=AYMF2T3;C]#]L7L1/^'&GKD8_XF^ .U0#!F$SS'" MD.W:"&JT#> ?;##S5@?N!+J).CECLQ+'3^==9(6Z$6H[C&;G:NW9'V0^OLS' ME_GX,A^_ZGS\@BP>+ MA2 <+Z#A8M1?7H (W'/N8N@J+@DOYIQBANMN+U$]T91,:S">@!1Y4E+ND*C[ M"T]:9IUAV)<2V #NZ,HZ:L[@-FF;+YCB"5Q0ZN#[Y=,7[9"[/*D3Z1';Y+%T M+I;9=3$9H\3\RO?6PBMBH#[X.&U'2RB=&QL*'_1O+<,[]MATO(K M?%ZARL6,U8AS68:ZO[2N? Z%BTA6$LV6S,-. " M&P)_#!O!EG7OXZ)LKU4J,E1N8Q&C.@%3AQ&:BA4OT: +04CO".^;EB X-MU( MK0EHZ:W.<>NX_ G?XD>9*RP.@9>LD >.@W1/+)ZF@Z^/ZVC^M89='347D/)% M\'(S[Y'>25,4&8(22WJ&XT^ V7O6#]ZF*NG\.F?S8%^@N/I1K00MPD$U2@\. MF'03'2*V"G*J6U,$:QDIRWV.F.Q48$&GNQ\M]?4MCR42T6ZM_+*=04 MVGVP7:Q#@W&)1$VPL>ZC'3?(BZKNIEB$&3YA P=NZ$9M)]*1UU6Z'T7TP^0Y M][K0ZBI_9>/S?E(["3LHYGH$%US=[&!2K9E>J"\W*A9>O>#U"B^[R@OMY:[, MW_V)O_"H#H\62^^$FPWL9GTXGPKN-%]N1MT+9&G 4X.7Z9,=:Z&-Q^B7KPX< MHMFMPY>*DQP'7B3G@9>OTJ>!P@R;;ZA>E&%CSN!=BE@G#=RZR"59=]^P)!,7 M9.)N80YF+QV]C'U+^^S_H@:H#C@OF/I!><]AB6C<S>%J MV!L,J^FY.>X-!WI%;^JKU8QIT.L;FF!T,GO:N)JU,WN&N7]V!S8C(1A>WE7Y M77+9K_(NN>Q7>9=<]JN\JR9?<'6^J5$!U]2^U/P7MAOUXPVZM"$I'-)6K#O! M$DZ2/)3&RI5>%C@Y7G[-2B\5\Q5?8+%V]$B/$RS?;67%''-@YT-M\O05GN+\ MQ0K)59$B)L#/++#/,72_86#_J@CQ>2,]Y7QD$"/P5(Q&'TF841C5C0$.U 5& MD9,Z@'ZM&ZTWROJBL*L4VX34PE$2N9:-6R-4LIF&8H>,8[$.H2Z]RC&0>2GQIG GY;^(0HO\%]BT!YYV+RXV^6/UTH MNMJE.1<;EF#I /%L@O];5DDL[=G,(1>@!H8-,]BT3=)\DN';S? C3?*[Y/?KX7?-'$F&EZ8MF+::*4U; M:=I>C^93>WU3JCZI^E#U:5+U%74L"^%PE7?)]$]YEUQV>5<]R[X3+&WGMB=@ M7#'?]"K90UWTT&,AFZW4XC7 8&N*3[JLT)QDM%3?W0<6)).KY M[%^;0&]]KO2^(+FA:=S0OM54#;F:[5E-?7R]JRDU]?::]'OJ0/)#&7XX-JK0 M%(/[OF1;A589WSEKU0 A'O4;(L+YHE#W:?I4IXSDAL9P0_M64VN8DU:NYMZ# M<5.,;ZFISV)\:TTY6@O"#^?V=E?<[:78TGPXKBOM.7!$->F+D=S0YM74F[(GR]4LL)I&4Y )I:8^3\J* MC*)4Z347R]"4=\FR=WE7?'NTE5W\->T-3B$/XCM8;O*%O4\[9U2S.-:%P M-06":S!H6(+MY>ML-P?"6X%H&02JUA1+JDW)V*MT81H'&G8VRK17C9]*&'%9 M96!((:X<<5G*T=7)D:I+.9)R).7HY$SS?E.OYF]+^0^( X/28MX8A MINQ)QFLWXZGCH60\R7CGG[1NF&(R7B76AC0XI/@)+7YJ3Q?4XI#R)[/:K_,N MN>Q7>9=<]JN\J_+6C0?V/*%LKJMK>5)V\82*F>XP(0<5MR ZIP%99BR5=[J2 MBUW]8E_9>I0]O,GEJ%<\RH;.I"YL[F+W>_VROLO&+W?;$S&NNB6(Z+"$^4LV M/-*!>6EP0+DJ$I&U?)A64K6&K(LC0Y!2@]1K7FEJ,]?EW+"O36S=T*)6"*)C MR^6OG]9O)L*;7!6)JEF6JB\&X^*M 21%"U!T5-80E=KC+":3?J1'ZM+KTG:_ M4A&D?.E+NO@RO1@.+MI#1IX"15N1%E)4TR1%JZ6H:4BM(=:*H/.H<6LB,P"O M\BZY[%=YEUSVJ[RK\GQ?L3'K=Y2ZM 6SOM3BM*D&KMS$Q;44!_VJ,UHOE#_9 M)G"N'Q&Z^'8MWG&"@B^H'/7L J&0^S22 "_DUNBE)V[")M$_J1' MNMF4EA4EB5YKGED5S"\6(QB:Y ,QNI-(K=M^K=N76K<@3+=D^#8PO#H:2(:7 M#'\]##]0)<-+NQI68]R8EH#2KI9:M^%:5^L9C>GE?6:U6\#UV[0V"#N\Y+(- M@KQ+UL=M;:I4JDMW*@<S0ON741G(U MV[.:PRM>3:FJU51-_7J74^KJK/T]:(K]+0@_M S&H)9>B-4--XM\D#?@ M(Y$/8LYO!O)!B]T ZTI6D@0+X!DA]:R0_N6H-*R"4NKI6;T]/ M;8J#0!!^:+L'_^I:@S;SZ*\UI3!5D(._Y(:VS^S'Z*O\%3=X_^V ]C*]!!+-5I?2 M.N-T$J'\-$:[)D"OIJ!YJ=WAN"GGY+):[4P0BFUJ [,K_;&1'-*F]C/5@B^V MJ"U7M8J\#6VY=BKZ03,5O6!]/Z4D7;DDZ<.FN**E'(G#-5*.LCN2/I([DCR: MG'8T:5BFCCR:R(U ;@1;Z9?-J=B1^X"@/*0WI0;PNOUL,]8U4T!^DR:%%+G6 MBIS:TW0I!=G:4MXE2RVN]J[*>QP>4'Y"[;E?0RLDBK>R/1@\HJ % 6UN M&*$3AYZR\FW/5^9V ,-5GHGEMQ*M^+0>Y6)M:"\&+ROKVW-.DZ+,6"IO#R77 M69@F<$U<"DTNA2A+88B[%%+[5;?._5Y?J[A)G?#+W?;@^C5VWHC8SFC257<>!9D3=J.1'IU M[7M%1S3;H=&./(Q<&E=,KHK$5(.AY)BE9+4=6\+$FEWLC)F1KT&[>6@C8:Z31*E5B!4 7 MUZT6J:NY+7E<5QBO9_U:?A3\N,(_.W7T8^O9D3=<#H6#?6#[P%KS[ M[\1RPD57^>!.>YLI]WN7B_/F#>X_M^HH=\78)=N=$3>\O<&;FK2&FFA+^-[S ME7 !J[?P":&5'RYVA]4-Y\+S9 MD^TXJ1=N&H\89_/+;Y_? M*@%YP%?VE/<)/C&; -Y"@)N6]!D<&PYG0EPRM\/M=Z5G:P?*3^9@8U1PB4\, M_G;I$Y;KKN%;9#YG Z1O]^&=/>4;OM"=^A2L#NZQL9&?O=SZ_M1[<&$)9\J, M@;K@2P\M"QV;OCDV2EP?06 "$@UN[JW]<*'\N;9\^#32F5Y-X)N+"JQ>4& K M%<]R3'V 9OJIK PVS7JY9O)?F*M' SU>I"U6FWMPNZ_\1F:H/'8QL,X8N##; M*D\6L,9@M,D:EAA\J_/1;3(NY]G9;J9-D:,,P];,GFJ_$'\B-8/U,A*^J;=< M>6[,@U/8/( +Z6786W&7"92E]0Q4F3NP,@HU""G8TPPG0;FW>43X)S#<:N4\ M*X^6_TRYA7-;H,S(BK 9>FS][9 L_RM07"M<^VR7PIO_!5P6@*C0?/:G!?'Q M1JZ0U[Y/9KN)LI,$=W^=^)@;L>,Y/H,AUBAF38 G>Q8NN.&:?HK3OI\\8DW M)%^'NQ_)='LM-KZ]BQV_B!EL\>#H40'6W+%6 ;F-_G@=91?8+ET\^M#KS0_D MV#KT>^QG/KGQ&&PJ'>?'DTWXA_G4>S#U5]GKNM93=3/WIWY/S;V^YU6&-JKJ M5:H^W/LJGE:SQ3$FM5-W9-KD'M8(T8::L3]?]I+O.) ^5+(D)FY>7''U\V%E ME-.RN\;/Y[?$5D>%"Y-/H.LAW7)6BF^=%?=5DG,.K(GV_U=#$7M!&OR^KT5] MO;.^W*3?)R2O.;,:HIZG&;K.^V+FC MH-#KG9TSRAWUTOIQPRW:GCE4_^,URC[G=G8A.Z].T9?O)XGY'[O'NDNS5+,U M:@?YCRKTW]>6&]HA\^K@61,N.-&_W\+NY7@!'$,#Y7[BK4-T9WPGH?+%#KXW M[@S^C1Z:%Q9,;$*(J[B>@CY1^O[IPG+19\5=,']N4^7/%%66C 9P'/^./K.8 M0FD/D[?VF96-/AOV5[3]_[<2P)V$^641J#'R[VP_$"Y \STLV#^H'XG]&3E! M;#CC('^O+%2.]BJ>.L@%]E!T\9JCD!]DNJ8R MY]S.#/!G]0E37_GT8S(9^N2((C>FD@B;)\IHJYBHBHO+/2V MP4N9C'Y9@S6FZM:-:KX@+Q4P,@CSI'^%4?EV:,,C[WXPS:#<3T/\DCK6#>4% MWM1)_]1Y^5*QZ%#RY%3YV4+W+G7OV4%$*!K8.9$>3)O!?+GF"1=6N'L@W:*$ M>D)%F?*,8]]+[]&>$06LZL!SJ1UK!? .BVDR"Z,$Z-!G"^V3/]>VS]SS$Q)] M,=:,\/O*\\,@1?(-.@.-T+T.!@_P$AU6$."?P7H)_(\^]RYWG.-KR(SR&]?< M(9QVE!4PL3<+% R:V7,[<:U_??=&\6'9V8QQP.PO.H-@/5UL3 /&84UYT /> M0=W5WG*Y=F&_Y\$'.%#!:8,&'H#LU@I&"\N%;43A1\MQO"MD'NN4&NCN8((,",B@@@P(R*%!U4& L@P(R M*""# C(H<'I08'S^H$"ND='J,,&@U]<&E5@4)@Q@J%?R*@T!J/(?D1&'NB,. M9PQ<'']*G,^/TNP%_96_PM'>87X\@K-JGB,/L_4<.HM5,@ME1H*I;T^8(^7 MOED%Y^9FH5,"S= Q1-TSM]1[Q#+-_VJ),1!EX9/YWSI_.;Q)@2PBWDY(E.%? M7UEWE[!%V-[-TS([.): UC5X6&Z WCKXB\HJ=78E3IRO(5R@>9@=ZH"P7:#$ M"HD1.=KL0.ED1 $T F'9BQ.:W4E\XD[)T4$,4VM*$ .#9$SYZL=6+0^*13ZO-"F4"4'W*'._$A9. MF_.?T!^Z#KC'N)-^JI-J;H:/;-V+3BZ::!U'VYCCZSUU]=(1S7F^//>_18G: M;\F4+"?PUCA7&S_TE:Q"?KD?I='3 < [V2#FMD-59!SS0!\SB_#]8^T2[M+C M#]/<\H#PD4\I6=.N.GBS-:/9X+'CCCO,@[43LEC'BC"U$W13CCM8D9G-0@J. M_>?:AG\\LY%.K6"AS('204_Y!*^:K&%P&#>QG,#C0YB0V*U(A9..CGH?GP@5 M<=<+,>4_ *''@3WA-1R+']]%W8 M<)GS\H4_>E][RH)Z 5#(@",?;=]S:5@!<^&1_+!&<^L1M"PO/UL'0H4*BFD3 M&@ZP%'=-10HX"&MP@FXN$6QW!@/UGY6%Q2-%#YX+YR*8@CV'!6>5)I2,8)[ M51:1H84;%LB8-<6X$76&\Q(3?"VM@O&]1WB1-20 -Q,,4'X@*O.QCV03*@;F*5+CREG_W# MQB"6O9RL0>+I:CODD3CP??@(C9"!-&Z0) JY8;F$Y=J,A1Q[:8X5&$#<\+7F+]>F?O> M$N8U)^0&[D<&>+2G6.PR(U2^,:@)(DDCG?'+:)0.M,E- ,/ =]+;@UCIQVL< M+.PY#9" ;GEFWX)O,Y4&5$S1X)&X:Y@,ACJ4A1>L[-!RHA6"82"U[2E,;[5X M#F"=+)?'2H/T2@?_^9>1I@Y?PQM@N1M93D)^8$7@?LE!>L"[;* 8_9N%6%,2 M!.HZ*CI:AS3Z^-D+ AM5S#9+IT)>>4X:T7.P&K"H<.RR X>G2J P/ZP=7A#U M@'$Z*I2X"\-1;$7OXL)-UG3VF"@PA7NZ:5[@<@H"@5S"Y3-2B* -0&'@'N.N MT?2BPC_EI:VC!FE8_ 1/98*+, M_/4#6I5^:-%&'',L>"-<'SI-G9Y786^&SYA^NCU@ S&[CEJ^6PLMMW< ( ZJ;RF)#X M?P34:.='\NQ1M%*5M]W7,'_X'U B.M MFI1[==0;C/<[P(M?-PVC&J^\VM.'^3]=;E!"4HH.:O^K2N+72[C[>@#C]X1[ MF/(I$_ Y4LEN@PKEQWL^TV3( @&?YDSIFX<6X$?J1:#Q5=@VOH+- GL%_BO: M3F;,^98#Q%)%R6]92$ M[0I +UQLR+$X"#U*.!Q]MGQZ_/A,3T=@U=^[KH?'!5H:\>!;RX!+M/92LF>^ M7&,&^@^*]23T:K]%T]M7_@>=AK#D0H^5B3B<:RVL?WL6>JS_C]!(03-$_H^X M_(.+]P[I%FS8+VPWPF\*\O10Z0RC*?V?*C.(*II_?OKB/RQW;?G/-']QIV&U M#_:4SWJNL=Q&%XNOBV,NE MYRXRXYJ]\:B=O'NMRH@&-[77[5Q4J9#:K9#TKC'6!63=8QM(-L6J>T\F_FEF M7G! M<+Q/=7DTC)],]3A#3(!C0HM7157[/;5L3R2Y,L)NC7)I!-T:*UJ88T^.A]I> MY8UKV!N:0NRB>Z+GIQPNCVX%)K0;+Y]8NAK;&N=79&?MTW9.UV))X2KD>CQ" M8$7R/N:S7^6M*(5S0.Y (J*>AW9)7@.$2^X"^>S(;1.(/Y.0,\, M[1*\2LXR!7O2%NV96'.3TX/DUK:ZM9_WTULDZN/LO[#>=PA8,>@JJCFD]5NF M2N&'/1@+0:,,+QI3U &L?$6X5M\"A&S7!$W8%6+GQW+K;JAIAC,H0G$')]< M"BRB#",\$ER0GSW+GS%L>:R-1 P5"D;]B+C5BDN>E)_TGLETRH3WGJ1; M!J%3XE?N9MV+EVE3W>#.*,T"O- YCX6T"U MKU0&[L;_QT'Z_VK_P+*RC^LE+;]&2 :8X1=$"IO>@(7J6DN8%)G.;I&@2$_U MWO>_2'0)0L M=O]?7VU\\&[[WUT$^V#H^UX9&FR-[IN_=,."@]/*4.'8C^B=NY#X2]NU"A ! ME&\G+244U 11"WP?R]MQD^T@>3KPS$TTHEWWP=Y,+%"U^'EL3I#J9?&50ZL9 M_=$+ZR5JY2\Q?(3R]>:_=[1:D##O$N9=PKQ+F/<:/I]_I-;Z$N9=PKR?<]82 MYKVE,._F2,*\UP_S;O0&HVJ@:<_#:VX; MZGLE[60'Q;Q#%VI_F0?%G2PHQ+_YPK?7,AD'N+N'>ZWRKG MGK:7K7TA%"^_/B"!%B6O-1)$(7_2/ KZWK=86'#MVBP&N@YFG6Q0%'N3+RTG M^%OG9A"%2-?!S8-EK6XY!P6;@5%WO;R9>727QR=!8\-0@#I,:G3O3Z(Y5 M-0J)1H.IH==5+1EU$@]%-&7687LTZY'E(8)(J5W3S,JR@#+5=ARS M-U[ >AA%[9J ?+N['S09 ZCVHQ^2\M/\%\^;!??N["MO>?45Z%E61$9@06K= M\ZX,NL.^=JIRERPDF/8[8-I7QD)&'XU]-!!& M4OU)WCV'*5L=[ZK N\:@:XQ/=OY<&&BPM%$M#)12/K?\XGL!]N7$=*?KZ\)0 MN^U+R?O9]^9V6%9D-!"9[MC("DQ#E+V GIU"8Y'0_Y6:T"=(@(X2,!R93?"' M2$Z\O"X^8(F?P(D8A>Z: QF$EA(@M"X^8,^?( $8O.WV!R>[+\[HFXX&$9<6 M["LI/NKP*)]OWO/M2=7+WS _K0CF2[L/B+F#53_!;9&TSJ/PG>7SYW^^[8&W MMW80^O9DC9M+5PF( [<\=)4'X@)?.Q00R)HM;1=OHR@B,9_+Z-PQ'HJOC,*_ M,/K>N[/[#>J^8\0M:RY@8DI7&V7-A888S-)3+9AE>\#+4 \78TI&5QV>G) A MN4DPG7C 4U /-XT0"G:8R8$;&,8I.5.,V5993QEPHK'&2J24I1]L[#\!\S9W.9WL]^Y M,_6FJNQ\9I<]H40U8POR)&93#"KRQ$K>$$5?':P1*<0;F#;0SS*'5%C7R)1G M*'8HQ)1ZYZZRT)&L7-B_NO=+#P;R;X;9C :C1]'@K>F?:YNA*=]0 &:"TP_V MH+DU^7!5F_4XM1:W:0H#@2E]4^3EU*7$S9$%HW,WZC=5/TL?@&#Z>8=!>3J; MFIV[8;;.1K)+L[7:#AOS='89("I.8W-5)9\*IM9VF)VG\^D0^/3TL[-T7A9: M\0_+E67[#&(6+=$7#Y;MOGSE8,D!, BKWH!?,J;*U80D##H*BX)I3NSF$$: MP-#AKTR2']#X5Z#P)_/^!6.&@_,P_K")U,/QF63X.6K*5N>X\U8T4]VYS=CO[#SW#,DI3U%I9&[4LPQAP MLFDLR*/D5M'4VJ%"T2.YU 0N-070:Q+=)5,,N-W>2V*\5)5(&A/Y@SOUE@3E M)DB#MM1C+ M8<1*SP(%2>TJ65T@[7K ZB[&ZF/0KN.J@EP2AT4^+W%8:CEZT:SK%S85Y9>O M.$C%M26XE')*'#IG(44_>JZWJ2;C.M9M33GL=^ZR!Z[BO@@9315L^SQT.#G M'^DZY[G]@\QN_DU\+X=O5#3@1IJJO18DG"I9J#(=<^BT45;':.CQE$I&% ZI MWS5>FD-TL-9L=AYVXHBI8Z M8 UB899C/>- R6XNNL:[).'J(=S59.2\XWDXRH3,/9\HS#^LA-:/(P&,#]%) M7)U\AH-,%$9[[WO+-_"H[:Z!%#S.YKG!SW01V'W?< G>_0A]"TAINY;__"$D MRP".^OA1WZ-@BI&:S]'O".]I-#;SO!0;73+^7%_P65Q).<,9ZYR2@A%LXV1L M$DY)44&WJR>#0]?.L3(U23Y_ MM:E)GWWOT0Y0K8#<5W8"%5;#GNF<"9J3._]^)BZA+?8RVA&+DR6ZA$Q5...A MK@A;8J/=TSNS2_X03&T5.D(5X0\#^&,D,<4E7Y[QP%*$+TWDRY.[&UVZU[ M.7R(4;:JFH])3A.:TVJW@/=RVJAS-U"E+I4<+K0N/6!+[^5P;.586>+L.2J) MQ4UO$O4N23A)N(L0[K3(6A$?BGR^><^WO0KM5Q($MTK: Z)88>C;DW5H31RB MA)[B;D32%9N'TJ^I#5N5H ! ZR3!X3Y%ZV]>T9R%<;]SE\W;E%BL0MG$58+V M5L$S:N2H!H2$-[/N MNX8XJ(_5$")A7K92F/-7M^7"7'M0\Y PFQC7S%:82*%JAU#)';*.^.TAH1I@ M"+?I>8M2F$439KE#UA&J/B3,F/F3 [4HH%!565R6&JA6+FE"OER^_((O+^TR MFDWP?X\.]1++E3CV5YTQ/!6"M_\OI,_*^HN/;Z*+7RV +P7LHQ M_.7(DS6V9"%!M5\%9OS6; MI7T9%I+(IO+YZI!-A3W,Y&]N_Z3_(+,;"T9D/1#%72\GQ%>\^49T-E"\=1B$ MEDLGM?/HT\3PX[4_?Y7AUXHFVA!#E8EPR6**2#/<,\7PD>J%3W.ZJ0>?$FU MZ9O-/E/["*UF[&YZ>!5K*DH9;_E(>2*4_>2F'6#BS.^0LE[(ZJ3R0 MP'WR4HY0*G?[S.125B>5!])W3U[*,2SEX("";8_]>IPS_K2I-EJ3'+>_I\_N M:2[,84"U7Z$NJ=B\%6@Q+[C#EUE,=7]QK%S,2^_Q91930\G,@K[*Q11EER^S MF#KN\]E84=X^+YV8\OGJG)B\?H5)XIX2%M&-Q#=6L%!F]J,](^XL0'%U0.QF MF1J4LI&',O01*67KU+3)8Z8O@KZO*;OEP\?WVUK_#>6JKZ$W_?XVXKOH76\Y M^^5$QE2C<]?OF?WFIO*7PQ"N+"$P08)*NCV1/GKAT#@ MURLOL''%;GWB6*']2%X_V;-P$;%:ZBE.EW[RB#6!$:S#W8_LHM_=7R?^J[N= MXRNV$ SU(AX0V^N-UU#G"=BEEZ4.O-S^ 6+!;+$._QW[FDQN/ M>R-3Q_EQIQ#_,)]Z#Z;^*GM=UWJJ;N;^U.^IN=?WO,K01E6]2M6'>U^5[QLU M][E&<\&."-&&FE'8/7?V=QQP\PF"$W-84^38/35^/M\DU=3"2#,GT/60;CDK MQ;< =Y0]M.<<6!/M_V_?I^NEP>_ZQ69]N4F_M]$:4K2^9BCO/7^IJ/V;WTNS M_Z8:B@R3@I/Y9B_!)OA(GI0OWM)R3S,RE.,VXW^M@]">/^_9UM/_Q;>BZ6C/ M5&.@C8>6-1R:1I_TQY,)F5OS27]JJ!HQ1O\[,#K10PL_H=H#N9GXQ/I^8\U! MX&\MY\EZ#I!^Z?'"8-,&SB[;I+BU5]9:.;MM I/K]=D$RQ@GFM$;C+1*+ JS MWQNK^8^4?96F]M1^(>.D^)&:&.I<-[>.%VGK@/U>86R.AQ5KTGOO8W/_:VSN M%\E3*#C_8A96\=?D'+L*25%U^XEVD*Y4"[Z)3U=OTJ>KA,A8XP&'Y95/%G ? MG)845MR540Z5;DE:H<&_^,.UUC,;!ORRA#+G5]!<-L4Y:*EE=9F)X$+C2A20 MVN]IVJ#4JW9?-XUJ3G]R4*4&M?^<7/#0EZL&QT7.,$QTA(D5?%OXA"B_P7V+ M0'D'*FZF_&;YTX6BJ]T"VT;KZ/$1KA0A1TW.@?/ZB]FP9F3JL6+C6["+B(]W MP99ANPI\S,$:Y$R[I\*^E1S/K,"+CT>V2J9ZE!]*5%KEGW*!5OJI"J( 140E M2CT,5 4/B4JQ@FQT;*>W9FCTPOU.%JF)5HME8 M+!L!^\Z4RJAHLK3*UC)'2>N!>K+]TCK&UFLG9RE*J9%[G "3KK"[VEZIT?K8 M6TWN<5):Y1XG1/NT_=*J8O.T;!JP@%(C2S_E\]65?@KKGJ% Z+]\CBPNCT[C'S^@L^W':SNO>?#/UUENO9]XDZ?E="'ESDTV*%8 M,TQ18K%[RYTI'O+^43#T.501"LVV=F\451L;R0\I8%NV!F_X$GS#%6!?O'=G MWY+UN(^7XR,)/\V_63_R[ @$J6^JS9\O/)=HCM(*KJ[=:W,^KM8[=Z*T&Y'< MM4]GOCC)O1' V.&OR_&9D<=GF>B^9+%+*K!2+)8YDU^QPY8ME%& M(HR1[&;):[RK/2?L3&,:_R4QYL&R7'VT5D+49O/.1UCK"L3<(_34] M'G05%Y[RYDIH_3CJ@)!#(Z$T406;7>:$<(0F0F"I]X[W]'R"_P,K@Q7NL MY_B"E<9!8,^!+I%FRM<_@\Y=%NVGN/K)Y^9+N-Y;P5@7M='+L]/<\Y=6^+>. M_2.\G=L_R.SFW\3W\MALB*>_D:9JKROR:4N.$T:556&W5Z'*1IV[+!JP5&6- M564' FAUL],X;V>\C+(ZUN]<.O W[ U-@8W1;UX(+_(.!5U.MC_+DD\HP1/$ M.-USZ-7[IVGJ8[F[1J?+\2GJK>7#B]JR^[A/KU+_6ZE!.1 M]?J!&,P9Y&0(>KV?E1,!^54>3^7SE1]/FY(G]BL)@MO<8Z=BI20?@??=#=F' MNYCP[X;=;'+2:AW1N$T=# HW74B,M-9J'V[%-,<.)!5PC38 5XR MC2A,4T>PJWJF,?I@STFF$85IZHA,U< TJA!,(XLDSEPD<:B)57-C-SO0A7?& M;C)&]%:[E"ZBI_>.! 8YG;XBP=54"RY5 6U$T/.7C(3E*70-HUI9E=X0[V== MZJG&//-*QGH$U%6[=$NU4%@MT2V7C![FZ18=2VJS2752QJ6,2_NA@1'7/!DW M.G>#?A8#5MH/4K>(K%ND_2!8E#I/MYAP-AE7C"]]&1DOVZ0[U<&LQ3V[*VM7 M*9M_R^;?LOFW;/Y==?-O33;_ELV_SSEKV?R[KX+D,V_ MTXPHFW^7;/[]L^4 N8GR=4%(0NA&R/@03'W5J*:KLM8SQ_D_'=/JN:)!J3W- MW*_#9 O?XC,6K,]JW)-9*=AQM: &$Y$"^7;F/]8N4?0^)<")#52+I 167'8J4LRRHGP(X<*.IZ0I^I+0L6/).0&:&D!P-IAM6L.LFC9#=F29$UAL_1X-6P[ MIFRK&Z)TDFO[&>F#^PC+Y/GV*2J[J&G66I4=4?$9.+\LRYM]8/EA5QLV/7%: M@,-#*[BU=DU]$K>JP*UF=VR<#/XD+>M"Z_[9)RO+GBGDQPJ#M[++\XFJFD)Q M,T?\D3:*J:&S1QW(%L[2LCZ+OJZ 91%(OJL/LL! TJJN8_'98BD+XLQPI90 MUD-:UL>H:T;)3_.W=K#R@(R_ 'E6,8HE7,6WV>Z:S#ZM",L>R>-_ ZR6+/,W M1%]+^[I9^KHBGC6!9T_W@US8S-Z9 B(V$M#>+@X;*0&U]&\05WC.I/"/M7,P M#FMVASG-VQNBZX\2FTO@=]<'WBTN\Y]IYSB6^1&46^^.]).#GK4SH03EOHJ4 MNET>+0_,GO Y3LU:88F'#!@?O65&!/WL6&YX[\[>130]QK\[0D^!,6QZ#PSI MW&K(EEE (GN03A#/#FB(K,( M&5PS\Q]$1"\K'(-^YV[0-1N/SR7=8 W1[+4PL8I,W!^=W%+N/&ZQ!H)\-^PP M06-C%;CBA!73;5 PPT1\S,%S4J+N0EBKG<-M6),88&[V&;#>EGDXPHA/UK]\O:# ME?QJ6Q/;L4.;YYQ_75@^67@.$"GXS[^,-'7X6GE+YO;4WNWDE>%7\:S*"-'$ M2=97PIHT*>IR/YW"Z,- 65G/6&XI(4W$1E"H_YS#&>(SXX0:D1PB$U.NB-5PI:<"2&,VT(KSZ<! 9'L_-319=*L(![V0UP8H !P#QEY.FH?>M7(/4W(.1;,@DI M#*#BWG M5V(%Y%-"^V-E:40C4J/&ICO(B%2SMH"2W)QEV''G;CB6J6MGS1N83OTUF:7/ MPC)A[?@D D;-E./H2-T][&.%?5]O>@1&@)-(*]CW3-D$E;&O2MG7K*K;L;3B M]S-"VE--&_V!1@\]GC]001&^Z*9-_89Z0N"25XM+]2NR[QM8LGS.O>%8<\D 7^,$<"1./$*A.1A,L;&1KN*0((BW6AY*D6ZT^B(BI=7+ )LA# :-#85(=UK#=L1ZV!CQ;;KCOG2K MG8?(M9%$Y]OSW:8K_CSZA]FK/Y! MYL\WZ13[V8\,FP"7% ZP3W:X\-9P=K5\Y1';S1VWH%(RV8+.[,?HW?P5-WC_ M[8"&#"Y1,;&&]?7A_ED<8JS;#BII/#).W&\_ZEGH-,[(7T-O^IWJIR"9:K'- M5H\WVU&_]/B&9QV?VKDS^WDI05L7%!1F6*39I:S=6*]\"()UPG.UKSW[W,&@ M>XJDVCF6O/RP],X=XA<=7NI838/*D:?/LJBAZ:7*Z;*Z-U]C9,A\#7G*/.LI M\T2&-7YLOW+*UB>8M"F=-#C1_JIU<,/.W= T"]C;L%Q.*N1[;C[;86XW M@]G*KF>>,5U@+4>U2\&1 QMCT7E>8'H'DRF7XC)&)<4*SS""?,[ZS?*G"V:J MZ&I7T?J:<3&1PRC@/]8N4?0^'8DN3V+'G\12LI1CU1X6HG$?8>]'LM15GL3. MN?.S&EF M>':&D=Z-;1-XP[NEV*X2^L0*UOYS%\\(4R\(;R]V4JCVJ/>-3XSN]WSKY^\I MN>T;G;M1-I='F*,=G&FJ/;U71SFS]C\-]OU?)"&#YR,>8RO@3YN:E1A;T_6(?;5^.9M;J&)J)4TB QFIXMN M$$D[O=%V^EE8V62V_2FN')%M>SXH'O[/=F9LYW;D;#5?++$]G8V@(C6NJK:! M=@6T$4'WG1/[]=Z=5>"G&+2K]79U2JM^L-C3QGI$Z^YV*:!J6WNW1 &=$WJW M&@4TK*T7RN7Z2HCB>B&8 M0:&'O#$C;D!0P;F45C1'86Z[ECO%+P8A7%C"8(/>9I97T7S2C8G>_77BO[K; M^2(^SB&LZNN5%]C()K>T_XC]2%X_V;-P$7%\ZBG^W7[RB#6!J:S#W8\<.;YB M$Z7LD0R.LB.LK&.M G(;_?%Z9@TW-.L%>6XS7BSBB5O6T__%]^*]JH]4XV!-AY: MUG!H&GW2'T\F9&[-)_VIH6K$&/TO]E'D#RW\A&H/Y&;B$^O[C34'@;^UG"?K M.4#ZI<<+@TT;.+MLD\JLJJ/AN-2;=E\W MC?V:J\EC&O6,P4"P,8E()Q''-.YIJB[8F$3DIW&O/SRH57*VQ$@9(OCK'KS] M??Z3O9OON,C)F1FMPGC+>9TYJQLN8)T8=67-'#[$;9%;WRZ[[22$G+O"SX#P>SX*5R*Y@V MM/.\(L((\_JGE%7#Q0P$/*8>-!#$3AU@PYJ1J<=ZCM^NX4CMXUUP0+7="/@C MR.3X%0[E-$YML(V*@[R>XJ8I$WH_UH=S1'A?8-+?+[VUNSL/OC@]*B*K7)VL M8$B)D!)QKM?LV(:/LMH,LW"*8G.89H>-MO )47Z#^Q:!\@XV])E"8;.4;3CG M\A90Z:S/9IA!G;N?+<=RIP2AS=Z2*5E.B!^12]])K@)EBFVJ9BD)6C%RL3&K$PLBTPBI55*:\NDM51Y MY_C,Y9T9T53[G3M#.P4RJ TR>:W&VVY>S;?>@%N*\>L>\.$L"ZJYR,S7Q8%R M5Y"[PHEB=@RRK:9J%!!9JP#F7\J?E+^6R)]Z<;,,L9IRSDM2**50MDC>385#O!1TH0@3S4,8#\W M1X)T_Q2)K>3S4BQ/,-"-_7+YV??F=KA+*(<58!,+*))-9HG3$?P.:.K]'#%" M-9UM5]L0++Y:>?'2>5@7L0\_[6@&UE5=>YO:7GWG/?+5>.]TP0WL>;?E=@[FZ@H(9XM,/GV!KF M7=F?['"Q(,X,_><*B9X$4WE/T5:3#ZV5%"FHYH;BUW-C&JPRX>W:QT@&C,J; ML0PW^M^?K8#,<$> [8#6T&X&,.;V#S*[^3?QO3S=K^)IPL9]'4KEV,E64@;#QW> M8CR.LTHJ1DSE:6.8X=J?;[+LU!YFJ49TS,Z=V=ANMB)%8RY_0)9W7=-=;0=I M>&L_VC/BS@)4@@ZHLT+X3(UTQU^S.[^*LHX##;UB3LK;_P:=.U6KH$I1AI?D M\Z(\WV1]4$=XKX0Z& JM#JXM),)0<8_9]H4\W99V*?\([%O7=O[6"7TL 3Y4 M@4')E?#RB+%(Q51K\IF\ G_6\8W;^>ID=#841Z!'U"YU BE;XY% M%CB)*@W4(7FFG)#8IKI!L4U'4AU)=2354>NL94"4MM(;2.US1&F M1J9^3R@\8*./>,#:(%L5W6Q#)#?*_XJ2;G\G]G^M@]">/V.G!U]R'8IG]"'7B\M_\%V(U*8J\SPZ0?9SZ^?[%FXN!V/>Z:IXU;& M-86O'-.H9@X%@ M8Q*13B*.:=S35%VP,8G(3^->?[A?J\CFTH6,[$/-I3>[);>](G%/VVBMEK;1 MXL::*D$=T0ZDBQ;/'#/4LS2-OM YL-JC7H-.-[!SGTY* ]9*/"YD+-;"Q+@X;RZX^ M\JZSW-5V#Z)L7UQWOKRN7K)]L6G(+IVM8*X\2S:#)U)#JT'3E%TZI?^S%L58 M!!*C/L4XD(JQ%O6W0.>!6JD1Q,'3G9DR!C M%846GZZ*XI/5VI\N8'&4E>\]^-8R/N0)&Z:X;O?>(>/^L_6\)&X8O/?\+_'B M?IJGJJ_S)&_+F,@HD/5< 9B\0JU_[\E8O* 1O\6$E! M, =3 $EI>T@E[E2-J^C 1C>3J=E7<]8NMR>>T/-\H&//\U-J\Z7O23XOV/-7 MK@\.;/Q[U8$AB#IHNS^-YE4)ZS,K_7QIG]1)[;L')F.1BJG6OO/":59$X4+1 M78V\!X/JJK ;?; ^)J9]C(1$"$P1_8>UR,FU/]\^/5&NHOSX%ID[%<4H3U$T MVOG6/B:I.OZ;QQF%\VX&X\KR;B[LCZJF]82PAFX*-WL/>GC)TUO;NK=6DPAW M0.B*(VH/^Y4@:E?*X'4[E,[1=JEF[A5*[HO#\E1(E0;*0ZDGJ&* M2#TC->L&< G\]NHIH( MO"[W=BG\4OC/[+;*($V?2^0'U>%82JF74G_U4E]NRS\^'> L;NLA YBO(*?Q M0KJ!!I9?4:+ _YW9CW=_A?]$H\WTCP9^H??&TV$#@ZDXUBH@M]$?KR.,*MNE M'$ ?>KVT_ ?;C>9HKC+CHM]C/[_F#;?'/=/4<;/@T6_^X?UMNO5^3S7V]^DN M^BH1N[6+."81N[6+2"<1QS3N::HNV)A$Y*=QKS_I5W'5CV MO4$XPSR]?T(B8BDF:4 TMF0PUCB ?EXBUW!42:YA6:&5O?K$]K.4FW@#Y2HO M:?Z 4%W(@3)&!\KP]*XP4D2EB(HHHN5JJS-X:N<.<([ZG3M3O]X6[U=IGI5- MEC,R,%D[V+1,UMQ([=P-94MSN0-<]PYPE&@=ERIR4.92Y MX[$IJK*Z$"?+K*!&70JB%$2A!+&4')ZI,C$K?D9U2#)2 @61P/R819LE,'_& MI;;"6[D6)JR=6ZU_I&$"K%\%P:<=-6C(Y'PL:V'BRRC M4 XTB ^2CJ^YDG\H',W4+->(=G!2#XOQ?($4SM3[+_5N,7WYG:X2RA;VE2L MR2R1;_M5J*GW<\0(U?0XPQ,1-YQ;%&27KMI0A6%FJ7;MB@,,$7=@#JT?[0$= MEL^WZOGV(6:6\W%GD!%VG.RID+])RWABH(.U_FG^S?J1>\3_;/G$S?6NC3MW MV:VAT?"KEWZ^RJ:)9,];P\[@O!R[(H0=XE0AE$Y<[,<^^A[Y8KQWLF M6,[J3;\K,'!*.7!$=E^8M^IJPFEW\S MI* 7;-;,TL1V=6LN#.0]5BL#\I8."]%\6)E@50UMP,>8)'5R,V(!>>?2SU\1 M[^8K1K4&O9AE7[V"S 8!N?>*N"=/\Q7!0CI9\QF=NZ'4?.U[OLFR4WN8HQK1 M091 -2L[,AS2IG (90?%)ZNU/UT 5R@KWWOPK65\?A0V%M)D]V']YX;/UO.2 MN&'PWO._Q(O[:9XJ.L\3>6Q&V#]YNY2^[BM@UM+E=@?,O8U2('9 N)_^N;;] M7$B$\5 (%[9DD>IB>V7X@UHR$7N\\8+P-Q(NO%Q&&77N1F;+6.7:GV^RJ-01 M.:Q&4L9P5!9!4MH>KHF;R^,J.K#1S8ZRL9MP2K_F4WX5>V(&-WA3TF-.RHJS MWL<&E54T\)%>+_F\*,\W61_4O_'O50>J(.J@[0XUFJXEK-/LTL\WV7*OP&EW M8#_?V?,]*\Y:=<7>(IULKX@_BKK)"A<;"F5ITE@*-TONT1=]H)-615$=2'35<'97S^9^[=VA6]XQ ]XQ.20RX M5N&7UORI68/:@7XO);#Y]?ZX4KRE>)];O"_=\$E7UE\$OAE\)_5G>9EFGUB' ?Z+1IM[#NK@# MN]![X^FP@<%4'&L5D-OHC]<1))OM4@:@#[U>6OZ#[49S-%>9<='OL9]?/]FS M<'$['O=,4\<]BB<9\ ^S7]4>,-2K['6]WU.-_)_@E]SKNUYE]$;#<:DW[;YN M&L/6CFG4,P8#P<8D(IU$'-.XIZFZ8&,2D9_&O?YPOU8YD ZU-V: F8V'TK5V M;@0Y>\'KC/86)N/S(UQ1?H/;%H'RSIV1V6:6E+ZQ>;:]@"25*_:/-=!%[U,B M:$>EBAWB$W'C1Y5DTYL'',_%L\%4(S\;3/;7JX;-A!+!-O?7.[V*Z9!07>CL MQ=KJJ2?W])$B*D541!$MY2\P#T8,RZ3WJ ML'-G&E?+;U+Q2\5?5J*.2[49H9-;U492U*2H7;6HZ1>WL<8(T2SW/"F(;1/$ M4G)H7"@%1>M7T$)82J"40!$EL-Q6>#P*1U6RJ&*CCX'(6V';<4T_DE AEN_" M6'>WDKLT@N"EGV\R@F$%6_7^G1HX*.EMFB?DF/.IF;*=CWQ>BF658IE)J]QJ M)N)[&(H@]7\:?[-^I%[@/YL^<3- M/3!CODP%,1R18"XO_?RU<_/EF'D@!C.?V\5#"W3.S1.?HU:18%NX&_XYQ>8. MNL3_0T?E\J\^6Y3:* _Z&WVS7\VEL@*F3MV2*:2ODO>\MOY 96:[P M$[E'3\1)O'R3$\DK9S"=8*>]/ORLJ!5\5=IF-G M!$BH,A9SJ+YI;L8*\- .F*XM9!U+OW\%;'N#KU8I.U6 M6;V895\USXQH/OM>$?OD:;[C>*>DYM,Z=\.J:HM%XIUK?_[*9><_"M97R,:T_:7VGS^$=@W[JV\[=.Z&--U5:ZA/6\ M)&X8O/?\+S'U/LU3\!,)0QN,DYI.P"OV8AUGA6Y4YC';\W[ZY]KV<_%(= S? M5@!X*SV=XG@ZRS (W24C_GCC!>%O)%QXL[+%G/J@2'@+IN:,N+, %]F!?7(FTQNOYOQ9#BWX %)5S$EY HTP!R,! M94[;* MD6NC#W:[()5*@CH\=[NS]OH\=ZQ!A-\6T5]MI;OSTL^W3T^]0,GC4MO:-E>2<*4?0.0J#KMO MU &[+VJ_M6I&>00\5UOZK56+W=7X?FNG'[@."?)EH/X-#O5_,L*$5 M2+4BU M<(3IK%\<[\\8@&%@G'(@NU;AE];MJ9E<^H'RU3)="XQAYVXHV5CN87(/._<> M5D:*C^J48(PZ=T;7K+ IB11O*=Y2O(N)=U%HK?I,5.S.($U4*?Q2^,_MMBI2 MKEZ'R)O]ZFJ I=1+J;]ZJ2^WY6<*:&K>\LL=!TP$".AJ.6[KIE@$-+#\BA(E M@O:#_T2C75K^@^U&@])A??D5'(F>UX"^4H92^X20 D]Y)\9 M<0.".L^EA+)"^,?<=BUWBE\,0KA 2S=[FY"&J7GSUP]A&5ZOO,#&);WUB6.% M]B-Y_63/PD6TAZ6>XF3J)X]8$QC!.MS]R"[ZW?UUXN/J[!A?=EWR7D17-1D< M92%8$,=:!>0V^N/US Y6CO5\:[N4LO2AUYL?,%<9#J+?8S_SR8W'O9&IX_QX MG@+_,)]Z#Z;^*GM=UWJJ;N;^U.^IN=?WO,K01E6]2M6'>U_%,S*V.,:D:7<[ M-MQ<(29$&VI&X=2QL[_C0.:)(#"GAS4%%;U-LZW&SP]S/Z\9A4%43Z#K(=UR M5HJ_L7R8![SL[\1RPH6RA_:< VNB_?_M^W2]-/A=O]BL+S?I]S9:2YB,92CO MP:A2U/[-[Z79?U,-179*P8@\+>6\V0]!TB_]'AAL&D#9Y=M4LS(.,9:.;MM I/K]=D$RQ@G MFM$;C+1*+ JSWQNK^8^4?96F]M1^(>.D^-&?&.I<-[<.(6GK@/U>85XH3XRM M2>^]C\W]K[&Y7Z0"J>#\BUE8Q5^3S\SH%V;!F9.KY%!3N%G8FXN-=(+ZVJ\#''$3ZSCC5"I]N^>"; ML_YH-U]I>*M"(J/^Q!A]]DD MN#T%1Z42YJH+%*'D)33U/KW W4<29V5;W/J!C_-K9$OZEB=6J\6E2QNFRO7%,7L%?N5IP*S\Z[ M U6-!$(ZYOFK, ON9^B$9MZ9T%-\.&:Y4]LAM#]/9"_@+_CO*1J5*]]#V*29 M,GD^8%6VIQ=@1:<%*I_#WM 46,&_)2M@ IL>M17+G2G6$E-D_DTOM+(74^UV M5IJD\+=#:,:1.[M/439OJS Z=Z:6+29HB 6V1P1D:Q,!S99CN=0$+E4'[>K( MT 1%_6&YLFR?[=RHIU\\6+;[\I4#=J<"G(!1"2^ 3WESQ0H"$@:TY]Y1&EQT M<* :-/B.3-)?@,9HV7]ROX(-W%2U%8%@9*=G->0ZYLA5N)^8.4*5UM3-6)ZQ1-^,CV7+,1B)V>"+D(>J M!FX3S3WU?4;O:X!LB)W2)]8,^&VR)WVQR;;Q.0*@C)CO/?^MMYZ$\[5S/YT" MC<(\\W> #:ME1%0>W,X51BS%G&KG;GCRCG%A1.(&*F0X+;L/1+'==#",GJRI M5\ZQK8GMT, 8];^A.X[,YV0:\L0L"UN1L8I0]L3,?B1!:(=K_\0,K;8&5)D6 MT'J:R&SQP9TBGA1EC-"W9MA&=TKL1TP.OZ;=NE1!_X'M.J+I6\+^[P?W2T+3 M/)6($/X#">(O#(O4W]*I-(OH&+T2H*]NE3MFDW2C[3X2-_1\^TBM*+I+X1): M\4-"T[*8)0,#VYKJPU.Z6DBG5..5YBD<9"(']=4*$:/$C5<_ 0.=@8-B0#H%5& M,^U!AJK=7Y/_S]ZW]K:-9(G^%4*[LYL LEKO1WI@P.TD/9F;CC-Q>AK[:4&1 M)8L=BM3P84>#_?'WG%-59%&D)%*B9-+A MOC2%2QZM1Y/Q-N)7(:Q;XG*V"K M$U*]JJX-/8<^3:"_DQ"^U==6H-N?6%9#T#&&DR>GV).-]EQ[[;D(OLP 7X:C MY\>78W7E(O7A=7#G?\I;YG**4IT;:)4BI;-KW ![+%O_+"#_R^9WGYE 3A+Z M-Q'PBRHN$YSZW!Y/TX16+]6[,+6=42\_O@' BZ60LVOT9Z20'E+(;%K6;/2S M8FI3MEJALM5+"YSMSB880?!+Z6R2Q^%0X^K3"MSHCAKD. 4"TR/\<.Y;IJ5[ M:LX$Z624*^$QL[%LCTMWTS=4+O;5O>& _"7TX86^SWP0+'<+I"SQC5E8?O11 M?O1F%7#[-Z;OI4S?8@B5QID!X$P%?"4O1V+NS!DV&#.%O%3SRY+L%92TXUAK MU3WMET@D)@B_!P"_C>%[MX@)(@O_AZWK)IVX"0:5@Z*'TXD/HZ@J\Q?6=V9> M_9MY;A;JCA!AIOU>_^X<9]N4*^4W!U5L*(V4;7S<>[0\]8 MZF )(;OF<87]PV'JK+"<3\$U].4;"4IWH3_JEHW9AF!<^MAYB!FA1U$:D(,N MILHHD,X@@&D7--WGUUL:/??<>F[):--K7:E6]S+& M=B0\%?[2]8(K9-%:8*T8W/#:]:U@QYBO%Z'-/$-T[@L0@F<9 3-O\;@+.'" M;93?%UJA0A595ZW&:>IYB%5H+R]$=HXP*K3P&?@5K M[BK?(;WR&WQA<3+;=1ZXP>[.85_W?A#P1+-K M'A15 6?4.Z W:"HU&B?"Q9VP^U!WK[M@UGLI[H*Z!_H,!9 MF9[8+VPMW&IWBX\ UZ\ 5DX-::S'CM]-LEAED./\11%%D -[?5>AL_$S1*CD MVBO=>["<*_X5+!3\+#Y!-P#OG_(<[M- _X[E$8J&[!\:A_>CQ+1*2BX#*$L M ["?K&"Y=&V$ \_906@3L(W]<\EFPTP&VVC"C29<!:WS+HD>L6YY,GE\) M:U3T2]1">#(+.UO>_&*^G-ED:''(L#FQ:&W.84?5EUAN1P_?.]Z8)D* M\-XM#N#[M'4]:?+$JH,GE^.)^_"D8)ABAF&*4;<":-0DANWN)?[3*Y$E]CHS M+-ZDB5VJJ_A["?U]V39PKT!5Z?+[FO@[FLRS.E# \V>>9=)"(?$S[/9H-%#& M>/1:)*85:QU>U<2R)C%M/TV]H\';-(+[N\'G=GMZP#3^-W<*49]IT:#I$9"\ M:?]Q ^9V#C C__UT,:*5: CL'.V;R ^7)+ [4!ROJ^7T& MC5_IXE+M0OB569%>-9]496((C83]$24LFKPFBT?1-N*T?'%Z$F/[#.=PS?3, M.L,.$; J"^5L-8L3#EO7@WX%AM8ULO;BLO;YD6\$:EZ_ HK>2P\.W6:P;DT/ MM#E[L!P'W9;8TY9N] <*%A6AJAWR?<7[NEONSOB&R/:6B&4*&X4SS7>+E8D#,I-A* MP>\_GP\V5>!BI\OH<968V!3L*F!B=6_W5CH3.W\\\K2]JMK!#\F+93/]^AWUNH)FG] M;G^HO0=M2NMUK_Y1&/V3;$AJ)3D/\]5:@4[PB3UI7]R5[IRF9&C'">,_0S^P M%IL]8EW]+ZZ*.J5E]H;C_FRBZY/):-AEW=E\SA;Z8MXUAKT^&T[_%X=P:R.=$I*T^'_1? MF=1;V@EN# .( +N(?H:-&Q;SO\)RO]A4420L^5Z7.QHL)V3F32 ^PY@4L[@/5[#O#7ZGW( 67X$F[V!+KAYSY5L7N^'_S;CZL]$"#X[%/7 ^?WK%W[;4'YDV9\S1 MF&W1U!YF=K2OL"&XB-#F^YF'/IS5QPD2.F]53QOB\XH9!=]TC\GC4%MS/%(1 M4% ?'_P1/D,EQ@03>!EW'.'[PC4R7/4A.3&YC;M=,RQ(8?9FMQ>KJH@#Y,P\ MYAA6+NEM=S0@__!R_+A9FS=P]) !Z[-YP &@OE'J'MPR_9&^\+6KA=@ M44)D6J#+EJ#U+_X4QDD!_+_IGK'D9O^@U^;FR"M:K17]M/6:+A3%6]):;6L? M'*-#F[+@U@H@J18Z-J"01 R$.UP:(1/@&,[X>K)\5K^K0YI?<,MNPW0",M6& M_#UTF#;H=K3DW2X4(Q"A"'\,!+WXQ2A&7!#"4WF_CQN@?"MYW[@1<=W==OSB MU,>#NA-14>X;L[ZUQ]:ZQQD7\F'/I(ZZV$>(X/M[Y[ZCW4=#Z0A^,O]0PS)L MR_>11[UJW;^[!=JQ'!^DJ>"V<$?;9.HGZ92H21$%EL.#+5)U "YGV*X?(J4( MDL'J8"DR\+;7'BQ@K8'"M ?F, ^$ 7W/UD',CW]W+/P7*:0^;/;7FYO/L%MD M$R0LK)4"*(]V"FMS:4C06.G?F(;-ZU>X MC[;V9V@^")1&P>3[X6HM0+?4 TWG=5A28/%]'2=D:'U#R$0$&\5(.J"$!2$\ M*5^QTC< 4 @-ND,^@F;H@#R&' MIGQ44Q$I=&VA6RAU%%562.;CZ$PJ"!VD'D!-N&R)W/!C9OOL">0 B\1;1")\ MIWYH+!/;11:(N@?<(]"+3??K(9EZ=+EZ "33X4P.3HZV9D#'5K&<*SGBC'@$ M$IKP 29;UN.9Q@$?EN' >)+:VP_+\8*$EX""&F24&EO<)U M6O1G]./6ZRV)]5/"<"IH1_V&BLTM()H+C_L'C*A^18PHVK06[;IVW.G.T6Y MD '-]3G*M[4G0#X'=5X#D( (":]^O=2!W@T6DM, 64C@6?.0D!8O%G,-?(Z^ M=^L@7'WY#BLM+> >0'\@B3!I$/%,) X2P7R__V&2PX9+T/K!YM#ZQ)\6WP T0ZS'!C#?>[L8YP58W^\FS4_X4A MJH DPC;P"0^DXF,"W<\QP:1+,X=GV#$*B[>1;JM]"9',/@'Q_0\+M!O31=VU M=DSL#X8JK+1T=3P%,@8+=$Z#>U,\>5$6ORA%C??E]:!ZC[_??XG:+R[\#VCR M[V_N?P%-WG4DV>?7$(!/,M0"4>U%)0>^#M>F+KS;H!<]6F[HBS/1;]J:!3J7 M ^H#:<=N; G)7(!"_),%T7+O;$"0 HC5]84V2%"-0%(UP[Y0,O]Y#XR%#W" MI"W=S_#FB$O[SJ3K04/+177\%T,+3^M/OZC?9AA:VJ M!!X!KO#'**XI?QE3MQ])8&>IDS/$BQ_WQ>.QH2MM1H%PH!6LN)H=+#TW?%@F M;&*<:JLX/N5JJ&L#%?BH.(,^_Q!:TJP'?$==G Q+5-A1[PQ]J:#&R#Q2=%-D M5@C,:)D57#,NHZ_7MD7R-?#_RYH;:;%9T;7#">SR3"+S#*ADR8OBS^&S?)56HDI29IIPH=(O6U M-($*:ME6['R*U\%?ZY:INJ>V20O46E=:^6#Z@:JD(U&A=U<#/$B#$&FFF5N??CZ7B\1<>QV2N)%P^+[G5)O]H< U)M;D,D*)O_Q. K)> M64%#SGL)X=8FO]G5%X%P"M96\72'B)KB)\)WXX_Q/!@%GU@KG%;P/5 MA/DX=P #LK%:'3NN(WYKZ-Z0 X1 MXK<98('C"80A1-& TWH^HC'P.'02&"R""#H 1Y/;HV@)"++;C3#>/[ 8@) M.*R%UY2[IE=KFTD&^V=H6L+3^VBQ)Q[,V*EG@F$3VMS-#Z\*UTMFFW2'W!AM M2YD#O F=4#Z^$W$ +LD3D1U^F0^6+]PXZ7@__BC&&C78(Z0-B1K2'SE+D,IC MW$PA+>&.%T"(35N,:[\0VN!-2U]-A-9D#G1&(H1Z MS07S%$0 +(J<'4A.&%4D@X@' LV,R-\]);36,0[S+@H/_%V'R_0V6D_)+N(> M2#@R\'\,4C@B^HV>R@?=L?ZM'(S(IW^ M&^US,H>)2H36#$DVV&CWZ.$@MZ@,9N+WO]KN'![]C9GTD\^>BT/DNRU_+@HZ5;O%>G-SMBML5^VEKGT+#QGP[7.RS!QNAC&9A843[ M:6MZ)V$Q%*S6R0$G.6]4X=^C1 MYEB0$^\RHO/HS(>M1A5*2E40NC IOQT]F,(YN?4BL4H;IVD()V@^E./;SHW[ MIV]8DRFSK.)@>,T?U =#C"B^0!(,M7 MN7,69^8,?&&CEUU.O0((,F+%T M &X/&Q%EIIJ2A4RGEODH,E2/1&IZ&/:6V5Y9F^4;Q/(3=LCQ4(8%D8E<),A- M9K@\I/&&1!O'H+_JU=B(MO10%?N/P]74O=Z4FT1:;_#7G_0SM$O,B_T8-MI& M;Z$UR.A6&B$.)>RF]-;\=>:PK=&1E>:"H]ZZJ[D@GSC*GZ'OCC.2<A]JK]?'-0O[HWO KYETB0_^JY?LXFA;,8#2=8LY\>V,@C&G/+MLF^ MYX-),H/_2C%2)PLL.+. BF [I&ZA3E6[@J("N.S/&E)S/P4L7?0[P*'_F'@ ML;05QJ37J-!$;T"'U5K"FY=[QM8*U?9]OO-;K]]HOWLN_-G6?@51Z:%LLKYS M6X+^35_A/T5IX)2:EH?+DB41V!" 7 ..A+4LU M4<@3Q][X 5OQ&Z7R>WPC*!I4F>_"XCK:8HO0%F6)9&>BVFHYE*KA9V &STSQ M _T;PT03_!A4AY#>I_,D$9Y3$#! W@=&.7F8S>'"LPX_I1Z! 5BM#EA.-:U< MRU8)?1%Z/#'F.UPCUC1CX2 618H$A&^,E!8/^#6J^*C.Z#[5EP$(/4)[_$FX M]G%:^$J^'%4OGQ''<=GQ!2*( M\"VT23(?!,VD=E;)3+I#3B^\?L[4U'8,2M:43,W)_A:AD\&52(7F14Z@>TI[ MTMXHM9AST*TQR4O-F1+NMZ1]2L6T7IQ&6DJST2-Q% X[G4_F$[\*Q\(A1 MM60&Q%6Z(C"6*AXWZ)M?%%5[J5G-W$!N1("4G&R8@H-&*+"Y&T*I MS-_2P65)]6$5WO*)N6]8P-,!82<<5O"%HOK&*B]/B)_$S?DX_:!=I>2(M6#ZYB^ M3 [Q6EYV#%QT30&?085/J(R![CQ8^*?.L1T4'[Q!/R&L0\>=P_L?Q6_682 U MB) \OKPX"16LC^R1V=H ,,*)&RI0-PANM(#VBJ9]'%R(NV,H3XFK/[#5)^P" M 0CDK:A-@-!F'5$%7#H_ M.'M=3!HVHNQMX>WT17N9 !.W[:U=T8-834VF;;")1)J$'"JC2)KDE#^A1]V] ML61F:+.[Q1]5YGP[K(X5_2U*BLX[V,P4_CP7[WT'L+G?L?0:TT/T0$R=4L MX%897I\^&/_#[K#FTS%K1<5?/=UD=&] NOT=I)MKEFP]QX\7PO=AV?C>W^/E M?.F3PI\%W=^B>\%=H\D;Y\R\&IR"]R]_AO+XP SEXG@_:%WW3Y[0=QDV+\U$ MV"C;76*P_=2)DY7W*)DG&"QBB2M\_LVP,RJY_55.@>.B]_2 *TDZ%4X71_D M^M((]L"\X(RX7=HCID=$O-IHYCFJDG+__H4IHCGL=X<%@A7\]$KQ*;XNP8S_08WUC GVCD(=*9!/72FNG&D?:8Q-DVU*'#IMY$O-19R5:B&]QOB3WZ);RF+=L9@ M9Y>EA+P,>Z..0NPSC@(!C4_6L\3Y48THJR)14O%?%CE.0)350Y*=A1KKL^C+ M$.1W(H72\+!7IF)/_'"R_%7%^8;RQ4[FD9T9G(KY-^[R4MSE"^;Q^61*,^8X M+;D<6JJG"*XL+7UR'2,_.YQQJ_ M>7TTY>S(V*#;NAZ,:N,O?]G2[U?7-;'O\@\GVLJD&0G$+&3OM:ZGH_08L4I: M@H>(3*0,]Y-TMI,"SQ'2'7SN>,8<[(;Y]Z: MD 1/[/%&5.DZD9]5W?Z*/W9944M5.*]ZK_E]I/^+!3K\M\R\T@$\^@-3:\)H MV$9V$K;E[Z]ZQLS=W#E<7V1!VHU2F\Q+I'L):@ 0&&_,T,."Z!C_<51HJOB9 MCXRO4#5DSMOJGW1;@9)L>_"*AI>[HB'H82_EA@8GW9"9E1]Z\*I&E[NJ4>MZ MENNJ]@Q$.0/+W-,+/=47+(5*S8"69D!+,Z"E&=!2]H"623.@I1G0:#]P>UG-)\YVA_#QVFC:CE MWP"[E/F\';RNF6R!7@%JLB3;@8D>\GR( &]D=A<&F&KCEZ]*G+6A_]??GJ^= MN1RK@-!4.V6^Q<:O]Z(;[JO6U[?WK==M;.+J>L$"F(7+FX@Z&_3\_&(#Y_X" M)*1]=)T'[2L#)>JS9SUBGZ);T?.-^A=_O?W2QA95[#OOD"]:4.\,73CA:HZI M-UL^HXD:O>AO\P&L!0DVO[%@Z9H?'*0(1)>[)^S.O+36GWF/+5! \H4CKOHQ M8\#>T^F8JVS;105"U(,+-!IX;=Q?$J,H-& ;B'/#.XD%:EM2WK_510JP-Z!_ M"A) F#U1&84(O="\>]0WOFL/V,JZ<+/NZ?ZX3X*%@K#*Y)V_PIL_NKY_Y\C' M"\=UIJWK4;H>1S8AVC\!ZM(M20=Y6Y+R'G?8R4UM2IJ@:?1+7EG?KY:6:3+G M#:P^[+:N<:O\&Y?_V1C2V2$AH R34(A/ZA@%U13(\=*%VMB"BAH M^1R'HJ9\N IQ6=$]^\&).D_""01NKXBLX#E)5SN0G"B[&&[.]N-F-EG[V#:4 MNH;&$KTH.@Y[&&:9[.^86R%O?D[>_@=3.S12 T4^$#Y2$F1SN=K*S6=Q&A!P M([EINHSW8%TQQ@%L>!:-N4.1.H=_VD"TU"41V_F9"D=5NGYSF5#;>ZB _A+- MA%.&0O%!43N&6IT2\SG";7+NEM#Y[:0O3,ZEP4B:8XI>XS;U)T]9!%EP=FVS8T1+0)O'^;K6VW0UCVCW#0*ICL#.0SSC7_K9< MA4=WA,U$*&I>GX%!@Q?2\=6/6[[B*(>M6V;REGUYRP=[LR*OW8H>/U.$],B^ MK,-)9S89EN--!"YXP)N8_Q6#X:"\3?7+:!:;Z:";Y8FI<8RH3-;A5QH>\1LW MT-XE1_0F')I-%]U

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�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�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cah-20240331_htm.xml IDEA: XBRL DOCUMENT 0000721371 2023-07-01 2024-03-31 0000721371 2024-04-26 0000721371 2024-01-01 2024-03-31 0000721371 2023-01-01 2023-03-31 0000721371 2022-07-01 2023-03-31 0000721371 2024-03-31 0000721371 2023-06-30 0000721371 us-gaap:CommonStockMember 2023-12-31 0000721371 us-gaap:RetainedEarningsMember 2023-12-31 0000721371 us-gaap:TreasuryStockCommonMember 2023-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2023-12-31 0000721371 2023-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0000721371 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000721371 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000721371 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000721371 us-gaap:CommonStockMember 2024-03-31 0000721371 us-gaap:RetainedEarningsMember 2024-03-31 0000721371 us-gaap:TreasuryStockCommonMember 2024-03-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000721371 us-gaap:NoncontrollingInterestMember 2024-03-31 0000721371 us-gaap:CommonStockMember 2022-12-31 0000721371 us-gaap:RetainedEarningsMember 2022-12-31 0000721371 us-gaap:TreasuryStockCommonMember 2022-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2022-12-31 0000721371 2022-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000721371 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000721371 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000721371 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000721371 us-gaap:CommonStockMember 2023-03-31 0000721371 us-gaap:RetainedEarningsMember 2023-03-31 0000721371 us-gaap:TreasuryStockCommonMember 2023-03-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000721371 us-gaap:NoncontrollingInterestMember 2023-03-31 0000721371 2023-03-31 0000721371 us-gaap:CommonStockMember 2023-06-30 0000721371 us-gaap:RetainedEarningsMember 2023-06-30 0000721371 us-gaap:TreasuryStockCommonMember 2023-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2023-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2023-07-01 2024-03-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2024-03-31 0000721371 us-gaap:CommonStockMember 2023-07-01 2024-03-31 0000721371 us-gaap:TreasuryStockCommonMember 2023-07-01 2024-03-31 0000721371 us-gaap:RetainedEarningsMember 2023-07-01 2024-03-31 0000721371 us-gaap:CommonStockMember 2022-06-30 0000721371 us-gaap:RetainedEarningsMember 2022-06-30 0000721371 us-gaap:TreasuryStockCommonMember 2022-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2022-06-30 0000721371 2022-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2022-07-01 2023-03-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2023-03-31 0000721371 us-gaap:CommonStockMember 2022-07-01 2023-03-31 0000721371 us-gaap:TreasuryStockCommonMember 2022-07-01 2023-03-31 0000721371 us-gaap:RetainedEarningsMember 2022-07-01 2023-03-31 0000721371 cah:OptumRxMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember cah:PharmaceuticalAndSpecialtySolutionsMember 2022-07-01 2023-06-30 0000721371 cah:SpecialtyNetworksMember 2024-01-01 2024-03-31 0000721371 cah:SpecialtyNetworksMember us-gaap:CustomerRelationshipsMember 2024-03-18 0000721371 cah:SpecialtyNetworksMember cah:TrademarksAndPatentsMember 2024-03-18 0000721371 cah:SpecialtyNetworksMember us-gaap:DevelopedTechnologyRightsMember 2024-03-18 0000721371 cah:SpecialtyNetworksMember 2024-03-18 0000721371 cah:TransactionDataSystemInvestmentMember 2024-03-31 0000721371 cah:OutcomesDivestitureMember 2023-07-01 2024-03-31 0000721371 cah:TransactionDataSystemInvestmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2023-07-10 0000721371 us-gaap:EmployeeSeveranceMember 2023-06-30 0000721371 us-gaap:FacilityClosingMember 2023-06-30 0000721371 us-gaap:EmployeeSeveranceMember 2023-07-01 2024-03-31 0000721371 us-gaap:FacilityClosingMember 2023-07-01 2024-03-31 0000721371 us-gaap:EmployeeSeveranceMember 2024-03-31 0000721371 us-gaap:FacilityClosingMember 2024-03-31 0000721371 cah:PharmaceuticalAndSpecialtySolutionsMember 2023-06-30 0000721371 cah:GMPDMember 2023-06-30 0000721371 us-gaap:AllOtherSegmentsMember 2023-06-30 0000721371 cah:PharmaceuticalAndSpecialtySolutionsMember 2023-07-01 2024-03-31 0000721371 cah:GMPDMember 2023-07-01 2024-03-31 0000721371 us-gaap:AllOtherSegmentsMember 2023-07-01 2024-03-31 0000721371 cah:PharmaceuticalAndSpecialtySolutionsMember 2024-03-31 0000721371 cah:GMPDMember 2024-03-31 0000721371 us-gaap:AllOtherSegmentsMember 2024-03-31 0000721371 cah:OptiFreightLogisticsMember 2024-03-31 0000721371 cah:PharmaceuticalAndSpecialtySolutionsMember 2022-07-01 2023-06-30 0000721371 us-gaap:AllOtherSegmentsMember 2022-07-01 2023-06-30 0000721371 cah:GMPDMember 2024-01-01 0000721371 cah:OptiFreightLogisticsMember us-gaap:AllOtherSegmentsMember 2024-03-31 0000721371 cah:GMPDMember 2024-01-01 2024-03-31 0000721371 cah:GMPDMember 2024-03-31 0000721371 cah:GMPDMember 2023-07-01 2023-09-30 0000721371 cah:GMPDMember 2022-10-01 2022-12-31 0000721371 cah:GMPDMember 2022-07-01 2022-09-30 0000721371 cah:GMPDMember 2023-03-31 0000721371 cah:IPRDTrademarksandOtherMember 2024-03-31 0000721371 us-gaap:CustomerRelationshipsMember 2024-03-31 0000721371 cah:TrademarksAndPatentsMember 2024-03-31 0000721371 us-gaap:DevelopedTechnologyRightsMember 2024-03-31 0000721371 cah:IPRDTrademarksandOtherMember 2023-06-30 0000721371 us-gaap:CustomerRelationshipsMember 2023-06-30 0000721371 cah:TrademarksAndPatentsMember 2023-06-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2023-06-30 0000721371 cah:A3.079Notesdue2024Member 2024-03-31 0000721371 cah:A3.079Notesdue2024Member 2023-06-30 0000721371 cah:A3.5NotesDue2024Member 2024-03-31 0000721371 cah:A3.5NotesDue2024Member 2023-06-30 0000721371 cah:A3.75NotesDue2025Member 2024-03-31 0000721371 cah:A3.75NotesDue2025Member 2023-06-30 0000721371 cah:A3.41Notesdue2027Member 2024-03-31 0000721371 cah:A3.41Notesdue2027Member 2023-06-30 0000721371 cah:A5.125NotesDue2029Member 2024-03-31 0000721371 cah:A5.125NotesDue2029Member 2023-06-30 0000721371 cah:A5.45NotesDue2034Member 2024-03-31 0000721371 cah:A5.45NotesDue2034Member 2023-06-30 0000721371 cah:A4.6Notesdue2043Member 2024-03-31 0000721371 cah:A4.6Notesdue2043Member 2023-06-30 0000721371 cah:A4.5Notesdue2044Member 2024-03-31 0000721371 cah:A4.5Notesdue2044Member 2023-06-30 0000721371 cah:A4.9Notesdue2045Member 2024-03-31 0000721371 cah:A4.9Notesdue2045Member 2023-06-30 0000721371 cah:A4.368Notesdue2047Member 2024-03-31 0000721371 cah:A4.368Notesdue2047Member 2023-06-30 0000721371 cah:A7.0Debenturesduefiscal2027Member 2024-03-31 0000721371 cah:A7.0Debenturesduefiscal2027Member 2023-06-30 0000721371 cah:A5.125NotesDue2029Member 2023-07-01 2024-03-31 0000721371 cah:A5.45NotesDue2034Member 2023-07-01 2024-03-31 0000721371 cah:RemainingCashFromDebtProceedsMember 2024-03-31 0000721371 us-gaap:CommercialPaperMember 2024-03-31 0000721371 us-gaap:RevolvingCreditFacilityMember 2024-03-31 0000721371 cah:ShortTermCreditFacilitiesMember cah:CommittedReceivablesSalesFacilityProgramMember 2024-03-31 0000721371 cah:CommittedReceivablesSalesFacilityProgramMember 2023-07-01 2024-03-31 0000721371 cah:ShortTermCreditFacilitiesMember 2024-03-31 0000721371 cah:CVSHealthMember 2014-07-31 2014-07-31 0000721371 cah:NewYorkOpioidStewardshipActMember 2018-04-30 0000721371 cah:NewYorkOpioidStewardshipActMember 2022-07-01 2023-06-30 0000721371 cah:NewYorkOpioidStewardshipActMember 2023-06-30 0000721371 cah:TotalOpioidLitigationMember 2024-03-31 0000721371 cah:TotalOpioidLitigationMember 2024-01-01 2024-03-31 0000721371 cah:OpioidLawsuitsMember 2024-03-31 0000721371 cah:OpioidLawsuitsMember stpr:AL 2023-11-30 0000721371 cah:OpioidLawsuitsMember stpr:AL 2023-07-01 2024-03-31 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember 2021-07-01 2024-04-30 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember 2024-05-01 2038-12-31 0000721371 cah:OpioidLawsuitsMember stpr:WV 2022-07-31 0000721371 cah:OpioidLawsuitsMember cah:NativeAmericanTribesMember 2022-10-31 0000721371 cah:OpioidLawsuitsMember 2024-01-01 2024-03-31 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember cah:PrivatePartiesMember 2024-04-26 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember cah:ClassActionLawsuitsMember cah:PrivatePartiesMember 2024-04-26 0000721371 cah:OpioidLawsuitsMember cah:ClassActionLawsuitsMember cah:PrivatePartiesMember 2024-03-31 0000721371 cah:OpioidLawsuitsMember stpr:GA cah:PrivatePartiesMember 2023-01-01 2023-03-31 0000721371 cah:OpioidLawsuitsMember stpr:AL us-gaap:SubsequentEventMember cah:PrivatePartiesMember 2024-07-01 2024-07-01 0000721371 cah:OpioidLawsuitsMember 2022-07-01 2023-06-30 0000721371 cah:ProductLiabilityLawsuitsMember us-gaap:SubsequentEventMember 2024-04-26 0000721371 cah:ProductLiabilityLawsuitsMember cah:AlamedaCountyMember us-gaap:SubsequentEventMember 2024-04-26 2024-04-26 0000721371 cah:IVCApril2023AgreementMember cah:ProductLiabilityLawsuitsMember 2023-04-30 2023-04-30 0000721371 cah:ProductLiabilityLawsuitsMember cah:IVCApril2023AgreementMember 2023-04-30 0000721371 cah:ProductLiabilityLawsuitsMember cah:IVCApril2023AgreementMember 2023-05-01 2023-09-30 0000721371 us-gaap:SubsequentEventMember cah:OtherAgreementsMember cah:ProductLiabilityLawsuitsMember 2021-07-01 2024-04-26 0000721371 cah:ProductLiabilityLawsuitsMember 2022-07-01 2023-06-30 0000721371 srt:MinimumMember cah:ProductLiabilityLawsuitsMember 2024-03-31 0000721371 srt:ScenarioForecastMember cah:GMPDMember 2023-07-01 2024-06-30 0000721371 us-gaap:SubsequentEventMember cah:GMPDMember 2024-04-01 2024-06-30 0000721371 srt:MinimumMember 2024-03-31 0000721371 srt:MaximumMember 2024-03-31 0000721371 cah:CareFusionMember 2024-03-31 0000721371 cah:CareFusionMember 2023-06-30 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000721371 us-gaap:CashFlowHedgingMember 2024-01-01 2024-03-31 0000721371 us-gaap:CashFlowHedgingMember 2023-01-01 2023-03-31 0000721371 us-gaap:CashFlowHedgingMember 2023-07-01 2024-03-31 0000721371 us-gaap:CashFlowHedgingMember 2022-07-01 2023-03-31 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2024-01-01 2024-03-31 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2023-01-01 2023-03-31 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2023-07-01 2024-03-31 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2022-07-01 2023-03-31 0000721371 srt:ScenarioForecastMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SubsequentEventMember 2024-04-01 2025-03-31 0000721371 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember cah:September2025Member 2024-03-31 0000721371 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember cah:June2027Member 2024-03-31 0000721371 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember cah:January2023Member 2024-03-31 0000721371 cah:January2023Member 2023-07-01 2024-03-31 0000721371 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember cah:September2025Member 2023-03-31 0000721371 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember cah:June2027Member 2023-03-31 0000721371 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember cah:March2025Member 2023-03-31 0000721371 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember cah:March2026Member 2023-03-31 0000721371 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember cah:March2022Member 2023-03-31 0000721371 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember cah:September2018Member 2023-03-31 0000721371 cah:March2022Member 2023-01-01 2023-03-31 0000721371 cah:September2018Member 2023-01-01 2023-03-31 0000721371 us-gaap:ForeignExchangeContractMember 2024-01-01 2024-03-31 0000721371 us-gaap:ForeignExchangeContractMember 2023-07-01 2024-03-31 0000721371 us-gaap:ForeignExchangeContractMember 2022-07-01 2023-03-31 0000721371 us-gaap:ForeignExchangeContractMember 2023-01-01 2023-03-31 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-07-01 2023-03-31 0000721371 us-gaap:FairValueInputsLevel2Member 2024-03-31 0000721371 us-gaap:FairValueInputsLevel2Member 2023-06-30 0000721371 cah:A250MillionShareRepurchaseProgramMember 2023-10-01 2023-12-31 0000721371 cah:A250MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-10-01 2023-12-31 0000721371 cah:A250MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-11-02 2023-11-02 0000721371 cah:A250MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-12-13 2023-12-13 0000721371 cah:A500MillionShareRepurchaseProgramMember 2023-07-01 2023-09-30 0000721371 cah:A500MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0000721371 cah:A500MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-07-01 2023-12-31 0000721371 cah:A500MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-10-31 2023-10-31 0000721371 cah:A500MillionShareRepurchaseProgramMember 2023-04-01 2023-06-30 0000721371 cah:A500MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000721371 cah:A500MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-04-01 2023-09-30 0000721371 cah:A500MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-08-16 2023-08-16 0000721371 cah:A250MillionShareRepurchaseProgramMember 2023-01-01 2023-03-31 0000721371 cah:A250MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000721371 cah:A250MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-01-01 2023-02-28 0000721371 cah:A250MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-02-28 2023-02-28 0000721371 cah:A300MillionShareRepurchaseProgramMember 2022-10-01 2022-12-31 0000721371 cah:A300MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2022-10-01 2022-12-31 0000721371 cah:A300MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2022-10-01 2023-03-31 0000721371 cah:A300MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2023-01-13 2023-01-13 0000721371 cah:A500MillionShareRepurchaseProgramMember 2022-07-01 2022-09-30 0000721371 cah:A500MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2022-07-01 2022-09-30 0000721371 cah:A500MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2022-07-01 2022-12-23 0000721371 cah:A500MillionShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2022-12-23 2022-12-23 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-07-01 2024-03-31 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2023-07-01 2024-03-31 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-07-01 2024-03-31 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-07-01 2023-03-31 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2022-07-01 2023-03-31 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-07-01 2023-03-31 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalAndSpecialtySolutionsMember 2024-01-01 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalAndSpecialtySolutionsMember 2023-01-01 2023-03-31 0000721371 us-gaap:OperatingSegmentsMember cah:GMPDMember 2024-01-01 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember cah:GMPDMember 2023-01-01 2023-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember cah:NuclearPrecisionHealthSolutionsMember 2024-01-01 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember cah:NuclearPrecisionHealthSolutionsMember 2023-01-01 2023-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember cah:AtHomeSolutionsMember 2024-01-01 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember cah:AtHomeSolutionsMember 2023-01-01 2023-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember cah:OptiFreightLogisticsMember 2024-01-01 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember cah:OptiFreightLogisticsMember 2023-01-01 2023-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2024-01-01 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2023-01-01 2023-03-31 0000721371 us-gaap:OperatingSegmentsMember 2024-01-01 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember 2023-01-01 2023-03-31 0000721371 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-03-31 0000721371 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-03-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalAndSpecialtySolutionsMember 2023-07-01 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalAndSpecialtySolutionsMember 2022-07-01 2023-03-31 0000721371 us-gaap:OperatingSegmentsMember cah:GMPDMember 2023-07-01 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember cah:GMPDMember 2022-07-01 2023-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember cah:NuclearPrecisionHealthSolutionsMember 2023-07-01 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember cah:NuclearPrecisionHealthSolutionsMember 2022-07-01 2023-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember cah:AtHomeSolutionsMember 2023-07-01 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember cah:AtHomeSolutionsMember 2022-07-01 2023-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember cah:OptiFreightLogisticsMember 2023-07-01 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember cah:OptiFreightLogisticsMember 2022-07-01 2023-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2023-07-01 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2022-07-01 2023-03-31 0000721371 us-gaap:OperatingSegmentsMember 2023-07-01 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember 2022-07-01 2023-03-31 0000721371 us-gaap:CorporateNonSegmentMember 2023-07-01 2024-03-31 0000721371 us-gaap:CorporateNonSegmentMember 2022-07-01 2023-03-31 0000721371 country:US 2024-01-01 2024-03-31 0000721371 country:US 2023-01-01 2023-03-31 0000721371 us-gaap:NonUsMember 2024-01-01 2024-03-31 0000721371 us-gaap:NonUsMember 2023-01-01 2023-03-31 0000721371 country:US 2023-07-01 2024-03-31 0000721371 country:US 2022-07-01 2023-03-31 0000721371 us-gaap:NonUsMember 2023-07-01 2024-03-31 0000721371 us-gaap:NonUsMember 2022-07-01 2023-03-31 0000721371 cah:GMPDMember 2022-07-01 2023-03-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalAndSpecialtySolutionsMember 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalAndSpecialtySolutionsMember 2023-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:GMPDMember 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember cah:GMPDMember 2023-06-30 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2024-03-31 0000721371 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2023-06-30 0000721371 us-gaap:CorporateNonSegmentMember 2024-03-31 0000721371 us-gaap:CorporateNonSegmentMember 2023-06-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0000721371 us-gaap:PerformanceSharesMember 2024-01-01 2024-03-31 0000721371 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2024-03-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2023-03-31 0000721371 us-gaap:PerformanceSharesMember 2023-07-01 2024-03-31 0000721371 us-gaap:PerformanceSharesMember 2022-07-01 2023-03-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0000721371 srt:MinimumMember cah:Fiscal2023Member us-gaap:PerformanceSharesMember 2023-07-01 2024-03-31 0000721371 srt:MinimumMember cah:Fiscal2022Member us-gaap:PerformanceSharesMember 2023-07-01 2024-03-31 0000721371 srt:MaximumMember cah:Fiscal2023Member us-gaap:PerformanceSharesMember 2023-07-01 2024-03-31 0000721371 srt:MaximumMember cah:Fiscal2022Member us-gaap:PerformanceSharesMember 2023-07-01 2024-03-31 0000721371 srt:MinimumMember cah:Fiscal2024Member us-gaap:PerformanceSharesMember 2023-07-01 2024-03-31 0000721371 srt:MaximumMember cah:Fiscal2024Member us-gaap:PerformanceSharesMember 2023-07-01 2024-03-31 0000721371 us-gaap:PerformanceSharesMember 2023-06-30 0000721371 us-gaap:PerformanceSharesMember 2024-03-31 shares iso4217:USD iso4217:USD shares pure utr:Rate cah:states cah:numberOfUSTerritories cah:lawsuit cah:plaintiff iso4217:JPY iso4217:EUR cah:segment cah:Segments 0000721371 --06-30 2024 Q3 false http://fasb.org/us-gaap/2024#GainLossOnSalesOfAssetsAndAssetImpairmentCharges 10-Q true 2024-03-31 false 1-11373 Cardinal Health, Inc. OH 31-0958666 7000 Cardinal Place Dublin OH 43017 614 757-5000 Common shares (without par value) CAH NYSE Yes Yes Large Accelerated Filer false false false 243566952 false false false false 54911000000 50487000000 167119000000 151559000000 52964000000 48702000000 161558000000 146497000000 1947000000 1785000000 5561000000 5062000000 1282000000 1179000000 3762000000 3567000000 53000000 16000000 106000000 62000000 80000000 74000000 207000000 216000000 -84000000 -20000000 -622000000 -883000000 -81000000 76000000 -29000000 256000000 367000000 572000000 835000000 590000000 7000000 0 25000000 5000000 33000000 28000000 55000000 78000000 341000000 544000000 805000000 517000000 82000000 197000000 186000000 189000000 259000000 347000000 619000000 328000000 1000000 2000000 3000000 3000000 258000000 345000000 616000000 325000000 1.06 1.35 2.51 1.24 1.05 1.34 2.49 1.23 243000000 256000000 245000000 263000000 245000000 258000000 247000000 264000000 0.5006 0.4957 1.5018 1.4871 259000000 347000000 619000000 328000000 1000000 4000000 -4000000 -34000000 -6000000 0 -5000000 6000000 -5000000 4000000 -9000000 -28000000 254000000 351000000 610000000 300000000 1000000 2000000 3000000 3000000 253000000 349000000 607000000 297000000 3718000000 4043000000 11566000000 11344000000 17277000000 15940000000 3161000000 2362000000 12000000 144000000 35734000000 33833000000 2470000000 2462000000 6507000000 6081000000 1169000000 1041000000 45880000000 43417000000 32089000000 29813000000 1187000000 792000000 3030000000 3059000000 0 42000000 36306000000 33706000000 4667000000 3909000000 8169000000 8653000000 500000 500000 0 0 0 0 755000000 755000000 327000000 327000000 2887000000 2747000000 -289000000 -534000000 83000000 76000000 5703000000 4914000000 -160000000 -151000000 -3265000000 -2852000000 3000000 1000000 -3262000000 -2851000000 45880000000 43417000000 327000000 2855000000 -425000000 -83000000 -5724000000 -155000000 2000000 -3447000000 258000000 1000000 259000000 -5000000 -5000000 0 32000000 0 21000000 53000000 123000000 123000000 -1000000 1000000 327000000 2887000000 -289000000 83000000 5703000000 -160000000 3000000 -3262000000 327000000 2747000000 -560000000 68000000 4254000000 -146000000 1000000 -2212000000 345000000 2000000 347000000 4000000 4000000 0 21000000 0 3000000 24000000 50000000 4000000 303000000 253000000 128000000 128000000 -1000000 -1000000 0 327000000 2818000000 -342000000 72000000 4554000000 -142000000 2000000 -2218000000 327000000 2747000000 -534000000 -76000000 -4914000000 -151000000 1000000 -2851000000 616000000 3000000 619000000 -9000000 -9000000 0 40000000 1000000 70000000 110000000 100000000 9000000 859000000 759000000 372000000 372000000 1000000 -1000000 -1000000 0 327000000 2887000000 -289000000 83000000 5703000000 -160000000 3000000 -3262000000 327000000 2813000000 -280000000 54000000 3128000000 -114000000 3000000 -706000000 325000000 3000000 328000000 -28000000 -28000000 2000000 -2000000 0 5000000 2000000 77000000 82000000 20000000 1503000000 1503000000 388000000 388000000 -1000000 -2000000 -1000000 327000000 2818000000 -342000000 72000000 4554000000 -142000000 2000000 -2218000000 619000000 328000000 524000000 516000000 -622000000 -883000000 88000000 69000000 59000000 79000000 262000000 510000000 1371000000 1012000000 2276000000 2473000000 870000000 845000000 1685000000 1981000000 1192000000 10000000 9000000 0 318000000 264000000 10000000 2000000 3000000 6000000 1000000 1000000 28000000 29000000 550000000 0 -2015000000 -248000000 1139000000 0 23000000 571000000 23000000 11000000 377000000 399000000 750000000 1500000000 12000000 -2459000000 -7000000 -1000000 -325000000 -727000000 4043000000 4717000000 3718000000 3990000000 <div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2024 and 2023 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2024 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2024. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (our "2023 Form 10-K").</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. Sales to OptumRx generated 16% of our consolidated revenue in fiscal 2023.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">and Disclosure Rules Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2023 Form 10-K.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in our fiscal 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Disclosure</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in our fiscal 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Climate-Related Disclosures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the SEC issued final rules on climate-related disclosures that will require annual disclosure of material climate-related risks and material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the rules require disclosure in the notes to the financial statements of the effects of severe weather events and other natural conditions, subject to certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates. These rules also require disclosure of climate risk oversight practices of the Board of Directors and management, and the disclosure of governance, risk management and strategy related to material climate-related risks. In April 2024, the SEC voluntarily stayed the new rules pending the completion of judicial review. The disclosure requirements, if ultimately upheld as adopted, will begin phasing in for reports and registration statements including financial information with respect to annual periods beginning in our fiscal 2026. We are currently evaluating the impact of adoption of these final rules on our disclosures.</span></div></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted during the nine months ended March 31, 2024.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Updated Segment Reporting Structure</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions segment and Global Medical Products and Distribution ("GMPD") segment. The remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics, are not significant enough to require separate reportable disclosures and are included in Other. The Pharmaceutical and Specialty Solutions reportable segment consists of all businesses formerly within our Pharmaceutical segment, excluding Nuclear and Precision Health Solutions. The Global Medical Products and Distribution reportable segment consists of all businesses formerly within our Medical segment, excluding at-Home Solutions and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id146297aa77540e09bbefafb0c412e48_118" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 13</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for segment results under the new reporting structure.</span></div> <div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2024 and 2023 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2024 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2024. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (our "2023 Form 10-K").</span></div> <div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. Sales to OptumRx generated 16% of our consolidated revenue in fiscal 2023.</span></div> 0.16 <div style="display:inline-block;vertical-align:top;width:48.215%"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">and Disclosure Rules Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2023 Form 10-K.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in our fiscal 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Disclosure</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in our fiscal 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Climate-Related Disclosures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the SEC issued final rules on climate-related disclosures that will require annual disclosure of material climate-related risks and material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the rules require disclosure in the notes to the financial statements of the effects of severe weather events and other natural conditions, subject to certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates. These rules also require disclosure of climate risk oversight practices of the Board of Directors and management, and the disclosure of governance, risk management and strategy related to material climate-related risks. In April 2024, the SEC voluntarily stayed the new rules pending the completion of judicial review. The disclosure requirements, if ultimately upheld as adopted, will begin phasing in for reports and registration statements including financial information with respect to annual periods beginning in our fiscal 2026. We are currently evaluating the impact of adoption of these final rules on our disclosures.</span></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted during the nine months ended March 31, 2024.</span></div> <div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Updated Segment Reporting Structure</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions segment and Global Medical Products and Distribution ("GMPD") segment. The remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics, are not significant enough to require separate reportable disclosures and are included in Other. The Pharmaceutical and Specialty Solutions reportable segment consists of all businesses formerly within our Pharmaceutical segment, excluding Nuclear and Precision Health Solutions. The Global Medical Products and Distribution reportable segment consists of all businesses formerly within our Medical segment, excluding at-Home Solutions and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id146297aa77540e09bbefafb0c412e48_118" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 13</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for segment results under the new reporting structure.</span></div> <div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Acquisitions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2024, we completed the acquisition of Specialty Networks for a purchase price of $1.2 billion in cash, subject to certain adjustments. Specialty Networks creates clinical and economic value for providers and partners across multiple specialty group purchasing organizations ("GPOs"): UroGPO, Gastrologix and GastroGPO, and United Rheumatology. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specialty Networks’ PPS Analytics platform analyzes data from electronic medical records, practice management, imaging, and dispensing systems and transforms it into meaningful and actionable insights for providers and other stakeholders by using artificial intelligence and modern data analytics capabilities. The acquisition further expands our offering in key therapeutic areas, accelerates our upstream data and research opportunities with biopharma manufacturers, and creates a platform for our expansion across therapeutic areas.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma results of operations and the results of operations for Specialty Networks have not been separately disclosed because the effects were not significant compared to the condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs associated with the Specialty Networks acquisition were $15 million during the three and nine months ended March 31, 2024, and are included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings.</span></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the purchase price for the acquisition of Specialty Networks is not yet finalized and is subject to adjustment as we complete the valuation analysis of the acquisition. The purchase price is also subject to adjustment based on working capital requirements as set forth in the acquisition agreement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of identifiable intangible assets utilizes significant unobservable inputs and thus represents a Level 3 nonrecurring fair value measurement. The estimated fair value of the identifiable intangible assets was determined using an income-based approach, which includes market participant expectations of the cash flows that an asset could generate over its remaining useful life, discounted back to present value using an appropriate rate of return. The discount rate used to arrive at the present value of the identifiable intangible assets was 10 percent, and reflects the internal rate of return and uncertainty in the cash flow projections.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date for Specialty Networks:</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Specialty Networks</span></div></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identifiable intangible assets:</span></div></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade names (2)</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology (3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identifiable net assets/(liabilities):</span></div></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables, net</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes and other liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets/(liabilities) acquired</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total net assets acquired</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,215</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    The weighted-average useful life of customer relationships is 14 years.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)    The weighted-average useful life of trade names is 8 years.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)    The weighted-average useful life of developed technology is 9 years.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span><br/></span></div></div> 1200000000 15000000 2024-03-31 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date for Specialty Networks:</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Specialty Networks</span></div></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identifiable intangible assets:</span></div></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade names (2)</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology (3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identifiable net assets/(liabilities):</span></div></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables, net</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes and other liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets/(liabilities) acquired</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total net assets acquired</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,215</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    The weighted-average useful life of customer relationships is 14 years.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)    The weighted-average useful life of trade names is 8 years.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)    The weighted-average useful life of developed technology is 9 years.</span></div> 404000000 15000000 20000000 439000000 23000000 19000000 2000000 15000000 109000000 359000000 856000000 1215000000 P14Y P8Y P9Y <div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 5, 2023 we signed a definitive agreement to contribute the Outcomes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> business to Transaction Data Systems ("TDS"), a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. The transaction closed on July 10, 2023 and we recognized a pre-tax gain of $53 million during the nine months ended March 31, 2024, which was included in <span style="-sec-ix-hidden:f-440">impairments and (gain)/loss on disposal of assets</span>, net in our condensed consolidated statements of earnings. This gain includes our initial recognition of an equity method investment in the combined entity for $147 million.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the divestiture of the Outcomes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business does not meet the criteria to be classified as discontinued operations. The Outcomes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> business operated within our former Pharmaceutical segment.</span></div> 0.16 53000000 2024-03-31 147000000 <div style="display:inline-block;vertical-align:top;width:48.215%"><div id="id146297aa77540e09bbefafb0c412e48_88"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Restructuring and Employee Severance</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize restructuring and employee severance:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">55</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional, project management and other service fees to support divestitures, costs associated with vacant facilities, and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and employee severance costs during the three and nine months ended March 31, 2024 and 2023 include costs related to the implementation of certain enterprise-wide cost-savings measures, which include certain initiatives to rationalize our manufacturing operations. The increase in restructuring costs during the three and nine months ended March 31, 2024 was primarily due to these initiatives and certain projects resulting from the review of our strategy portfolio, capital-allocation framework and operations. During the three and nine months ended March 31, 2023, restructuring and employee severance costs also included costs related to the divestiture of the Cordis business. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">61</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></div> <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize restructuring and employee severance:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">55</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 36000000 3000000 17000000 13000000 53000000 16000000 51000000 32000000 55000000 30000000 106000000 62000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">61</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 44000000 2000000 46000000 38000000 13000000 51000000 21000000 6000000 27000000 61000000 9000000 70000000 <div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (2) (3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023 (4)</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,762 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">677 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,170 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,609</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">853</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,618</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,170</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,788</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Prior-period goodwill impairment charges related to the former Medical segment were allocated to the GMPD segment. At March 31, 2024 and June 30, 2023, the GMPD segment accumulated goodwill impairment loss was $5.4 billion and $4.7 billion, respectively.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Logistics.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Reflects $48 million allocated to OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Logistics.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Reflects a $110 million reclassification between Pharmaceutical and Specialty Solutions and Other, which does not impact our previously reported condensed consolidated financial statements or results of our impairment tests.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in the Pharmaceutical and Specialty Solutions segment goodwill is due to the Specialty Networks acquisition. Goodwill recognized in connection with this acquisition primarily represents the expected benefits from anticipated growth from new technology capabilities, synergies of integrating this business and the existing workforce of the acquired entity.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the segment change discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id146297aa77540e09bbefafb0c412e48_79" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Not</a><a href="#id146297aa77540e09bbefafb0c412e48_79" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">e</a><a href="#id146297aa77540e09bbefafb0c412e48_79" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> 1</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we allocated $90 million and $48 million of goodwill from the former Medical Unit to GMPD and OptiFreight® Logistics, respectively, based on the estimated relative fair values of the reporting units. We also assessed goodwill for impairment for these reporting units before and after the reallocation and determined there was no impairment for the Medical Unit and OptiFreight® Logistics during the three months ended March 31, 2024 as their fair values substantially exceeded their carrying values. However, the quantitative test resulted in an impairment of GMPD’s remaining goodwill balance of $90 million.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determination of the estimated fair value of the GMPD reporting unit is based on a combination of the income-based approach (using a discount rate of 11 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company method, and 10 percent to the guideline transaction method.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2023, we did not identify any indicators of impairment within our reporting units. During the three months ended September 30, 2023, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the former Medical Unit due to an increase in the risk-free interest rate used in the discount rate. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $581 million for the former Medical Unit, which was recognized during the three months ended September 30, 2023 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This impairment charge was driven by an increase of 1 percent in the discount rate primarily due to an increase in the risk-free interest rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2022 and September 30, 2022, we performed quantitative goodwill impairment testing for the former Medical Unit. This quantitative testing resulted in the carrying amount of the former Medical Unit exceeding the fair value, resulting in pre-tax goodwill impairment charges of $709 million and $154 million recorded during the three months ended December 31, 2022 and September 30, 2022, respectively. We also performed interim quantitative goodwill impairment testing at March 31, 2023 and concluded that there was no impairment as of March 31, 2023 as the estimated fair value of the former Medical Unit exceeded its carrying value by approximately 4 percent. The impairment charge recognized in the second quarter of fiscal 2023 was driven by certain reductions in our long-term financial plan assumptions, and the impairment charge recognized in the first quarter of fiscal 2023 was driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate.</span></div></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,564</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,387</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,177</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">561</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">401</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">160</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,043</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">672</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">371</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,168</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,460</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,708</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,179</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,460</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,719</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,741 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,280 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,461 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,752 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,280 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in definite-life intangibles is due to the Specialty Networks acquisition. Total amortization of intangible assets was $64 million and $69 million for the three months ended March 31, 2024 and 2023, respectively, and $191 million and $211 million for the nine months ended March 31, 2024 and 2023, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2024 through 2028 is as follows: $69 million, $256 million, $241 million, $213 million and $186 million.</span></div> <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (2) (3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023 (4)</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,762 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">677 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,170 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,609</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">853</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,618</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,170</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,788</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Prior-period goodwill impairment charges related to the former Medical segment were allocated to the GMPD segment. At March 31, 2024 and June 30, 2023, the GMPD segment accumulated goodwill impairment loss was $5.4 billion and $4.7 billion, respectively.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Logistics.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Reflects $48 million allocated to OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Logistics.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Reflects a $110 million reclassification between Pharmaceutical and Specialty Solutions and Other, which does not impact our previously reported condensed consolidated financial statements or results of our impairment tests.</span></div> 2762000000 677000000 1170000000 4609000000 856000000 -3000000 0 853000000 0 -3000000 0 -3000000 0 671000000 0 671000000 3618000000 0 1170000000 4788000000 5400000000 4700000000 48000000 110000000 -110000000 90000000 48000000 90000000 0.11 0.02 581000000 709000000 154000000 0.04 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,564</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,387</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,177</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">561</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">401</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">160</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,043</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">672</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">371</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,168</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,460</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,708</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,179</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,460</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,719</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,741 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,280 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,461 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,752 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,280 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 11000000 11000000 11000000 11000000 3564000000 2387000000 1177000000 P10Y 561000000 401000000 160000000 P7Y 1043000000 672000000 371000000 P7Y 5168000000 3460000000 1708000000 P9Y 5179000000 3460000000 1719000000 11000000 11000000 11000000 11000000 3174000000 2274000000 900000000 546000000 380000000 166000000 1021000000 626000000 395000000 4741000000 3280000000 1461000000 4752000000 3280000000 1472000000 64000000 69000000 191000000 211000000 69000000 256000000 241000000 213000000 186000000 <div style="display:inline-block;vertical-align:top;width:48.215%"><div id="id146297aa77540e09bbefafb0c412e48_97"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Long-Term Obligations and Other Short-Term Borrowings</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-term obligations and other short-term borrowings at:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions) (1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.079% Notes due 2024</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">753</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5% Notes due 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.75% Notes due 2025</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">508</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.41% Notes due 2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,192</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.125% Notes due 2029</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">644</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.45% Notes due 2034</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">494</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6% Notes due 2043</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">311</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5% Notes due 2044</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">330</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9% Notes due 2045</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">428</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.368% Notes due 2047</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">564</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0% Debentures due 2026</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">124</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,854</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,701 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion of long-term obligations and other short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,187</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term obligations, less current portion</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,667</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,909 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Maturities are presented on a calendar year basis. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of existing long-term obligations and other short-term borrowings for the remainder of fiscal 2024 through 2028 and thereafter are as follows: $762 million, $436 million, $535 million, $1.3 billion, $11 million and $2.8 billion.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $5.9 billion and $4.7 billion at March 31, 2024 and June 30, 2023, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $32.1 billion and $29.8 billion at March 31, 2024 and June 30, 2023, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, we issued additional debt with the aggregate principal amount of $1.15 billion to fund the repayment of all of the aggregate principal amount outstanding of our 3.5% Notes due 2024 and 3.079% Notes due 2024, at their respective maturities, and for general corporate purposes. The notes issued are $650 million aggregate principal amount of 5.125% Notes that mature on February 15, 2029 and $500 million aggregate principal amount of 5.45% Notes that mature on February 15, 2034. The proceeds of the notes issued, net of discounts, premiums, and debt issuance costs, were $1.14 billion. A portion of the proceeds were invested in short-term time deposits of $550 million with initial effective maturities of more than three months and classified as prepaid </span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses and other in our condensed consolidated balance sheets as of March 31, 2024. The remaining proceeds of $589 million were invested in short-term time deposits classified as cash and equivalents in our condensed consolidated balance sheets as of March 31, 2024.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a change of control, as defined in the notes, and if the notes receive specified ratings below investment grade by each of Standard &amp; Poor's Ratings Services, Moody’s Investors Services and Fitch Ratings, any holder of the notes, excluding the debentures, can require with respect to the notes owned by such holder, or we can offer, to repurchase the notes at 101% of the principal amount plus accrued and unpaid interest.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. During the nine months ended March 31, 2024, under our commercial paper program and our committed receivables program, we had maximum combined total daily amounts outstanding of $1.3 billion and an average combined daily amount outstanding of $25 million. At March 31, 2024, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we extended our $2.0 billion revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2025. In September 2023, Cardinal Health 23 Funding, LLC ("CH-23 Funding") was added as a seller under our committed receivables sales facility. Each of CHF and CH-23 Funding was organized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, each of CHF and CH-23 Funding is a separate legal entity from Cardinal Health, Inc. and from our respective subsidiary that sells receivables to CHF or CH-23 Funding, as applicable. Each of CHF and CH-23 Funding is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its respective creditors. </span></div>Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of March 31, 2024, we were in compliance with this financial covenant. <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-term obligations and other short-term borrowings at:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions) (1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.079% Notes due 2024</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">753</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5% Notes due 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.75% Notes due 2025</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">508</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.41% Notes due 2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,192</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.125% Notes due 2029</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">644</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.45% Notes due 2034</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">494</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6% Notes due 2043</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">311</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5% Notes due 2044</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">330</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9% Notes due 2045</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">428</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.368% Notes due 2047</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">564</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0% Debentures due 2026</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">124</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,854</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,701 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion of long-term obligations and other short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,187</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term obligations, less current portion</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,667</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,909 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div>(1)    Maturities are presented on a calendar year basis. 753000000 764000000 402000000 404000000 508000000 513000000 1192000000 1184000000 644000000 0 494000000 0 311000000 306000000 330000000 331000000 428000000 428000000 564000000 561000000 124000000 124000000 104000000 86000000 5854000000 4701000000 1187000000 792000000 4667000000 3909000000 762000000 436000000 535000000 1300000000 11000000 2800000000 5900000000 4700000000 32100000000 29800000000 1150000000 650000000 500000000 1140000000 550000000 589000000 2000000000 2000000000 1000000000 1300000000 25000000 0 2000000000 <div style="display:inline-block;vertical-align:top;width:48.215%"><div id="id146297aa77540e09bbefafb0c412e48_100"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Commitments, Contingent Liabilities and Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. During the fiscal year 2023, we recorded $6 million of income to reduce the previously estimated accrual to the invoiced amount for the calendar year 2018 assessment. At June 30, 2023, we had an outstanding liability of $3 million, which was paid in full during the first quarter of fiscal year 2024. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we distribute, source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, restrictions on importation, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and </span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health, other Pharmaceutical wholesalers and other participants in the pharmaceutical supply chain have been named as a defendant in lawsuits related to the distribution of opioid pain medications. These lawsuits seek equitable relief and monetary damages based on a variety of legal theories, including various common law claims, such as public nuisance, negligence, unjust enrichment, personal injury, as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organization Act and various other statutes. Plaintiffs in these lawsuits include governmental entities as well as private parties, such as unions and other health and welfare funds, hospital </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">system and other healthcare providers, businesses and individuals. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information, subpoenas and other requests from other DOJ offices. These investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcomes of any of these investigations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, as of March 31, 2024, we have $5.3 billion accrued for these matters, of which $438 million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During the three months ended March 31, 2024, we recognized expense of $193 million in connection with opioid-related matters, which was partially offset by a benefit of $105 million related to prepayments at a prenegotiated discount of certain future payments totaling $344 million.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgements about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of the settlements described below is an admission of liability or wrong-doing. Please see below for additional description of these matters. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we along with two other national distributors (collectively, the "Distributors") independently approved a settlement agreement (the "National Opioid Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and political subdivisions. This National Opioid Settlement Agreement became effective on April 2, 2022. In addition to the Distributors, parties to the National Opioid Settlement Agreement include 48 states, the District of Columbia and 5 U.S. territories. Over 99 percent of political subdivisions in settling states (by population as calculated under the National Opioid Settlement Agreement) that had brought opioid-related suits against us have chosen to join the National Opioid Settlement Agreement or have had their claims addressed by state legislation (together with settling states and territories, the "Settling Governmental Entities"). </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, we finalized an agreement with the Alabama Attorney General, under which we agreed to pay approximately </span></div></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$123 million to the State of Alabama over a period of ten years to resolve opioid-related claims brought by the State and its political subdivisions. This agreement is subject to certain contingencies, including subdivision participation. During the nine months ended March 31, 2024, we recognized a $22 million charge in litigation (recoveries)/charge, net in the condensed consolidated statements of earnings related to this agreement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through April 2024, we have paid the Settling Governmental Entities approximately $1.5 billion, which includes the January 2024 prepayment of certain future payment amounts described below. We expect to pay Settling Governmental Entities additional amounts up to $4.8 billion through 2038. The National Opioid Settlement Agreement also includes injunctive relief terms related to Distributors' controlled substance anti-diversion programs. A monitor is overseeing compliance with these provisions until 2027. In addition, the Distributors are engaging a third-party vendor to act as a clearinghouse for data aggregation and reporting, which Distributors will fund for 10 years. As a result of the National Opioid Settlement Agreement, the vast majority of lawsuits brought against us by State and other political subdivisions have been dismissed. We continue to engage in resolution discussions with certain nonparticipating political subdivisions. A trial in the case brought by the city of Baltimore, which is the largest remaining nonparticipating subdivision by population, is scheduled to begin in September 2024. We intend to defend ourselves vigorously against all remaining lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Settlements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes were not a part of the National Opioid Settlement Agreement, and we had separate settlement negotiations with these groups. In July 2022, a judgment in favor of the Distributors was entered in bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington. Plaintiffs have appealed this decision to the Fourth Circuit Court of Appeals. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $124 million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we executed a final settlement agreement with the Native American tribes, pursuant to which we will pay up to approximately $136 million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prepayment of Future Payment Years</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, we made payments of approximately $239 million to prepay at a prenegotiated discount of certain future payment amounts totaling approximately $344 million owed under each of the National Opioid Settlement Agreement, West Virginia Subdivisions Settlement Agreement and settlement agreements with Native American tribes and Cherokee Nation. The majority of </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the prepayment relates to the seventh annual payment as due under the National Opioid Settlement Agreement. As a result of these prepayments, we recognized income of approximately $105 million in litigation charges/(recoveries), net in our condensed consolidated statements of earnings during the three months ended March 31, 2024.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The National Opioid Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Lawsuits brought by private plaintiffs that were pending as of April 26, 2024 were approximately 380. Of these, 103 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are engaged in resolution discussions with certain private plaintiffs and have reached agreements in principle with counsel representing classes of third-party payors and acute care hospitals and have accrued $213 million in connection with those matters, which represents our anticipated share of those possible settlements. The agreements in principle remain subject to contingencies. We are vigorously defending ourselves in all these matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in a case involving 21 plaintiffs began in state court in Georgia in January 2023 and concluded in March 2023 with a verdict for the company and other defendants on all claims. In July 2023, the judge denied the plaintiffs' motion for a new trial. Plaintiffs have filed a notice of appeal and defendants have filed a notice of cross-appeal. A trial involving eight hospital plaintiffs is scheduled to begin in Alabama in July 2024.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in ongoing legal proceedings with insurers related to their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. During fiscal year 2023, we received approximately $10 million in insurance recoveries related to these matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Department of Justice Civil Investigative Demand </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we received a Civil Investigative Demand ("CID") from the Department of Justice focused on potential violations of the Anti-Kickback Statute and False Claims Act in connection with a 2022 transaction in which we purchased a minority ownership interest in a rheumatology managed services organization and a group purchasing organization. We are cooperating with this investigation. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in approximately 400 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 4,500 plaintiffs that allege personal injuries associated with the use of inferior vena cava ("IVC") filter products. These lawsuits sought a variety of remedies, including unspecified monetary damages. The divestiture of the Cordis business did not include product liability </span></div></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the IVC filters in the U.S. and Canada, which we retained.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve 4,375 claims for $275 million. This settlement agreement is subject to certain conditions, including certain opt-in thresholds. Between May and September 2023, we made settlement payments totaling $275 million into a qualified settlement fund, which will be disbursed to the plaintiffs if required conditions are satisfied. Since July 2021, we have also entered into other agreements to settle approximately 2,800 product liability claims. While these settlements will resolve the vast majority of IVC filter product liability claims, they will not resolve all of them and we intend to continue to vigorously defend ourselves in the remaining lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized income of $103 million during fiscal year 2023, primarily related to a reduction of the reserve for the estimated settlement and defense costs for these matters due to the execution of the settlements noted above. At March 31, 2024, we had a total of $296 million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the amended complaint. We are vigorously defending ourselves in this matter. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation Proceeds</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $6 million and $77 million during the three and nine months ended March 31, 2024, respectively, and $66 million during the nine months ended March 31, 2023.</span></div> P10Y 100000000 -6000000 3000000 5300000000 438000000 193000000 105000000 -344000000 48 5 123000000 22000000 1500000000 4800000000 124000000 136000000 239000000 -344000000 105000000 380 103 213000000 21 8 10000000 400 4500 4375 275000000 275000000 2800 -103000000 296000000 6000000 77000000 66000000 <div style="display:inline-block;vertical-align:top;width:48.215%"><div id="id146297aa77540e09bbefafb0c412e48_103"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Income Taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for income taxes as a percentage of pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March 31, 2024, the effective tax rate was 24.2 percent and 23.2 percent, respectively, and reflects any impact of the tax effects of the goodwill impairment charges recognized during the three and nine months ended March 31, 2024. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March 31, 2023, the effective tax rate was 36.3 percent and 36.7 percent, respectively, and reflects the impact of the tax effect of the goodwill impairment charges recognized during the nine months ended March 31, 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March 31, 2024, we recognized pre-tax goodwill impairment charges of $671 million. The net tax benefit related to these charges is $56 million for fiscal 2024. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charges during the nine months ended March 31, 2024 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to the pre-tax income for the nine months ended March 31, 2024 resulted in recognizing an incremental interim tax benefit of approximately $36 million, which impacted the provision for income taxes in the condensed consolidated statements of earnings during the nine months ended March 31, 2024 and prepaid expenses and other assets in the condensed consolidated balance sheet at March 31, 2024. The incremental interim tax benefit will reverse in the fourth quarter of fiscal 2024.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $937.0 million and $1.0 billion of unrecognized tax benefits, at March 31, 2024 and June 30, 2023, respectively. The March 31, 2024 and June 30, 2023 balances include $850 million and $873 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024 and June 30, 2023, we had $57 million and $65 million, respectively, accrued for the payment of interest and </span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">penalties related to unrecognized tax benefits, which we recognize in the benefit from income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $20 million, exclusive of penalties and interest.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. In December 2023, the estimated tax exposure was updated to reflect adjustments based on settlement discussions with the IRS. Additionally, Cardinal received a partial payment from CareFusion to be applied towards the anticipated liability. The indemnification receivable was $20 million and $82 million at March 31, 2024 and June 30, 2023, respectively, and is included in other assets in the condensed consolidated balance sheets.</span></div> 0.242 0.232 0.363 0.367 671000000 -56000000 -36000000 937000000 1000000000 850000000 873000000 57000000 65000000 0 20000000 20000000 82000000 <div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Fair Value Measurements</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,013</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,013</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(70)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(70)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Assets Measured on a Nonrecurring Basis</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id146297aa77540e09bbefafb0c412e48_82" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on July 10, 2023, we closed the transaction to contribute the Outcomes™ business to TDS, a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. We accounted for this investment initially at its fair value using Level 3 unobservable inputs under the discounted cash flow method. Accordingly, we recognized a $147 million equity method investment at closing during the first quarter of fiscal 2024.</span></div> <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,013</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,013</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(70)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(70)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div> 2013000000 0 0 2013000000 105000000 0 0 105000000 0 -70000000 0 -70000000 1253000000 0 0 1253000000 101000000 0 0 101000000 0 -73000000 0 -73000000 0.16 147000000 <div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk but are not designated as hedging instruments. These derivative instruments are adjusted to current </span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three and nine months ended March 31, 2024 and 2023, there were no gains or losses recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March 31, 2024 and 2023, we entered into pay-floating interest rate swaps with total notional amounts of $500 million and $200 million, respectively. These </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains recognized in other comprehensive income/(loss) were $1 million and $2 million for the three months ended March 31, 2024 and 2023, respectively, and $2 million and $4 million for the nine months ended March 31, 2024 and 2023, respectively. Gains recognized in accumulated other comprehensive loss and reclassified into earnings were $2 million and $4 million for the three months ended March 31, 2024 and 2023, respectively, and $4 million and $8 million for the nine months ended March 31, 2024 and 2023, respectively. Gains currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are $3 million.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we entered into ¥18 billion ($120 million) cross-currency swaps maturing in September 2025 and ¥18 billion ($120 million) cross-currency swaps maturing in June 2027.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we terminated the ¥38 billion ($300 million) cross-currency swaps entered into in January 2023 and received net settlement in cash of $28 million, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we entered into ¥19 billion ($150 million) cross-currency swaps maturing in September 2025 and ¥19 billion ($150 million) cross-currency swaps maturing in June 2027. In March 2023, we entered into €100 million ($107 million) cross-currency swaps maturing in March 2025 and €100 million ($107 million) cross-currency swaps maturing in March 2026.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January and March 2023, we terminated the ¥48 billion ($400 million) cross-currency swaps entered into in March 2022 and the €200 million ($233 million) cross-currency swap entered into in September 2018, respectively, and received net settlements of $10 million and $19 million in cash, respectively, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows.</span></div></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains and losses from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive income/(loss) were a $19 million gain and an immaterial loss during the three months ended March 31, 2024 and 2023, respectively, and a $14 million gain and a $21 million loss during the nine months ended March 31, 2024 and 2023, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $3 million and $4 million during the three months ended March 31, 2024 and 2023, respectively, and $10 million and $12 million during the nine months ended March 31, 2024 and 2023, respectively.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded an immaterial gain and an immaterial loss during the three months ended March 31, 2024 and 2023, respectively, and an immaterial loss and a $3 million loss during the nine months ended March 31, 2024 and 2023, respectively. The principal currencies managed through foreign currency contracts are Chinese renminbi, Canadian dollar, Indian rupee, Euro and British pound.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at March 31, 2024 and June 30, 2023 approximate fair value due to their short-term maturities.</span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,650</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,417 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,854</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,701 </span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div> 0 0 0 0 500000000 200000000 1000000 2000000 2000000 4000000 2000000 4000000 4000000 8000000 3000000 18000000000 120000000 18000000000 120000000 38000000000 300000000 28000000 19000000000 150000000 19000000000 150000000 100000000 107000000 100000000 107000000 48000000000 400000000 200000000 233000000 10000000 19000000 19000000 14000000 21000000 3000000 4000000 10000000 12000000 3000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,650</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,417 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,854</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,701 </span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5650000000 4417000000 5854000000 4701000000 <div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Shareholders' Deficit</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We repurchased $750 million and $1.5 billion of our common shares, in the aggregate, through share repurchase programs during the nine months ended March 31, 2024 and 2023, respectively. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2023, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.0 million common shares using a reference price of $101.66. The program concluded on December 13, 2023 at a volume weighted average price per common share of $103.67 resulting in a final delivery of 0.4 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 4.4 million common shares using a reference price of $90.57. The program concluded on October 31, 2023 at a volume weighted average price per common share of $88.22 resulting in a final delivery of 1.3 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase of $500 million. We received an initial delivery of 4.6 million common shares using a reference price of $87.18. The program concluded on August 16, 2023 at a volume weighted average price per common share of $91.15 resulting in a final delivery of 0.9 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.6 million common shares using a reference price of $77.03. The program concluded on February 28, 2023 at a volume weighted average price per common share of $77.27 resulting in a final delivery of 0.6 million common shares. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delivery of 2.6 million common shares using a reference price of $76.58. The program concluded on January 13, 2023 at a volume weighted average price per common share of $77.50 resulting in a final delivery of 0.6 million common shares. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $1.0 billion. We received an initial delivery of 12.0 million common shares using a reference price of $66.74. The program concluded on December 23, 2022 at a volume weighted average price per common share of $73.36 resulting in a final delivery of 1.6 million common shares.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(151)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $4 million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(141)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(160)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax benefit of $5 million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 750000000 1500000000 250000000 2000000 101.66 103.67 400000 500000000 4400000 90.57 88.22 1300000 500000000 4600000 87.18 91.15 900000 250000000 2600000 77.03 77.27 600000 250000000 2600000 76.58 77.50 600000 1000000000 12000000 66.74 73.36 1600000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(151)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $4 million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(141)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(160)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax benefit of $5 million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -137000000 -14000000 -151000000 -4000000 1000000 -3000000 0 6000000 6000000 -4000000 -4000000 -5000000 -9000000 -141000000 -19000000 -160000000 -102000000 -12000000 -114000000 -34000000 15000000 -19000000 0 9000000 9000000 5000000 -34000000 6000000 -28000000 -136000000 -6000000 -142000000 <div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Earnings Per Share Attributable to Cardinal Health, Inc.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables reconcile the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares–basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">243</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares–diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">245</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares–basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">245</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares–diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">247</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were immaterial and 1 million for the three and nine months ended March 31, 2024, respectively, and 2 million for both the three and nine months ended March 31, 2023.</span></div> <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables reconcile the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares–basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">243</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares–diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">245</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares–basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">245</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares–diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">247</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 243000000 256000000 2000000 2000000 245000000 258000000 245000000 263000000 2000000 1000000 247000000 264000000 1000000 1000000 2000000 2000000 <div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Segment Information</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions segment and GMPD segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for </span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over the counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining three operating segments included in Other are Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics. These operating segments respectively operate nuclear pharmacies and radiopharmaceutical manufacturing facilities, distribute medical products to patients' homes in the United States and provide supply chain services and solutions to our customers.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue for the two reportable segments and the remaining operating segments, included in Other, and Corporate:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,651</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,496 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,113</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,989 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">at-Home Solutions </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">743</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Logistics</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,167</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,025 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">54,931</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,510 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">54,911</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,487 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">154,524</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139,441 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,264</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,140 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,006</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">at-Home Solutions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,188</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Logistics</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">198</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,392</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,038 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">167,180</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,619 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">167,119</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,559 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53,715</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,343 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,216</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">54,931</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,510 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">54,911</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,487 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">163,548</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148,186 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,632</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">167,180</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,619 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">167,119</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,559 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate technology and shared function expenses, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the operating segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shareholder cooperation agreement costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets, net; in connection with goodwill impairment testing for the GMPD segment as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id146297aa77540e09bbefafb0c412e48_91" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized pre-tax goodwill impairment charges of $90 million during the three months ended March 31, 2024 and $671 million and $863 million during the nine months ended March 31, 2024 and 2023, respectively; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt; or</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for/(benefit from) income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $17 million and $9 million for the three months ended March 31, 2024 and 2023, respectively, and $37 million and $20 million for the nine months ended March 31, 2024 and 2023, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:50.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">580</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">711</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(344)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">367</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,541</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,394 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,878</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,524 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,043)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">835</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Logistics.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Assets</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for the two reportable segments and the remaining operating segments, included in Other, and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></div></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,496</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,615 </span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,357</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,961 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,692</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,621 </span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,335</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,880</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,417 </span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Logistics.</span></div> 2 3 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue for the two reportable segments and the remaining operating segments, included in Other, and Corporate:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,651</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,496 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,113</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,989 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">at-Home Solutions </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">743</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Logistics</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,167</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,025 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">54,931</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,510 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">54,911</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,487 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">154,524</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139,441 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,264</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,140 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,006</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">at-Home Solutions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,188</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Logistics</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">198</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,392</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,038 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">167,180</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,619 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">167,119</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,559 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div> 50651000000 46496000000 3113000000 2989000000 352000000 313000000 743000000 651000000 72000000 61000000 1167000000 1025000000 54931000000 50510000000 -20000000 -23000000 54911000000 50487000000 154524000000 139441000000 9264000000 9140000000 1006000000 875000000 2188000000 1986000000 198000000 177000000 3392000000 3038000000 167180000000 151619000000 -61000000 -60000000 167119000000 151559000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53,715</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,343 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,216</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">54,931</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,510 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">54,911</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,487 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">163,548</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148,186 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,632</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">167,180</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,619 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">167,119</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,559 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div> 53715000000 49343000000 1216000000 1167000000 54931000000 50510000000 -20000000 -23000000 54911000000 50487000000 163548000000 148186000000 3632000000 3433000000 167180000000 151619000000 -61000000 -60000000 167119000000 151559000000 90000000 671000000 863000000 17000000 9000000 37000000 20000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:50.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">580</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">711</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(344)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">367</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,541</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,394 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,878</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,524 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,043)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">835</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Logistics.</span></div> 580000000 560000000 20000000 -46000000 111000000 106000000 711000000 620000000 -344000000 -48000000 367000000 572000000 1541000000 1394000000 18000000 -175000000 319000000 305000000 1878000000 1524000000 -1043000000 -934000000 835000000 590000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for the two reportable segments and the remaining operating segments, included in Other, and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></div></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,496</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,615 </span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,357</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,961 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,692</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,621 </span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,335</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,880</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,417 </span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Logistics.</span></div> 30496000000 27615000000 7357000000 7961000000 2692000000 2621000000 5335000000 5220000000 45880000000 43417000000 <div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">14. Share-Based Compensation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">58</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $4 million and $3 million for the three months ended March 31, 2024 and 2023, respectively, and $12 million and $9 million for the nine months ended March 31, 2024 and 2023, respectively.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units </span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.37 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.83 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.96</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $86 million, which is expected to be recognized over a weighted-average period of two years.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 234 percent of the target award amount for both the fiscal 2022 and 2023 grants and zero to 240 percent of the target award for the fiscal 2024 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:49.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.17 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.26 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96.80</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $53 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div> <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">58</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 20000000 17000000 11000000 4000000 31000000 21000000 58000000 49000000 30000000 20000000 88000000 69000000 4000000 3000000 12000000 9000000 P3Y <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.37 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.83 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.96</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2200000 57.37 900000 90.78 1100000 60.83 100000 71.21 1900000 69.96 86000000 P2Y 3 0 0 2.34 2.34 0 2.40 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:49.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.17 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.26 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96.80</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1200000 82.17 500000 94.66 400000 62.26 0 0 1300000 96.80 53000000 P2Y

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